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Abstract 
Background 
Polypharmacy-related harm affects many older Australians.  Clinician supervised withdrawal 
or dose reduction of potentially inappropriate medicines (PIMs), defined as deprescribing, 
aims to reduce this harm. General practitioners (GPs), with the support of consultant 
pharmacists (CPs), are well positioned to initiate deprescribing in community living older 
people with potentially inappropriate polypharmacy.  Effecting prescribing change is difficult 
however, and there is little research into GP-led deprescribing interventions in this patient 
group which evaluates clinicians’ barriers and enablers to change.   
 
Research aims   
To: 1) investigate factors which shape prescribers’ behaviour towards continuing or 
discontinuing PIMs in adults; 2) explore the views of GPs and CPs about potentially 
inappropriate polypharmacy and the reasoning they apply to deprescribing in community 
living older people; and 3) investigate the feasibility, effectiveness and safety of a GP-led 
deprescribing intervention involving such people in primary care. 
 
Methodology 
A sequential, exploratory mixed methods design with three phases which aligned to three 
research aims was used.  Phase One involved a systematic review and thematic synthesis 
of studies exploring prescribers’ perceived barriers and enablers to minimising chronically-
prescribed PIMs in adults.   
Phase Two, a qualitative investigation, comprised seven focus group discussions involving 
32 GPs and 15 CPs recruited from within metropolitan Southeast Queensland using a mix 
of convenience and snowball sampling. Data were analysed thematically using the 
Framework method.   
Phase One and Two findings informed the design of the multifaceted GP-led deprescribing 
intervention piloted in Phase Three.  A pragmatic, controlled pre-post mixed methods design 
was used to evaluate intervention feasibility, effectiveness and safety.  Convenience 
sampling was used to recruit five general practices and 22 clinicians.  Seventy-eight 
intervention and 67 usual care patients were consecutively sampled. Quantitative and 
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qualitative data were collected at both clinician and patient levels. The primary outcome was 
the mean difference in the number of regular medications deprescribed (i.e. ceased or dose-
reduced) per patient over the 18-week study period.  Secondary outcomes comprised 
intervention impact on patients’ medication regimens, self-reported health status, attitudes 
towards medicines and deprescribing, and GP/patient reports of actual or suspected 
adverse outcomes or experiences.  Qualitative data from semi-structured interviews were 
used to help explain quantitative results and the intervention’s feasibility, acceptability and 
sustainability.   
 
Results  
The systematic review addressing the first research aim of exploring prescribers’ perceived 
barriers and enablers to minimising PIMs comprised studies mostly exploring primary care 
physicians’ perspectives on managing older, community living adults.  Four major themes 
emerged: problem awareness; perceived value of ceasing versus continuing PIMs; self-
efficacy regarding clinicians’ ability to alter prescribing; and feasibility of altering prescribing 
in routine care environments given external constraints.   
Two major themes were derived in response to the second thesis aim regarding GPs’ and 
CPs’ views and reasoning about potentially inappropriate polypharmacy: 1) Working through 
uncertainty encapsulated the immense complexity clinicians face when assessing an older 
person with potentially inappropriate polypharmacy, such that weighing harm against benefit 
in absolute terms at the level of the individual was perceived as unfeasible.  However, 
strategies and circumstances were identified that could mitigate this uncertainty; 2) 
Perceived risk as a frame of reference referred to the dichotomised view that deprescribing 
was a risk to be avoided or risk to be reconciled, with tipping points in risk perception 
identified which might trigger action towards deprescribing. 
The exploratory pilot study addressed the third aim of investigating the feasibility, 
effectiveness and safety of the multifaceted intervention in community living older people in 
primary care.  The mean difference between intervention and usual care groups in the 
number of regular medications deprescribed per patient was -0.55, 95%CI -0.897 to -0.212, 
p = 0.002.  The respective proportions of patients having at least one medication 
deprescribed were 52.6% versus 28.4%, p = 0.005, such that intervention patients were 2.3 
times more likely to have at least one regular medication deprescribed (incidence rate ratio 
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[IRR] 2.3; 95% CI 1.297-3.964, p = 0.004).  The intervention was not associated with any 
reported harm or deterioration in health-related quality of life which may have resulted from 
injudicious attempts at deprescribing appropriate medication.  A subset of intervention 
patients reported greater certainty in the necessity and appropriateness of their medications 
at study completion.  Qualitative data showed the majority of GPs and patients derived 
satisfaction from the process of medication review and consultation during dedicated 
deprescribing appointment/s, irrespective of whether the outcome of successful medication 
withdrawal was achieved.  Whilst seen as feasible in the short-term, GPs gave mixed 
responses regarding the sustainability of the intervention in routine care. 
 
Conclusions and recommendations 
This multi-phase, mixed methods study demonstrated immense diversity in clinicians’ 
perceived barriers and enablers to deprescribing in community living older people.  The 
multifaceted intervention addressing local barriers was feasible and safe in the short-term 
and conferred a clinically modest deprescribing effect.   Further research into the long-term 
effectiveness and safety of deprescribing interventions targeting community living older 
people at high-risk of medication misadventure is warranted.    
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Chapter 1 Introduction  
There is an urgent and growing need to minimise iatrogenic harm from potentially 
inappropriate polypharmacy in ageing populations with multimorbidity.  The single biggest 
risk factor for taking one or more potentially inappropriate medicines (PIMs) is the number 
of medicines prescribed. (1, 2) ‘Deprescribing’ has been proposed as way to minimise 
potentially inappropriate polypharmacy.  It is defined as the proactive, systematic process 
of identifying and discontinuing medicines where the actual or potential harms of 
medicines outweigh the benefits, after giving consideration to an individual patient’s care 
goals, physical and mental function, life expectancy, values, and preferences.  (3)  
Although deprescribing is a relatively new term in the medical lexicon, appropriate 
cessation or reduction of medication is a long accepted component of competent 
prescribing. (4, 5)    
General practitioners (GPs) play a central role in the coordination and delivery of 
healthcare to the Australian community.  (6)  They have a critical role in the management 
of patients with multimorbidity and associated polypharmacy and attendant risks, all of 
which increase with age.  (7)  Deprescribing is a challenging and complex intervention 
however, complicated by many factors at the patient, provider and health system levels.  
(8, 9)  This study focussed on a GP-led intervention to minimise potentially inappropriate 
polypharmacy in community living older people in primary care.  Specifically, the aim was 
to develop and pilot a multifaceted GP-led intervention to minimise potentially 
inappropriate polypharmacy in this patient group, addressing GP and consultant 
pharmacist (CP) barriers and enablers to deprescribing in routine care. 
 Rationale for this study 
Like other OECD countries, Australia’s population is ageing.  Between 2014 and 2064, the 
proportion of older people (those aged 65 years or more) is projected to increase from 
15% to 23% of Australia’s population and the number of very old people (aged 85 years or 
more) is projected to increase from 1.9% to 5%. (10, 11)  The overwhelming majority of 
older individuals, including the very old, reside in private dwellings in the community, not in 
residential aged care. (12)  This is likely to continue, given the policy setting over the past 
decade in Australia, to increasingly support older people ‘ageing in place’ (i.e. residing in 
their own homes, rather than transitioning to care) which is in line with individual 
preferences and is more economically sustainable.  (13)   
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Older people are more likely to have multiple chronic conditions and take multiple 
concurrent medicines.  (14)  According to recent Australian general practice data, 57% of 
people aged 65 years and older had three or more chronic conditions (defined as 
multimorbidity) and almost 10% had seven or more chronic conditions. (15) One in two 
older Australians report taking five or more prescription, over-the-counter and/or 
complementary medicines daily, with 20% taking more than ten. (16, 17)  Despite 
representing 13% of the population, people 65 years and over contributed to more than 
half of all PBS expenditure between 2006 and 2011, and half of this expenditure was 
related to people 75 years and older. (18)   
Safe and effective prescribing in older people is particularly challenging.  A range of 
pharmacokinetic and pharmacodynamic changes increase exposure to adverse 
medication effects and diminish the predictability of response to therapy.  (19)   This is 
compounded by inadequate research and knowledge of geriatric therapeutics and 
toxicology, due to the under-representation/exclusion of older people from most clinical 
trials.  (20, 21)   
The appropriate prescription and use of medicines can extend the duration and improve 
the quality of life in older people.  The use of PIMs however, the probability of which 
increases with the number of concomitant medications prescribed, is associated with 
significant harm including adverse drug events (ADEs), hospital presentations, poorer 
health related quality of life and functioning, geriatric syndromes (e.g., delirium, falls, or 
frailty) and even death. (22-26). It also contributes to unnecessary direct and indirect 
health costs.  (27)   It is estimated that one in five medicines commonly used in older 
adults in primary care may be inappropriate. (28, 29)  
Although the harm associated with polypharmacy in observational studies supports the 
need for deprescribing, there is a dearth of direct evidence demonstrating the long-term 
safety and effectiveness of deprescribing.  Two recently published systematic reviews of 
deprescribing studies showed no-effect (30) or a potentially beneficial effect (31) on 
mortality of deprescribing interventions.  The 2016 systematic review by Page et al found 
mortality was significantly reduced in randomised studies in which patient-specific 
interventions to deprescribe one or more medicines in older adults were applied. (31) The 
2016 systematic review and meta-analysis by Johansson et al, however, found no effect of 
complex interventions to reduce polypharmacy or mortality, rates of hospital admissions or 
the number of medications used. (30)  This implies that more effective strategies to reduce 
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potentially inappropriate polypharmacy need to be developed and tested in large-scale, 
pragmatic, controlled trials.  Equally, there is need to elicit and evaluate outcomes that 
matter to patients so that interventions can be designed to improve these outcomes.    
 Setting for this study 
Most Australians receive primary health care through their GP who also acts as a 
coordinator and gatekeeper for government-subsidised specialist and allied health 
services.  (32) Consequently, GPs and the primary health care setting are routinely 
targeted in major health initiatives to improve population health. (33) Primary health care in 
Australia encompasses a large range of providers and services across the public, private 
and non-government sectors.   General practice is partially funded under Medicare, 
predominantly through a ‘fee-for-service’ model, whereby GPs receive government 
remuneration for individual patient consultations and treatments thereby offsetting the out-
of-pocket cost for the patient.   Bulk-billing is where a practice directly bills Medicare for a 
health service and does not charge the patient an out-of-pocket fee.  Under the National 
Health Reform Agreement, strengthening GP and primary health care services has been 
identified as a critical step towards ensuring the effectiveness and efficiency of the 
Australian health system.  (34)  General practitioners are therefore arguably the most 
important agents in improving the care for patients in the community.  This includes 
ensuring the Quality Use of Medicines (QUM), defined under the National Medicines Policy 
as the safe, judicious, effective and cost-effective use of medicines in all Australians.  (35) 
Consultant pharmacists (CPs), who are accredited to undertake medication reviews, also 
have an important role in enhancing QUM in Australia. Consultant pharmacists are 
reimbursed by government to undertake comprehensive medication reviews in the 
patients’ place of residence on referral from their GP.  For individuals residing in the 
community, this service is known as a Home Medicines Review (HMR), which is funded by 
government through the Sixth Community Pharmacy Guild Government agreement. (36)   
There is currently support for greater involvement and integration of pharmacists into 
general practices in Australia, as is the case in the United Kingdom (UK), United States 
(US) and Canada, to improve QUM and outcomes of patients with chronic disease.  (37, 
38) 
Effecting any clinician-led behaviour change in primary care, including facilitating GP-led 
deprescribing in older people, is difficult and requires complex, or multifaceted, 
intervention. (39)  Factors influencing the use and prescription of one or more PIMs in 
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older people are broad and multi-dimensional.  The likelihood of successful 
implementation of a complex intervention is increased when the ‘implementers’ have been 
engaged in eliciting, understanding and addressing  barriers and enablers to change in a 
particular context and using those insights in designing the intervention. (40)  
Consequently, this study sought to develop and pilot a multifaceted GP-led intervention to 
minimise potentially inappropriate polypharmacy in community living older people, 
addressing GP and CP barriers and enablers to deprescribing in primary care in Australia.   
A mixed methods approach was used to address the research problem for this study with 
pragmatism being the paradigm applied to the investigation, given the potential application 
of these research findings to real-world practice. (41, 42)   The three specific aims of the 
study, which aligned with three specific study phases were: 
 Phase 1 – To investigate prescribers’ perspectives on factors which shape 
their behaviour towards continuing or discontinuing PIMs in adults 
 Phase 2 – To explore the views of a sample of general practitioners and 
consultant pharmacists about potentially inappropriate polypharmacy and the 
reasoning they apply to deprescribing in older people in primary care, 
including factors that influence this process 
 Phase 3 – To evaluate the feasibility, effectiveness and safety of a 
multifaceted GP-led intervention in community living older people in primary 
care, which was developed using the findings from Phases 1 and 2.   
Many deprescribing intervention studies to date have been led by clinicians who do not 
have an ongoing therapeutic relationship with, and tacit knowledge of, the patient and 
have occurred in the hospital or residential aged care setting.  This research addresses 
this shortcoming and will contribute to knowledge regarding strategies to facilitate GP-led 
deprescribing with their community living older patients in the Australian primary care 
setting.  The developmental qualitative work will provide a greater understanding of 
clinicians’ perspectives of potentially inappropriate polypharmacy and factors that inhibit or 
facilitate deprescribing.  The use of mixed methods in the exploratory study will allow 
critical components of a successful intervention to be identified for future application in 
clinical practice, or, if the intervention is unsuccessful, whether this was the consequence 
of implementation failure or genuine ineffectiveness of the intervention, learnings from 
which can be applied to future studies.  Importantly, the qualitative evaluation of the 
exploratory study will highlight perceived value, if any, from the GPs’ and patients’ 
perspective, which may assist in identifying meaningful measures and outcomes to inform 
future deprescribing studies and policy decisions. 
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 Overview of thesis structure  
This thesis comprises nine chapters.  This first chapter provides an overview of the 
research problem and context, and presents the thesis aims and structure.  Chapter 2 is a 
comprehensive review of current literature pertaining to the potential harms from 
polypharmacy, the need for deprescribing and the way in which this study intends to 
contribute to the body of knowledge in this important and emerging field of research.  In 
Chapter 3, the research approach used in this three-phased mixed methods study will be 
described, including the research paradigm applied to the investigation and research 
design.  Chapter 4 presents the methods and findings of the systematic review and 
thematic synthesis of available literature of prescribers’ perceived barriers and enablers to 
minimising potentially inappropriate medicines (PIMs) chronically prescribed in adults.   
Recognising the importance of context to the success or failure of complex interventions, 
Chapter 5 presents the methods and findings of a qualitative investigation involving a 
sample of South-East Queensland GPs and CPs caring for older people with 
polypharmacy still residing in the community.  Their views were sought regarding 
potentially inappropriate polypharmacy, the reasoning they apply to deprescribing in 
primary care as well as factors that support or inhibit this cognitive process.  Findings from 
Chapter 4 and 5 were subsequently used to inform the design of a multifaceted 
deprescribing intervention.  Detailed methods for this exploratory, mixed methods study 
are presented in Chapter 6.   Quantitative results and qualitative findings of the exploratory 
study are presented in Chapters 7 and 8, respectively.  Chapters 4, 5, 7 and 8 all provide a 
discussion at the end of each chapter, stating the strengths and limitations of the relevant 
investigations for each phase of the study, comparison of findings to existing literature, and 
new insights from the research.  The final chapter, Chapter 9, is a synthesis and 
interpretation of the all three phases of the investigation, including the significance of the 
research findings and potential implications for practice, policy and future research. 
  
6 
 
Chapter 2  Literature review   
This chapter provides an overview of the research literature on polypharmacy, 
deprescribing and behaviour change interventions influencing primary care physicians’ 
practice, including prescribing decisions.  Specifically, the objectives of this chapter are to: 
1) provide definitions of common terms used in this thesis to ensure a mutual 
understanding of essential nomenclature; 2) outline the prevalence and evidence of harm 
from polypharmacy and potentially inappropriate medication (PIM) use; 3) appraise the 
evidence of the safety and efficacy of deprescribing interventions and interventions to 
change clinicians’ behaviour in primary care and; 4) highlight areas where further research 
is required and how this study will contribute to the knowledge in this field.  In identifying 
relevant literature for this chapter, keyword searches of PubMed, Scopus, Google Scholar, 
the University of Queensland library website and the candidate’s personal reference library 
were undertaken throughout the period of candidature and up until November 2017.  
Formal search strategies were augmented by snowballing techniques (i.e. identifying 
relevant papers from reference lists of pertinent articles) and notification by colleagues of 
newly published articles.     
 Definitions  
 Polypharmacy, potentially inappropriate medicines and potentially inappropriate 
prescribing   
Polypharmacy has been defined in two ways in the literature: the concomitant use of 
multiple drugs as measured by a simple count of medications or; the use of more 
medications than are clinically indicated which considers the appropriateness of each 
therapy.  (43)  The bulk of the literature looking at the epidemiology and consequences of 
‘polypharmacy’ has employed the first definition that uses medication counts and 
thresholds for harm.  (24)   
For the first definition of polypharmacy centred on ‘many medicines’, there is no 
consensus regarding the number of medications that constitutes polypharmacy, (44) 
although a threshold of five or more medicines is commonly used for ‘polypharmacy’ and 
ten or more medicines for ‘hyperpolypharmacy’. (45, 46)  It is important to note that the 
concurrent use of multiple medicines may be entirely appropriate, especially in individuals 
with multimorbidity. (47, 48)  Therefore, the term ‘potentially inappropriate polypharmacy’ 
has been used to distinguish polypharmacy in which one or more medicines are possibly 
inappropriate when multiple regular medicines are used concurrently. (3)  As asserted by 
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Aronson, to ascertain whether polypharmacy is or is not appropriate, each medicine must 
be considered individually, in the context of the person for whom it is prescribed, as well as 
in the context of the whole prescription.  (47)  A ‘potentially inappropriate medicine’ (PIM) 
has been defined as that in which the actual or potential harms of medication therapy 
outweigh the actual or potential benefits. (49) The addition of the term ‘potentially’ when 
discussing either polypharmacy or single medicines is important, especially in older 
people, where there is a lack of strong clinical evidence on the risks and benefits of 
medicines.   Often, it is not until reduction or withdrawal of therapy is attempted that it 
becomes clear if continuing therapy is in fact necessary and appropriate in an individual.  
(50) 
The term ‘potentially inappropriate prescribing’ or PIP, however, is far more 
encompassing.  The definition includes not only the overuse, but also misuse and under-
use of medicines (i.e. fewer medicines than are clinically indicated). (49, 51)   Under-
prescribing has emerged as a matter of concern in older people with polypharmacy in 
more recent times, but there is evidence that under-prescribing and polypharmacy often 
coexist. (52) (53) In one study of 150 older people, among participants receiving five or 
more medicines, 42.9% were under-treated, compared to 13.5% of those using four or 
fewer medicines (odds ratio [OR] 4.8, 95% Confidence Interval [CI] 2.0 to 11.2). (54)  One 
explanation of this finding is the unwillingness of doctors to prescribe additional medicines 
for patients with polypharmacy due to concerns around regimen complexity, fear of 
adverse events or interactions and poor adherence.  (54)   
Under-prescribing as a component of PIP will not be examined as part of this thesis.  
Although under-prescribing is acknowledged as an important issue, it is hypothesised that 
minimising potentially inappropriate polypharmacy may provide an entry point for more 
appropriate prescribing generally, including the initiation of essential medicines in older 
people with polypharmacy.   
Throughout this thesis, ‘polypharmacy’ refers to the use of multiple medicines concurrently 
(usually five or more regular medicines, unless otherwise stated).  If there is reference to 
one or more medicines being potentially inappropriate, the terms PIM or potentially 
inappropriate polypharmacy will be used.  The terms medicine/s, medication/s and drug/s 
have also been used interchangeably throughout this thesis.   
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 Prevalence of, and outcomes associated with, polypharmacy and PIMs in 
community living older people 
 Prevalence and trends in polypharmacy 
Polypharmacy can occur at any age, but it is older people who continue to be the greatest 
users of medicines and who experience a disproportionate number of medication-related 
events or harm.  Studies in the United States and Australia indicate at least one in two 
older people (aged 65 years or greater) living in the community use five or more 
prescription, over-the-counter or complementary medicines every day, and the number 
used increases with age. (16, 55)  The percentage of older people in the community using 
ten or more medications has been estimated to be between 5 and 26%, with higher rates 
again reported in residential aged care.  (16, 46, 56)   
The prevalence of polypharmacy is also increasing over time.  A nationally representative 
survey of trends in prescription drug use among 37,959 non-institutionalised US adults 
aged 20 years and older from 1999-2012 found that the prevalence of polypharmacy (i.e. ≥ 
5 prescription drugs) increased, across all age groups (estimated prevalence 8.2% in 
1999-2000 to 15% in 2011-2012; difference 6.6%, 95% CI, 4.4%-8.2%; p for trend 
<0.001).  The highest prevalence of polypharmacy was in people aged ≥ 65 years (39% in 
2011-2012, 95% CI 35-44%). (57) 
Similarly, a large repeated cross-sectional study of pharmacy claims data in Ireland from 
1997 to 2012 (range 338,025 – 539,752 individuals), found that the prevalence of 
polypharmacy (i.e. ≥ 5 prescription drugs) increased, particularly among older individuals 
(from 17.8% to 60.4% in those aged ≥65 years). The adjusted incidence rate ratio (IRR) for 
polypharmacy in 2012 compared to 1997 was 4.16 (95% CI 3.23 to 5.36), and for 
excessive polypharmacy (defined as ≥ 10 regular medicines) it was 10.53 (95% CI 8.58 to 
12.91). (58) 
Whilst a directly comparable, current Australian study is not available, figures from the 
Pharmaceutical Benefits Scheme (PBS) showed the number of prescriptions in Australia 
rose from 179 million in 1997 to more than 288 million in 2014.  (59) This implies trends in 
Australia may be broadly consistent with those reported internationally.  Polypharmacy is 
therefore the paradigm for modern prescribing. (60) 
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 Drivers of polypharmacy   
Key drivers of polypharmacy are the ageing population, rising tide of multimorbidity and 
plethora of disease-specific, evidence-based guidelines for the management of long-term 
conditions. (48)  Australian general practice data from 2015-2016 indicates that 57% of 
people aged 65 years and older have three or more chronic conditions and almost 10% 
had seven or more chronic conditions. (15)  This is consistent with international data.  A 
cross-sectional study in the UK in which data were extracted from the primary care 
electronic health records of 1.75 million people indicated that 64.9% of people aged 65-84 
years and 81.5% of people aged ≥85 years were classified as having multimorbidity 
(defined in their study as two or more chronic conditions concurrently). (61)   
Disease-specific guidelines rarely account for managing patients with multimorbidity and 
so, the application of multiple disease-specific guidelines by clinicians to a patient with a 
number of chronic conditions, increases the likelihood of potentially inappropriate 
polypharmacy. (14)  This can be exacerbated by guideline-derived quality indicators and 
performance incentives at the health system level. (62)  
There are a range of other drivers of polypharmacy including a lack of knowledge of 
geriatric pharmacology and exclusion of older multimorbid patients from clinical trials.  
Patient or carer expectations regarding health and medicines and a focus on 
pharmacological versus non-pharmacological therapies can also drive polypharmacy.(20)  
At the provider level, intervening to withdraw a chronically-prescribed medication can be a 
difficult and time-consuming task in this patient group.  In time-pressured, routine care 
environments, there is often a focus on the management of acute illness, rather than 
proactive management of chronic disease.  (63)  It can be challenging for clinicians to 
identify adverse drug events (ADEs), and their misinterpretation as new disease, may 
invoke the addition of more medicines.  (63)  Fear of precipitating disease relapse or drug 
withdrawal syndromes and prescriber sensitivity to accusations of ageist discrimination if 
not prescribing more drugs can further undermine proactive attempts to minimise 
PIMs.(20)  The provider is also faced with a range of health system drivers of 
polypharmacy such as the involvement of multiple specialist prescribers across different 
care settings who again take a disease-specific, rather than coordinated, whole-patient 
approach to care. (64)  Prior to the publication of the systematic review of factors which 
shape prescribers’ behaviour towards continuing or discontinuing PIMs in adults published 
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in 2014 as part of this thesis, syntheses of literature on drivers of polypharmacy at the 
provider level were lacking.  (9)     
 Harms from polypharmacy   
The use of multiple concurrent medications has been associated with poor health 
outcomes in single observational studies, but a systematic review of adverse health 
outcomes associated with polypharmacy in community dwelling older adults published in 
2014 by Fried et al found mixed results. (44)  However, no minimum threshold number of 
medications was specified to define polypharmacy.  The authors were particularly 
interested in examining the relationship between the number of medications prescribed 
and patient outcomes regardless of the appropriateness of each medication.  A total of 50 
observational studies were included in the review, but due to marked heterogeneity among 
studies regarding their definition of polypharmacy and the outcomes studied, no attempt 
was made to combine the results.  Studies were rated for their adjustment of comorbidity, 
a significant confounder between the relationship of polypharmacy and outcomes, and the 
majority of studies were rated as ‘good’ in this regard.  Some studies demonstrated an 
association of polypharmacy with falls, related risk factors and injury, ADEs, adverse 
symptoms, decline in physical and cognitive function, hospitalisation and mortality, while 
other studies failed to find these associations.  Three studies examined multiple categories 
of a number of medications and did not find associations between three or fewer 
medications versus no medications and the outcome of interest, but did find associations 
for categories including a higher number of medications. (65-67)  The reviews’ authors 
expected that studies with less adjustment for comorbidity would be more likely to 
demonstrate an association between polypharmacy and adverse outcomes because they 
hypothesised that polypharmacy was predominantly a marker of patients’ underlying 
health status.  This was not clearly shown though and the authors concluded that this 
indicates the multifactorial nature of the outcomes examined in the included studies.  A key 
difficulty in interpreting this review was the lack of a minimum threshold of medicines 
constituting polypharmacy.    
An Australian study of 1,705 community dwelling older men aged 70 years attempted to 
identify medication thresholds associated with medication-related adverse effects.  After 
adjusting for age and number of comorbidities, the study found that a threshold of five or 
more medications was associated with medication related adverse effects for frailty, 
disability, mortality, and falls.  (68)  Specifically, the number of concomitant medications 
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was 6.5, 5.5, 4.5, and 4.5 medicines in association with frailty, disability, mortality, and 
falls, respectively, and the association strengthened with each additional medication.  That 
is, for each one medicine increase in the number of medicines, the adjusted odds ratios 
(AORs) were 1.13 (95% CI 1.06 to 1.21) for frailty, 1.08 (95% CI 1.00 to 1.15) for disability, 
1.09 (95% CI 1.04 to1.15) for mortality, and 1.07 (95% CI 1.03 to 1.12) for incident falls.  
Although this study was limited by its ability to adjust for the severity of comorbidities, it 
lends support to the threshold of five or more medications as being appropriate for the 
definition of polypharmacy. (69) 
A large study from Payne et al (70), published after the 2014 systematic review by Fried et 
al, again attempted to adjust for the degree of comorbid conditions on the association 
between polypharmacy and adverse outcomes. They reported the findings of a 
retrospective cohort analysis using linked electronic health records from primary and 
secondary care for 180,815 Scottish adults with long-term conditions and taking multiple 
medicines.  In the study, authors modelled the association of polypharmacy with 
unplanned admission for patients, but used an interaction term in their multiple logistic 
regression modelling to adjust for the different numbers of long-term conditions.  The 
authors found that unplanned hospitalisation was strongly and consistently associated with 
the number of regular medications prescribed (OR 1.25, 95%CI 1.11 to 1.42 for four to six 
medications and OR 3.42, 95% CI 2.72 to 4.28 for ≥10 medications, compared to one to 
three medications, respectively).  However, this effect was greatly reduced for individuals 
with multiple chronic conditions.  In patients with six or more conditions, those on four to 
six medications were no more likely to have unplanned admissions that those with fewer 
than three medications (OR 1.00, 95% CI 0.88 to 1.14).  The use of ≥ 10 medications 
remained consistently associated with an increased risk of unplanned hospitalisation, 
regardless of the number of comorbidities, although the size of the effect was reduced in 
those with four to six comorbidities (OR 1.50, 95% CI 1.31 to 1.71).  The median age of 
study participants was 49 years (36-63 years).  The authors repeated their analysis 
restricting age to those 65 years and older though, and found very similar results.(71)  This 
study’s findings indicate the importance of considering polypharmacy in the clinical context 
for which medications are being prescribed.  The attenuation in strength of association 
between polypharmacy and unplanned hospital admission with increasing number of 
comorbidities suggests the use of multiple medicines is not necessarily harmful and 
therefore inappropriate.   
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Several conclusions can be drawn from the aforementioned observational studies.  The 
concurrent use of multiple medicines is associated with harm in many situations, but not 
always.  Polypharmacy may therefore be entirely appropriate, especially in individuals with 
multimorbidity.  Evidence suggests that four to five or more concurrently used medicines 
appears the threshold at which there is an association with many adverse outcomes.  
However, given that thresholds vary depending upon the outcome of interest, it would 
seem that more sophisticated alternatives, which consider the appropriateness of therapy 
in the context of individuals and all their clinical circumstances, may be of greater value in 
predicting or determining patient harm from polypharmacy. (71) Randomised controlled 
trials, which could mitigate confounding due to the complex relationship between 
medication regimens and comorbidities, may be required to definitively answer the 
question of attributing outcomes to polypharmacy. (44)  Until better risk-adjusted predictive 
tools for medication-related outcomes become available, polypharmacy, defined by 
medication number alone, appears a useful proxy of potential medication-related harm, 
especially in older people.   
 Polypharmacy and PIMs 
Polypharmacy is also an indicator of PIP and PIM use.  (26)  This is based on the finding 
that the number of medicines prescribed is the single most important predictor of the 
presence of one or more inappropriate medicines. (1, 2) There are multiple tools that 
attempt to identify PIMs.  These tools are either explicit (based on predetermined criteria 
or standards) or implicit (requiring the clinical judgment of the assessor). (72)   
Explicit criteria are usually developed from reviews of published evidence and, in the 
absence of evidence, expert opinion and consensus.  Explicit criteria are generally drug- or 
disease-orientated and can be applied with little to no clinical judgement.  (49)  They are 
therefore useful to apply at a population level to identify, for example, the prevalence of 
PIMs from prescribing databases.  The usefulness of explicit criteria is more limited at an 
individual level however, because they may not account for factors consistent with high-
quality, individualised care, such as levels of comorbidity and patient preferences. (49)  In 
other words, they do not encompass the clinical context in which decisions are made. (73)  
Other key limitations include low physician acceptability due to the perception that explicit 
criteria limit freedom to prescribe (74), and that consensus approaches from which explicit 
criteria are often derived have little evidence of validity and reliability. (49)  Examples of 
explicit tools identifying PIMs from multiple medicine and therapeutic classes include the 
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Beers (75), PRISCUS (German abbreviation) (76), McLeod (77), ‘Improved Prescribing in 
the Elderly’ (IPET) (78), ‘Fit for The Aged’ (FORTA) (79), and ‘Screening Tool to Alert 
doctors to Right Treatments’ (STOPP) criteria. (80)   
The Medication Appropriateness Index (MAI) appears to be the most widely utilised implicit 
tool, but its use is time consuming and so is generally restricted to the research setting. 
(49)  It rates ten elements of prescribing:  indication, effectiveness, dose, correct 
directions, practical directions, drug–drug and drug–disease interactions, duplication, 
duration and cost. The standardised rating process generates a weighted score of overall 
prescribing appropriateness. The tool demonstrates good reliability and content validity, 
although its utility is limited by potential floor effects, such that the number of 
‘inappropriateness’ ratings tends to be low. (81)    
 Prevalence and trends in PIMs  
The reported prevalence of PIMs may vary depending upon the tools or criteria being used 
to measure prescribing appropriateness.   A systematic review of 19 studies (7 from the 
US and 10 from countries in Europe and Asia), estimated that one in five prescriptions in 
primary care for individuals >65 years was inappropriate. (28)  Fourteen of these studies 
used the Beers criteria to determine appropriateness.  A more recently published 
systematic review of 52 studies conducted in Europe estimated the overall prevalence of 
potentially inappropriate prescribing in community dwelling older people was 22.6% (95% 
CI 19.2 to 26.7%), although this study also considered examples of under-prescribing in 
the assessment of PIP. (82)   
A large Australian cohort study involving 192,363 veterans 70 years and older found that 
approximately 20% of this population were taking one or more PIMs, as defined by Beers 
or McLeod criteria.  This suggests that the prevalence of PIM use in Australia appears 
broadly consistent with international data.  (29)  Higher rates again have been reported in 
residential aged care facilities (RACFs) with up to one in two older Australians taking at 
least one PIM, (83, 84) which is again broadly consistent with international data.  (85) 
Only one study could be found which reported contemporary data regarding trends in the 
prevalence of PIM use.  It was the previously mentioned large repeated cross-sectional 
study of pharmacy claims data in Ireland from 1997 to 2012 (range 338,025 – 539,752 
individuals) which found the prevalence of PIM use (as defined by the STOPP criteria) 
rose from 32.6% in 1997 to 37.3% in 2012, but the odds of having any PIM were lower in 
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2012 compared to 1997, after adjusting for gender and the number of medicines (OR 0.39 
CI 0.39-0.4).  In considering specific examples of PIM use, the authors found that some 
examples of PIM use had decreased over time (e.g. high dose aspirin and digoxin) whilst 
others had substantially increased (e.g. long-term proton pump inhibitors at maximal dose 
increased from 0.8% to 23.8%).  (58)   It is difficult to extrapolate these findings to trends in 
PIMs use in other countries, including Australia.  It does however confirm that, whilst rates 
of prescribing of PIMs remain high, patterns of prescribing change over time, such that 
PIMs that were once commonly prescribed may reduce over time, with other new 
examples emerging.  The usefulness of explicit criteria to identify PIMs is therefore time-
sensitive, meaning the criteria must be updated regularly so they do not become 
redundant.  In contrast, structured decision guides or frameworks, (86) which provide 
prescribers with a systematic approach to reviewing an individual’s medicines are not time-
sensitive, as they require a consideration of current evidence of appropriateness of 
medications.   
 Harms from PIMs 
Observational studies have shown that PIM use is independently associated with a range 
of adverse health outcomes in community living older people including ADEs, hospital 
presentations and poorer health-related quality of life. (22, 87)   In older people in 
residential care, individuals who begin use of a PIM in the previous year are at a higher 
risk of hospitalisation and dying compared to non-PIM users. (23)  This was shown in a 
retrospective claims database analysis of 7,594 elderly nursing home residents in Indiana 
(mean age, 83.07 years).  Incident PIM users were more likely to be hospitalised (OR 
1.27, 95% CI 1.10 to 1.46) and more likely to die (OR 1.46, 95% CI 1.31 to 1.62) in the 12 
months after first receiving a PIM than non-users, after adjusting for demographic and 
clinical risk factors.  (23) 
A retrospective cohort study of 174,275 insured persons 65 years and older in the US 
looked at the ability of three different explicit criteria (2003 and 2012 Beers, and the 2008 
STOPP criteria) to predict ADEs, hospitalisations and emergency department (ED) visits.  
(87)   The data source was managed care administrative claims from 2006-2009 and 
mean follow-up period of the cohort was approximately two years.  The prevalence of 
inappropriate prescribing was 34.1%, 32.2%, and 27.6% for the 2012 Beers, 2003 Beers, 
and the STOPP Criteria, respectively.  Exposure to a PIM according to any of these criteria 
was strongly associated with an increased risk of ADEs, Emergency Department (ED) 
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visits, and hospitalisations in both unadjusted and adjusted models. In the primary 
unadjusted model, PIM exposure was associated with a 2- to 3-fold increased risk across 
all outcomes for the 2003 Beers, 2012 Beers, and STOPP Criteria.  The relationship 
between PIM exposure with all of criteria and each of the three outcomes was stronger 
(HRs: 3.67 – 5.30) in the time varying models in which exposure and outcome were 
assessed in the same month. Not all adverse outcomes examined could be attributed to 
the presence of PIMs however, highlighting the need to combine these criteria with clinical 
judgement.   
A retrospective cohort study by Cahir et al of 931 community dwelling patients aged ≥ 70 
in Ireland evaluated the prevalence of, and harms from, PIMs according to the 2008 
STOPP criteria.  (22) Forty-two percent of patients had one or more PIMs, which is slightly 
higher than the prevalence reported in other community living older people in the 
aforementioned systematic reviews. (28, 82)  After adjusting for covariates, the study 
found that patients with two or more PIMs were twice as likely to have an ADE (AOR 2.21, 
95% CI 1.02 to 4.83, p < 0.05), have significantly lower quality of life (p < 0.001) and nearly 
a two-fold increased risk in the rate of accident and emergency visits (adjusted IRR 1.85, 
95% CI 1.32 to 2.58, p < 0.001). (22) 
It is clear the presence of PIMs as determined by explicit criteria is associated with 
significant adverse outcomes, contributing to considerable direct and indirect health costs, 
although this cost is yet to be quantified in the Australian context.  Lists of PIMs such as 
Beers and STOPP criteria comprise medicines whose benefits are outweighed by harms in 
most circumstances, e.g. non-steroidal anti-inflammatory drugs, anticholinergic agents and 
benzodiazepines. (63)  In the Australian context, these drugs account for relatively few 
ADEs, reinforcing the point that these criteria may only predict a fraction of medication-
related adverse outcomes. (88)  Furthermore, whilst such criteria may be of use at a 
population level to gauge medication appropriateness, their utility at an individual patient 
level is limited for two key reasons: their inability to fully account for the clinical context in 
which medicines are being used; and failure to identify other medicines not appearing in 
such lists which may be associated with significant potential for harm in an individual 
patient.  The process of identifying medicines as potentially inappropriate in an individual 
patient is therefore more complex than simply applying a standardised list of ‘drugs to 
avoid’.   Several decision guides or frameworks that have been developed to support the 
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process of identifying and discontinuing or deprescribing one or more PIMs and these will 
be discussed in 2.3.4, ‘Structured guides to assist deprescribing’.   
Thus far, it has been established that polypharmacy is associated with patient harm in 
many, but not all instances.  The number of medicines used is also the single most 
important predictor of the presence of one or more PIMs, which is also independently 
associated with adverse outcomes.  Therefore, polypharmacy, defined by medication 
number alone, appears a useful proxy of potential medicine-related harm, especially in 
older people.  In the next section, the definition and current evidence on the efficacy and 
safety of deprescribing will be examined.   
 Deprescribing  
 Definition of deprescribing 
The term deprescribing first entered the medical lexicon in 2003 (89)  and embodied a 
response to the harms of polypharmacy and PIMs. However, no single definition for 
deprescribing exists in the medical literature.  One of the most comprehensive definitions 
offered to date is that by Scott et al, page 827, which defines deprescribing as, “the 
systematic process of identifying and discontinuing drugs in instances in which existing or 
potential harms outweigh existing or potential benefits within the context of an individual 
patient’s care goals, current level of functioning, life expectancy, values, and preferences.”  
Reeve et al also states that two of the essential characteristics of a definition of 
deprescribing are that medications to be ceased are inappropriate and that deprescribing 
is supervised by a health care professional, so that deprescribing is distinguished from 
what it is not (i.e. patient non-adherence or prescribers denying effective treatment). (90)  
However, as identified by Reeve herself, it may be almost impossible to identify a priori 
medicines that are unequivocally inappropriate as it is often not until discontinuation is 
attempted and the individual is followed-up that the actual benefit (or harm) of a medicine 
in an individual becomes apparent.  (50) 
There is also debate regarding whether dose reduction, as opposed to complete 
discontinuation, should be included in the definition.  For example, Reeve also states that, 
although controversial, deprescribing should only refer to medication withdrawal, not 
reduction, on the basis that if a medication truly is inappropriate, it should be ceased 
completely. (90) However, it is important to acknowledge that deprescribing sits on the 
spectrum of ‘good prescribing’, spanning therapy initiation, dose titration, changing or 
adding medicines, and switching, reducing or ceasing medicines. (3)  This raises 
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questions as to whether Reeve’s purist definition is anchored in the reality of clinical 
practice.  There may be instances in which a reduction in dosing rather than complete 
cessation of a medicine meets the definition of deprescribing (e.g. changing a regular dose 
to as required [prn] benzodiazepine or proton pump inhibitor use). (91) 
 
The concept of stopping or reducing medicines is well known to clinicians and is 
documented in the World Health Organisation’s (WHO) Guide to Good Prescribing.  (92)   
Furthermore, deprescribing embodies Quality Use of Medicines (QUM) principles (i.e. the 
safe, judicious, effective and cost-effective use of medicines) as outlined in Australia’s 
National Medicines Policy which was first launched in December 1999.  (35)  Reviewing 
and discontinuing therapy also features in Australia’s National Prescribing Services’ 
Prescribing Competencies, which aim to guide Australian prescribers to put QUM into 
practice.  (5)   
Like other interventions such as initiating a medication, deprescribing is a positive, 
affirmative action that carries potential harms and benefits and requires informed consent, 
adherence and monitoring. (3)  It has been suggested by clinicians and researchers that 
deprescribing be considered whenever there is polypharmacy, suspected or probable 
adverse medication effects, a lack of efficacy or absence of a clear indication for a 
medicine, or there has been a change in patient care goals or health trajectory. (50, 93)   
 Deprescribing interventions targeting multiple medication classes (polypharmacy)  
A vast number of studies spanning several decades have examined the effect of 
interventions to improve or optimise prescribing broadly, which directly or indirectly 
encompassed attempts to reduce the number of medicines prescribed or the prevalence of 
PIMs. In other words, these studies may have included deprescribing, or elements of it, but 
they were not specifically focussed on deprescribing.  For example, three previous 
Cochrane Reviews reported on interventions to optimise prescribing in older patients in the 
community, (94) care homes, (95) and hospitals. (96)  Interventions included multi-
disciplinary case-conferencing, education for patients and clinicians, computerised 
decision support, information transfer and pharmacist-mediated medication reviews or a 
combination of these elements.  Medication reviews by a pharmacist may have involved 
support from a specialist and/or the use of criteria based processes (e.g. application of the 
MAI or STOPP/START criteria).  (94-96)  These interventions demonstrated improvements 
in prescribing (such as improvements in MAI score or a reduction in medicines listed as 
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inappropriate based on explicit criteria) but their effects on clinical outcomes, such as 
ADEs, quality of life, hospitalisations, morbidity and mortality have been mixed.   
Comparatively fewer studies have focused exclusively on deprescribing, although 
published research in this area has increased in the last ten years.   
The goal of deprescribing is to minimise potentially inappropriate polypharmacy and 
improve outcomes, (63) but long-term efficacy and safety data derived from controlled 
trials are lacking.  Evidence to date suggests short-term efficacy and/or a lack of harm 
from withdrawing medicines from a single therapeutic category in people 65 years and 
older, such as antihypertensive, benzodiazepine and psychotropic agents.  (97)     
Evaluation of the limited evidence to date on the impacts of deprescribing interventions 
targeting multiple medicines has shown little to no beneficial impact regarding ‘clinically 
meaningful outcomes’.  A 2016 systematic review and meta-analysis examined the effects 
of strategies to reduce polypharmacy on mortality, hospitalisation and number of changed 
medicines.  (30)  Studies were limited to those selecting patients 65 years or older taking 
four or more medicines, and without terminal illness.  A total of 25 studies (21 randomised 
controlled trials, four non-randomised controlled studies) including 10,980 participants, 
across all health settings were in included in the analysis.  Only five of the 25 studies 
explicitly aimed to reduce the quantity (dose or number) of medicines, with the remaining 
studies aiming to improve the appropriateness of the medication regimen by removing, 
where possible, inappropriate medicines.  Interventions were complex and targeted 
polypharmacy or multiple drug classes (rather than a single drug class) but common to all 
interventions was a process of medication review.  Thirteen studies reported on 
pharmacist-led interventions, eight on multidisciplinary team-led interventions and four on 
physician-led interventions.  Studies used a variety of methods to support the medication 
review process, including: appropriateness criteria (e.g. MAI); lists of drug interactions; and 
reconciliation methods and expert opinion.  All of these methods may have been 
supported by a range of electronic or non-electronic strategies (e.g. clinical decision 
support, reminders).  Fifteen studies were conducted in primary care, seven in nursing 
homes and three in hospital.  The duration of study follow-up ranged from six weeks to 18 
months and studies were conducted in developed countries in Europe, in the UK, USA, 
Canada and Australia.   
Meta-analysis of eighteen studies reporting on all-cause mortality showed no effect in 
favour of intervention (OR 1.02, 95% CI 0.84 to 1.23).  Although statistical heterogeneity 
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was low (I2 = 8%; p = 0.362) in regard to effect measures, there was a high degree of 
methodological heterogeneity regarding study design.  Study results were unable to be 
pooled for the outcomes of hospitalisation, but authors noted that only two of eleven 
studies reported reductions in hospital admissions in favour of intervention.  For changes 
in the number of drugs taken, the authors noted that, at baseline, patients were taking on 
average 7.4 medicines in both the intervention and the control groups.  The weighted 
mean number of drugs at follow-up was reduced (-0.2) in the intervention group, but 
increased (+0.2) in control group. Whether these results were statistically significant could 
not be determined as most studies did not report standard deviations.    
There are some key strengths and limitations to this review.  Importantly, this review only 
considered ‘clinically relevant endpoints’ (mortality and hospitalisation) as opposed to 
previous reviews of prescribing interventions which focused on surrogate parameters such 
as medication appropriateness assessed by the application of implicit or explicit criteria.  It 
also evaluated change in numbers of drugs taken which is important given the association 
between the number of medicines and ADEs seen in observational studies.  The authors 
attempted to account for the clinical and methodological heterogeneity of included studies 
by only pooling those for which there was sufficient homogeneity to do so and applying 
random effects to the meta-analysis regardless of the degree of statistical heterogeneity.  
The follow-up in included studies was short (range six weeks to 18 months) for the 
outcome of mortality, and so questions remain regarding the long-term impact of 
deprescribing on mortality.  A key challenge in conducting this review was the absence of 
clear and comprehensive descriptions of study methods and the authors stated that future 
intervention studies should take greater care in reporting these.   The authors concluded 
that the evidence of effectiveness of interventions to reduce polypharmacy is very limited.  
They cautioned that, given the quality of existing evidence was categorised as low to very 
low, any estimates of effect should be deemed highly uncertain, owing to imprecise results 
due to small numbers of outcome events and wide confidence intervals.  The authors 
identified an ongoing need to develop effective complex interventions for testing in large-
scale RCTs.   
The difficulty in generalising the results of this review to a GP-led intervention in primary 
care is that, in all but one study set in a nursing home, the clinician conducting the 
medication review was not the physician primarily responsible for the patient’s care. (98)   
Furthermore, only a minority of interventions appeared to actively involve patients in the 
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review process (e.g. through education) or, if they did, study authors failed to report this.  
Therefore, the impact on mortality and hospitalisations of a medication review, conducted 
by a GP upskilled in deprescribing, who has an ongoing therapeutic relationship with their 
patient, requires further investigation.   
A second systematic review and meta-analysis published in 2016 examined the feasibility 
and effect of deprescribing in older adults on mortality and health. (31) Unlike the 
previously described review, the authors included experimental and observational 
deprescribing studies targeting one or more prescription medications or classes of 
medications in older people.  One hundred and thirty-two studies, including 34,143 
participants aged 73.8 ± 5.4 years, across all health settings, met the inclusion criteria.  
The majority of studies investigated the withdrawal of a single medication, class of 
medications (e.g. beta blockers) or therapeutic category (e.g. antihypertensive agents). All 
but four studies were conducted in nations throughout Europe and in the UK, USA, 
Canada, Australia and New Zealand.    Interventions were categorised as patient-specific 
(i.e. where one or more target medications were flagged for deprescribing through 
processes such as medication review or clinical decision support) or educational (where 
educational sessions were delivered to clinicians to modify prescribing behaviour).  
Studies with palliative, terminal or moribund patients were excluded.  The primary outcome 
measure was mortality, but a range of secondary outcomes measures were also 
investigated.   
Twenty-one studies included in the review investigated deprescribing polypharmacy.  Of 
the interventions investigated, 18 were ‘patient-specific’ and three were ‘educational’ 
interventions.  Eleven of the 18 patient-specific interventions (e.g. involving medication 
reconciliation or review) were physician-led, (99-109) with the rest led by pharmacists or 
nurses.   In none of these 11 studies was the intervention delivered by the patient’s usual 
treating GP or physician, either because the physician was the investigator and/or 
because the study occurred in the hospital setting.  The three educational interventions did 
target the patient’s usual care team (including the doctor in two studies) but all three 
occurred in a residential aged care setting.   
Of the twenty-one studies which looked at deprescribing polypharmacy, ten randomised 
trials (four each in primary and residential care, two in hospital) reported on mortality but 
pooling these study findings found no statistically significant effect on mortality (OR 0.82, 
95% CI 0.61 to 1.11; participants = 3,151; studies = 10; follow-up duration; weighted mean 
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(SD) of 9.6 ± 3.9 months).  However, when a sub-group analysis was conducted assessing 
mortality according to type of intervention, patient-specific interventions significantly 
reduced mortality (OR 0.62, 95% CI 0.43–0.88; participants = 1906; studies = 8), whereas 
generalised educational programmes did not (OR 1.21, 95% CI 0.86–1.69; participants = 
1245; studies = 2).   The authors concluded that patient-specific, individualised 
deprescribing approaches are needed in older adults.   
In the same review, deprescribing was also not associated with a statistically significant 
change in adverse drug withdrawal events, incidence of ADEs, or changes in cognitive 
function or quality of life using standardised measures.  Deprescribing to reduce 
polypharmacy did not significantly reduce the risk of experiencing single falls (OR 0.65, 
95% CI 0.40 to 1.05; participants = 2,173; studies = 5), although, those who did fall had 
significantly fewer falls overall in the intervention compared to control group (Mean 
Difference [MD] -0.11, 95% CI -0.21 to -0.02; participants = 844; studies = 3).  
A key limitation of this systematic review was the methodological heterogeneity of studies, 
compounded by very broad inclusion criteria.  The follow-up durations (which were usually 
short), health care setting, age and health status of participants were highly variable, and 
most studies demonstrated uncertain or high risk of bias. A further limitation of this review 
was the high number of sub-analyses which were not specified a priori, (110) increasing 
the potential for spurious  statistically significant associations.   
Considering these two reviews, it appears deprescribing interventions to minimise 
potentially inappropriate polypharmacy have little to no impact on clinically meaningful 
endpoints, except for patient-specific interventions in older patients.   However, the studies 
included in these reviews have been implemented primarily by investigators or hospital 
clinicians where tacit knowledge of the patient or an ongoing therapeutic relationship 
between prescriber and patient are lacking.    In the next section, studies investigating GP-
led interventions to deprescribe multiple medicines will be considered.   
 GP-led deprescribing interventions in community living older people 
The foregoing discussion raises an important question: could primary care physicians, who 
have tacit knowledge of, and an ongoing therapeutic relationship with their patients, realise 
better medication-related outcomes if they were to be upskilled in the practice of 
deprescribing?  This question is yet to be examined in the Australian healthcare context.  
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Most studies targeting GPs caring for community living older people have investigated the 
effects of complex educational interventions to deprescribe single or a relatively few 
medicines from therapeutic categories.  In the Australian context, for example, Bolton et al 
(111) investigated a quality assurance activity involving GPs undertaking medication 
review to reduce inappropriate polypharmacy in their community living older patients.  
Sixty-two GPs from four geographic locations participated, each with up to 12 patients 
aged ≥65 years with polypharmacy.  The intervention consisted of: two training workshops 
for GPs (one focussed on cardiovascular medicines and the other on psychotropic 
medicines); the GP conducting a medication review with the patient which involved taking 
a comprehensive medication history, identification and discussion of any medicine-related 
problems, and development of an action plan; and the GP conducting a follow-up 
medication review with the patient at six months.  Of the 694 patients enrolled in the study, 
640 had one or more medication reviews completed.  At baseline, the median age of 
participants was 74 years (IQR 61-98) and median number of medications taken was nine 
(IQR 7-11).  The authors found that for the 484 patients who had two medication reviews, 
the intervention was associated with a statistically significant reduction in the total number 
of medications (p < 0.00005 using the Wilcoxon sign-rank test).  They also observed a 
reduction in the dose (p = 0.028) and frequency (p = 0.0077) of benzodiazepine 
prescriptions, and an increase in the number of selective serotonin reuptake inhibitors 
(SSRI) antidepressants used (p = 0.0075).  These results suggest that medication review 
by GPs of patients with complex care needs can reduce the median number of 
medications that patients take.  This study was limited by the lack of a control group, 
failure to describe how GPs were recruited to the study and consequently how they 
selected patients (such that selection bias was probable), and possible reporting bias by 
GPs who self-reported changes to medicines.  Patient dropout was also an issue with only 
484 (82.9%) of 584 patients completing both the first and second medication review.   The 
clinical significance of this intervention remains unknown but it suggests that interactive 
training workshops targeting single therapeutic classes are effective in reducing medicine 
use.  It remains unknown if an interactive workshop targeting multiple medicines would be 
effective in reducing the overall number of medicines and what the clinical consequences 
may be.   
Pit et al also investigated the effectiveness of an educational QUM program, delivered at 
the level of general practice, to reduce a range of PIMs (but also promote the use of a 
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small number of other medicines such as thiazide diuretics as first line choice for 
hypertension) in Australia. (112)  The primary outcome was a composite score reflecting 
use of just three of the medicines which had been targeted - non-steroidal anti-
inflammatory drugs (NSAIDs), low dose thiazide diuretics and long-term benzodiazepine 
use - in community living Australians aged 65 years and over.  Twenty GPs and 849 
patients participated in the cluster Randomised Controlled Trial (RCT).  The intervention 
comprised three main elements: education of the GP (i.e. academic detailing provided by a 
pharmacist skilled in medication review for nursing-home patients, provision of prescribing 
information and feedback), medication risk assessment completed by the patient, and GPs 
conducting a medication review and completing a checklist with their patients.  In the 
control group, patients completed the medication risk assessment and GPs received no 
intervention except for participating in a clinical audit to encourage involvement in the 
study, which included feedback on medication risk factors and reviews conducted.  The 
follow-up period was 12 months.  Compared with the control group, at four months follow-
up, participants in the intervention group had reduced odds of using NSAIDs (OR 0.62, 
95% CI 0.39 to 0.99) and showed a non-significant reduction in use of benzodiazepines 
(OR 0.51, 95% CI 0.20 to 1.30) and thiazide diuretics (OR 0.70, 95% CI 0.48 to 1.01). 
Changes in medicines use were not significant at 12-month follow-up. At 12 months, 
intervention-group participants had lower AORs for having a fall (AOR 0.61, 95% CI 0.41 
to 0.91), fall-related injury (AOR 0.56, 95% CI 0.32 to 0.96), and fall-related injury requiring 
medical attention (AOR 0.46, 95% CI 0.30–0.70). However, study authors conceded these 
results were not wholly explained by changes in medicines, and that broader effects of the 
intervention (e.g. assessment and management of postural hypotension) may have been 
at least partly responsible, or the effects may reflect a false positive (type 1) error.  Quality-
of-life scores using standardised instruments were unaffected by the intervention.  While 
the study design was, in many respects robust, a key limitation was the recording of the 
usage of three target drugs as a crude measure of appropriateness for which recording or 
evaluation of the indications for prescribing were not performed.  Still, the study results   
suggested this type of intervention was feasible, that it did not adversely affect quality of 
life, and that the process of medication review facilitated by the patient’s usual GP may 
have conferred other benefits beyond those intended.   
Two recently published cluster RCTs conducted overseas investigated the effect of a 
multifaceted educational intervention delivered to GPs.  The studies used population level 
24 
 
prescribing data to identify a range of PIP criteria to be targeted for improvement by the 
GPs and measured effects accordingly.  (113, 114)  The first study, conducted in Norway, 
investigated the effect of educational outreach visits, and audit and feedback  on PIMs in 
older people,  using GPs as academic detailers within existing continuing medical 
education (CME) small groups.(113)  Control participants received another educational 
intervention targeting antibiotic prescribing practice for respiratory tract infections.  
Potentially inappropriate prescriptions according to lists of explicit criteria were measured 
as the number of new PIPs (from a list of 13 different medications) for each of the one-
year observation periods.  A total of 449 GPs (96.6%) completed the study; 250 in the 
intervention group and 199 in the control group. After adjusting for baseline PIP 
differences and clustering effects at the peer CME group level, and employing a 
difference-in-differences analytic method, a reduction of 10.3% (95% CI 5.9 to 15.0) 
potential inappropriate prescriptions per 100 prescriptions per patient 70 years and older 
was obtained in the intervention compared to control group between baseline and study 
end.   
A second cluster RCT, OPTI-SCRIPT, conducted in Ireland, investigated the effect of a 
complex, multifaceted intervention to reduce prescribing of the top five nationally reported 
PIMs (maximum dose proton pump inhibitors for >8 weeks, long-term NSAIDs and 
benzodiazepines, therapeutic duplication and tricyclic antidepressants with an opiate or 
calcium channel blocker).  The intervention targeted GPs and incorporated one 30-minute 
academic detailing session with a pharmacist, review of medicines by GPs supported by 
web-based pharmaceutical treatment algorithms, and tailored patient information leaflets.  
Control practices received basic, patient-level prescribing feedback.  Two primary 
outcomes were used: 1) the proportion of patients with PIMs, a composite measure 
capturing any number of the predefined PIMs in the study to address multiple PIMs in 
individual patients; and 2) the mean number of PIMs per group.  Twenty-one practices and 
190 patients were followed.  Outcome data were collected approximately four to six 
months after baseline data collection.  Compared to control, patients in the intervention 
group had significantly lower odds of having PIMs (AOR 0.32, 95% CI 0.15 to 0.70, p = 
0.02). The mean number of PIMs per group in the intervention group was 0.70, compared 
with 1.18 in the control group (p = 0.02) but this effect was principally achieved through 
reduced prescribing of proton pump inhibitors at maximal dose (AOR 0.30, 95% CI 0.14-
0.68, p = 0.04).   
25 
 
These two studies show that complex educational interventions delivered to GPs, targeting 
explicit lists of PIMs, and informed by national population prescribing data, reduce 
prescribing of PIMs in the short-term but the clinical relevance and impact on long-term 
outcomes remain unknown.  The use of explicit lists may provide an entry point to 
deprescribe one or more PIMs, but achieving reductions in a larger number of medications 
requires identification of all medicines which are actually or potentially inappropriate at a 
patient level by means of a more nuanced, individualised decision-making process.   
One recent study of an intervention to support review and minimisation of potentially 
inappropriate polypharmacy based on implicit criteria was the mixed methods pilot study 
published by Muth et al. (115)  The complex intervention targeted GPs in prioritising 
medications in community dwelling people ≥65 years of age with ≥3 chronic conditions and 
≥5 chronic prescriptions across 20 general practices in Germany over 12 weeks.  The 
intervention comprised medication reconciliation and training in using, during patient 
consultations, a computerised decision support package that provided prompts for 
identifying and minimising potentially inappropriate polypharmacy (but also undertreatment 
of conditions such as pain).  The primary outcome was a change in the MAI at the patient 
level, which was not shown to be statistically significant at study end.  One of the key 
reasons for the lack of an apparent change in MAI was that the baseline scores were very 
low (indicating a high pre-existing level of medication appropriateness), leaving very little 
scope for a further decrease in MAI scoring.  (115)  Other exploratory outcomes included 
quality of life, functional status and adherence-related measures for which no statistically 
significant differences between groups were seen.  Although the intervention was shown to 
be feasible and without harm in the short-term, it did not lead to any overall improvement 
in medication appropriateness or improvement in function or quality or life, although the 
short timeframe was a limiting factor.   
In summary, while use of explicit appropriateness criteria may improve QUM, interventions 
that support GPs in taking an individualised approach to deprescribing in older people with 
polypharmacy using more wholistic decision guides or frameworks may realise greater 
effects.  This is discussed in more detail below.     
 Structured guides to assist deprescribing  
As a secondary publication to this thesis, a narrative review of structured guides for 
deprescribing was recently published. (86)  The full publication is available at 
http://ejhp.bmj.com/content/24/1/51).  Structured guides are those that take the clinician 
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through sequential steps in deciding which medications used by an individual should be 
targeted for discontinuation after due consideration of relevant contextual factors. They 
take account of the interactive complexity of polypharmacy and prompt a more systematic 
appraisal of all medications being used.  (86)  As low self-efficacy in deprescribing  has 
been identified as a key barrier for GPs, (9) structured guides depicting  a logical 
sequence of decision steps which are easy to assimilate and apply to patient care may 
support GP-led deprescribing.  (86) 
Two guides focus on deprescribing in older patients – ‘The Good Palliative-Geriatric 
Practice’ (GPGP) guide and ‘Confirm, Estimate, Assess, Sort, Eliminate’ or ‘CEASE’ guide 
- and both have been subject to a process of development and refinement over time 
involving prescribers from different subspecialties and pharmacists.  (86) The GPGP starts 
by querying if an evidence base exists suggesting benefit of a medicine in its current dose, 
given a patient’s age and level of disability, and whether such benefits outweigh all known 
adverse effects.  If the answer is no, then the drug should be discontinued.  Furthermore, if 
adverse effects are apparent from a medicine that otherwise is indicated because of strong 
potential for benefit in disease-related outcomes, then it should be changed to an alternate 
medicine or continued at a reduced dose.  (103)  The GPGP was first designed for 
application to disabled patients in the nursing home setting (103) and later applied to a 
group of non-palliative community dwelling adults.  (102)   
The CEASE framework is a five-step guide and a condensed form of an earlier ten-step 
protocol developed by the same research team (20, 116).   It provides a more granular 
decision framework for clinicians than the GPGP and is outlined in Appendix 2.  CEASE 
was originally designed for application in the hospital setting, but has assumed different 
forms according to the needs of different health settings. (91) Neither the GPGP or CEASE 
guides have had their evidence of effectiveness tested in randomised controlled trials. (91)  
Studies evaluating the use and effects of the GPGP and CEASE are considered below.    
2.3.4.1 Good Palliative-Geriatric Practice (GPGP) Guide 
The GPGP was first applied to 119 disabled patients in six geriatric nursing departments 
and compared with 71 control patients within the same wards and who were cared for by 
the same treating physicians.  Intervention and control patients were of comparable age, 
gender and comorbidities and it is noteworthy that 94% and 93%, of the intervention and 
control group, respectively, had moderate to severe dementia.  (103)  After 12 months 
follow-up, 332 different medications were discontinued among intervention patients (mean 
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2.8 medicines per patient), compared with no change among controls. Medicine 
discontinuation was not associated with significant adverse effects.  The overall rate of 
medicine discontinuation failure (i.e. onset of withdrawal syndromes prompting re-initiation 
or up-titration in dose) was 18% of all patients and 10% of all medicines. The 12-month 
unadjusted mortality rate was 45% in the control group versus 21% in the intervention 
group (p<0.001), while the annual referral rate to acute care facilities was 30% compared 
to 12% (p<0.002).  Key limitations of this study include failure by the study authors to 
disclose the process of patient recruitment and sampling (leaving this author to assume 
that a convenience sample was used, introducing the potential for significant selection 
bias) and the absence of intra- or inter-rater reliability in the guide’s application.  The 
generalisability of these study findings to older patients without dementia is also 
questionable.   
The algorithm was next evaluated in a prospective cohort feasibility study in a consecutive 
sample of non-palliative, community based older adults.  (102)  Participants were referred 
to a hospital geriatric clinic by their family physician or family members for comprehensive 
geriatric assessments. Geriatricians applied the GPGP to 70 eligible multimorbid 
community based adults.  Discussions were held with patients and carers and then the 
geriatrician wrote letters to each individual’s family physician requesting them to stop as 
many ‘non-life saving drugs’ as possible for at least 3 months. Patients were of mean (SD) 
age 82.8 years (6.9) and used a mean (SD) of 7.7 (3.7) medications.  The application of 
the algorithm by the geriatrician recommended discontinuation of 4.4 (2.5) medications per 
patient, corresponding to discontinuation of 311 medications in 64 patients.  Mean follow-
up was 19 months and successful discontinuation was achieved in 81% of cases.  No 
significant adverse effects or deaths were attributable to discontinuation and 88% of 
patients reported global improvements in health, although the authors did not divulge how 
this was evaluated.   Important limitations of this study included: failure to detail participant 
recruitment and sampling, introducing the risk of selection bias, although the study authors 
stated a consecutive sample of patients was used; the lack of a control group; and failure 
to evaluate intra- and inter-rater reliability.  An interesting feature of the study design 
however, was that researchers optimised the chance of GPs and the patient/family 
members accepting the geriatrician’s recommendations to deprescribe medicines because 
the request was solicited in response to the GP or patient’s family identifying a 
deterioration in the  patient’s clinical trajectory.  (102)   
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2.3.4.2 CEASE Guide  
The first study examining the utility of CEASE aimed to determine the effects of the guide 
on clinician prescribing intentions.  (117)  Sixty-one clinicians (19 consultant physicians, 17 
medical registrars, seven interns/residents and 17 clinical pharmacists) were presented 
with clinical information about a hypothetical 81-year-old female patient with 12 chronic 
diseases, receiving 19 different medications. On a standardised, anonymous form, each 
participant indicated, as a pre-test, which medications they felt strongly inclined to 
discontinue or continue. The guide was then presented and participants were asked to 
review the case again, repeating the medicine selection process. Among the entire cohort, 
the mean (standard deviation [SD]) number of medications selected for discontinuation 
increased from 6.0 (2.7) pre-test to 9.6 (3.2) post-test (p<0.001).  The greatest increases 
seen were among consultant physicians (6.6 [2.3] to 11.5 [2.9], p<0.001) and clinical 
pharmacists (5.3 [2.6] to 8.9 [2.2], p<0.001). (117)  Although limited by the application of 
the guide to a hypothetical case by a convenience sample of hospital clinicians at a single 
point in time, this study suggests CEASE could facilitate deprescribing of PIMs by reducing 
clinician uncertainty.    
The efficacy of CEASE has also been evaluated in a prospective cohort study of 50 
hospitalised patients.  Patients were of median age 83 years, had six comorbidities and 
were in receipt of eight or more regular medications.  Participating clinicians comprised six 
consultants, six medical registrars, eleven interns and three clinical pharmacists. 
Application of the guide led to the discontinuation of 186 of 542 regular medications 
(34.3%), representing a clinically significant reduction in the median (interquartile range 
[IQR]) number of medications per patient at discharge (7 [5–9]) compared to that at 
presentation (10 [9–12] p<0.001). (118) The classes of medicines most frequently ceased 
were statins, gastric acid suppressive agents, ACE inhibitors/angiotensin receptor 
antagonists and inhaled bronchodilators.  Thirty-nine of the 50 patients had follow-up 
status ascertained at a median of 78 days, and only 5 of 413 (1.2%) ceased medications 
were recommenced among three patients due to symptom relapse. There were no 
instances of hospital readmissions or ADEs arising from deprescribing.  This pilot study 
was limited by the use of a small convenience sample of patients from one tertiary centre 
(limiting the generalisability of results to more robust older patients in different care 
settings), the lack of a control group, and failure to determine intra- and inter-rater 
reliability.  However, results do indicate that CEASE provided a feasible and effective 
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method of medication review for application by a range of clinicians in the hospital setting.  
Further testing is required to evaluate its feasibility of use by clinicians and impact in other 
care settings.   
Overall, the evidence pertaining to the application of deprescribing frameworks in older 
people is very limited.  More research is needed determining the effectiveness and ease of 
use of these guides, as part of a broader intervention, in routine clinical practice, especially 
in primary care.  These guides are worthy of further investigation as they may provide a 
mechanism by which clinicians can negotiate the uncertainty of undertaking proactive 
review of all medications in older patients with a view to identifying and minimising 
potentially inappropriate polypharmacy.      
 Challenges of deprescribing  
The current behaviour of clinicians to overprescribe or continue PIMs in some older people 
with polypharmacy is better understood when both the drivers for PIMs (as previously 
detailed in section 2.2.2, ‘Drivers of polypharmacy’) and the difficulties associated with 
deprescribing are considered.  Regarding the latter, the act of stopping a medication 
prescribed over preceding months to years is complicated by many factors at both the 
patient and clinician level, and which need to be examined if effective deprescribing 
strategies are to be developed.   These factors operating within the patient-clinician dyad 
are compounded by organisational and health system factors that add further challenges 
to deprescribing.  For example, GPs, in reviewing medications of their patients with 
multiple conditions, have to deal with the recommendations of multiple specialists across 
different care settings.  For this reason, it has been proposed that an interdisciplinary 
effort, focussed on the wholistic health needs of the patient, is required when managing 
older patients with multimorbidity and polypharmacy. (119)   
Patient goals and expectations regarding deprescribing is an unstudied area of research.  
A review by Reeve et al however, identified several patient barriers to, and enablers of, 
deprescribing. (8)  A belief that the medication is appropriate, fear of, or difficulties in, 
stopping medications, and previous negative experience with medicine discontinuation 
were some of the main barriers to deprescribing.  Conversely, actual or feared adverse 
effects of continuing medications, benefits of stopping, a dislike of medications, 
reassurance that a medication could be restarted if needed, and the support and influence 
of their primary care clinicians were identified as facilitative factors for patients in 
deprescribing.     
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A similar review of prescribers’ barriers and enablers to deprescribing was undertaken as 
part of this PhD project (see Chapter 4).  The key findings of this review demonstrated that 
the reasons prescribers continue or do not stop PIMs are multifactorial and highly 
interdependent.  Barriers and enablers to minimising PIMs emerged within four analytic 
themes: awareness of examples of PIMs and the problem of potentially inappropriate 
polypharmacy; clinical inertia secondary to PIM cessation being viewed as a lower value 
proposition compared with their continuation; self-efficacy regarding ability to alter 
prescribing; and feasibility of altering prescribing in routine care environments given 
external constraints. (9) There is a dearth of qualitative literature assessing the views of 
other clinicians, such as nurses and clinical pharmacists, towards deprescribing in older 
people in the primary care setting.   
Comparison of these two reviews suggests that prescribers’ barriers are concordant with 
those of patients with respect to resistance to change, poor acceptance of non-drug 
alternatives, and fear of negative consequences of discontinuation.  However, GPs in 
particular appear to underestimate their capacity to influence patients to stop medications.  
In the presence of a PIM, GPs could explore and leverage enabling factors from the 
patient’s perspective, such as negative experience/s with, fears and dislike of, medications 
and the assurance that a ceased/reduced dose medication could be recommenced or 
increased if necessary. (8) 
It is well established that knowledge of pharmacology is not the only factor impacting 
prescribing decisions. (120)  Rather, these decisions result from interacting clinical, social 
and cultural factors impacting on both patient and prescriber. (120-122)  Facilitating 
effective and sustainable behaviour change must target the determinants of a prescribing 
behaviour. (123)  The National Institute of Clinical Excellence (NICE) advocates for the  
identification of clinician barriers to change as a  critical step in developing interventions to 
effect change in primary care. (40)  This is not to suggest that patient barriers to change 
are any less important, but simply that clinicians, and certainly GPs, offer an entry point for 
patients to be brought into a discussion on the pros and cons of deprescribing.   
 Changing practice in primary care  
Nearly all changes in primary care involve complex interventions, i.e. those with multiple 
components that interact. (124)  Components may occur at one or more levels, for 
example:  at an individual professional level, e.g. to influence a clinician’s diagnostic or 
treatment decisions; at an organisational level, e.g. (re)allocation of duties to other 
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members of the multi-disciplinary team; or at a system level, through altered funding 
arrangements or changes to policy or legislation. (125)  To date, the overwhelming 
majority of interventions have examined strategies to effect change at the individual 
professional level. (126) 
Chauhan et al published a systematic review of reviews in 2017 evaluating the evidence 
on behaviour change interventions and policies directed at primary care clinicians. (127)  
One hundred and thirty-eight reviews (including systematic reviews, overviews of reviews, 
scoping and rapid reviews, and health technology reports) representing 3502 individual 
studies in developed countries were included. (127)  The authors summarised findings 
based on the authors’ conclusions, qualitative data, quantitative data with statistically 
significant group differences in terms of patients’ and providers’ outcomes, and 
methodological quality.  All behaviour change interventions and policies identified from the 
data were classified according to the behaviour change wheel framework proposed by 
Michie et al. (128)  This framework describes the interplay between behaviour, intervention 
and policy and describes nine intervention types: education (to increase knowledge or 
skills), persuasion, incentivisation, coercion, training (imparting skills), restriction, 
environmental restructuring (e.g. changing the physical or social context), modelling 
(providing an example for people to emulate) and enablement (increasing means/reducing 
barriers to increase capability or opportunity to change,  beyond education and training 
and environmental restructuring). (128)   
Most systematic reviews (91%) investigated behaviour and practice changes among family 
physicians (i.e. GPs) managing patients with chronic disease.  Twenty-eight reviews 
evaluated educational interventions, which included continuing medical education 
programs, academic detailing (visits by trained health professionals in the doctor’s place of 
work) and small group learning workshops.  Some educational interventions were 
evaluated as components of multifaceted education interventions, and thus combined with 
reminder systems and audit and feedback, whereas others were not.  Sixteen reviews 
evaluated the use of information technology (IT) including interactive analysis systems, 
clinical decision support systems and the use of electronic health records and 
prescriptions.  Considering evidence from moderate to high quality reviews, interactive and 
multifaceted education programs, training with audit and feedback, and computerised 
clinical decision support systems were shown to be beneficial in improving clinician 
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knowledge, optimising prescriptions, enhancing patient outcomes, and reducing adverse 
events. (127) 
Although the evidence was limited, changing the physical or social context (including the 
use of collaborative or shared-care practices or the institution of specialist nurses or 
pharmacists to primary care practices) and the use of behaviour modelling (i.e. local 
opinion leaders providing an example for others to emulate) appeared promising in 
improving professional collaboration and adherence to guidelines, respectively.  
Interventions shown to be ineffective included financial incentives to family physicians (to 
facilitate long-term behaviour change) and passive guideline dissemination. (127) 
This was a large and comprehensive overview of reviews, meaning that the findings are 
highly generalisable to physicians in primary care in developed countries.  A clear 
limitation was the inability to quantify the magnitude of effects due to the heterogeneity of 
included reviews, primary care contexts, and diversity of the outcomes being examined in 
each review.  Another limitation, perhaps because it was a review of reviews, was failure 
to indicate the time over which the interventions were implemented, the duration of any 
beneficial effects, time to decay and the frequency or need for follow-up interventions to 
ensure the sustainability of effects.  Despite these limitations, this reviews' findings were 
consistent with earlier systematic reviews which have found that active and multifaceted 
educational interventions targeting different barriers to change are more likely to be 
effective than single, passive interventions in changing prescriber behaviour. (129, 130)  
Specifically, the literature suggests the following elements should be considered in 
designing an effective and workable complex intervention to change primary care 
physician behaviour: 
 Systems change, for example, using computerised decision support and 
electronic health records to support change in practice; 
 Education and training around the focus of change; 
 Role modelling using key opinion leaders and/or senior clinicians to 
champion the trialling and adoption of new and better ways of doing things; 
and 
 Audit and feedback, that is, having a process for monitoring and reflexive 
learning through the provision of data pertaining to the physicians’ 
performance  
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 The potential facilitative role of consultant pharmacists in Australia 
The findings of the review by Chauhan et al (127) that collaborative models of care, 
involving the placement of specialist pharmacists within primary care practices to facilitate 
practice change, warrants further investigation.  In Australia, pharmacists are key health 
professionals in promoting QUM.  This raises the question, that, depending upon factors 
that GPs identified as barriers to deprescribing, what role, if any, could pharmacists play in 
supporting a multifaceted, GP-led deprescribing intervention in primary care?  Speculation 
on this issue in the Australian health care context was based on two factors: (1) the current 
policy context promoting greater collaboration between pharmacists and GPs in primary 
care; and (2) evidence that pharmacist-led interventions may improve prescribing 
appropriateness in community living older adults.   
  
The call for greater collaboration between pharmacists and GPs in primary care in 
Australia has stemmed from the demonstrated enhanced role and impact of pharmacists, 
particularly when integrated into the general practice team.  (37) For example, integrating 
a pharmacist into general practice has been associated with an increase in the timeliness 
and completion rate of medication reviews and greater acceptance and implementation of 
pharmacist recommendations by GPs.  (131, 132)  A systematic review also found that 
pharmacists co-located in general practice clinics led to improvements in chronic disease 
management and quality use of medicines, primarily through medication review services. 
(38)  Furthermore, a recently published systematic review found that medication reviews 
undertaken by pharmacists in physician practices, where there was access to 
comprehensive medical notes and feedback to physicians, may improve prescribing 
appropriateness in community living older adults. (133)    
In Australia, medication review services are funded through the Sixth Pharmacy Guild 
Government agreement.  (36)  Pharmacists accredited to undertake comprehensive 
medication review are referred to as consultant pharmacists (CPs).  Most consultant 
pharmacists work external to GPs’ practices, but an increasing number are being 
integrated within general practice teams.  (134)  It was therefore proposed that 
involvement of a consultant pharmacist could be one worthy element of any multifaceted 
GP-led deprescribing intervention. 
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 Summary 
Given the significant burden associated with potentially inappropriate polypharmacy in 
many community living older people, including ADEs, decreased physical and cognitive 
functioning, and increased risk of falls, geriatric syndromes, hospital admissions and 
death, there is an urgent and growing need to minimise this harm.  The evidence of 
efficacy of deprescribing interventions to date, however, is limited.   
Deprescribing of single medications/therapeutic categories appears feasible and safe in 
the short-term.  Single studies have shown modest short-term effectiveness for selected 
outcomes which vary depending upon the therapeutic category being targeted.   Meta-
analysis of deprescribing interventions to minimise potentially inappropriate polypharmacy 
across multiple health settings have shown little to no impact on clinically meaningful 
outcomes to date.   Deprescribing interventions appear to have no effect on mortality, 
although a beneficial effect is apparent if interventions are patient-specific and decisions 
are fully informed by the clinical context.    Studies evaluating deprescribing interventions 
to reduce potentially inappropriate polypharmacy do not indicate that deprescribing 
reduces hospitalisations, medication burden, ADEs, or occurrence of first falls or lead to 
improvements in quality of life.  However, in participants who did fall, deprescribing 
appears to reduce the number of subsequent falls.  These findings are limited by high 
study heterogeneity, low-numbers of events, low-quality and relatively short follow-up for 
the outcomes being measured.   Furthermore, almost without exception, the studies 
included in these reviews were led by an investigator or clinician, who, unlike a GP, did not 
have an ongoing therapeutic relationship with, and tacit knowledge of, the patient.  
Leveraging an existing therapeutic relationship may lead to greater patient involvement in 
the decision-making process which, in turn, may guide and support deprescribing.   
Single studies that have examined the impact of GP-led interventions in community living 
older people with up to 12 months follow-up, have demonstrated improvements in 
prescribing quality and medication burden.  These studies have involved multifaceted 
educational interventions for GPs, a central component of which has been the provision of 
an explicit list of PIMs which should be avoided.  Whilst feasible and effective, the longer-
term impact of these interventions on clinically meaningful outcomes remains unknown.  A 
key difficulty of the use of such explicit lists is that, in the Australian context, medicines 
commonly identified as being potentially inappropriate, account for relatively few ADEs. 
Therefore, feasible strategies are required which support the identification of medicines 
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which are inappropriate at an individual patient level after considering the clinical context. 
Deprescribing decision guides or frameworks could form part of such a strategy but more 
research is needed in determining the effectiveness and ease of use of these guides in 
routine clinical practice, especially in the primary care setting.     
Changing practice in the primary care setting is challenging.  Multifaceted educational 
interventions targeting GPs, and which account for the context in which change is to occur, 
have been shown to be effective.  Furthermore, quality improvement interventions in which 
front-line clinical staff have been engaged to identify local barriers and enablers to change 
and then use this knowledge to inform intervention design, have been shown to be more 
likely to be implemented and therefore effective.   
General practitioners, with long-term therapeutic relationships with patients, offer an entry 
point to facilitate deprescribing with patients.  Given the policy context to see greater GP 
and pharmacist collaboration in primary care in Australia, it was speculated that CPs could 
be supportive to GPs in this process, and help overcome factors that GPs identified as 
potential barriers to deprescribing in routine care.   
The overarching aim of this study therefore was to develop and pilot a multifaceted GP-led 
intervention to minimise potentially inappropriate polypharmacy in community living older 
people, addressing GP and CP barriers and enablers to deprescribing in routine care. The 
three specific aims of the study were to: 
 Investigate prescribers’ perspectives on factors which shape their behaviour 
towards continuing or discontinuing PIMs in adults (Phase 1); 
 Explore the views of a sample of GPs and CPs about potentially 
inappropriate polypharmacy and the reasoning they apply to deprescribing in 
older people in primary care, including factors that influence this process 
(Phase 2); and  
 To evaluate the feasibility, effectiveness and safety of a multifaceted GP-led 
intervention in community living older people in primary care, developed from 
Phases 1 and 2 (Phase 3).   
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Chapter 3  Research Approach  
In Chapter 2, the need for research into a GP-led deprescribing intervention to minimise 
potentially inappropriate polypharmacy in community living older Australians was 
established.  The principles of behaviour change to be considered in the design of a 
complex intervention in primary care were also outlined.  In this chapter, the research 
approach, informed by the United Kingdom (UK) Medical Research Council (MRC) guide 
to complex interventions is described.  The research paradigm utilised in this investigation 
and an overview of the three-phased, mixed methods research design is then presented.  
Detailed methods corresponding to each of the three phases will be described in later 
chapters.  The methods for Phases 1 and 2, which are qualitative in nature, are presented 
in Chapters 4 and 5, alongside findings for each of those phases.  Detailed methods for 
the Phase 3 exploratory study are presented in Chapter 6, as a standalone methods 
chapter.   
 Research approach  
Changing the behaviour of health professionals to improve patient care is often difficult, 
especially in primary care, due to the complex relationships between health professionals 
and patients, and the organisational, social, cultural and geographical systems in which 
both parties operate.  (40, 135, 136)  Consequently, nearly all changes in healthcare, 
including primary care, involve complex interventions, i.e. those with multiple components 
that interact.  (124)  Supporting GPs to facilitate deprescribing with their community living 
older patients is no exception.  Factors influencing the prescription and use of PIMs and 
barriers to deprescribing are broad and multi-dimensional. (8, 9)   As outlined in Chapter 2, 
evidence to date suggests that multifaceted educational interventions, which address 
locally identified barriers to change, in a given care context, increase the likelihood of 
implementation and effectiveness. (40, 127)   Moreover, evidence to date suggests the 
design of complex interventions in primary care should consider principles of behaviour 
change such as systems change (e.g. using information technology and computerised 
decision support), education and training, role modelling and audit and feedback.  (127)    
The UK MRC offers guidance on, rather than a prescriptive approach to, the design and 
evaluation of trials of complex health interventions. (124).  Complex interventions are 
defined as those comprising a number of separate elements which seem essential for the 
intervention’s effectiveness, although the ‘active ingredient’ and contribution of each 
ingredient, both relative and collective to the outcome, can be difficult to determine.  (124)  
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Within scope of this thesis   
The MRC guidance describes key elements associated with the design and evaluation of 
complex interventions, three of which were considered within scope of this thesis, as 
outlined in Figure 3-1, which has been adapted from Craig et al, 2013. (137)  The MRC 
has also advocated the use of qualitative research methods in addition to quantitative 
methods, to better understand how and why something happens, either in the initial 
development or evaluation of an intervention, or both.  (138, 139) 
 
 
FIGURE 3-1 KEY ELEMENTS OF THE DEVELOPMENT AND EVALUATION OF A COMPLEX 
INTERVENTION 
In the development phase, the MRC guidance is that a sound theoretical understanding of 
the research problem and how an intervention may cause change is crucial, so that any 
knowledge and/or practice gap can be addressed in the design of an intervention.  (137)  
The framework also highlights the importance of feasibility or pilot testing an intervention 
and conducting a thorough evaluation including both process and outcome measures 
before widescale roll-out and implementation.  The rationale for this is that the evaluation 
of complex interventions is often undermined by issues pertaining to implementation (i.e. 
recruitment, intervention delivery, acceptability, compliance).  Therefore, undertaking a 
process evaluation may assist in determining if any lack of effect is due to genuine 
ineffectiveness of the intervention, rather than implementation challenges or failure.  (137)   
 
Informed by the MRC guidance, a three-phased, mixed methods design was used to 
address the overarching study aim to develop and pilot a multifaceted GP-led intervention 
Feasiblity/piloting
(Phase 3)
Evaluation
(Phase 3)
Wide scale 
implementation
Development
(Phases 1 & 2)
38 
 
to minimise potentially inappropriate polypharmacy in community living older people, 
addressing GPs’ and CPs’ barriers and enablers to deprescribing in routine care.  The 
three phases, specific aims and how they mapped to the UK MRC guidance,(137) are 
detailed in Figure 3-2 below.  In conceptualising the scope of this study, this work is 
developmental, and will help inform a future, longer-term, large-scale cluster RCT for 
further evaluation and potential widescale roll-out into primary care.     
 
FIGURE 3-2 THREE PHASES OF THE RESEARCH STUDY ALIGNED WITH KEY PHASES FROM THE 
UK MRC FRAMEWORK  
Ch = Chapter.  
In conducting mixed methods research, Creswell and Plano Clark describe four 
foundational worldviews which can be used: post-positivism; constructivism; 
transformation; and pragmatism. (140)  Given the ultimate intention for these research 
findings to be applied (i.e. to facilitate deprescribing by frontline clinicians to minimise 
potentially inappropriate polypharmacy in older people), a pragmatic paradigm was utilised 
for this project.  Pragmatism is a common paradigm used in applied health services 
research for the very reason that it is oriented towards real world practice. (41, 42)   
Pragmatism also offers a ‘paradigm of choices’ (141), prioritising the usefulness and 
Phase 1 - DEVELOPMENT (Identify existing evidence) 
Qualitative systematic review and thematic synthesis (refer to Ch 4) 
Aim - To investigate prescribers’ perspectives on factors which shape their 
behaviour towards continuing or discontinuing PIMs in adults.
Phase 2 - DEVELOPMENT (Identify/develop new theory)
Focus group discussions with GPs & CPs (refer to Ch 5)
Aim - To explore the views of a sample of general practitioners (GPs) and 
consultant pharmacists (CPs) about potentially  inappropriate 
polypharmacy and the reasoning they apply to deprescribing in primary 
care, including factors that influence this process
Phase 3 - FEASIBILITY (& PRELIMINARY) EVALUATION
Exploratory mixed methods study (refer to Ch 6, 7 & 8)
Aim - To evaluate the feasibility, effectiveness and safety of a 
multifaceted GP-led intervention in community living older people in 
primary care, developed from Phases 1 and 2. 
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efficiency of methodological approaches over philosophical purism which may otherwise 
constrain methodological choice.  (42) 
 Research design  
An exploratory mixed methods design was used to address the specific research aims.  
(140)   The first two sequential developmental qualitative phases were used to provide a 
greater understanding of the context for change and aid in the development of key 
elements of the multifaceted deprescribing intervention to be piloted in the exploratory 
study in the third phase.  In this third phase, qualitative data relating to the feasibility and 
experience of all parties participating in the intervention was used to elaborate and explain 
key quantitative results on its effectiveness.  (140) 
Phase 1 was the systematic review and thematic synthesis of qualitative studies that 
explored prescribers’ perceived barriers and enablers to minimising potentially 
inappropriate medications (PIMs) that are chronically prescribed in adults.  This 
developmental phase was required to maximise the likelihood that the design of the 
intervention would be concordant with, and able to address, real-world needs and 
concerns of practising clinicians in undertaking deprescribing.  A broad systematic review 
of the literature, not restricted to type of prescriber or age of adult patient, was conducted.  
It was specified a priori, that, depending upon the studies yielded, sub-analyses by 
prescriber type, care setting and/or patient age could be subsequently undertaken to 
ensure the generalisability of findings to GPs caring for community living older people in 
primary care.   
Phase 2 was developmental and explored the views of a sample of GPs and CPs about 
potentially inappropriate polypharmacy and the reasoning they apply to deprescribing in 
older people in primary care, including factors that influence this reasoning process.  A 
qualitative descriptive design was employed incorporating the focus group method. (142)  
Qualitative description is an appropriate choice in health services research based on 
mixed methods where a key purpose is to ascertain professional’s views on a particular 
topic. (142)  The Framework method was used to discern major and minor themes from 
the data.    (143) The purpose of conducting the focus group discussions in the context of 
the overall study design was two-fold: 1) to further develop a theoretical understanding of 
the anticipated process of change (or barriers to it) in the local context; and 2) inform the 
elements of the deprescribing intervention most likely to support local GPs and CPs in 
undertaking deprescribing with their patients.   
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Phase 3 was the exploratory mixed methods study, to assess the feasibility, effectiveness 
and safety of the intervention to facilitate GP-led deprescribing in community living older 
people in primary care.  A non-randomised, controlled pre-post mixed methods design was 
used. Both quantitative and qualitative data were collected and analysed to assess the 
feasibility and impact of the intervention.  The study involved a convenience sample of five 
general practices and twenty GPs in Metropolitan South-East Queensland across two 
study arms. The intervention was targeted at the level of the clinician, with quantitative and 
qualitative measures gathered at the clinician and patient level.  Quantitative data were 
collected from the usual care and intervention group before and after exposure to the 
intervention regarding the intervention’s effectiveness.  Qualitative data were collected at 
follow-up by semi-structured interviews involving GPs and patients who participated in the 
intervention.  Data were collected to explain quantitative findings, (140) and examine 
aspects of the feasibility and implementation of the intervention, including adoption of each 
of its elements, acceptability, and the likelihood of sustainability in routine care.  (144)  An 
overview of the study design and timing of data collection is shown in Figure 3-3, but 
detailed information pertaining to study methods is presented in full Chapter 6.   
 
FIGURE 3-3 PHASE 3 EXPLORATORY STUDY DESIGN OVERVIEW  
(F-2-F = face-to-face; appt = appointment).   
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 Methodological and ethical considerations  
The key ethical issues for this study pertained to recruitment, informed consent, privacy 
and confidentiality.  With regards to recruitment of general practice sites, GPs, CPs and 
patients, at no point was an individual’s or organisation’s details provided to the research 
team without prior permission from the party, unless that information was publicly available 
without restriction.  The recruitment of patients to the study by the research team, rather 
than their GP, minimised the potential for power asymmetries in the doctor-patient 
relationship to affect patients’ decisions to participate.   
Informed consent was acquired from all participants by the research team members before 
partaking in the study.  At all stages of the study, it was made clear that participation was 
entirely voluntary and that withdrawal from the study would bear no negative 
consequences for the individual in any way.   
All personal details of participants and information provided to the researcher were kept 
confidential and stored on a secured server. Data were stored in a de-identified manner 
with a master list of each participant’s name and unique identifier kept in a password 
protected document separate to the participant’s data coded by unique identifier.   All 
information was reported in de-identified format. 
For Phase 2 focus group discussions, there were no foreseeable added risks above the 
risks of everyday living as clinicians provided personal perspectives and opinions and 
chose the amount and extent of information revealed.  For the exploratory study in Phase 
3, there were two additional ethical considerations.  Firstly, although the potential for 
patient harm was assessed as minimal because at all times, the patient’s usual GP would 
remain responsible for patient care, a protocol to alert the research team of any adverse 
events (actual or potential) arising from intervention was implemented.  The adverse event 
form for completion and forwarding to the research team can be found in Appendix 3.   
Secondly, through a small grant from Greater Metro South Primary Health Network, 
practices were able to access $1000 for generating a list of eligible patients who 
consented to be contacted by the research team.  This figure was offered to recognise the 
time and resources that GPs, practice managers and administrative staff would spend in 
generating this list.  The GPs and CPs were also eligible to receive $500 each in 
recognition of potential lost earnings as a result of attending the five-hour deprescribing 
training workshop. No additional remuneration was offered to clinicians for patient contact 
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time, i.e. any remuneration occurred through existing Medicare items for GPs and 
Community Pharmacy Agreement arrangements for CPs, should they be required to 
conduct a Home Medicines Review.   
Ethical approval from the University of Queensland’s Ethical Review Committee was 
obtained for Phase 2 and Phase 3 of the study, with Approval numbers 2014001296 and 
2015000044, respectively.  These approvals can be seen in Appendix 1.   
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Chapter 4  Phase 1 Systematic review and thematic synthesis 
This chapter details the methods, findings and discussion of the Phase 1 systematic 
review and thematic synthesis, the aim of which was to synthesise qualitative studies that 
explored prescribers’ perceived barriers and enablers to minimising potentially 
inappropriate medications (PIMs) chronically prescribed in adults.  As advocated by the 
National Institute of Clinical Excellence, identifying clinician’s barriers and levers to change 
are critical to the development of effective interventions to facilitate behaviour change, (40) 
and so this work was undertaken as a key developmental step under the UK MRC 
guidance.  (124)  
A broad systematic review of the literature, not restricting to type of prescriber or age of 
adult patient, was conducted for this first phase.  It was specified a priori, that, depending 
upon the studies yielded, sub-analyses by prescriber type, care setting and/or patient age 
could be subsequently undertaken to ensure the generalisability of findings to GPs caring 
for community living older people in primary care.   
The contents of this chapter have already been published as a standalone article in BMJ 
Open in December 2014, a full version of which is available online at 
http://bmjopen.bmj.com/content/4/12/e006544 . (9)   Since publication in 2014, another 11 
eligible studies have been published.  The characteristics and key findings of these studies 
have been reported and synthesised in the context of the review’s findings at the end of 
this chapter, in section 4.4 ‘Relevant studies published since 2014’.   
 Method  
In the absence of a universally accepted method to conduct a systematic review of 
qualitative data, the principles of quantitative systematic review were applied to qualitative 
research, (145)  with guidance from the Cochrane endorsed ENTREQ (Enhancing 
transparency in reporting the synthesis of qualitative research) position statement. (146)  
 Search strategy and sources 
An initial search was conducted to ensure no systematic review on the same topic already 
existed.  Two experienced health librarians were independently consulted in developing a 
comprehensive search strategy, which was informed by extensive prior scoping.  (147)   
PubMed, Embase, Scopus (limited to Health Sciences), PsycINFO, CINAHL and 
INFORMIT (Health Collection) electronic databases were searched from inception to 
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March 2014.  Filters to identify qualitative research were used and adapted to improve 
search sensitivity.  (148)  These were combined with terms and text words for: medical 
and non-medical prescribers and either inappropriate prescribing or reducing, stopping or 
optimising medications.  Terms/text words were searched in all/any fields or restricted to 
title, abstract or keyword, depending upon the size of the database and sophistication of its 
indexing.  Reference lists and related citations of relevant articles were reviewed for 
additional studies.  The full search strategy is detailed in Appendix 4. 
 Study selection 
After duplicate citations were excluded, titles and abstracts were screened and where 
necessary full text read, to create a list of potentially relevant full text articles.  Articles 
were required to meet provisional, intentionally overly inclusive, eligibility criteria to 
minimise the risk of inappropriate exclusions by the single reviewer.  This list was 
forwarded to three members of the advisory team who independently assessed the articles 
for inclusion.  Discrepant views were resolved by group discussion to create the final list of 
included papers based on refined eligibility criteria.   
 Inclusion and exclusion criteria  
Inclusion criteria comprised: 1) original research articles with a qualitative component (i.e. 
qualitative, mixed or multi method studies all accepted); and 2) focus on eliciting 
prescribers’ perspectives of factors that influence their decision to continue or cease 
chronically prescribed PIMs (as defined by the authors of each study) in adults.   No limits 
were placed on the care or practice setting of the patient or prescriber respectively, or 
whether the article related to single or multiple medications.   
Exclusion criteria comprised: 1) reviews, papers not published in English, and those for 
which the abstract or full text were not available; 2) focus on medication management 
decisions in the final weeks of life; 3) focus entirely on initiation of PIMs; and 4) reporting of 
only quantitative data derived from structured questionnaires.   
 Assessment of the quality of studies 
Reporting of studies was assessed using the Consolidated Criteria for Reporting 
Qualitative Research (COREQ) checklist.  (149)This reporting guideline, endorsed by the 
Cochrane Collaboration, assesses the completeness of reporting and potential for bias in 
studies of interviews or focus groups according to three domains: 1) the characteristics of 
the research team, relationship with participants and reflexivity; 2) the study design and 
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setting; and 3) transparency in data analysis and consistency and clarify in reporting of 
findings. (149)  Any instances of interpretive uncertainty arising from the checklist were 
discussed and resolved with the broader advisory team.   
Studies were not excluded or findings weighted on the basis of the COREQ assessment.  
Rather, the decision was made to include all studies, ascribing to the theory that the value 
of insights contained within individual studies may only become apparent  at the point of 
synthesis rather than during the appraisal process. (150)  
 Data extraction process 
For all included articles, data were extracted about study aims, location, setting, study 
design, participants, recruitment, PIMs examined, and prescribers’ perspectives of factors 
influencing the chronic prescription of PIMs.  Data for thematic analysis were only 
extracted from the results (not discussion) section of papers, with particular notice taken of 
quotations from prescriber participants.  
 Synthesis of results 
The method used to synthesise results was based on the technique of thematic synthesis 
described by Thomas and Harden. (151)  Following multiple readings of the papers to 
achieve immersion, text was manually coded and extracted, from which subthemes were 
developed until no further subthemes could be identified.  This process was verified with 
two members of the advisory team who independently read all papers and then reviewed, 
extracted, coded text and subthemes to confirm comprehensiveness and reliability of the 
findings (152).  Descriptive and draft analytic themes were subsequently developed, 
presented to, and discussed with, the advisory team in developing and finalising the new 
analytic construct.   Study characteristics and results were analysed for associations 
between specific themes and studies.   
 Findings 
 Study selection 
The search yielded 6,011 papers, 21 of which met the selection criteria (see Figure 4-1).  
There were no studies exploring the perspectives of non-medical prescribers.   
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FIGURE 4-1 FLOWCHART OF STUDY SELECTION 
 Study characteristics  
Characteristics of included studies are presented in Table 4-1.  All but one, which collected 
data by survey, used focus groups and semi-structured interviews to collect qualitative 
data. (153)  Four papers explored prescribers’ views in relation to multiple medications (i.e. 
polypharmacy) (154-157) whilst the remaining papers investigated prescribers’ views in 
relation to single PIMs or classes of medications (ten described one or more centrally 
acting agents such as psychotropics, hypnotics, benzodiazepines, minor opiates and 
antidepressants(158-167); two for proton pump inhibitors (168, 169) and five for  
miscellaneous PIMs defined according to pre-specified criteria, a pre-set medication list or 
clinical judgement.  (153, 170-173)  Eighteen studies elicited the views of prescribers 
practising in primary care, (153-165, 168-172) one of prescribers in secondary care,(173) 
and two of prescribers servicing residential aged care facilities (RACFs). (166, 167)  
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TABLE 4-1 STUDIES INVESTIGATING THE PERSPECTIVES OF PRESCRIBERS IN VARIOUS SETTINGS 
Year of 
publication 
Lead 
author 
Country Aim Medication types Participants & 
setting 
Age 
focusa 
Data collection 
method 
Analysis 
1995 Britten  England To identify patients whose 
current medication is the 
result of past treatment 
decisions and is regarded by 
their current GP as no longer 
appropriate, and to describe 
the drugs and the 
circumstances in which they 
continue to be prescribed 
Miscellaneous 
PIMs 
7 GPs, primary 
care 
All 
ages 
Descriptive survey; 
GP selected patients 
prescribed 
inappropriate 
medicines, 
structured data 
extraction from 
notes & GP-
facilitated interview 
of patient 
N/A 
1997 Dybwad Norway To understand factors that 
could result in variations 
between GPs in order to form 
hypotheses and build 
theories about prescribing 
(main focus on factors that 
explain higher rates of 
prescribing) 
Benzodiazepines 
and minor opiates  
38 GPs (18 high 
rate prescribers, 
20 medium-to-
low rate 
prescribers), 
primary care 
All 
ages 
SSIs (combined with 
prescription 
registration 
information) 
Not stated 
1999 Damestoy Canada To explore physicians' 
perceptions and attitudes 
and the decision-making 
process associated with 
prescribing psychotropic 
medications for elderly 
patients 
Psychotropics 
(sedatives, 
hypnotics, 
anxiolytics and 
antidepressants) 
9 physicians 
who conduct 
home visits, 
primary care 
Older 
patients 
(Presumed face-to-
face) SSIs 
Grounded 
theory 
analysis 
2000 Cantrill England & 
Scotland 
To explore factors which may 
contribute to inappropriate 
long-term prescribing in 
United Kingdom general 
practice 
Miscellaneous 
PIMs 
22 GPs, primary 
care 
All 
ages 
Face-to-face & 
telephone interviews 
informed by specific 
examples of PIMs 
identified by 
validated indicators 
Not stated 
2004 Iliffe England To explore beliefs and 
attitudes about continuing or 
stopping benzodiazepine 
Benzodiazepines 72 GPs, primary 
care 
Older 
patients 
Non-standardized 
interview group 
discussions 
Not stated 
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Year of 
publication 
Lead 
author 
Country Aim Medication types Participants & 
setting 
Age 
focusa 
Data collection 
method 
Analysis 
hypnotics amongst older 
patients using such 
medicines, and amongst their 
general practitioners 
2005 Spinewine Belgium To explore the processes 
leading to inappropriate use 
of medicines for elderly 
patients admitted for acute 
care 
Miscellaneous 
PIMs 
3 geriatricians & 
2 house 
officers, hospital 
elderly acute 
care wards 
Older 
patients 
SSIs with health 
professionals 
triangulated with 
observation on 
wards and FGs with 
elderly inpatients  
Not stated 
2005 Raghunath England To understand the 
prescribing behaviour of GPs 
by exploring their knowledge, 
understanding and attitudes 
towards PPIs 
PPIs 49 GPs, primary 
care 
All 
ages 
Focus groups Not stated  
2006 Parr Australia To gain more detailed 
understanding of GP and 
benzodiazepine user 
perceptions relating to 
starting, continuing and 
stopping benzodiazepine use 
Benzodiazepines 28 GPs, primary 
care 
All 
ages 
SSIs  Not stated 
2007 Cook  USA To understand factors 
influencing chronic use of 
benzodiazepines in older 
adults 
Benzodiazepines 33 primary care 
physicians 
Older 
patients 
Face-to-face and 
telephone SSIs 
Narrative 
analysis 
2007 Rogers England To explore the dilemma the 
controversial benzodiazepine 
legacy has created for recent 
practitioners & their view of 
prescribing benzodiazepines 
Benzodiazepines 22 GPs, primary 
care 
All 
ages 
SSIs Not stated 
2010 Anthierens Belgium To describe GPs' views and 
beliefs on polypharmacy in 
order to identify the role of 
the GP in improving 
prescribing behaviour 
Polypharmacy  65 GPs, primary 
care 
Older 
patients 
Face-to-face 
individual SSIs 
(literature informed 
interview guide) 
Content 
analysis 
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Year of 
publication 
Lead 
author 
Country Aim Medication types Participants & 
setting 
Age 
focusa 
Data collection 
method 
Analysis 
2010 Dickinson United 
Kingdom 
To explore the attitudes of 
older patients and their GPs 
to chronic prescribing of 
antidepressant therapy, and 
factors influencing such 
prescribing  
Antidepressants 10 GPs, primary 
care 
Older 
patients 
SSIs Framework 
analysis 
2010 Frich Norway To explore GPs’ and tutors' 
experiences with peer group 
academic detailing, and to 
explore GPs' reasons for 
deviating from recommended 
prescribing practice 
Miscellaneous 
PIMs 
20 GPs (39 
GPs also 
interviewed on 
topics outside 
scope of this 
review) 
Older 
patients 
Focus group 
interviews following 
individual receipt of 
prescription profile 
report  
Thematic 
content 
analysis 
2010 Moen Sweden To explore GPs' perspectives 
of treating older users of 
multiple medicines 
Polypharmacy  31 GPs (4 
private, 27 
county-
employed), 
primary care 
Older 
patients 
Focus groups 
(literature informed 
question guide) 
Conventional 
content 
analysis  
2010 Subelj Slovenia To investigate how high-
prescribing family physicians 
explain their own prescription 
Benzodiazepines 10 family 
physicians (5 
high and 5 low 
prescribers), 
primary care 
All 
ages 
SSIs Not stated 
2011 Fried USA To explore clinicians' 
perspectives of and 
experiences with therapeutic 
decision making for older 
persons with multiple medical 
conditions 
Polypharmacy 36 physicians, 
primary care, 
Vet affairs and 
academia 
Older 
patients 
Focus groups  Content 
analysis 
2011 Iden Norway To explore decision-making 
among doctors and nurses 
on antidepressant treatment 
in nursing homes 
Antidepressants 16 doctors, 8 
each working 
full & part time 
in residential 
aged care 
facilities 
Older 
patients 
Focus groups Systematic 
text 
condensation 
& analysis 
2012 Flick Germany To explore, given the specific 
risks and the limited effect of 
Hypnotics 20 doctors 
servicing  
Older 
patients 
Episodic interviews Thematic 
analysis 
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Year of 
publication 
Lead 
author 
Country Aim Medication types Participants & 
setting 
Age 
focusa 
Data collection 
method 
Analysis 
sleeping medication, why 
doctors prescribe hypnotics 
for the elderly in long-term 
care settings  
residential aged 
care facilities 
2012 Schuling The 
Netherlands 
To explore how experienced 
GPs feel about deprescribing 
medication in older patients 
with multimorbidity and to 
what extent they involve 
patients in these decisions 
Polypharmacy 29 GPs, primary 
care 
Older 
patients 
Focus groups Not stated 
2013 Clyne Ireland To evaluate GP perspectives 
on a pilot intervention (to 
reduce PIP in Irish primary 
care) 
Miscellaneous 
PIMs 
8 GPs in focus 
group & 5 GPs 
for SSIs, 
primary care 
Older 
patients 
Focus group & SSIs  Thematic 
analysis 
2013 Wermeling Germany To describe factors and 
motives associated with the 
inappropriate continuation of 
prescriptions of PPIs in 
primary care 
PPIs 10 GPs (5 who 
frequently 
continue and 5 
who frequently 
discontinue 
PPIs), primary 
care 
All 
ages  
SSIs Framework 
analysis 
GPs = General Practitioners; PIMs = Potentially inappropriate medications; PIP = Potentially inappropriate prescribing; PPIs = Proton Pump Inhibitors; 
SSIs = Semi-structured interviews.   
a Age focus refers to the indicative age group of patients who were the focus of participant discussions, as suggested by the terms used in each article, which did not 
specify exact age ranges. 
51 
 
TABLE 4-2 COMPREHENSIVENESS OF REPORTING ASSESSMENT (COREQ CHECKLIST)  
Reporting Criteria Number 
N=x of 21 
References of studies reporting each 
criterion 
DOMAIN 1:   
Characteristics of research team   
Interviewer/facilitator identified 14 (154-158, 161, 162, 166, 168-173) 
Credentials 12 (153, 154, 157-159, 162-164, 166, 
170, 171, 173) 
Occupation 7 (158, 162-164, 166, 170, 173) 
Gender 16 (154-159, 161-163, 166, 167, 169-
173) 
Experience and training 2 (162, 163) 
Relationship with participants   
Relationship established before study started 5 (158, 160, 165, 168, 169) 
Participant knowledge of the interviewer 3 (158, 160, 165) 
Interviewer characteristics 4 (162, 163, 166, 171) 
DOMAIN 2: 
Study design   
Methodological theory identified 15 (154, 156-159, 161, 162, 164, 166-
169, 171-173) 
Participant selection   
Sampling method (e.g. purposive, convenience) 21 (153-173) 
Method of approach 13 (154, 156, 158, 161, 162, 164-167, 
169-171, 173) 
Sample size 21 (153-173) 
Number/reasons for non-participation 7 (156, 158, 159, 161, 164, 165, 168) 
Setting   
Setting of data collection 11 (153-156, 158, 160, 161, 163, 165, 
169, 170) 
Presence of non-participants 0 - 
Description of sample 17 (153-158, 161-169, 171, 173) 
Data collection    
Interview guide 16 (153-159, 161, 162, 164-167, 170, 
171, 173) 
Repeat interviews 0 - 
Audio/visual recording 19 (154-159, 161-173) 
Field notes 6 (154, 156, 161, 164, 166, 171) 
Duration  12 (154, 155, 157, 159, 161, 165-169, 
172, 173) 
Data saturation 7 (154, 155, 159, 161-163, 168) 
Transcripts returned to participants 1 (168) 
DOMAIN 3  
Data analysis   
Number of data coders 16 (154-158, 160, 161, 163-166, 168-
171, 173) 
Description of coding tree 15 (154-158, 161, 163-169, 171, 173) 
Derivation of themes 18 (154-158, 160-171, 173) 
Software 6 (154, 162, 164, 168, 172, 173) 
Participant checking 2 (161, 173) 
Reporting   
Participant quotations presented 18 (154-158, 161-173) 
Data and findings consistent  20 (153-159, 161-173) 
Clarity of major themes 18 (153-158, 161-171, 173) 
Clarity of minor themes 14 (153-155, 157, 158, 160, 161, 163-
165, 167-169, 173) 
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 COREQ assessment 
The completeness of reporting varied across studies, with an average of 17 (range 8-22) 
of 32 items from the COREQ checklist clearly documented, see Table 4-2.  The single 
descriptive survey reported nine of 24 applicable fields.  (153)  See Appendix 5 for the 
completed COREQ assessment for each study.   
Lowest rates of reporting were observed in Domain 1 meaning that researcher bias (poor 
confirmability) cannot be excluded. (150)  Greater transparency was apparent with 
Domains 2 and 3 allowing comparatively better assessment of the credibility, dependability 
and transferability of study findings.  For example, all studies reported the sample size and 
method and most reported a description of the sample and interview guide.  There was 
consistency between raw data and interpretive findings in all papers except one in which 
the interpretation was so brief that its accuracy was considered doubtful.  (160)  For five 
papers it was unclear whether ethics approval was obtained.  (153, 158, 167, 168, 170) 
 Synthesis of findings  
Thematic synthesis yielded 42 subthemes, 12 unique descriptive themes and four analytic 
themes (see Figure 4-2), with multiple interdependencies and relationships.  Barrier and 
enabler descriptive themes and subthemes tended to mirror each other for each analytic 
theme of awareness, inertia, self-efficacy and feasibility.  The first three themes reflect 
factors intrinsic to the prescriber and his/her decision-making process while the fourth 
deals with extrinsic factors.  Table 4-3 and Table 4-4 provide illustrative quotations from 
either primary study participants or study authors relating to barrier and enabler 
subthemes, respectively.  
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FIGURE 4-2 SCHEMATIC REPRESENTATION OF BARRIERS AND ENABLERS ASSOCIATED WITH EACH ANALYTIC AND DESCRIPTIVE THEME
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TABLE 4-3 ILLUSTRATIVE QUOTATIONS FOR BARRIER THEMES AND SUBTHEMES  
Analytic & 
Descriptive 
themes 
Subtheme and 
References 
Characteristics of studies from 
which subthemes were derived:  
Type of PIMs; Age focusa; 
Setting (number of references). 
Illustrative quotations 
 “Italicised text” = Primary quote (i.e. quote from a study participant from an 
included paper) 
‘Non-italicised text’ = Secondary quote (i.e. quote from study authors’ findings 
from an included paper) 
AWARENESS 
 Poor insight (170, 171, 
173) 
 
 
Misc PIMs (3);  
Older (2) & all ages (1); 
Primary (2) & secondary care 
(1).   
“When I saw the list of patients [to be discussed with the researcher], I was quite 
happy about the prescriptions…but obviously when you look at them in more 
detail there are anomalies there that ought to be either checked on, reviewed or 
even altered.” (170) 
 Discrepant beliefs and 
practice (155, 158, 162, 
165, 168)  
Benzos (2) & minor opiates (1), 
Polypharm (1), PPIs (1);  
Older (1) & all ages (4); 
Primary care (5).   
‘In contrast to stated beliefs about best practice, physicians estimated that 5-10% 
of their older adult patients were using benzodiazepines on a daily basis for at 
least the past 3 months.’ (162)  
INERTIA 
PRESCRIBER 
BELIEFs/ 
ATTITUDE 
Fear of 
unknown/negative 
consequences of 
change (for the 
prescriber, patient and 
staff) (153-155, 158-
160, 162, 164, 166-171, 
173) 
 
 
Antidepressants (2), Benzos (2) 
& minor opiates (1), Hypnotics 
(1), Misc PIMs (4), Polypharm 
(2), PPIs (2), Psychotropics (1);  
Older (9) & all ages (6); 
Primary (12), residential aged 
(2) & secondary (1) care.   
"He gets very worried and excitable if you attempt to change anything… even just 
something minor would cause him virtually a breakdown." (170) 
 
"We can't predict the effect [of deprescribing] for the individual patient." (155) 
 
“It’s scary to stop a medication that’s been going for a long time, because you 
kind of think am I opening a can of worms here, because I don’t know what the 
reasons were for them starting that medication.  To explore all that will take, you 
know, I can’t do all that now, I will have to do that another time.”  (164) 
 
"I suggest to them that ideally we should try to get them off of that, but if they're 
saying, been there, done that, that didn't work for me when I came off of this, I 
don't think it's worth getting into a big knock-down drag-out [fight] with them or 
having them leave my practice over this issue".  (162) 
Drugs work, few side 
effects (158, 159, 162, 
163, 165, 167-169, 171) 
 
Benzos (3) & minor opiates (1), 
Hypnotics (1), Misc PIMs (1), 
PPIs (2), Psychotropics (1);  
Older (4) & all ages (5); 
Primary (8) & residential aged 
(1) care.     
‘In their [the physicians’] view psychotropic medication helps the elderly patient 
remain functional and is the least problematic solution... The physicians stated 
that they often do not see side effects and that patients often do not report 
them...’  (159)  
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Prescribing is kind, 
meets needs (of patient, 
staff, carer) (158, 161-
165, 167, 168) 
 
 
Antidepressants (1), Benzos (4) 
& minor opiates (1), Hypnotics 
(1), PPIs (1); 
Older (3) & all ages (5); 
Primary (7) & residential aged 
(1) care.  
 “There is a paradox concerning older patients.  You do not want to make them 
grow dull, but on the other hand you know their chronic problems, and you know 
that at their age the drugs are not so addictive.  You want them to keep their 
minds clear, but on the other hand I do have a tendency to be permissive to older 
patients.”  (158) 
 
"...It treats our own pain as well as our patients' pain, 'cos we want to help people 
and make people feel better.  So if we give people something and make them 
feel better, then everybody seems to be happier."  (163)  
Stopping is difficult, 
futile has/will fail (155, 
158, 160-162, 166, 167, 
170, 171) 
 
,  
Antidepressants (1), Benzos (3) 
& minor opiates (1), Hypnotics 
(1), Polypharm (1), Misc PIMs 
(2); 
Older (6) & all ages (3); 
Primary (7) & residential aged 
(2) care.   
"Let's pretend it's an octogenarian...if it's gonna make the patient feel better, I 
don't care if the patient's on it for the rest of their life."  (162) 
 
‘Most frequent concern identified was the difficulty anticipated in persuading older 
patients to withdraw after years of using benzodiazepines.’ (160) 
 
“In my experience, patients get hooked on PPIs, it is almost addictive like heroin 
and people appear to experience severe indigestion symptoms on attempting to 
stop them.”  (168) 
Stopping is a lower 
priority issue (162, 164, 
168, 169, 173) 
 
Antidepressants (1), Benzos 
(1), Misc PIMs (1), PPIs (2);  
Older (3) & all ages (2); 
Primary (4) & secondary (1) 
care.   
“... We are always faced with multiple problems and PPIs are just one issue...”   
(168) 
PRESCRIBER 
BEHAVIOUR 
Devolve responsibility 
(153, 158, 159, 164-
167, 173) 
 
 
Antidepressants (2), Benzos (1) 
& minor opiates (1), Hypnotics 
(1), Misc PIMs (2), 
Psychotropics (1); 
Older (5) & all ages (3); 
Primary (5), secondary (1) & 
residential aged (2) care.   
‘They [the physicians] recognized that the inappropriate use of psychotropic 
medication for elderly patients was a public health problem, but they felt that it 
was beyond the scope of the individual physician.’  (159) 
 
“(...) I ask them if it should be a sleeping pill or another of the available options 
and mostly they have a need for sleeping pills.” (167) 
 
"I have been running this practice for twelve years.  I took it over from an older 
colleague.  I took over all his patients.  They were mostly old people.  Prescribing 
policy has been rather liberal, and I have continued this policy." (158) 
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SELF-EFFICACY 
SKILLS/ 
KNOWLEDGE 
Skills/knowledge gaps 
(154-159, 164, 169, 
173) 
 
Antidepressants (1), Benzos & 
minor opiates (1), Misc PIMs 
(1), Polypharm (4), PPIs (1), 
Psychotropics (1);  
Older (7) & all ages (2);  
Primary (8) & secondary (1) 
care.   
“I don’t have enough time for education about the newest information on 
psychiatric disorders, and better communication with specialists would be very 
helpful.” (165) 
 
‘Side effects are not always recognised as such.’ (156) 
 
"When house officers come on our ward, they haven't necessarily been trained in 
geriatrics.  So they arrive here, and then they start with 10mg of morphine every 
four hours.  That's too much." (Hospital based geriatrician) (173) 
 
"You look at the medication list and want to reduce it but then you can't find 
things you can eliminate."  (155) 
INFORMATION/ 
INFLUENCERS 
Lack of evidence (154, 
155, 157) 
 
Polypharm (3); 
Older age (3);  
Primary care (3).   
“To me, the guidelines are kind of a hindrance.  At the moment they do not cater 
for older patients” (155) 
Incomplete clinical 
picture (154-157, 164, 
165, 170, 171, 173) 
 
 
Antidepressants (1), Benzos 
(1), Misc PIMs (3), Polypharm 
(4); 
Older (7) & all ages (2); 
Primary (8) & secondary (1) 
care.   
"The problem is that the medication lists of the doctors involved are not 
exchanged and are consequently inconsistent." (155) 
"One has discovered that they might have completely different expectations than 
what the doctor had from the beginning.  Do they want to survive for five more 
years or?  And so on.  What are their expectations?"   (154) 
 
‘…Medicines, (mainly for chronic conditions) were sometimes not appropriately 
reviewed because there was no written information on indication and follow-up or 
because this was not readily available.’ (173) 
 
"...sometimes the older people decide for themselves to reduce some of their 
medication or to adjust the doses without telling their GP.  Therefore as their GP 
you can have the wrong impression about their medication intake..."   (156) 
Guidelines/specialists 
(154-157, 162, 168, 
170, 173) 
 
 
Benzos (1), Misc PIMs (2),  
Polypharm (4), PPIs (1); 
Older (6) & all ages (2); 
Primary (7) & secondary (1) 
care.   
‘When existing guidelines are debated, GPs felt deceived and insecure... The 
importance of individualising treatment was also expressed and many guidelines 
were perceived as too rigid leading to a standardized 'kit' of medicines per 
indication...’ (154)  
 
“I have difficulty not following the guidelines if I don't have good reasons to do 
so."  (155) 
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"When the hospital consultant recommends a treatment it's difficult… for us not to 
prescribe unless there is a very good reason.  To some extent we feel obliged to 
carry on when they have initiated it."  (170) 
Other Health 
Professionals (Aged 
Care) (166, 167) 
 
Antidepressants (1) & 
Hypnotics (1); 
Older patients (2); 
Aged care (2). 
"(…) in such a situation it amounts to the sleeping pill, because everybody else's 
need is the sleeping pill, and I would have to fight tooth and nail if really I wanted 
to avoid this." (167) 
 
 “They (RACF nurses) called me on the carpet to tell me that withdrawing 
antidepressants was not a clever thing to do because the patient became angrier 
and resisted care. They therefore demanded that I reinstate medication.”  (166) 
FEASIBILITY 
PATIENT Ambivalence/resistance 
to change (153-156, 
159, 161, 162, 164, 167, 
168, 170, 172, 173) 
 
Antidepressants (2), Benzos 
(2), Hypnotics (1), Misc PIMs 
(4), Polypharm (3), PPIs (1), 
Psychotropics (1); 
Older (9) & all ages (4); 
Primary (11), secondary (1) & 
residential aged (1) care.   
"When I said initially we wanted her to come off it, she said, oh no, I've been on 
that for ages, and I don't want to come off it.” (172) 
 
"The discontent rarely lies with the patient themselves." (155) 
 Poor acceptance of 
alternatives (161, 162, 
166-168) 
 
 
Antidepressants (1), Benzos 
(2), Hypnotics (1), PPIs (1); 
Older (3) & all ages (2); 
Primary (3) & residential aged 
(2) care.   
“... these types of people and they tend not to want to help themselves, you know 
they won’t take the hypnotherapy and they won’t go to yoga classes and they 
won’t do anything else.  They just want a quick fix.”  (161) 
 Difficult & intractable 
adverse circumstance 
(158, 159, 161, 163, 
164) 
 
Antidepressants (1), Benzos (2) 
& minor opiates (1), 
Psychotropics (1); 
Older (2) & all ages (3); 
Primary care (5).   
"I think they have horrible lives, a lot of them… I think it's a combination of all 
things, their health, their social circumstances… I think a lot of people are on 
antidepressants because of everything put together.  And you can't… change 
most of the factors that cause it.” (164) 
 Discrepant goals to 
prescriber (154, 157) 
 
Polypharmacy (2); 
Older age (2); 
Primary care (2).   
"I kind of get aggravated that half of the medicines that I think are totally rubbish 
are the ones that the patient really wants to take."  (157)  
RESOURCES  Time and effort (154, 
157, 158, 161, 162, 164-
166, 170, 172, 173) 
 
Antidepressants (2), Benzos (3) 
& minor opiates (1), Misc PIMs 
(3), Polypharm (2); 
Older (7) & all ages (4); 
Primary (9), secondary (1) & 
residential aged (1) care.   
"We have a big problem with long-term hypnotic use.  It would take an awful lot of 
work and it's purely a time and work problem".  (170) 
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 Insufficient 
reimbursement (161, 
162) 
 
Benzos (2); 
Older (1) & all ages (1); 
Primary (2) care.   
‘… a lack time or resources to provide counselling, especially due to the absence 
of remuneration for doing so.’ (161) 
 Limited availability of 
effective alternatives 
(161, 162, 165-167) 
 
Antidepressants (1), Benzos 
(3), Hypnotics (1);  
Older (3) & all ages (2); 
Primary (3) & residential aged 
(2) care.   
 ‘...There is hardly any alternative to medicamentous therapy.’  (167) 
WORK 
PRACTICES 
Prescribe without review 
(158, 159, 166, 167, 
169-171) 
 
 
Antidepressants (1), Benzos & 
minor opiates (1), Hypnotics (1), 
Misc PIMs (2), PPIs (1), 
Psychotropics (1);  
Older (4) & all ages (3); 
Primary (5) & residential aged 
(2) care.   
“(...) then he gets something and he continues this pill, and then the issue is over 
for him, then it’s quiet, and then he has his pill and then he sleeps through, and 
from time to time you may enquire, it if occurs to you while looking at his 
medication.”  (167)“When we work in a large health centre, then we sign 
prescriptions for each other... when a colleague is absent, we issue prescriptions 
for him that day.  Any prescription I issue is my responsibility, but if you are asked 
to prescribe a particular drug [for a colleague] then you sign it in the reception.  I 
don’t check which other drugs that person uses.”   (171) 
MEDICAL 
CULTURE 
Respect prescriber’s 
right to autonomy & 
hierarchy (153, 154, 
158, 161, 169, 170, 173) 
Benzos (1) & minor opiates (1), 
Misc PIMs (3), Polypharm (1), 
PPIs (1); 
Older (2) & all ages (5); 
Primary (6) & secondary (1) 
care. 
‘The GPs rarely contact colleagues, for example, hospital specialists, as there is 
a perceived lack of routines for this as well as an informal understanding not to 
pursue colleagues’ motivations for prescriptions. ‘ (154) 
 
HEALTH 
BELIEFS & 
CULTURE 
Culture to prescribe 
more (156, 166, 171) 
 
 
Antidepressants (1), Misc PIMs 
(1), Polypharm (1); 
Older patients (3),  
Primary (2) & residential aged 
(1) care. 
“The number of medications grows slowly.  There is a complaint, we give new 
medication, it continues without really stopping it after a while… and it is our 
responsibility to try and withdraw it from the patient" (156) 
 Prescribing validates 
illness (158, 164, 167) 
 
 
Antidepressants (1), Benzos & 
minor opiates (1), Hypnotics (1); 
Older (2) & all ages (1); 
Primary (2) & residential aged 
(1) care.   
"They feel that unless they are on a tablet for it then they are not having any 
treatment.  There are a lot of those kinds of people." (164) 
REGULATORY Quality measure driven 
care (157) 
  
 
Polypharm (1); 
Older (1); 
Primary care (1).   
"Another factor that we experience at the VA is these electronic reminders that 
tell you to do things…What I do really depends on who is in front of me…So the 
reminder comes up and it makes no sense.  This guy's LDL is 101.8… Should I 
go from 40 to 80 of simvastatin? And what's the risk and benefit there?" (157) 
Benzos = Benzodiazepines; Misc = Miscellaneous, PIMs = Potentially inappropriate medications; Polypharm = Polypharmacy, PPIs = Proton Pump Inhibitors.a Age range refers to the indicative 
age group of patients who were the focus of participant discussions, as suggested by the terms used in each article, which did not specify exact age ranges. 
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TABLE 4-4  ILLUSTRATIVE QUOTATIONS FOR ENABLER THEMES AND SUBTHEMES 
Analytic & 
Descriptive themes 
Subtheme Characteristics of studies from 
which subthemes were derived 
including:  
Type of PIMs; Age focusa; 
Setting (number of 
references). 
Illustrative quotations 
 “Italicised text” = Primary quote (i.e. quote from a study participant from an 
included paper) 
‘Non-italicised text’ = Secondary quote (i.e. quote from study authors’ 
findings from an included paper) 
AWARENESS 
 Review, observation, 
audit & feedback (170, 
171, 173) 
Misc PIMs (3);  
Older (2) & all ages (1);  
Primary (2) & secondary (1) 
care.   
As above.(170) 
INERTIA 
PRESCRIBER 
BELIEFs/ATTITUDE 
Fear of negative/unknown 
consequences of 
continuation 
(168) 
PPIs (1);  
All ages (1);  
Primary care (1). 
“Miracle all right, but too good of anything can be dangerous.  Would just like 
to reiterate that, let me say they [PPIs] even work too well, what worries me 
is won’t there be long-term missed cancers?”  (168) 
Positive attitude toward 
deprescribing 
(155)  
Polypharm (1);  
Older age (1);  
Primary care (1).   
“You can have a field day with crossing off medication: ‘sure, scrap half of 
it’.” (155) 
Stopping brings benefits 
(160, 161, 172) 
Benzos (2) & Misc PIMs (1);  
Older (2) & all ages (1);  
Primary care (3).   
“O ya, and she was delighted, I stopped some of her other medications 
because she was in front of me and I had a bit of time to do it.” (172) 
PRESCRIBER 
BEHAVIOUR 
Devolve responsibility   
(153, 164, 168) 
Antidepressants (1), Misc 
PIMs (1), PPIs (1);  
Older (1) & all ages (2);  
Primary care (1).   
‘Some [GPs] preferred to wait until the patient went to hospital where they 
would be taken off their drugs without the GP being blamed.  The GP might 
even write and ask a hospital doctor to do this.’  (153) 
 
“Why not be honest and say, the NHS can’t afford to keep giving you these 
drugs unless there’s a very good reason.  The patients understand that, and 
in this day and age they understand perfectly well about cost.”  (168) 
SELF-EFFICACY 
SKILLS/ ATTITUDE Confidence (to stop 
therapy/deviate from 
guidelines) (157, 169) 
  
Polypharm (1), PPIs (1); 
 Older patients (1) & all ages 
(1);  
Primary care (2).   
“It’s not as if the life of the patient is suddenly at risk because I take away a 
pill, yes. [...] in the worst-case heartburn may re-occur or there is upper 
abdominal discomfort, but that will not immediately cause a bleeding ulcer.” 
(169)  
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“I sort of you know tone those goals down.  I am not looking for a 
Hemaglobin A1C of 7 anymore…so I take the pressure off them and I start 
removing those medications especially the ones that cause hypoglycaemia.”  
(157) 
 Work experience, skills & 
training  
(154, 169, 173) 
Misc PIMs (1), Polypharm (1), 
PPIs (1); Older (2) & all ages 
(1); 
Primary (2) & secondary (1) 
care.   
“Yes, maybe problem oriented when you are new.  Maybe now one thinks 
more about consequences, in another way.” (154) 
INFORMATION/ 
DECISION 
SUPPORT 
Data to quantify 
benefits/harms (154-156, 
172) 
 
Misc PIMs (1), Polypharm (3);  
Older (4); 
Primary care (4).   
"…because actually what you could do is to give him (patient) some more 
'hard core' facts like:  'If you refrain from treatment your chance of stroke is 
20%..." (154) 
 Dialogue with patients 
(153, 154, 168, 170) 
 
Misc PIMs (2), Polypharm (1), 
PPIs (1); 
Older (1) & all ages (3); 
Primary care (4).   
‘Discussion during the research interview made some patients more willing 
to consider a change in medication.’  (153) 
 
‘Adequate discussion with patients was widely recognised as one of the keys 
to influencing change, but although practiced by some GPs it was not always 
successful.’ (170) 
 Access to specialists 
(164, 165, 168, 173) 
 
Antidepressants (1), Benzos 
(1), Misc PIMs (1), PPIs (1);  
Older (2) & all ages (2); 
Primary (3) & secondary (1) 
care.   
‘They (low benzodiazepine prescribing family physicians) desired better 
cooperation and clear instructions from psychiatrists.’ (165) 
FEASIBILITY  
PATIENT Receptivity/motivation to 
change (157, 161, 170) 
  
Benzos (1), Misc PIMs (1), 
Polypharm (1); 
Older (1) & all ages (2); 
Primary care (3).   
"He's fairly amenable to tinkering with his pills, so we'll look at that".  (170) 
 Poor prognosis (173) 
  
Misc PIMs (1);  
Older age (1); 
Secondary care (1).   
“Sometimes people have taken 10 medicines while they were in curative 
care, and gradually they move on to palliative care.  Then we must 
reconsider all the prescriptions, drug by drug, saying: OK, what’s the goal?  
To improve your comfort?  Well, this medicine will make you feel more 
comfortable; we can stop this other one.”  (173) 
RESOURCES Adequate reimbursement 
(162) 
 
Benzos (1); 
Older age (1); 
Primary care (1).   
“Reimbursement is very low... I think if it was something that we did get 
reimbursed on I think you would see physicians’ attitudes a lot different.  
You’d be more willing to spend time.”  (162) 
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 Access to support 
services (155, 161, 165, 
170) 
 
Benzos (2), Polypharm (1), 
Misc PIMs (1); Older (1) & all 
ages (3); 
Primary care (4).   
‘Most GPs work closely with a local pharmacist [when undertaking 
medication review to stop medicines]: the task perception of such 
pharmacists was an important factor when a GP was looking for decision 
support in medication review’  (155) 
WORK PRACTICE Stimulus to review (153, 
155, 164, 168, 172, 173) 
 
Antidepressants (1), Misc 
PIMs (3); Polypharm (1), PPIs 
(1); Older (4) & all ages (2); 
Primary (5) & secondary (1) 
care.   
‘A new patient entering the practice list is welcomed as an opportunity to 
review their medication.’  (155) 
REGULATORY Raise prescribing 
threshold (168, 169) 
 
PPIs (2);  
All ages (2);  
Primary care (2) 
“I think we are all sitting here and debating about this mainly because of the 
pressure on us by our pharmaceutical advisors not to prescribe PPIs 
because of cost implications to the NHS; I bet that this will not be an 
important topic in 2 years when Losec goes generic.” (168) 
 Monitoring by authorities 
(158) 
Benzos & minor opiates (1);  
All ages (1);  
Primary care (1).   
‘The continuous monitoring of prescriptions by health authorities also put 
stress on the doctors...’  (158) 
Benzos = Benzodiazepines; Misc = Miscellaneous, PIMs = Potentially inappropriate medications; Polypharm = Polypharmacy, PPIs = Proton Pump 
Inhibitors.  aAge focus refers to the indicative age group of patients who were the focus of participant discussions, as suggested by the terms used in each article, 
which did not specify exact age ranges.
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Fewer enablers were reported than barriers and there was variation in the relative contribution 
of each study to each theme.   
4.2.4.1 Awareness 
The theme of awareness was apparent in the three papers which utilised audit or informal 
third-party (e.g. other health professional) observation and feedback. (170, 171, 173)  Poor 
insight was an observed rather than reported barrier, with interventions to raise prescriber 
awareness an enabler to minimising the prescription of PIMs.  Prescriber beliefs at a 
population level did not necessarily translate to prescribing practices at an individual level.  
For example, agreement among prescribers that benzodiazepines should not be used 
regularly or long-term did not necessarily preclude such prescribing in individual patients. 
(158, 162, 165) 
4.2.4.2 Inertia 
Inertia was defined as failure to act, despite awareness that prescribing is potentially 
inappropriate, because ceasing PIMs was perceived to be a lower value proposition than 
continuing PIMs.    
Fear of unknown/negative consequences of change featured in 15 of 22 papers, and related 
to consequences for: the prescriber (threatened therapeutic relationship, diminished 
credibility, increased initial and ongoing workload, potential for litigation, conflict with other 
prescribers/health professionals); (153-155, 158-160, 162, 164, 167-171, 173) the patient 
(withdrawal syndrome, symptom relapse or increased risk of the condition/event for which 
preventive medication was originally prescribed); (160, 162, 164, 166-171) and other health 
professionals (increased workload and safety concerns of staff in RACFs). (166, 167)  The 
prescriber beliefs that facilitate cessation were the converse, that is, fear of unknown/negative 
consequences of continuation,(168) a positive attitude to stopping medicines (155) and a 
belief this practice can bring benefits. (160, 161, 172) 
The barrier belief that drugs appear to work with few adverse effects was apparent in nine 
papers (158, 159, 162, 163, 165, 167-169, 171) of which two studied ‘high-rate’ and ‘low-rate’ 
benzodiazepine prescribers.  ‘High-rate’ prescribers consistently downplayed risks of harm, 
whereas ‘low/ medium-rate’ prescribers were more conscious of such risks. (158, 165)  The 
futility and potential harm of cessation in patients of advanced age was a subtheme 
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predominantly present in papers considering psychoactive agents. (158, 159, 162, 167, 170, 
171)   
Another barrier was the devolvement to another party of responsibility for the decision to 
continue or cease a medication (e.g. another prescriber, health professional, society, or the 
patient).  One example was continuation of PIMs in patients that prescribers had inherited 
from colleagues where the former failed to question the rationale used by the latter in 
prescribing such drugs. (153, 158, 165, 173)  Another example was the provision of PIMs 
upon the request of RACF nursing staff (166) or patients (158, 164, 167) without critical 
prescriber review.  Finally, inappropriate prescribing of psychotropics, while viewed as a 
public health concern, was considered beyond the scope of individual prescribers. (159) 
4.2.4.3 Self-efficacy 
The analytic theme of self-efficacy refers to factors that influence a prescriber’s belief and 
confidence in his or her ability to address PIM use.  It involves subthemes relating to 
knowledge, skill, attitudes, influences, information and decision support.   
Knowledge or skill deficits, (154-159, 164, 169, 173) including difficulty balancing the benefits 
and harms of therapy, (154-157) recognising adverse drug effects (155, 156) and establishing 
clear cut diagnoses/indications for medicines (158, 159, 164) were challenges prescribers 
faced in identifying and managing PIMs.  Balancing the benefits and harms was perceived to 
be especially difficult when reviewing preventive medications in multimorbid older people with 
polypharmacy where shorter life expectancy, uncertain future benefits and higher 
susceptibility to more immediate adverse drug effects must all be considered. (154-157)  On 
the other hand, better quantification of the benefits and harms of therapy, (154-156, 172) 
confidence to deviate from guidelines and stop  medications if thought necessary, (157, 169) 
greater experience, (154, 169) and targeted training, especially in prescribing for older 
people, (173) were seen as enabling factors.     
Compounding generic knowledge and skill gaps were information deficits specific to individual 
prescribing decisions, resulting from poor communication with multiple prescribers and 
specialists involved in patient care, inadequate transfer of information at care interfaces, 
fragmented and difficult-to-access patient medical records, and failure of patients to 
know/disclose their full medical history/medication lists to prescribers.  (154-157, 164, 165, 
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170, 171, 173)  This subtheme linked strongly with demands on prescribers in regards to time 
and effort, and in two papers was associated with low motivation arising from a perceived 
inability to efficiently access all information required for optimal prescribing. (164, 173)   
Eight papers discussed the influence of care recommendations from guidelines and 
specialists. (154-157, 162, 168, 170, 173) Guidelines were often viewed negatively, with 
prescribers feeling pressured to comply with recommendations at odds with the complexities 
of clinical practice. (154-156, 168, 170)   Pressure from staff to continue prescribing PIMs, 
often to maintain facility routines, was presented as a barrier unique to RACFs. (166, 167)  
Offsetting this were enablers centred on greater dialogue with patients to increase 
understanding and facilitate shared decision making,(153, 154, 168, 170) as well as timely 
access to, and decision support from, specialists, particularly geriatricians and psychiatrists. 
(161, 164, 165, 168, 170, 173) 
4.2.4.4 Feasibility  
Feasibility refers to factors, external to the prescriber, which determine the ease or likelihood 
of change.  They relate to patient characteristics, resource availability, work practices, 
medical and societal health beliefs and culture, and regulations.   
The most frequently expressed barrier concerning patients was their ambivalence or 
resistance to change (153-156, 159, 161, 162, 164, 167, 168, 170, 172, 173) and their poor 
acceptance of alternative therapies. (161, 162, 166-168)  In contrast, receptivity and capacity 
to change was identified as an enabler in three studies, (157, 161, 170) as was a poor 
prognosis which helped crystallise care goals and prompt review of the appropriateness of 
existing drug regimens. (173)   
Limited time and effort to review and discontinue medications (154, 157, 158, 161, 162, 164-
166, 170, 172, 173) was the most common resource constraint followed by limited availability 
of effective non-drug treatment options.  (159, 161, 162, 165-167)  Adequate reimbursement 
(162) and access to support services such as mental health workers and pharmacists for 
medication review (155, 161, 165, 170) emerged as enablers.    
Certain work practices were raised as barriers to deprescribing, such as provision of repeats 
for a prescriber’s own or colleague’s patients, (158, 170, 171) and the absence of explicit 
treatment plans or formal or scheduled medication review. (158, 167)  The mirroring enablers 
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were opportunities to review medication regimens (e.g. hospital admission,(153, 173) change 
of prescriber,(155) or specialist(164) or scheduled review). (168, 172)  
Remaining descriptive themes related to medical and societal health beliefs, cultural and 
regulatory factors.  The most frequently mentioned were discomfort and reluctance to 
question a colleague’s prescribing decisions (153, 154, 158, 161, 169, 170, 173) associated 
with respect for professional autonomy or the medical hierarchy when specialist prescribers 
were involved.   
Externally imposed guideline-based quality measures were presented as a barrier to 
minimising the prescription of PIMs. (157) Raising the prescribing threshold for medications 
(e.g. through increased cost or restricted access) and monitoring by authorities were seen by 
prescribers as unwelcome and potentially perverse enablers. (168, 169)   
 Discussion   
This systematic review comprehensively investigated prescriber barriers and enablers to 
minimising the prevalence of chronically prescribed PIMs in adults. The thematic construct 
developed from published literature centred on awareness, inertia, self-efficacy and feasibility.  
It principally reflects the perspectives of primary care physicians (i.e. GPs) caring for older, 
community living adults.  Although the themes and subthemes have been presented 
separately, the reasons doctors continue to prescribe, or do not cease, PIMs are 
multifactorial, highly interdependent and impacted by considerable clinical complexity.   
Many subthemes were common to papers regardless of inter-study differences in the PIMs 
discussed, patient age and clinical setting (e.g. primary, secondary or residential aged care).  
Subthemes varied according to whether studies focussed on polypharmacy or single PIMs or 
classes of PIMs, which was also associated with differing levels of prescriber insight and 
certainty.  In the four studies focussed on polypharmacy, prescribers were aware of 
polypharmacy-related harm but could not easily identify which medications were potentially or 
actually inappropriate, as reflected by the subthemes ‘difficulty/inability to balance benefits 
and harms of therapy’, (154-157) ‘inability to recognise adverse drug effects, (155, 156) ‘lack 
of evidence’ (154, 155, 157) and ‘incomplete clinical picture’. (154-157)  In other studies 
focussing on  specific classes of over-prescribed medications, prescribers were aware of this 
inappropriateness, but  in response voiced various rationalisations for continued prescribing  
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such as ‘drugs work, few adverse effects’,  (158, 159, 162, 163, 165, 167-169, 171) 
‘prescribing is kind and meets needs’, (158, 161-165, 167, 168) ‘stopping is difficult, futile, has 
or will fail’, (158, 160-162, 166, 167, 171) ‘poor (patient) acceptance of alternatives’, (161, 
162, 166-168)  and ‘difficult and intractable adverse (patient) circumstance’. (158, 159, 161, 
163, 164) 
However, in other studies focussing on miscellaneous PIMs, prescribers were generally not 
aware of their potential or actual inappropriate prescribing until this was revealed to them (e.g. 
through audit and feedback). (170, 171, 173)  
No definite thematic pattern was observed from the subthemes of six studies which did not 
specifically focus on the care of older people (153, 161, 163, 165, 168, 169) compared to the 
remaining 15 which did.  Compared to studies in primary care, unique themes emerged from 
papers set in RACFs and acute care settings.  For example, pressure on prescribers to 
continue prescribing PIMs at the request of RACF nursing staff was unique to this setting. 
(166, 167)  The one study set in acute care highlighted inexperience and training deficiencies 
of junior prescribers, as assessed by three geriatricians. (173)  
The finding that poor insight into potentially inappropriate prescribing practices was only 
apparent in studies where prescribers were made aware of this is unsurprising, given 
prescribers do not intentionally prescribe medications inappropriately.  It demonstrates the 
importance of awareness-raising strategies for prescribers. Inertia, as in failure to deprescribe 
when appropriate, sits at odds with the more traditional use of the word as symbolising failure 
to intensify therapy when indicated. (174)  Inertia has been linked to ‘omission bias’ where 
individuals deem harm resulting from an act of commission to be worse than that resulting 
from an act of omission.(175, 176)  In the case of deprescribing as an act of commission, it 
becomes more a matter of reconciling a level of expected utility (accrual of benefits) with a 
level of acceptable regret (potential to cause some harm). (177) Fear of negative 
consequences resulting from deprescribing contributes to inertia and is not easily allayed by 
the current limited evidence base regarding the safety and efficacy of deprescribing. (178)  In 
the same papers in which prescribers rationalised continuation of therapy with the belief that 
drugs work and have few adverse effects, (158, 159, 162, 163, 165, 167-169, 171)  
prescribers also identified different thresholds for initiating versus continuing the same 
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therapy.  This anomaly suggests either a lack of prescriber insight, clear differences in 
prescribers’ attitudes toward initiation versus continuation, or a social response bias towards 
a false belief induced by the methodology used by interviewers.     
 Relevance to previous literature 
One meta-synthesis of seven papers exploring prescribers’ perspectives of why potentially 
inappropriate prescribing (PIP) occurs in older people has recently been published.(179)  
Compared to the review conducted in this thesis, this more recent study had a generic focus 
on PIP, including under-prescribing and its search strategy retrieved fewer articles (n= 7).   
Scanning the reference list did not reveal any additional papers which would have met the 
selection criteria in the thesis study and therefore would not have yielded any additional 
themes.   
These findings are consistent with the literature (largely focused on initiation of therapy) 
suggesting that pharmacological considerations are not the only factors impacting doctors’ 
prescribing decisions. (120)  Rather, prescribing decisions result from interacting clinical, 
social and cultural factors impacting on both the patient and prescriber. (120-122)   
Reeve et al published a review of patient barriers and enablers to deprescribing (8) and 
emphasised the importance of a patient-centred deprescribing process.(50) When comparing 
their findings with those from the thesis study, prescribers’ barriers are concordant with those 
of patients with respect to resistance to change, poor acceptance of non-drug alternatives, 
and fear of negative consequences of discontinuation.  However, prescribers also 
underestimate enabling factors including patients’ experiences/concerns of adverse effects, 
dislike of multiple medicines, and being assured that a ceased medication can be 
recommenced if necessary.  Patients also reported their GP could be highly influential in 
encouraging them to discontinue therapy, a perception not echoed amongst prescribers. (8)  
Prescribers need to discuss, rather than assume, patient attitudes towards their medicines 
and to deprescribing, in the context of their current care goals.     
Previous reviews of interventions to change prescribing behaviour have found that active and 
multifaceted interventions targeting a range of barriers to change are more likely to be 
effective than single, passive interventions.  (129, 130)  The findings from this systematic 
review appear to support this, but further research is required to identify the barriers and 
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enablers with the greatest potential for impact when designing targeted deprescribing 
interventions for a given care setting.   
 Strengths and limitations  
Inconsistent terminology and poor indexing of search terms relating to deprescribing and 
inappropriate therapy greatly hampered ability to identify relevant studies.  In this case, the 
mitigation efforts comprised a comprehensive pre-scoping exercise, a highly iterative search 
strategy tailored to each database, and snowballing from reference lists and related citations. 
Despite no search restrictions on patient age, clinical setting, or type of PIM, most study 
participants were experienced GPs/primary care physicians caring for older, community living 
adults.  Caution is therefore needed when generalising the findings from the systematic 
review conducted for this thesis to other settings or patient groups.  However, two recent 
cross-sectional studies looking at barriers to discontinuation of benzodiazepines and 
antipsychotics in nursing homes reflected subthemes identified in this review -  fear of 
negative consequences of discontinuation such as poorer quality of life, symptom recurrence, 
greater workload and a lack of available, effective, non-drug alternatives. (180, 181)   
Many of the papers focussed on relatively few drug classes (psychotropics and PPIs) and 
only four focussed on polypharmacy.  Although some subthemes were common to all types of 
studies (single and miscellaneous PIMs and polypharmacy papers), others were not.  It is 
possible that, had more medication classes been studied, some of this review’s findings may 
have been different.   
The strengths of the review included adherence to a peer-reviewed, documented 
methodology for thematic synthesis, COREQ assessment of studies allowing assessment of 
potential for bias, compliance with ENTREQ reporting requirements and a multi-disciplinary 
team of investigators to validate theme identification and synthesis.   
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 Relevant studies published since 2014 
Since the publication of the systematic review in 2014, 11 original research papers meeting 
the eligibility criteria have been published, the study characteristics and key findings of which 
have been summarised in Table 4-5 and Table 4-6, respectively.  To identify these studies, 
the original search strategy (i.e. searching all five databases and snowballing from reference 
lists) and the process for study selection was repeated.  Again, these studies principally 
investigated GPs’ views regarding the management of older adults in the primary care setting, 
although there was a higher proportion of studies eliciting prescribers’ views on 
polypharmacy.  That is, six papers explored prescribers’ views in relation to polypharmacy 
(182-187), and the remaining papers investigated prescribers’ views in relation to classes of 
PIMs [two papers on preventive cardiovascular medications (188, 189), two on a range of 
PIMs (190, 191), and one exclusively on anticholinergic and sedative medications (192)].  All 
but one study (185), based on data collected using the nominal group technique, involved 
focus groups or semi-structured interviews to collect qualitative data.  Six papers elicited 
views of prescribers’ practising exclusively in primary care (183, 186, 188-191), two of 
prescribers’ practising in primary care and the hospital setting (187, 192), and three papers of 
prescribers’ practising in residential aged.(182, 184, 185)     
Analysis and synthesis of key findings from these papers resulted in very minor changes to 
the barriers/enablers published in the systematic review and no change to the overarching 
themes or conceptual framework.  The minor changes reflect the PIMs examined and the 
practice setting.  For example, studies by Ailabouni et al (182) and Palagyi et al (184), which 
elicited residential aged care prescribers’ perspectives, described more barriers pertaining to 
the regulatory and organisational factors of residential aged care, such as policies, work 
practices and/or resources (including staff and IT platform limitations).  Similarly, the papers 
reporting prescribers’ perspectives from the residential aged care and hospital settings, where 
patients tend to be sicker, noted more barriers to patient engagement and agency, such as 
impairments affecting communication or an inability to cope with change.(182, 184, 185, 187)  
There was a greater emphasis on factors pertaining to the fragmentation of care, the need for 
better inter-professional relationships and communication and the desire for more team-based 
approaches to care. (183, 186, 187, 192) This finding is potentially the consequence of the 
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higher proportion of papers in more recent times investigating prescribers’ views on 
polypharmacy (involving multiple prescribers and health care practitioners across settings), 
rather than earlier published papers which tended to focus on individual classes of PIMs.     
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TABLE 4-5 STUDIES REPORTING PRESCRIBERS' BARRIERS AND ENABLERS TO MINIMISING PIM SINCE DECEMBER 2014  
Year of 
publication 
Lead 
author 
Country Aima Medication 
types 
Participants & setting Age 
focusb 
Data 
collection 
method 
Analysis 
2015 Magin Australia To explore the 
prescribing, and the 
rationale for this 
prescribing, of PIMs in 
older persons by 
Australian GPs 
Miscellaneous 
PIMs  
22 GPs, primary care Older 
patients 
SSIs Thematic 
analysis 
2016 Ailabouni New 
Zealand 
To investigate GPs’ 
perceived challenges 
to deprescribing in 
residential care and 
possible enablers 
supporting GPs 
implement 
deprescribing 
Polypharmacy 10 GPs, residential aged 
care 
Older 
patients 
SSIs Thematic 
analysis 
using TDF 
2016 Clyne Ireland To explore 
qualitatively, GP 
perspectives regarding 
prescribing and PIP in 
older primary care 
patients 
Polypharmacy  17 GPs, primary care Older 
patients 
SSIs Thematic 
analysis 
2016 Kouladjian Australia To investigate 
perspectives of health 
care practitioners 
(HCPs) surrounding 
deprescribing 
(withdrawal) of 
anticholinergic and 
sedative medications 
in older adults 
Anticholinergic 
& sedative 
medications 
12 GPs, primary care;  
13 specialist physicians c, 
hospital setting 
(also 12 accredited 
pharmacists, primary 
care) 
Older 
patients 
Focus group 
discussions 
and SSIs 
Thematic 
analysis 
2016 Luymesd Netherlands To identify GP (and 
patients) barriers to 
and enablers of 
deprescribing 
potentially 
inappropriate 
Preventive 
cardiovascular 
medications 
10 GPs, primary care 
(also 49 patients but 
excluded from this 
analysis) 
All 
adults 
Audiotaping 
consultations 
between 
GPs and 
patients 
Content & 
Framework 
analysis 
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Year of 
publication 
Lead 
author 
Country Aima Medication 
types 
Participants & setting Age 
focusb 
Data 
collection 
method 
Analysis 
cardiovascular 
medication 
2016 Nixon Denmark To examine how GPs 
make decisions about 
discontinuing 
medication 
(Note two other aims 
were not directly 
relevant to SR) 
Statins 24 GPs, primary care All 
adults 
SSIs with 
participant 
observations   
Thematic 
analysis 
using Gioia 
method   
2016 Palagyi Australia To explore 
perceptions of 
medication use and 
the concept of 
deprescribing in 
LTCFs 
Polypharmacy 8 GPs, residential aged 
care  
(Also 25 LTCF residents, 
16 relatives, 19 LTCF 
staff members) 
Older 
patients 
Focus group 
discussions 
Thematic 
analysis 
using the 
Integrative 
Model of 
Behaviour 
Prediction 
2016 Turner Australia To rank factors that 
GPs, nurses, 
pharmacists and 
residents perceive as 
most important when 
deciding whether or 
not to deprescribe 
medications 
Polypharmacy  19 GPs, residential aged 
care (also 11 
residents/representatives, 
12 nurses and 14 
pharmacists)  
Older 
patients 
Nominal 
group 
technique 
Nominal 
group 
technique  
2016 Voigt Germany Multiple aims, one of 
which was to 
understand family 
physicians’ reasons 
for prescription of 
PIMs 
Miscellaneous 
PIMs, with a 
focus on 
sedatives/ 
hypnotics 
7 Family Physicians, 
primary care  
Older 
patients 
SSIs  Content 
analysis 
2017 Anderson Australia To explore the views 
of GPs and CPs about 
inappropriate 
polypharmacy and the 
reasoning they apply 
to deprescribing in 
primary care, and to 
Polypharmacy  32 GPs (and 15 CPs), 
primary care 
Older 
patients 
Focus group 
discussions 
Framework 
analysis 
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Year of 
publication 
Lead 
author 
Country Aima Medication 
types 
Participants & setting Age 
focusb 
Data 
collection 
method 
Analysis 
identify factors that 
support or inhibit this 
cognitive process 
2017 McNamara Australia To explore current 
approaches to 
multimorbidity 
management, and 
perceived barriers and 
enablers to deliver 
appropriate 
medications 
management for 
community dwelling 
patients with 
multimorbidity and 
polypharmacy 
Polypharmacy 14 prescribers, from 
primary care and hospital 
setting (8 GPs, 3 general 
internists, 2 geriatricians, 
1 clinical pharmacologist 
(also 12 HCPs) 
Older 
patients 
SSIs Thematic 
analysis 
(deductive) 
CPs = consultant pharmacists; GPs = general practitioners; LTCFs = long-term care facilities; PIMs = potentially inappropriate medications; 
PIP = potentially inappropriate prescribing; PPIs = proton pump inhibitors; SSIs = semi-structured interviews, TDF = Theoretical Domains 
Framework. 
a Only the aim directly relevant to the systematic review has been described, i.e. other aims of the study were not listed here. bAge focus refers to the 
indicative age group of patients who were the focus of participant discussions, as suggested by the terms used in each article, which did not specify exact 
age ranges. c Specialist physicians consisted of 10 geriatricians, an addiction/pain specialist, a neurologist and an endocrinologist. d This study presented 
an integrated perspective of patients and GPs but only those barriers and enablers relevant to GPs were extracted and presented.       
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TABLE 4-6 SUBTHEMES FROM STUDIES REPORTING PRESCRIBERS' BARRIERS AND ENABLERS TO MINIMISING PIMS SINCE DECEMBER 
2014 AND HOW THEY RELATE TO THE CONCEPTUAL FRAMEWORK 
Lead 
author & 
Year of 
publication 
Major themesa  Relevant overarching theme from systematic review according to major themes/subthemes 
pertaining to barriers and enablers to minimising PIMsb,c 
Magin, 
2015 
Knowledge and awareness of 
potential adverse effects of 
PIMs 
Harm benefit decisions 
regarding the use of PIMs 
 
The difficulty of ceasing as 
opposed to initiating PIMs 
Awareness (of potential adverse effects of PIMs)  
 
 
Self-efficacy – information (limitations of guidelines); Inertia – prescriber beliefs/attitude (prescribing is 
kind and meets needs), Self-efficacy (difficulty weighing benefits and harms to inform course of action); 
Feasibility – organisational factors (e.g. RACF context could facilitate supervised benzodiazepine 
withdrawal)  
Self-efficacy – Information (lack of decision support to quantify harms/benefits)  
Inertia – prescriber beliefs/attitude (stopping has/will fail); prescriber behaviour (defer decision making; 
devolve responsibility if medication originally specialist initiated. Feasibility - patient (trust in 
prescriber).  
Ailabouni, 
2016 
Problem recognition Awareness 
 Behaviour change factors  
 
   
Prescribing challenges  
Inertia – beliefs/attitudes (fear, uncertainty, low confidence, trying to do good).  
Self-efficacy – knowledge/skills gaps; information/influencers (lack of evidence; incomplete clinical 
picture, incl. communication at interface of care, role of guidelines/specialists, role of RACF staff).  
Feasibility – patient/family/care staff (discrepant goals, patient inability to communicate); resources 
(time, reimbursement), regulatory/organisational factors (nursing home policies). 
 Enablers Self-efficacy – information/decision support (guidelines, education); confidence (defined as 
empowerment)  
Feasibility – resources (more time achieved through pharmacist medication review; 
reimbursement) 
Clyne, 
2016 
Complexity of prescribing 
environment  
 
 
Paternalistic doctor-patient 
relationship 
Perceived value of PIP 
concept 
Self-efficacy – Influencers (specialists), Information (incomplete clinical picture -framed as 
fragmentation of care, poor communication between hospital/community) 
Feasibility – medical culture (professional autonomy and hierarchy (e.g. specialists – framed as GPs 
feeling pressured to continue medications initiated by other prescribers, especially GPs) 
Feasibility –  medical culture (paternalistic approach); patient (lack of agency and health literacy) 
 
Awareness (and acceptance that PIP exists) 
Inertia – prescriber beliefs/attitude (stopping is futile, has/will fail, prescribing is kind/meets needs – 
framed in context of continuing long-term benzodiazepine use in older people) 
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Self-efficacy – guidelines (limited applicability of PIP guidelines to real-world patients) 
Kouladjian, 
2016 
Barriers: 
It’s not my fault/job 
 
Lack of communication  
Fragmentation of care  
(hospital and community) 
 
External barriers  
 
Clinical uncertainty (re: 
capacity for deprescribing) 
 
Patient and/or carer issues 
Practice-based issues   
 
Enablers: 
Harms from medications 
Collaboration with 
patients/HCPs 
Triggers of deprescribing 
 
Inertia – prescriber behaviour (devolve responsibility) 
Self-efficacy – Information/influencers (Other health care practitioners, specialists) 
(Self-efficacy) - Incomplete clinical picture  
(Self-efficacy) - Information/influences (incomplete clinical picture), Feasibility – medical culture (respect 
prescribers’ right to autonomy and hierarchy) 
 
Feasibility – regulatory 
 
Inertia – prescriber beliefs/attitude 
 
 
Feasibility – patient/carer 
Feasibility – resources (time, effort); Self-efficacy (knowledge) 
 
 
Inertia – Prescriber belief/attitude (negative consequences of continuation of therapy) 
Self-efficacy – decision support; Feasibility – patient (receptivity/motivation to change) 
 
Contextual (spans awareness, feasibility)   
Luymes, 
2016 
Appropriateness  
 
 
 
Fear 
Process  
Influences 
 
Dislike 
Other 
Prescribing is appropriate – not previously coded – result of analysis of data collection. 
Awareness - identification that medication is unnecessary/inappropriate 
Feasibility – patient (barrier - poor acceptance of alternatives, e.g. smoking cessation to lower CV risk) 
Inertia – prescriber belief/attitude (deprescribing is positive) 
Inertia – prescriber belief/attitude (fear) 
Feasibility – resources (limited time), work practices (postpone, stepwise approach, follow-up) 
Feasibility – patient (context/circumstance; poor acceptance of alternatives) 
Self-efficacy – information/influences (specialists) 
Enabler to inertia – prescriber belief/attitude (deprescribing is positive – framed as dislike of 
prescribing medicines) 
Enabler to inertia – prescriber belief/attitude (stopping brings benefits)  
Palagyi, 
2016 
Environmental factors 
 
 
 
Skills & Abilities 
 
Control beliefs & Self-efficacy 
Attitudes  
Feasibility – Organisational factors in LTCF (lack of coordinated care, poor communication with other 
providers/family, lack of uniform documentation, technology issues, nursing shortages and lack of 
skilled personnel), work practices (lack of timely review post-hospital discharge), regulatory factors 
(LTCF policies, RMMR business rules), resources (poor quality RMMRs; time and effort).  
Self-efficacy – Skills/knowledge gaps (low confidence), information/influencers (unwilling to question 
specialists) 
Inertia – fear (negative consequences of deprescribing, medicolegal concerns); Feasibility – perceived 
patient/relative expectations 
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 Inertia – low motivation/apathy due to lack of support; linked to Feasibility – resources (insufficient 
reimbursement), patient/relative expectations (which are often unrealistic).  
Turner, 
2016 
Evidence for deprescribing 
 
Communication with 
resident/family & resident 
willingness to deprescribe  
 
Health system structure – 
adequacy of medical & 
medication history and 
funding for service  
 
Fear of deterioration 
Self-efficacy – Information (evidence for deprescribing)  
 
Feasibility – patient/carer (capacity to communicate; attitude to change) 
 
 
 
Feasibility – resources (adequate reimbursement); (Self-efficacy)- information (incomplete clinical 
picture)  
 
 
 
 
Inertia – prescriber beliefs/attitude (fear negative consequences of deprescribing) 
Voigt, 2016 Not clearly articulated in 
article – content analysis 
 
Inertia – prescriber beliefs/attitudes (no alternatives to medication/s; prescribing is kind and meets 
needs; stopping is difficult, futile, has/will fail – especially in relation to sedatives;  
Feasibility – patient (poor acceptance of alternatives); resources (time; limited availability of effective 
alternatives/access to specialist services)  
Self-efficacy – guidelines (lack of applicability to ‘real-world’); information/influencers (incomplete clinical 
picture – framed as poor communication with other prescribers/specialists) 
Anderson, 
2017 
Working through uncertainty: 
Weighing unmeasurable 
harms & benefits 
Strategies/circumstances that 
mitigate uncertainty 
 
Risk as a frame of reference:  
Deprescribing as a risk to be 
avoided  
Deprescribing as a risk to be 
reconciled  
Risk tipping points  
 
Patient heterogeneity and complexity 
(Self-efficacy)- information (incomplete clinical picture; lack of evidence) 
Feasibility – resources constraints 
Feasibility – patient and/or carer (attitude to change; therapeutic relationship); inter-professional 
relationships and communication 
 
 
Inertia – prescriber beliefs/attitudes – fear unknown/negative consequences of deprescribing 
 
Work practices – proactive strategies to facilitate deprescribing 
 
Feasibility – context (trigger to deprescribe/low hanging fruit); Self-efficacy – confidence and 
experience  
McNamara, 
2017 
Incorporation of shared 
decision making and patient 
preferences  
Evidence base 
 
Feasibility – work practices (failure to elicit patient preferences/patient-centred goals); resources (time, 
especially for GPs); patient (physical impairments limiting communication). 
 
Self-efficacy – Information/evidence (limitation of guidelines); Influencers (junior doctors reliant on 
advice of senior doctors) 
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Patient prognosis (focus on 
uncertainty)  
Clinical feasibility of treatment 
plans 
Optimising therapies and 
health management plans 
(lack of routine engagement) 
 
(Poor) coordination of care 
(very broad theme) 
Self-efficacy – Information (incomplete clinical picture); Inertia – fear of negative consequences of 
deprescribing (also litigation for withholding preventive therapies). 
Feasibility – patient (framed as inability to assess patients’ capacity to cope with changing treatment 
plans) 
 
Inertia – prescriber belief/attitude (stopping is a lower priority issue; fear of negative consequences of 
change); Feasibility – patient (reluctance to change); medical culture (respect other prescriber’s right to 
autonomy & hierarchy); work practices (lack of systematic approach to deprescribing); Self-efficacy – 
skill/knowledge gaps (esp. junior doctors; Information/influencers (limitations of decision support tools). 
Inertia – prescriber behaviour – devolve responsibility to others (due to lack of key care coordinator or 
infeasibility of GP to take on more).   
Feasibility – resources (adequate remuneration; team based approach to care, incl. nomination 
of key care coordinators)   
Self-efficacy – information/decision support (better evidence/guidelines; improved IT platforms  
a Only those themes pertaining to prescribers’ barriers and enablers were extracted and included. b Subthemes underlined indicate findings previously not 
reported in the systematic review.  c Bolded text (excluding headings) refers exclusively to enablers to minimising PIMs.   
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 Conclusion 
   
The thematic synthesis of studies from the original systematic review and those 
subsequently published indicate that prescribers’ barriers and enablers to minimising 
PIMs, chronically prescribed in adults relate to four analytic themes:  problem awareness; 
inertia secondary to lower perceived value proposition for ceasing versus continuing PIMs; 
self-efficacy in regard to personal ability to alter prescribing; and feasibility of altering 
prescribing in routine care environments given external constraints. The first three themes 
are intrinsic to the prescriber (e.g. beliefs, attitudes, knowledge, skills, behaviour) and the 
fourth is extrinsic (e.g. patient, work setting, health system and cultural factors).   
The factors shaping prescribers’ behaviour towards continuing or discontinuing PIMs are 
complex and highly context dependent, i.e. they are contingent on the PIMs examined, 
patient group and care setting.  Therefore, whilst the review’s findings provided a 
mechanism to understand and conceptualise prescribers’ barriers and enablers to 
minimising PIMs in the international context, investigation at a local level was required to 
inform the development of a deprescribing intervention meeting the needs of Australian 
GPs caring for older people living in the community.  The views of CPs would also be 
sought as they too had been identified as potential change agents in the Australian 
context.  The findings of this investigation are reported in the next chapter, as is an 
explanation of how and which findings from Phase 1 and 2 investigations were used to 
inform the elements of the multifaceted deprescribing intervention to be piloted in the 
Phase 3 exploratory study. 
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Chapter 5   Phase 2 Focus group discussions with clinicians  
Chapter 5 details the methods, findings and discussion of the Phase 2 qualitative 
investigation.  The primary aims of this investigation were to explore the views of general 
practitioners (GPs) and consultant pharmacists (CPs) about potentially inappropriate 
polypharmacy, to ascertain the reasoning they apply to deprescribing in primary care, and 
to identify factors that support or inhibit their reasoning.  The purpose of the focus group 
discussions in the context of the overall study design were: 1) to develop a theoretical 
understanding of the anticipated process of change (or barriers to it) in the local context, 
corresponding to the second developmental phase of the UK MRC framework for complex 
interventions (124); and 2) to inform the development of the elements of the deprescribing 
intervention most likely to support local GPs and CPs in undertaking deprescribing with 
their patients.   
The contents of this chapter have already been published as a standalone article in 
Qualitative Health Research January 2017.  The link to the full manuscript, entitled 
‘Negotiating “Unmeasurable harm and benefit”: Perspectives of general practitioners and 
consultant pharmacists on deprescribing in the primary care setting’, is available online at 
http://journals.sagepub.com/doi/full/10.1177/1049732316687732 .  
 Methods  
 Design and setting 
A qualitative descriptive design was employed, (142) incorporating the focus group method 
with a sample of GPs and CPs recruited from South East Queensland (SEQ).  Qualitative 
description is an appropriate choice in health services research based on mixed methods 
where a key purpose is to ascertain professionals’ views on a particular topic. (142)  
The rationale for using focus groups was to use a time efficient method which could also 
provoke detailed and valid responses not otherwise elicited during semi-structured 
interviews. (193) It was anticipated that group dynamics would facilitate exploration of 
areas of consensus and discrepancy. (194) However, in recognition of the potential for 
discomfort and a lack of familiarity between GPs and CPs who had not previously worked 
together, separate focus groups were organised for each profession. (193)   
 Sampling and Recruitment  
A mix of convenience and snowball sampling was used to recruit GPs and CPs within 
metropolitan SEQ. A local Primary Health Network (i.e. a primary health organisation) and 
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founding principal of a longstanding teaching group practice assisted in identifying general 
practices staffed with seven or more GPs in which one GP, typically with a predisposition 
to supporting quality improvement activities, could act as a study sponsor.  The sponsor’s 
role was to provide all GPs within the practice written information and an invitation to 
participate in the research study.  Existing groups of GPs in larger practices were targeted 
to optimise participant familiarity and comfort sharing thoughts, feelings and experiences 
and for recruitment efficiency. (195) GPs had to be working in primary health care with 
experience caring for people 65 years and older with polypharmacy who were still residing 
in the community.  GPs who primarily serviced RACFs were excluded, recognising their 
responses may be influenced by the different care setting.    
Potential CP participants were identified through a nationally available register of CPs and 
contacts of the research team.  The main criterion for recruitment of CPs was experience 
conducting comprehensive medication reviews (CMR) through the HMR program in SEQ 
(by default CPs conducting CMRs will primarily see older people with polypharmacy).  
Individuals were approached in the first instance via email and/or phone contact and 
invited to participate.     
 Participants 
Approximately half of all individuals invited to participate in the study agreed, such that a 
total of 32 GPs from five practices, and 15 CPs, participated in five and two focus groups, 
respectively.  GPs and CPs were comparably aged, with a mean of 47 years for GPs 
(range 28-70, noting one participant declined to provide this response) and 48 years for 
CPs (range 28-63).  Far more CPs than GPs were female (87% vs 44%), reflecting the 
nature of the CP workforce in Australia.  The GPs had twice the experience, averaging 18 
years in the role (range 1-50 years, with the upper limit an estimate) compared to CPs who 
averaged 9 years in the role (range 1-18) but again this was expected as remuneration for 
CMRs has only existed in Australia since 2001.   Sixty-three percent of the GP participants 
worked full-time.  Administrative rules preclude full-time equivalent hours for CPs to 
contain CMR program expenditure.    
 Data collection  
Focus groups were conducted over a two-month period from October 2014 to December 
2014.  Five GP focus groups were conducted in the GPs’ workplace and two CP focus 
groups were conducted at the University of Queensland.  Each focus group was facilitated 
with the support of a researcher who acted as a co-facilitator. The PhD candidate, with the 
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support of the co-facilitator led four of the five GP focus group discussions, excluding the 
fifth practice where she was employed on a part-time basis and where her role was 
assumed by two other researchers experienced in the focus group method.   
A focus group guide incorporating key topics was used to ensure consistency of approach 
across focus groups.  In addition, the same case study of a community living older person 
with multimorbidity and polypharmacy, but without a terminal prognosis, was used to 
stimulate discussion in all focus groups. The case study was developed by the consultant 
general physician in the research team, in consultation with two experienced GPs with 
backgrounds in medical education.  This was done to ensure the case study was 
representative of a typical multimorbid older patient that an average GP would encounter, 
but which showcased several examples of potentially inappropriate prescribing. The case 
was complemented with the question guide for focus group discussions (see Appendix 6) 
and presentation of the CEASE framework (see Appendix 2) to stimulate and focus 
conversation. (91)  
Focus group discussions lasted an average of 75 min (range 55-99min) and were 
transcribed in real-time by a qualified transcriptionist and audio recorded for subsequent 
accuracy checks.  Relevant field notes were made by the co-facilitator to support the 
accuracy of interpretation.   
 Analysis  
Transcripts were inductively coded and analysed thematically using the Framework 
method (143).  The first three transcripts (which were GP transcripts) were read and, line-
by-line, independently segmented and coded text, to develop a coding framework.  This 
process was independently repeated by a research team member.  The coding framework 
was then discussed, reviewed and refined with one advisor experienced in conducting 
qualitative research.  This coding framework was then applied to all transcripts digitally 
using NVivo Pro 11 software (QSR International Pty Ltd, Melbourne, Australia).  The 
coding framework required no significant alteration when applied to all transcripts, 
including CP transcripts, indicating data saturation.  Data were then charted into a framing 
matrix to highlight patterns and linkages in the data, from which major conceptual themes 
were developed with the assistance of the advisory team.  This final step involved 
revisiting the literature to interrogate and make sense of patterns from the dataset by 
reflecting on key concepts relevant to the topic.  Extracts reflect both divergent and 
convergent views and were labelled with a unique identifier according to the specific focus 
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group by profession and the participant number (e.g. GP1, P5 = the first GP group, and 
fifth participant).   
 Findings 
Two major themes were derived from the analysis: 1) Working through uncertainty; and 2) 
Perceived risk as a frame of reference.  Deprescribing was considered by all participants 
as one option to improve medication appropriateness, as was therapeutic substitution, 
dose alteration and initiation.  Table 5-1 provides an overview of the major and minor 
themes and subthemes elicited from the analysis.  In the following presentation of these 
themes, key factors that support or inhibit deprescribing have been highlighted.  Analysis 
yielded themes common to both GPs and CPs.  Consequently, findings have not been 
separated by profession, but rather have been presented collectively, with striking 
differences within and between professional groups highlighted as appropriate.   
TABLE 5-1 OVERVIEW OF MAJOR AND MINOR THEMES AND SUBTHEMES 
Major theme Subtheme Minor subthemes 
Working through 
uncertainty 
Weighing unmeasurable harms and 
benefits 
Patient heterogeneity and complexity 
Incomplete information  
Lack of evidence  
Time and resource constraints (for GPs) 
Strategies/ circumstances that 
mitigate uncertainty 
Low risk strategies  
Patient and/or carer attitude 
Patient relationship (facilitator for GPs; 
barrier for CPs) 
Inter-professional relationships and 
communication 
Major theme Subtheme  Minor subthemes 
Risk as a frame of 
reference 
Deprescribing = risk to be avoided Fear of unknown/harm from 
deprescribing 
Deprescribing = risk to be reconciled Proactive strategies to facilitate 
deprescribing 
Risk tipping points Low hanging fruit 
Clear triggers of potential medicine-
related harm 
Self-efficacy Confidence & experience 
  
 Theme 1 – Working through uncertainty 
Focus group discussions revealed the inherent uncertainties confronting clinicians when 
assessing an older patient with potentially inappropriate polypharmacy, and how they 
resolve this in practice.  This was represented by the following two subthemes.  
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5.2.1.1 Subtheme: Weighing unmeasurable harm against benefit 
From participants’ perspectives, the process of making a decision in a patient with 
potentially inappropriate polypharmacy involved trying to estimate and weigh up the harms 
and benefits of therapeutic options in the face of many unknowns in this diverse and 
complex patient group.  This subtheme was clearly articulated by one participant who 
alluded to strong internal reasoning during this process: 
The problem is that you are trying to weigh up unmeasurable harm quite often 
against unmeasurable benefit.  We are trying to do that in our minds and trying to 
work out - is it more likely to be doing benefit or more likely to harm.  The truth is 
that, in many cases, I don’t know.  (GP5, P5) 
Discussions made clear that nothing could be taken for granted when balancing harms 
against benefits in these heterogeneous patients.  Even for two seemingly comparable 
individuals, clinicians might take legitimate actions for, or against, deprescribing depending 
on subtle differences in patient function, prioritisation of inferred or explicit care goals and 
likely future clinical trajectory, all of which can change over time between and within 
individuals.  This meant relying on any one factor such as age when making decisions 
could result in erroneous decisions:  
It depends on what she is like at 81, too.  If she is really frail, you think her life 
expectancy probably isn’t another 10 years, then I feel more comfortable stopping 
the statin.  If she was a really good 80-year-old, who you thought – which she 
doesn’t really sound like it from her past history – I might be more inclined to 
continue with the statin if she didn’t have so many comorbidities.  (GP3, P1) 
According to participants, a key reason for uncertainty when balancing benefits and harms 
of therapy was inadequate research in older polymedicated people, frequently 
compounded by information gaps relating to the care of individual patients.  The original 
indication for a medicine was often unclear, due to the initiating prescriber failing to 
document or communicate this to other providers, as occurs typically when the patient is 
returned to the GP’s care following hospital admission.  As one participant described: 
Sometimes, as (another participant) was saying, they come back from the hospital 
and they are on PPI (proton pump inhibitor) or whatever and they might have 
thought this is really useful because they’re having some mild gastritis symptoms 
and then I’d normally take it off but when they come back you really don’t know why 
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it was started.  Did they have haematemesis, you know, or was there an ulcer or 
something like that or was the plan for it just to be temporary? (GP1, P5) 
The paucity of scientific evidence not only pertained to the concurrent use of multiple 
medicines but also single, commonly prescribed classes of drugs in this patient group. The 
lack of scientific evidence presented difficulties for professional accountability. One CP 
participant suggested that formulating a professional recommendation when there is 
uncertainty could lead to inaction: 
I find statins very hard sometimes to recommend either reducing or withdrawing 
because there is not a whole lot of hard evidence out there as to end points, 
particularly when you get into this age group. Sometimes it has just been too hard 
to write the report so I have left it out (group laughs) … When my gut feeling is they 
don’t need it anymore, but it's just a bit awkward. Particularly, if the patient really 
doesn’t mind taking it and there are no other adverse effects, it stays. (CP 1, P6) 
This example, as others, demonstrates an internal logic or intuitive knowledge at work 
(e.g. ‘gut feeling’).  This was reinforced by the comment from another participant, a GP, 
about ‘keeping it in your head’ when reconciling divergent opinions among specialists 
about the evidence of benefit versus harm. The need for readily accessible and reliable 
information sources as a form of security to help undertake complex reasoning in a 
pressured environment was emphasised in this excerpt:   
Then you go to a meeting and the two specialists who are there argue completely in 
opposite directions. They interpret the data from this trial differently from the data 
from that trial. Putting that together is quite difficult. Keeping it in your head in a 
complex environment and limited timeframe is, I think, really the big challenge. I 
think, therefore, sometimes you are doing it without the really significant evidence 
based security - or at least I don’t even know.  I use UpToDate in a consult and I 
Google in a consult but there is only so much time you have got to be trawling 
through the evidence base and looking for complexity.  (GP4, P4) 
Participants in the GP focus groups viewed deprescribing as a time and resource intensive 
process, requiring not just an upfront, but ongoing commitment of effort, particularly when 
there are competing clinical priorities, as is often the case for the patient group in question:    
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So you’re really setting them up for another consultation, another couple of 
consultations to do it properly I suppose – you can’t do it at that time, you’ve got 
other priorities at the time. (GP3, P3) 
5.2.1.2 Subtheme: Strategies and circumstances that mitigate uncertainty 
Participants used a range of strategies, or identified circumstances, that mitigated the 
perceived uncertainty surrounding deprescribing decisions.  Strategies included targeting 
medicines which are easier and less harmful to deprescribe in the first instance, adopting a 
gradual approach to changing medicine regimens, and deferring to patients in making a 
deprescribing decision. Medicines for which decisions to discontinue were endowed with 
greater certainty were those perceived to be overused, whose cessation was unlikely to be 
resisted by patients, or where a favourable outcome of withdrawal seemed more 
predictable.  Examples of these ‘easy options’ included statins for primary cardiovascular 
prevention, bisphosphonates, proton pump inhibitors and complementary medicines.  Two 
participants described their inclination to immediately consider these ‘easier’ options as: 
Priority.  Pick all the low hanging fruit first. (GP2, P7) 
Straightaway my first thought was what are the low flying ones that we can get rid 
of. (CP1, P1) 
However, participants acknowledged that this prioritising of the ‘low hanging fruit’ may 
deliver early wins but not necessarily the best benefit as it sidestepped drugs with potential 
to do more harm, such as anticoagulant and psychotropic agents and opioid analgesics.  
Adopting a gradual approach with close patient follow-up was another strategy.  Even for 
medicines that pharmacologically do not require tapering, a gradual approach served to 
reassure not only the patient, but also the clinician.  For some GPs though, the need for 
prolonged follow-up which may not be remunerated, constrained their ability to promptly 
detect and reverse adverse effects after reducing or ceasing medications, and this 
constituted a barrier perceived as too great to contemplate changes. Some considered 
deprescribing in the hospital setting a better option:   
 Put them in hospital and stop everything.  (GP3, P4) 
The inability to maintain any follow-up with patients over time to support a gradual process 
of deprescribing was a major frustration for CPs.  One participant cited administrative rules 
as an impediment to follow-up:  
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I think that the two-year window [for reimbursement] makes it difficult to follow-up, 
especially for the complex patients that need that stepwise approach. (CP2, P5) 
These comments highlighted an important difference between GPs and CPs.  GPs felt 
they lacked the dedicated time to proactively deprescribe in routine practice but suggested 
annual health assessments could provide an opportunity for this.  In contrast, CPs, for 
whom comprehensive medication review is core business, had more time but lacked 
detailed knowledge of their patients.  CPs resolved this uncertainty by adopting a strategy 
of posing questions to GPs about medication appropriateness, rather than making 
recommendations to the GP to cease PIMs.   
Reinforcing a predisposition to low risk strategies, participants perceived the patient’s 
attitude towards deprescribing as a factor in balancing benefit against harm.  Further, as 
one GP participant reported, a patient’s attitudes to change could relieve the clinician of 
any responsibility for deprescribing: 
Even if you don’t know what right and wrong is, you don’t necessarily have to 
provide the answer.  It will be the patient that will provide the answer as to how 
willing they are to stop something… (GP5, P6) 
An underpinning element to working through uncertainty in regard to deprescribing was the 
consideration of relationships. For GP participants, a continuous therapeutic relationship 
with a patient was critical to better assessing harms and benefits and committing to the 
potentially protracted process of deprescribing: 
But that’s the starting point - to establish what the relationship is. I guess that’s my 
point. So, until you know what the relationship is - whether it is an on-going 
relationship or whether it’s an episodic one; then that would lead to where you take 
the consultation and if it’s appropriate. That’s the starting point: who the person’s 
primary GP is. (GP2, P5) 
Under-developed inter-professional relationships (e.g. between GPs and CPs or GPs and 
specialists) was seen as hampering the deprescribing process, largely due to poor 
communication and insight into each other’s decision making.  Good working relationships, 
i.e. between GPs and CPs or in the following case between a GP and specialist, facilitated 
timely, collaborative deprescribing decisions:   
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That strategy of phoning specialists there and then, in front of them - we collaborate 
on this and this is what we are doing. (GP5, P6) 
Unsurprisingly, specialists were deemed highly influential in shaping not only clinicians’ but 
also patients’ willingness to consider deprescribing due to their perceived higher authority.  
I do think one of our biggest barriers is our specialist colleagues because [patient 
comment], “Doctor X said I must never, ever stop that.” (GP5, P2) 
Better evidence that deprescribing is safe and effective and decision support provided in a 
format that is easily accessible at the point of care (e.g. integrated into the practice 
software) for use in discussion with patients, was offered by participants as a key 
facilitative strategy.  However, in regards to decision support, when participants were 
asked about the utility of the CEASE framework (the published decision framework to 
support deprescribing) (91), the clear consensus was that it would not be used at the point 
of care by experienced clinicians who already had internalised its individual steps into their 
prescribing reasoning.   
I think in practice you are not going to use it, myself. I think we have already 
intellectualised it. (GP5, P2) 
I think that is a very intuitive thing, anyway. (CP1, P6) 
The value of the CEASE decision framework, if any, was as a tool for education and 
reflection, especially for junior clinicians.     
I think it would be very good for people starting out in general practice to have that 
so they can approach it logically. (GP5, P4) 
This theme shows that clinicians have to contend with considerable uncertainty when 
faced with the dilemma of problematic polypharmacy in this diverse and complex patient 
group.  Various strategies are used to mitigate uncertainty, and are influenced by many 
contextual factors.  As the next major theme indicates, a decision to intervene is influenced 
strongly by how clinicians conceptualize the risk attached to polypharmacy and 
deprescribing.   
 Theme 2 – Perceived risk as a frame of reference 
As can be inferred from comments in working through uncertainty, perceived risk was 
shaping participants’ views about deprescribing.  However, perceived risk as a frame of 
reference warrants its own discussion as a second major theme since it denotes 
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something much deeper than strategies and processes intended to resolve uncertainty, 
and offers a window into participants’ internal reasoning. There were differences among 
participants in their risk framework but also some consensus in relation to the tipping 
points in risk perception which might facilitate deprescribing.  These findings are discussed 
in the following two subthemes.   
5.2.2.1 Subtheme: Deprescribing as a risk to be avoided or reconciled 
Participants demonstrated varying perspectives on the level of perceived risk surrounding 
deprescribing decisions. However, two contrasting risk frames of reference were 
distinguishable in the comments as discussed below.  
5.2.2.1.1 Risk to be avoided 
Contributing to the risk to be avoided frame was the unpredictability of the outcome 
trajectory of deprescribing, which is unsurprising given the issues discussed in the first 
theme. However, this unpredictability introduced fear of the unknown and fear of harm, 
which was used to justify not taking any action:  
The thing is, it is not often easy to tell if something is having no effect on persistent 
symptoms.  They might be a whole lot worse if you stop it.  That’s the thing that you 
don’t know. (CP2, P6) 
Fear, that they’ll have a negative outcome from you reducing some of these 
medicines. (GP2, P4) 
Likewise, the fear of contributing to a worse outcome, possibly death, as a result of 
deprescribing was part of the justification for maintaining the status quo. As this participant 
revealed, the more unstable or ill the patient or the more complicated the issues, the better 
to find an alternative path to avoid creating a more serious risk, especially among patients 
who express no desire or expectation for change in their medicines:    
Sometimes people just come in and say, “I want my scripts”, and they don’t really 
care if you don’t do anything more than measure their blood pressure. You have got 
a professional duty of care and …if you have got a sorry history, you don’t really 
want to contribute to another event. It can be a terminal event; it can become a risk. 
It becomes serious. It means that you wouldn’t also stop some medicine that 
protects their bones, alendronate, cholecalciferol, Caltrate. Even (if) the Caltrate is 
contributing to the constipation, find something else to blame. (GP5, P6) 
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In both cases, risk perception was in one direction – the risk of harm incurred by 
deprescribing irrespective of the risk of harm incurred by continuing potentially 
inappropriate polypharmacy. 
5.2.2.1.2 Risk to be reconciled 
The contrasting frame of reference was to perceive deprescribing as a proactive attempt to 
reconcile risks of maintaining the status quo versus risks of deprescribing.  For some GP 
and CP participants, the continuation of problematic polypharmacy incurred a risk of future 
medicine-related adverse events which should not be dismissed. Taking this frame of 
reference, one participant preferred to view polypharmacy as an emergent health problem 
that warranted proactive intervention like any other such as stroke or heart attack, 
particularly with advancing age:    
I think one solution to it is to actually indicate that polypharmacy is a problem (to the 
patient).  “It’s a health problem.  So, risk of stroke is a problem, there are all these 
other problems but this is another one. And this one’s becoming more dangerous as 
you’re getting older.”  That risk is up there with the other risks and why you want to 
do something. (GP2, P7) 
One of the CP participants went further by inferring that disclosing a risk of medicine-
related harm in a considered and polite way, and making a recommendation to 
discontinue, was a professional obligation, even if the GP or others may not accept it. This 
sentiment met with group approval:   
If it is something serious, I think we still do - we spend a lot of time rewording so 
that it doesn’t sound like we are being bombastic in our approach, that we you 
know, we just want the doctor to consider it and to think about it and he may not 
take it on board initially, but I think you still have to put it down. …you can’t not put it 
down because that could be dangerous too, especially if down the track you have 
somebody come back and say, “Why didn’t you pick that up?” (CP1, P7) 
Interestingly, the undertone of fear expressed relates to fear of not being seen to 
intervene, as opposed to the fear of intervening.    
The participants who perceived deprescribing as involving risks to be confronted also 
expressed a desire to proactively identify deprescribing opportunities and discuss these 
with their patients.  However, as expressed here, part of the challenge was addressing and 
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recalibrating the risk perceptions of patients, some of which may have a long history and 
were influenced by past encounters with specialists:  
…Sometimes they say to me, “The specialist told me I’ve got to stay on this for the 
rest of my life”. You go, “Well, in this setting 20 years ago, that was the 
recommendation but the evidence basis has changed so maybe that might be 
something you can reconsider”, so that might have a shift, get them to start thinking 
that maybe that whatever someone told them 20 years ago may be something that 
you could, that needs to be done differently. (CP2, P6) 
5.2.2.2 Subtheme: The risk tipping points 
Arguably, those with a risk to be avoided frame of reference needed more convincing 
evidence or overt indications to deprescribe, whereas those with a risk to be reconciled 
frame of reference demonstrated a willingness to consider competing risks and 
deprescribe when the benefit/risk equation was in its favour.  Scenarios which favoured 
the latter and which attracted consensus among participants comprised overt adverse 
events or specific situations such as falls, patient non-adherence, and direct requests by 
patients/carers to cease medicines:  
If it is very obvious like an adverse effect, I feel more confident… I think, if it is 
somebody who I know, I know their background, what the plan is and where we are 
heading, I am involved in the care relationship with them, that gives me confidence. 
(Other participant)’s patient coming to me because they need another script, then I 
don’t worry about it and I’m not so confident. (GP1, P6) 
What is also notable in this extract is that, as an external trigger, an adverse event could 
engender more certainty and confidence in some participants to act, although not 
universally:   
That is a clear trigger to make a decision, the fact that previously he hadn’t been 
falling; he was getting more benefit than risk. And then, he starts having some 
stage, he falls, so the risks start to outweigh the benefits and it’s easy to have the 
discussion, “Now that you are falling over, this medication is more risky so therefore 
we are going to stop it”. You can do that with complete confidence.  (GP4, P2) 
Semi-complete confidence. (P4) 
 Yeah.  (Group agrees)  
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These comments indicate that the risks entailed in decision-making are rarely 
unidimensional as other factors, such as the therapeutic relationship noted in the first 
theme, are taken into account. This explains, in part, the variability in how participants 
might view risks and respond. These extracts also highlight the extent to which confidence 
dealing with uncertainty is required for self-efficacy in deprescribing. It is likely that those 
with a risk to be reconciled mindset make their own judgements about ceasing medicines 
rather than justify the status quo by deferring to past expert opinion, as expressed in the 
following extract:  
I think, if you are not comfortable in your own skin, in your abilities as a clinician, it 
is much easier to pay attention or to go along with what the ‘expert’ says. Therefore, 
you end up building up a list of medicines.  It might be 10 years from the last time 
that person was seen by that specialist but still it becomes part of their DNA, so to 
speak. (GP1, P7)   
This was reinforced by an example provided by one CP participant who perceived that a 
lack of confidence in clinical ability had deterred a GP from taking action where a specialist 
was involved: 
I was doing this HMR and this patient had a few issues and he (the GP) said he (the 
patient) was being looked after by the specialist, (so) don’t worry about it. Even if I 
made any suggestions… I think it is the confidence of the doctor (the GP). (CP2, 
P1) 
Experience might also contribute to self-confidence and how risk is viewed.  Negative 
experiences reinforced a tendency to opt for the status quo, whereas positive or neutral 
experiences fostered open mindedness towards deprescribing.  In the following interaction 
regarding statins for stroke risk reduction, the absence of a negative consequence from 
ceasing a statin served as a reminder to one GP participant that the fear of adverse 
withdrawal effects might be overstated. The exchange between these participants 
demonstrates how repeated positive experiences can shift the risk frame.  It also again 
reinforces the desire for better evidence that deprescribing is safe and effective: 
I think there is that fear we will stop it and have a stroke the next week but I think 
that fear might be a little bit – (GP5, P4) 
Exaggerated. (P6) 
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Exactly. (P4) 
It would be good to have some figures so - there is going to be a big push to be not 
prescribing statins forever - so some figures to back it up. (P3) 
I think, as you get older, you realise that is not really true because you have done it 
so many times and they have not had a stroke the next week. (P4) 
Experience comes into it. (P2) 
As this theme indicates, the way clinicians frame issues and risks inherent to 
polypharmacy significantly affects how clinicians decide whether to persist with the status 
quo or deprescribe.  There are clear triggers which can tip the balance toward 
deprescribing for both professional groups but self-efficacy and prior experience with 
discontinuing medicines also play a part.   
 Discussion  
These findings indicate deprescribing is an inherently uncertain venture for both GPs and 
CPs and the internal reasoning underpinning decisions is complex. The option to 
deprescribe is shaped by many factors, including a clinician’s perception of the risk/benefit 
ratio of persisting with the status quo versus deprescribing.  As summarised in Figure 5-1, 
deprescribing is more likely to occur in the presence of a continuous therapeutic 
relationship between the GP and patient and in response to a clear clinical trigger or the 
finding of ‘low hanging fruit’.  On the other hand, poorly developed inter-professional 
relationships and a lack of dedicated time and tacit knowledge/familiarity with patients for 
GPs and CPs are important barriers to deprescribing.  
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FIGURE 5-1 RELATIONSHIPS BETWEEN THEMES AND CRITICAL CONTINGENCIES FOR 
DEPRESCRIBING 
Note. GPs = general practitioners; CPs = consultant pharmacists 
 
This in-depth analysis of how and why both GPs and CPs in clinical practice consider 
deprescribing decisions in community-based older people with polypharmacy adds to the 
literature on prescribers’ barriers and enablers to reducing potentially inappropriate 
polypharmacy (154-157, 196, 197).    Similar to previous research on how clinicians decide 
if initiating new medicines is likely to confer more benefit than harm (198), when 
contemplating deprescribing, clinicians sought to  determine the balance of probability of 
harm versus benefit in deciding whether to persist with the status quo or deprescribe.  
There are however some unique differences between initiating therapy and deprescribing.  
Not knowing the original indications for existing medicines and a lack of scientific evidence 
for deprescribing instil more uncertainty into decision-making.  Moreover, the act of 
prescribing a medicine is often in response to a problem that the patient presents to the 
clinician.  The challenge with deprescribing, however, is that the patient with polypharmacy 
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often does not present with a recognisable clinical syndrome and, even those who do 
manifest clinical features of medicine-related harm, are often labelled as suffering 
unrelated geriatric syndromes or simply the effects of ageing or chronic ill-health (3).  This 
may help to explain the finding that approaches to deprescribing appear largely reactive 
i.e. clinicians require a clear clinical or situational trigger such as a patent adverse event or 
near and obvious risk of harm (clear and present danger) to cease a medication.   
This analysis indicates that the way clinicians work through uncertainty and their 
predisposition to deprescribe appears strongly influenced by their framing of risk in regard 
to continuing or ceasing medication.   Commission or regret bias arising from ill-fated 
action may partly explain a clinician’s hesitancy to proactively manage potentially 
inappropriate polypharmacy (198).  For participants in this study, continuing with the status 
quo might provide the yard stick against which the consequences of any alternative course 
of action is compared, and losses resulting from alternative actions tend to loom larger 
than gains (199).  The seriousness of negative deprescribing consequences in clinical 
practice compounds this issue.  For example, the consequence of an embolic stroke in an 
older person with atrial fibrillation in whom an anticoagulant is ceased because of high 
bleeding risk is tangible.  On the other hand, the avoidance of a major intracranial bleed by 
ceasing the anticoagulant is not, potentially skewing the weighing of harm/benefit and 
framing of risk in the clinician’s (and patient’s) mind.   
These findings echo those of Sinnott et al in that GPs use a range of decision making 
strategies to reconcile therapeutic uncertainty in multimorbid patients (196).  Their major 
finding was the use of ‘satisficing’ by GPs (pursuing an acceptable, rather than ‘ideal’ 
therapeutic regimen).  Whilst this term was not used in the current study, both GPs and 
CPs did individualise therapy according to a patient’s unique circumstances.  Common to 
both analyses was the use of ‘gut feelings’ by clinicians and deferring to patients or 
specialists in resolving uncertainty, although Sinnott et al highlighted the largely facilitative 
role of the specialist.  These findings uniquely suggest that clinicians’ conceptualisation of 
the risks attached to different prescribing options profoundly influence whether they make 
or do not make changes.  The fact that, in this study, GPs were specifically questioned 
regarding minimisation of problematic polypharmacy, whereas Sinnott et al took a broader 
view of management decisions in multimorbid older people, may explain the difference in 
findings.  Apparent from both analyses is that, when dealing with prescribing decisions in 
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complex patients, neither the process for arriving at a decision (for each clinician) nor the 
clinical course and outcomes (for a patient) is linear or predictable.   
In the earlier systematic review of prescribers’ barriers and enablers to minimising PIMs in 
adults (9), four major themes were identified: problem awareness; perceived value for 
ceasing versus continuing PIMs; self-efficacy in regard to personal ability to alter 
prescribing; and feasibility of altering prescribing in routine care environments given 
external constraints.  The findings of the focus groups complement those of the systematic 
review.  Participants’ mention of medications commonly cited as being overused in the 
medical literature as ‘low-hanging fruit’, reinforced how greater awareness primes 
clinicians to consider certain medicines for deprescribing.  Moreover, in the absence of 
‘low hanging fruit’ or a clear trigger to cease therapy, deprescribing, compared with 
initiating therapy, appears a riskier, less certain, and more cognitively and socially 
demanding process, with minimal decision support.  This helps to explain the 
predisposition towards therapeutic inertia in the absence of a ‘risk to be reconciled’ frame 
of reference and high self-efficacy.  This study also reinforces the complex interactions 
between contextual factors which affect the feasibility of deprescribing.    
 Strengths and Limitations 
In addition to the use of rigorous and reproducible methods for data collection and 
thematic analysis, this study provides unique insights into the reasoning GPs and CPs 
apply to deprescribing and how this is shaped by their perceptions of risk.  Understanding 
this process is a critical first step to assisting clinicians in partnering with patients to 
improve quality use of medicines through deprescribing.   
Given that participants were a convenience sample confined to GPs and CPs in one 
geographic region in Australia, this may limit the generalisability of findings.  Similarly, the 
case study focussed on older adults residing in the community so these results may not be 
generalisable to deprescribing decisions involving institutionalised populations with 
morbidity that is more advanced and prognoses that are more predictable.  Furthermore, 
other prescribers of medicines, such as medical specialists, were not included although 
they clearly exert a strong influence on prescribing decisions.   
Efforts were made to limit the impact of any prior professional relationship between focus 
group facilitators and participants on their responses, although it is impossible to rule out a 
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social bias effect from this. Techniques such as revisiting and challenging potentially 
socially desirable responses were used to ensure the validity of findings.   
 Conclusion  
The findings in this chapter indicate that deprescribing requires an estimation and 
comparison of benefits and harms of ceasing medicines which are inherently uncertain in 
this complex and heterogeneous older patient group.  GPs and CPs use a range of 
strategies to mitigate this uncertainty which is heavily influenced by the clinical context and 
the way the GP or CP frames deprescribing risk.  The learnings from these focus group 
discussions, informed by the principles of behaviour change interventions described in 
Chapter 2 and findings of the Phase 1 systematic review were used to inform the 
development of the elements of the multifaceted intervention.  The intervention and full 
methods of the Phase 3 exploratory study are described in the next chapter.   
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Chapter 6  Phase 3 Exploratory mixed methods study methods 
Chapter 6 describes the methods for Phase 3 which is the mixed methods exploratory 
study.  As described previously, this phase represents early-phase piloting and 
developmental work, informed by the UK MRC guidance for complex interventions.  This 
chapter details the study: aim and objectives; design and setting; process for sampling and 
recruitment; intervention; outcome measures; and procedure for data collection and 
analysis.    
Given the pragmatics of scope and time for a PhD, this exploratory phase was time-
limited, with only four-months elapsing between commencement of the intervention and 
follow-up data collection.  Consequently, although Phase 3 aims to answer whether a GP-
led deprescribing intervention can be done, and done safely in the short-term, it does not 
address other important issues, such as the long-term safety and effectiveness of the 
intervention and whether the intervention can be implemented and sustained on a wider-
scale.  Subsequent studies, including a larger cluster RCT evaluating patient outcomes 
over the longer term, would be required to address these questions, which is beyond the 
scope of this PhD study.        
 Study aim and objectives 
The aim of the mixed methods exploratory study was to pilot and evaluate the feasibility, 
effectiveness and safety of a multifaceted GP-led intervention in community living older 
people in primary care, developed from Phases 1 and 2.   
Study objectives pertaining to effectiveness (reported in Chapter 7) included:   
 To investigate the impact of a multifaceted deprescribing intervention on the 
medication regimens of older community based patients with polypharmacy 
 To investigate the impact of a multifaceted deprescribing intervention on 
patient’s attitude towards their medication regimen and self-reported health 
status 
Study objectives pertaining to safety (reported in Chapter 7) included:   
 To investigate reports of suspected/actual adverse events or experiences 
arising from the multifaceted deprescribing intervention  
Study objectives pertaining to feasibility (reported in Chapter 8) included:  
 To explore how the multifaceted deprescribing intervention was adopted in 
practice by GPs 
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 To explore how acceptable the deprescribing intervention was perceived by 
GPs and patients and how likely, if at all, the intervention could be sustained 
over the longer term  
The mean difference in the number of agreed regular medications deprescribed per 
person was the primary outcome (Objective 1).  A range of secondary outcomes and 
measures were reported to address the remaining objectives.  See section 7.4, 
‘Effectiveness outcomes – Medication-specific outcomes’, for details and definitions of the 
primary and secondary outcome measures.   
 Overview of design, setting and timing of data collection 
A non-randomised, controlled pre-post mixed methods design was used. Both quantitative 
and qualitative data were collected and analysed to assess the feasibility and impact of the 
intervention in primary care.  The study involved five general practices and 20 GPs in 
Metropolitan SEQ across two study arms: an intervention arm comprising 10 GPs working 
at three sites who were exposed to the intervention, and a control (herein referred to as 
‘usual care’) arm of 10 GPs at two sites who delivered usual care. The intervention was 
targeted at the level of the clinician, with quantitative and qualitative measures gathered at 
the clinician and patient level.  Quantitative data were collected from the intervention and 
usual care group before and after exposure to the intervention.  Qualitative data were 
collected at follow-up from the intervention group to explain quantitative findings and 
explore participants’ views regarding the feasibility of the intervention. (140)  An overview 
of the study design and timing of data collection is shown in Figure 6-1.   
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FIGURE 6-1 PHASE 3 EXPLORATORY STUDY DESIGN OVERVIEW  
(F-2-F = face-to-face; appt = appointment). 
 Recruitment 
 Participants 
Recruitment involved three participant groups:  1) general practitioners; 2) consultant 
pharmacists; and 3) patients.    
6.3.1.1 General Practitioners (GPs)  
Inclusion criteria:   
 Working in primary health care and caring for community living older people with 
polypharmacy 
 Available to attend a deprescribing training workshop in August or September 2015 
(intervention arm only)  
 Working the equivalent of four or more, three-hour sessions per week (to ensure 
adequate access for patients to their usual GP) 
Exclusion criteria: 
 Primarily caring for people aged 65 years or older with polypharmacy residing in aged 
care facilities (as this was not the care setting of interest) 
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While it was intended to recruit a diverse sample of GPs based on age, years of 
experience and gender balance, it was anticipated that GPs who had been in practice for a 
longer period may see a higher proportion of older patients compared to more recently 
qualified GPs.  It was therefore accepted that the eligibility criteria may naturally lead to the 
recruitment of more experienced GPs and this was accepted as a limitation of the study.   
6.3.1.2 Consultant Pharmacists (CPs) 
Inclusion criteria: 
 Experienced in and/or actively conducting Home Medicines Reviews (HMRs) (5 or 
more years since attaining accreditation preferred)  
 Available to attend a deprescribing training workshop in August or September 2015  
 Willing to travel to provide HMR services to patients of recruited intervention practices   
Exclusion criteria:  
 Conduct medication reviews primarily for residents in aged care facilities (as this was 
not the population of interest) 
6.3.1.3 Patients 
Inclusion criteria:  
 Active patient of the practice as defined by the Royal Australian College of General 
Practitioner (RACGP) standards (i.e. had attended the practice three or more times 
in the past two years) and a regular patient of one of the GPs recruited to the study  
 Aged 65 years or older and living in the community (and not in a RACF)  
 Taking eight or more regular medications as listed in the GPs electronic medical 
records 
 Capacity to give consent 
 Proficient in speaking and reading English 
 Contactable by telephone 
These criteria were selected given the evidence of harm in patients aged 65 years and 
older with polypharmacy.  The minimum threshold of eight regular medicines as reported 
in the GP’s electronic record was arbitrary in identifying potentially eligible patients  but 
selected on the basis that medication lists were likely to be out of date and inflated due to 
the inclusion of past prescriptions of time-limited courses of medications used to treat 
acute conditions which had since resolved. (200) To address this, when phoning patients 
identified as potentially eligible for the study, only those taking five or more prescribed 
medicines each day would be recruited, as five medications was the threshold above 
which harm has been shown to become evident. (69)  The rationale for English proficiency 
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and the need to own a functioning telephone was that questionnaires would be 
administered pre- and post- intervention over the telephone by the research team.   
Exclusion criteria:   
 Confusion, cognitive impairment, mental health disorders with psychosis and/or 
communication difficulties (as documented or confirmed by the patient’s GP) that 
would preclude informed consent  
 A terminal illness (life expectancy less than six months) (201) 
 A Home Medicines Review (HMR) in the 12 months prior to recruitment 
These criteria were selected due to the ethical requirement to recruit patients with capacity 
to give informed consent.  Patients with a terminal illness were excluded as it was 
anticipated that higher rates of deprescribing may be seen in this patient group and they 
were not the focus of the intervention.  Patients who had had an HMR in the past 12 
months were excluded given the potential for medication lists to have been recently 
reviewed, with inappropriate or unnecessary medicines potentially already ceased in this 
group by GPs likely to be motivated to consider the issue.  It should be noted however 
that, if an HMR occurred between recruitment and data extraction, this was considered to 
have occurred within the study period and so was simply recorded. 
To minimise the potential to cause harm and to meet the University of Queensland’s 
ethical requirements, under exceptional circumstances, a GP could review eligible patient 
lists and exclude an individual who he or she felt may be distressed or harmed by contact 
with the research team.   Examples included individuals prone to extreme anxiety if 
contacted by strangers or who had a history of significantly poor adherence to medicines.   
In these instances, the GP was required to provide the rationale for excluding a patient to 
mitigate potential selection bias.   
 Method of recruitment 
6.3.2.1 Recruitment of GPs 
A mix of convenience and snowball sampling was used to recruit GPs within metropolitan 
SEQ.   Greater Metro South Brisbane Medicare Local (subsequently renamed Brisbane 
South Primary Health Network [BSPHN]) assisted in identifying practices within their 
catchment staffed with seven or more GPs.  Larger practices were targeted as nodes for 
GP recruitment in the interests of efficiency and to ensure comparable practice sizes.  A 
shortlist of practices was developed in which a contact, known to the research team or 
their associates, could act as a study sponsor.  The role of the sponsor would be to assist 
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with access to the site and recruit GPs.  Typically, the potential sponsor was a principal, 
practice manager or GP with a predisposition to supporting quality improvement activities 
within BSPHN.   
Phone calls to the study sponsors were made outlining the study.  Written information was 
then sent via email or fax with an invitation to participate to all GPs in the practice.  The 
sponsor GP would then indicate, on the site’s behalf, the practice’s willingness to 
participate in the study and, if so, as either an intervention or usual care site.  The PhD 
candidate conducted face-to-face meetings with interested practices to detail study 
requirements and facilitate individual GP recruitment and to obtain their written consent.   
From a list of 15 practices in whom sponsors were contacted, five were recruited to 
participate – three intervention sites and two usual care sites.  One of the usual care sites 
was recruited outside the BSPHN catchment due to their willingness to participate.  This 
occurred at a time when other practices that had already been approached to participate 
had declined and recruitment deadlines had already been breached.   
6.3.2.2 Recruitment of CPs 
Recruitment of CPs occurred after recruitment of practices as one of the eligibility criteria for 
CPs was their willingness to travel to provide HMR services to patients of recruited 
intervention practices.   CPs were recruited by convenience sampling, as contacts known to 
the research team to be actively conducting HMRs in the BSPHN area.  The number of CPs 
to be recruited would be contingent on the number of intervention sites for whom HMR 
services would possibly be required.   A sufficient number would be that which could 
ensure timely provision of HMR service should GPs in the intervention arm refer patients 
for HMR.  Individuals were approached in the first instance via phone contact, with 
information provided in writing prior to obtaining written consent.     
6.3.2.3 Recruitment of patients 
A detailed process was developed and provided to all participating GPs and practices so 
that a shortlist of up to 15 to 20 patients meeting the study’s eligibility criteria could be 
generated per GP (see 6.4.1.1, Identification of a consecutive sample of eligible older 
patients with polypharmacy).  This would allow for patient refusals such that a minimum 
sample of five patients per GP could be recruited to the study.  Figure 6-2 summarises the 
process and is explained below.   
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FIGURE 6-2 FLOW CHART FOR PATIENT RECRUITMENT 
Once each GP had a consecutive list of 15 to 20 active patients meeting the eligibility 
criteria, GPs (or where appropriate, a practice nurse/manager liaising with the GP) 
contacted eligible patients in person or by phone to gain verbal consent to be contacted by 
the research team.  Where ‘consent to contact’ was obtained, the PhD candidate 
contacted patients by phone with further details about the study and an information sheet 
and consent form were mailed to interested patients.  During this initial phone call, patients 
were asked to confirm they were taking a minimum of five prescription medications daily.  
Those patients who did not fulfil these criteria were excluded from participating.     
 Sample size 
Arbitrary minimum recruitment targets were set to test the feasibility of the intervention 
including –  
 Three GPs per site (so the number of practices with whom to liaise was manageable) 
 Ten GPs each in the intervention and usual care arms  
 Five patients per GP 
In total, a provisional sample size of 150 patients (approximately 75 each in the 
intervention and usual care arms of the study) was determined for this exploratory study.  
There was limited data available on which to base the sample size.  A feasibility study in 
104 
 
which the CEASE deprescribing guide was applied to acute hospitalised older patients 
with polypharmacy (defined as eight or more regular medications in this study) in the 
inpatient setting demonstrated a statistically and clinically significant effect in a sample of 
50 patients. (118) The primary care cohort in this study, however, would be potentially 
healthier and more robust, and deprescribing would be more likely to be anticipatory, 
rather than reactive (i.e. in response to a hospital admission), making the process of 
deprescribing, and its benefits, potentially more difficult to achieve.  For this reason, it was 
speculated a larger sample would be required.  It was also reasoned that the larger 
sample size would deliver a suitably diverse patient group with respect to age, gender, 
comorbidity burden, chronic prescription medication load and usual GP, whilst also 
allowing for patient drop-outs.   
 The intervention 
The multifaceted, GP-led deprescribing intervention was designed based on principles of 
behaviour change as described in section 2.4 ‘Changing practice in primary care’ and the 
findings of the Phase 1 and 2 investigations.  The way in which this information was used 
to design the complex intervention is detailed in Table 6-1.
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TABLE 6-1 ELEMENTS OF THE GP-LED DEPRESCRIBING INTERVENTION, AS INFORMED BY PRINCIPLES OF BEHAVIOUR CHANGE AND PHASE 1 AND 
2 FINDINGS 
Principle of 
behaviour 
change(127) 
Mapped to 
concept from 
systematic 
review 
(Phase 1) 
Focus group finding (Phase 2)  Element of the intervention indicated (Phase 3) 
Systems change 
Audit & feedback  
AWARENESS A continuous therapeutic relationship is a 
critical contingency for GPs to deprescribe  
Work with practices to develop and implement a software query to identify 
eligible participants who are regular patients of GPs recruited to the study 
Systems change FEASIBILITY GPs felt they lacked the opportunity to 
conduct comprehensive medication review 
in routine care  
 
Work with practice staff to schedule an extended appointment for study 
participants with the express purpose of comprehensive medication review 
Systems change 
Education & training  
 
FEASIBILITY Have experienced CPs attend the deprescribing workshop and be 
available to provide HMR services to patients at the intervention sites, 
should the GP wish to engage them.   
Environmental 
restructuring 
 
FEASIBILITY CPs, for whom medication review is core 
business, had time, but felt they lacked 
adequate information/knowledge about the 
patients 
Facilitate full CP access to medical records and/or place CP within 
practice/s should GPs refer patients for HMR  
Education & training 
Role modelling  
 
INERTIA  
&  
SELF-
EFFICACY 
Clinicians who perceived deprescribing as 
entailing risk to be reconciled, rather than 
avoided, reported greater inclination to 
consider and seek out opportunities to 
address potentially inappropriate 
polypharmacy    
 
Develop a deprescribing workshop and key opinion leader to present 
evidence to raise awareness of potentially inappropriate polypharmacy to 
recalibrate perspectives on the potential for harm of potentially 
inappropriate polypharmacy, and the safety of deprescribing 
106 
 
Education & training SELF-
EFFICACY 
A lack of scientific evidence and clinical 
information gaps regarding the future 
benefits and harms of medications were 
major contributors to uncertainty when 
deciding if medications were potentially 
inappropriate and hence eligible for 
cessation 
At the deprescribing workshop, review the available evidence of benefit 
and harm of commonly prescribed medications in older people and identify 
scenarios where cessation may be appropriate  
Education & training 
 
SELF-
EFFICACY 
Clinicians felt that the CEASE frameworka 
may be useful for reflection and learning but 
was not easy to apply at the point of care 
 
Apply the CEASE frameworka to case studies during the deprescribing 
workshop for learning.  Where relevant, have participants identify 
elements of the CEASE framework directly applicable to deprescribing in 
clinical practice 
Systems change FEASIBILITY Integration of decision support relating to 
deprescribing into GP software 
 
Co-design (at the deprescribing workshop) an auto-fill template for use by 
GPs during deprescribing consultations which included prompts from the 
CEASE (if acceptable/desired by GPs). 
aCEASE framework refers to: ascertaining all Current medications; assessing the level  of Elevated risk of medication-related harm in an individual patient; 
Assessing each medicine for usefulness in relation to its potential benefits and harms; Sorting medicines – prioritising medicines for discontinuation; and Eliminating 
medicines according to a structured discontinuation protocol.  (91) 
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 Operationalising the intervention elements for practices, GPs and CPs 
6.4.1.1 Identification of a consecutive sample of eligible older patients with polypharmacy  
Working closely with practice principals (or delegates) of recruited GPs, a standardised but 
customisable patient management software query was developed and run to help identify 
eligible, active patients of those GPs.  This involved the use of the same medical software 
(Best Practice® Software) at all but one site. A comparable query was performed using an 
external reporting software tool (Pencat®) at the site that used different software (Medical 
Director®).  
To account for variations in data quality across the sites, the software query was combined 
with a documented manual screening process so that each GP (or practice delegate) 
could generate a sample of consecutive eligible patients for study recruitment. This 
procedure can be seen in Appendix 7.    
6.4.1.2 Deprescribing workshop  
Adult learning principles informed the development of the five-hour, face-to-face 
deprescribing workshop for GPs and CPs.  A consultant general physician and expert in 
deprescribing delivered a one-hour didactic summary of the evidence for deprescribing, 
with the aim of reframing the benefits and harms of polypharmacy and deprescribing.  The 
rest of the workshop was interactive.  Three hours were spent working through two cases 
– one fictional and one real (supplied in advance by one of the attending GPs) – in which 
the CEASE framework was applied systematically to each case in identifying PIMs  eligible 
for deprescribing.(91)  Facilitated group discussions followed, including evidence 
summaries for the PIMs to be deprescribed, barriers and facilitators anticipated in practice, 
and resources available to support deprescribing.  The final hour of the workshop involved 
group interaction with, and feedback on, the autofill template for use by the GPs during 
deprescribing appointments.  GPs were asked to import the template into the consultation 
notes section of the software during deprescribing appointments.  The template served 
three purposes: 1) a data collection tool; 2) decision support, prompting GPs to consider 
and apply key steps in the CEASE protocol during a deprescribing appointment; and 3) a 
framework for the GP for documenting the deprescribing consultation.  See Appendix 8 for 
the auto-fill deprescribing template.  Each participant was also provided with a 
deprescribing resource kit which provided a summary of available resources for further 
reading/decision support.     
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6.4.1.3 Deprescribing appointment between GPs and patients  
Practice administration staff were responsible for ensuring that each intervention patient 
had an extended appointment (known as a deprescribing appointment) scheduled with 
their GP after that GP had attended the deprescribing training workshop.  In the booking 
process, reception staff reinforced with patients the need to bring all medicines 
(prescribed, over the counter [OTC] or complementary) to this appointment.  
Approximately two months after the training workshop, practice staff were prompted to 
schedule any outstanding initial deprescribing appointments with recruited patients.  At this 
time, a follow-up email was sent to GPs encouraging them to see any patients who were 
yet to have their initial deprescribing appointment.  In this email, GPs were provided with 
the protocol for alerting the research team to any actual or suspected deprescribing 
adverse effects (see Appendix 3 for a copy of this form).   
6.4.1.4 Referral to CPs for HMR (Optional element)  
Referral for an HMR was not mandated as part of the project.  However, in response to 
learnings from Phases 1 and 2, for GPs who wished to refer patients for HMR as a means 
to improve their deprescribing capacity, it was requested they would – 
 Refer to one of the CPs who attended the deprescribing workshop 
 Allow that CP full access to the GP practice record to ensure recommendations could 
be as informed as possible 
 Allocation to intervention or control (i.e. usual care) 
Allocation to intervention or control (i.e. usual care) was made at a practice level according 
to the willingness of the GPs in those practices to participate in either the intervention or 
usual care arm.  The small numbers of practices involved precluded conducting a cluster 
randomised controlled trial (RCT).  It was inappropriate for the unit of allocation to be the 
GP or patient given the potential for contamination effects within practices. That is, 
patients could not be the unit of randomisation, as the premise of the study was to have 
the deprescribing appointment with the patient’s usual GP and intervention GPs could not 
‘unknow’ what had been learned at the deprescribing workshop.  Furthermore, 
randomisation of GPs within a practice was equally deemed inappropriate, acknowledging 
that learnings may be shared between colleagues throughout a practice. 
 Usual Care 
Care normally provided by GPs to patients with polypharmacy continued, including referral 
to specialists, allied health professionals and CPs for HMR.  The study was described as a 
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quality use of medicines activity for community living older patients with polypharmacy to 
avoid using the term deprescribing which, while used in the intervention sites, did not apply 
to the usual care sites.   
 Outcome and process measures 
TABLE 6-2 SUMMARY OF STUDY MEASURES FOR THE MIXED METHODS EXPLORATORY STUDY 
Outcome measures pertaining to intervention effectiveness  
Medications Primary outcome -  
 Mean difference between groups in the number of agreeda regular medications 
deprescribedb per patientc  
Secondary outcomes -  
 Proportion of total agreeda regular medications deprescribedb  
 Proportions of patients who had ≥1, ≥2, ≥3, or ≥4 medications deprescribed 
 Mean difference between groups in the number of agreeda regular medicines per 
patient that werec-   
o Deprescribed, excluding supplements 
o Ceased 
o Dose reduced 
o Commenced  
o Reconciled  
 Medication classes most frequently deprescribedb, ceased and reduced 
Patients’ self-
reported health 
status and 
attitudes towards 
medications and 
deprescribing  
 Worsening of health-related quality of life (HRQoL) as measured by the EQ-5D-
5L (202) 
 Changes in intervention Patients’ Attitudes Towards Deprescribing (PATD) as 
measured by the PATD questionnaire (203) 
 
Unplanned 
hospitalisations 
 Mean number of self-reportedd unplanned hospital presentations/admissions 
during the study period 
Process measure pertaining to intervention safety 
Patients’ or 
clinicians’ report 
of adverse 
experiences or 
outcomes 
possibly related 
to the intervention 
 Report completion using supplied template (see Appendix 3) as per safety 
protocol  
 
 
 
Outcome measures pertaining to intervention feasibility (adoption, acceptability, sustainability)  
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GP/CP service 
utilisation   
 Proportion of patients in the intervention arm who had a deprescribing 
appointment  
 Proportion of patients who had an HMR since recruitment to the study 
 Difference between the mean number GP visits per patient during the study 
period between the intervention and usual care group  
Qualitative 
measures e 
GPs’ and patients’ experiences of implementing the deprescribing intervention, 
specifically an exploration of views regarding -  
 Adoption of the interventions’ elements (GPs) 
 Acceptability (GPs and patients)   
 Sustainability (GPs)   
a Agreed indicates agreement of the deprescribing change between the GP record and patient-report.  
Please see further explanation in section 6.5.1.1.1.   
b Includes ceased and dose-reduced medications. 
c Corresponding Incidence Rate Ratios (IRRs) were calculated and reported for each of these outcomes 
d Cross-referencing patient and GP records to confirm details of unplanned hospital 
presentations/admissions was not possible in every instance due to incomplete GP records.  Please see 
further explanation in section 6.5.2.3.  
e Constructs of adoption, acceptability and sustainability have been defined using the work by Proctor et al. 
(144)  Please see further explanation in section 6.5.3.2.   
  
 Effectiveness outcomes - Medication-specific outcome measures 
6.5.1.1 Primary outcome 
The primary outcome was the mean difference in the number of regular medicines 
deprescribed per patient for which there was agreement between the GP record and 
patient self-report at baseline and at study end.  ‘Deprescribed’ was defined as medicines 
ceased or those which had doses reduced.  Dose reduction was included in the definition 
for two reasons: 1) focus group discussion findings indicated that dose reduction is used 
by clinicians as a low risk strategy to facilitate medicine cessation, even if weaning the 
dose was not required pharmacologically (186); and 2) complete cessation may not have 
been possible within the four-month study period based on the assumption that some 
medications need to be weaned slowly over several months.     
6.5.1.1.1  An explanation for using GP-patient agreed medication lists 
The rationale for the use of GP and patient agreed medication lists and changes was 
related to the pragmatic design of the study.  Unlike previously published studies reporting 
changes to medications, there was no single, reconciled medication list at one or more 
time points to determine the nature of medication changes over the study period.  
Developing such a list was not pursued for two reasons:  1) resources were not available 
to have research staff located across five sites simultaneously to create reconciled 
medication lists for all study patients; and 2) the intent was for the usual care group to 
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reflect ‘usual care’ as closely as possible and so it was decided that creating a non-routine 
opportunity for patients’ GPs to reconcile medication lists – akin to a Hawthorne effect - 
may lead to review and change of medications that would not otherwise occur under 
normal circumstances.  Medication reconciliation is the first step of the CEASE framework 
and so creating an opportunity for GPs to do this in the usual care arm would have 
constituted a form of ‘intervention’.   
For this study therefore, the source of truth regarding medications prescribed, and 
changes made to those medications, were ‘agreed’ medication lists.  This comprised 
medications (and their doses) collected and reported from GP records and patient self-
report, at baseline and follow-up, that were totally concordant with each other. These 
‘agreed’ lists and changes are what constituted the medication measures reported 
throughout this and the next chapter. For completeness, GP and patient-reported 
measures, which may or may not have been concordant, were also separately reported in 
the relevant appendices.  Whilst the approach of presenting GP-patient agreed medication 
changes had potential to diminish the outcome effect sizes (because it did not account for 
additional medications/changes that the patient instigated of their own accord or instances 
of patient non-adherence), it was deemed the most valid way to present the data.   
Two additional strategies were employed to account for the use of ‘real-world’ data.  
Firstly, short course therapies were excluded from the analysis, these being defined as 
oral and topical antimicrobial therapies at treatment doses, high dose steroids, pain 
relievers for acute complaints, any medication whose instructions included (‘for x days’) 
and intra-articular injections.  Vaccinations and non-medicated topical therapies were also 
excluded from the analysis.   
Secondly, follow-up medication lists taken from GP records in the intervention group were 
adjusted for reconciliation, i.e. they were adjusted for changes which occurred simply on 
paper, as a result of the GP cleaning up or updating the medication record just prior to, or 
during, the first patient appointment undertaken during the study period. This was done so 
as not to bias GP-reported outcomes in favour of the intervention, because GPs in the 
intervention group, unlike usual care prescribers, were afforded the opportunity to reconcile 
medications at the dedicated deprescribing appointment.  The standardised process for 
adjusting follow-up GP medication lists for reconciliation is detailed in Appendix 9 and the 
consistency of its application was tested by inter-rater reliability in assessing changes in 
medication regimens.   
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6.5.1.1.1.1 Inter-rater reliability in assessing changes in medication regimens 
The medication lists of a random sample of 25 patients (13 intervention, 12 usual care) 
were independently reviewed by the PhD candidate and a research team member, also a 
pharmacist.  This process was undertaken to ensure reliability in the application of the 
documented process to adjust GP records for medication reconciliation (see Appendix 9).  
A total of 243 medications were identified by both reviewers as being unchanged and so 
were not considered as part of the inter-rater reliability task.  The rationale for this was that 
it was assumed that most medications would be unchanged during the study period, and 
including the unchanged medications in the inter-rater calculations would artificially 
improve the level of inter-rater agreement.  Furthermore, 135 medications were identified 
by both/either reviewer as having undergone some kind of change during the study period 
(i.e. ceased, commenced, dose changed, added or removed from the list through 
reconciliation).  In 124 of the 135 instances, there was total agreement between the two 
raters for both the occurrence and nature of the change, representing 92% agreement 
(kappa = 0.84).   
6.5.1.2 Secondary outcomes  
A range of secondary medication-specific outcomes were also specified a priori, including 
the proportion of medications deprescribed as a proportion of total medications between 
intervention and usual care groups and the proportions of intervention and usual care 
patients who had at least one, two, three or four or more medications deprescribed.  
Additional secondary outcomes included the mean difference in the number of agreed 
regular medications per patient over the study period that were: deprescribed, excluding 
supplements; ceased; reduced in dose; commenced; and those reconciled (which is step 
one of the CEASE framework).  This range of measures was specified to assess the 
overall impact and effectiveness of the intervention on the medication regimens of study 
participants.  The medication classes most frequently deprescribed, ceased and to have 
doses reduced were also reported.   
 Other effectiveness outcome measures 
6.5.2.1 EQ-5D-5L 
The EQ-5D-5L – Telephone interview version was selected to measure, and assess 
changes in, health-related quality of life (HRQoL). (202) It consists of five descriptive 
statements pertaining to five dimensions of health: mobility, self-care, usual activities, 
pain/discomfort, anxiety/depression.  For each dimension, the responses record five levels 
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of severity (no problems/slight problems/moderate problems/severe problems/extreme 
problems) within a particular EQ-5D dimension.  There is also a 100-point ‘Visual Analogue 
Scale’, which is adapted for telephone interview, in which a respondent indicates global 
health. (204)  The rationale for including a HRQoL tool in such a short study was as a ‘red 
flag indicator’, i.e. to ensure there was not a sudden deterioration in HRQoL associated with 
imprudent deprescribing attempts by GPs. It was not included to demonstrate a benefit in 
HRQoL from deprescribing, as literature supports that much longer study periods are 
generally required to demonstrate such effects from any clinical intervention. (205) The 
rationale for choosing the EQ-5D-5L was two-fold:  1) its brevity and ability to be easily 
administered over the phone; and 2) experimental 5-level versions of EQ-5D significantly 
increase reliability and sensitivity while maintaining feasibility. (204) Although the EQ-5D, 
like other brief measures of functional status and HRQoL, such as the SF-12, were not 
originally designed specifically for use in older adult populations, there is evidence of 
comparable reliability of HRQoL in samples of cognitively intact older adults and adults in 
general.  (204, 206)  
6.5.2.2 PATD 
In the intervention group, an assessment was made of the change in patients’ attitude to 
deprescribing before and after the intervention using the Patients’ Attitudes Towards 
Deprescribing (PATD) Questionnaire. (203)  This tool was selected because, at the time of 
study design, it was the only survey with demonstrated content validity that was available to 
assess patients’ views of medication appropriateness and burden and their willingness to 
deprescribe medicines under the supervision of a clinician. (203) Unlike surveys like the 
Brief Medication Questionnaire, the PATD is not specific to any particular medication class 
or indication lending itself to an intervention such as the one in the study that focussed on 
reducing inappropriate medication of any type.  A limitation of the PATD is that it has no 
scoring system.  Consequently, although administered in an unaltered way, only the ten first 
person statements with Likert scales were utilised for analysis, as evidence of item 
sensitivity, reliability and/or validity was lacking for the remaining items.  (203)  The authors 
of the PATD, who published a significantly revised version of the tool in 2016 (207), were 
contacted to confirm this decision was appropriate. The PATD was only administered to 
intervention patients to minimise suggestion bias towards deprescribing in usual care 
participants.   
114 
 
6.5.2.3 Self-reported unplanned hospitalisations  
The mean number of self-reported unplanned hospital presentations and admissions 
during the study period between intervention and usual care patients was reported.  This 
measure was primarily included as another ‘red flag indicator’ of imprudent deprescribing 
attempts on the part of either the GPs or patients.  Although an attempt was made to 
cross-reference patient and GP records to confirm details of every unplanned hospital 
presentation/admission during the study period, this was not possible in every instance 
due to incomplete GP records.  Therefore, in the interest of presenting data in the most 
valid way, this measure was presented simply as a ‘patient self-reported’ outcome.  
Unfortunately, ethics approval had only been sought in advance to verify records with 
public, not private hospitals, to which many patients presented, so cross-referencing 
patient-reported presentations/admissions with hospital records was also unviable.   
 Feasibility outcomes 
6.5.3.1 GP/CP service utilisation  
The proportion of patients in the intervention arm who had a deprescribing appointment 
was reported to indicate the level of protocol adherence.  Between group differences were 
also reported at follow-up regarding the mean number of GP visits per patient over the 
study period and the proportion of patients who had an HMR since recruitment to the study 
(to determine the relative uptake of this optional element of the intervention).   
6.5.3.2 Qualitative measure of the intervention’s feasibility  
The adoption, acceptability and sustainability of the intervention would be evaluated to 
determine the feasibility of the intervention.  The three aforementioned constructs have 
been defined using the work by Proctor et al (144), such that: adoption is the ‘intention, 
initial decision or action to try or employ an innovation or evidence-based practice’; 
acceptability is the ‘perception among participants that a given treatment, service, practice, 
or innovation is agreeable, palatable or satisfactory’ and; sustainability is ‘the extent to 
which a newly implemented treatment is maintained or institutionalised within a service 
setting’s ongoing, stable operations’. 
 Safety protocol  
As detailed previously, at all times the patient remained under the care of their usual GP 
and this was clearly articulated to the patients involved in the study.  To ensure timely 
detection and reporting of any actual or suspected adverse consequences arising from 
deprescribing, GPs were provided with an adverse event reporting form and protocol.  See 
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Appendix 3 for the form to record and report suspected adverse outcomes or experiences 
to the research team.  Patients were, however, also invited to directly contact the research 
team should they have any non-acute concerns or problems throughout the study period.   
 Data collection 
 Patient telephone survey 
Data were collected from the patient via questionnaire completed in an interview-style over 
the phone at baseline and follow-up.  Phone questionnaires were administered by 
experienced pharmacists (the PhD candidate and two casual research assistants) trained 
in taking a comprehensive medication history, as per the Australian Commission on Safety 
and Quality in Healthcare’s process to conduct a best possible medication history. (208) 
Three key measures were taken to ensure a standardised approach to data collection from 
patients over the phone, including: 1) the development and use of a standardised data 
collection template and question guide for interviewers (see Appendix 10 data collection 
form); 2) in-person training of the casual research assistants prior to commencing in the 
role and again, by phone, after conducting their first three to five interviews; and 3) 
ensuring, wherever possible, the same individual conducted the baseline and follow-up 
survey.   
In addition to taking a medication history, detailed demographic information such as the 
country of birth, language spoken at home and pensioner status, which were deemed as 
variables potentially influencing medication related outcomes, were also collected.  All 
patients were surveyed on their Health-related quality of life (HRQoL) as measured by the 
EQ-5D-5L at baseline and follow-up.  (204) For patients in the intervention arm of the study, 
the PATD questionnaire was also collected at baseline and follow-up. (203)  At follow-up, 
the number and details of any unplanned hospital presentations/admissions and the 
occurrence of any HMRs in the six to 12 months prior to, and throughout, the study period 
were also collected.     
 Patient data from general practice records 
Patient data collected from the medical record at baseline included the patient’s age, 
gender, usual GP, number of regular and prn medications (excluding short-term therapies) 
and number of documented chronic medical conditions.  This latter data was based on the 
20 most frequently encountered chronic conditions in primary care in Australia according 
to the Bettering the Evaluation and Care of Health (BEACH) primary care dataset (209).  
The process of reviewing the medical record until saturation was reached was used for this 
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data collection (that is, active and past medical conditions, hospital discharge and 
specialist letters and other relevant documents in the file were reviewed until no new 
documented chronic diagnoses could be found).   
At baseline and follow-up, data were collected on: the frequency and details of GP 
appointments during the study period; the number and details of any HMRs in the 12 
months prior to recruitment and during the study period; and the number and details of any 
unplanned hospital presentations or admissions six months prior to and throughout the 
study period (where available).   
For intervention patients at follow-up, data were also collected on: completion of the 
deprescribing consultation template by GPs in the intervention arm; and details of any 
deprescribing decisions/outcomes.   
 Baseline practice and clinician level data collected by survey  
At baseline, basic descriptive data were collected from practices and clinicians to provide 
essential context to the study.  Practices completed brief surveys to provide information 
regarding staffing and co-located services.  Clinicians completed surveys to provide basic 
demographic information and details regarding their experience and work status (e.g. part-
time or full-time work status).  Copies of the data collection forms are contained in 
Appendix 11 and Appendix 12.   
 Qualitative data  
Qualitative data were used to examine feasibility of the intervention and to help explain and 
contextualise the quantitative findings.  At completion of the study, in-depth face-to-face 
semi-structured interviews were conducted with all 10 intervention GPs.  Interviews were on 
average 29 minutes in duration, range 15-51 minutes.  By comparison, much briefer 
interviews (average duration 6 mins, range 1.5-16 minutes) were conducted with a 
convenience sample of 52 intervention patients by telephone (determined by those willing 
to have their responses audio recorded at the end of the follow-up phone survey for verbatim 
transcription at a later point).  The patient interviews were conducted by the PhD candidate 
and one of the research assistants who underwent additional training in the technique of 
conducting semi-structured interviews.   
As the primary adopters of the intervention, the key focus of interviews with GPs was to 
explore the:  1) adoption of the elements of the intervention (i.e. identifying potentially eligible 
patients, participating in the deprescribing training workshop and having at least one 
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extended deprescribing appointment with their patients); 2) acceptability of the intervention; 
and 3) likelihood of sustainability of deprescribing in routine care, including future 
commitment and resource requirements required to facilitate this.  In contrast, the primary 
focus of interviews with patients, as secondary adopters of the intervention was their 
perceived acceptability of the deprescribing appointment/s with their GP.   
All topics were explored both generally and specifically with each participant, by the 
interviewer raising examples of relevant positive and negative deprescribing outcomes and 
experiences throughout each interview.  The interview guides for the intervention GPs and 
patients are included in Appendix 13 and Appendix 10 (as part of the Intervention patient 
follow-up data collection form), respectively.   
 Follow-up period  
The median follow-up period was 125 days (IQR = 118-132.5, full range = 86-198) and 126 
days (IQR = 124-129, full range = 123-132) days for the intervention and usual care groups, 
respectively.  The date range was wider for the intervention group because each patient had 
their own individual timeline determined by the date of their initial deprescribing 
appointment, and it was impractical to return to the practice to collect follow-up data for each 
person individually at a uniform time after this appointment.  Rather, the date for follow-up 
data collection was determined for each GP, and was approximately four months from the 
midpoint of all of his or her initial deprescribing appointments.  All baseline phone interviews 
with intervention patients occurred prior to their deprescribing appointments. Appendix 14 
provides more detail of the exact timing of data collection.   
 Data analyses  
 Between group differences at baseline  
The characteristics of intervention and usual care patients and GPs were reported at 
baseline.  For non-normally distributed continuous or ordinal variables, medians and 
interquartile (IQR) ranges were reported.  For normally distributed continuous variables, 
the mean (standard deviation [SD]) was reported.   The following tests were employed to 
check for statistically significant differences between groups using two-sided criteria and 
alpha of 0.05 -  
1. Independent samples t-test and Mann-Whitney U Test, for continuous variables 
which were normally and non-normally distributed, respectively  
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2. Chi-square test for Independence for categorical variables or Fisher’s exact test in 
instances where cells had expected counts less than five (as occurred in several 
instances when comparing the characteristics of GPs) 
 
 Outcomes pertaining to medication changes 
Analyses were conducted on the intent-to-treat (ITT) basis. Applying the ITT principle 
refers to undertaking the analysis according to the allocation to, rather than actual receipt 
of, the intervention by the study participants and is undertaken to minimise bias introduced 
by excluding patients who are non-adherent to the study protocol. (210)  Empirical 
evidence suggests that non-adherent patients invariably have worse outcomes than 
adherent patients and so the exclusion of non-adherent patients may otherwise artificially 
improve controlled study outcomes.(210)   
As the primary and secondary outcomes pertaining to differences in the mean number of 
medication changes per patient were non-normally distributed counts, Negative binomial 
or Poisson regression was used depending upon the variance-to-mean ratio (i.e. if the 
variance to mean ratio >1.5, Negative binomial regression was used, as is convention).  A 
description of variables tested in the General Linear Modelling as possible predictors of the 
primary outcome is detailed in Table 6-3.   
TABLE 6-3 DESCRIPTION OF COVARIATES AND FACTORS TESTED IN THE GENERAL LINEAR 
MODELLING AS PREDICTORS OF THE PRIMARY OUTCOME 
Variable Variable 
type  
Description of 
categories a 
Statistically 
significant? Y/N 
Age (in years) Continuous  N/A N 
Gender Categorical  Female; Male. N 
Allocation to intervention  Categorical Usual care (reference); 
Intervention.   
Y 
Number of regular baseline medicationsb Continuous N/A Y 
Medications packed by pharmacy at 
baseline (e.g. Webster® pack or sachets) 
Categorical  Yes or No N 
Self-managing medicines (i.e. responsibility 
of medication management not devolved to 
carer)  
Categorical  Yes or No N 
Baseline PATD scores Continuous N/A N 
General Practice Categorical 1,2,3,4,5.  N 
aFor categorical variables the first category listed was used as the reference value.    
bThe source for the number of regular baseline medications imputed into the model was consistent with the 
outcome to be reported.  For example, for an ‘agreed’ medication outcome, the ‘agreed’ number of baseline 
regular medications was used, for a patient-reported medication outcome, the patient reported number of 
baseline regular medications was used etc.  Exploration of the data did not show a change in the statistical 
significance of medication outcomes when the number of baseline medications from another source were 
tested.   
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Apart from age and gender, only allocation to intervention and the number of regular 
baseline medications were statistically significant (p value <0.05) predictors of the primary 
(and secondary) outcome/s, and so were retained in the main effects Generalised Linear 
Model. Effect estimates from the model’s output were reported as Incidence Rate Ratios 
(IRRs).   
Given the exploratory nature of this study, in the regression analysis, associations 
between the primary outcome and pre-specified criteria were also undertaken, such as the 
association between the number of baseline medications and the number of medicines 
deprescribed per patient.  The impact of HMR services on the primary outcome were also 
examined.   
Given that the outcomes pertaining to medication changes were non-normally distributed 
counts, usual statistical convention would be to report the change in the median number of 
medications per person with the inter-quartile range (IQR).  The distribution of the data 
(the large number of ‘zeros’ and low kurtosis) meant that the mean proved to be the better 
descriptor of central tendency (as the median was too limited by its small range).   
A per-protocol sensitivity analysis was also specified a priori.(210)  Additional post-hoc 
sensitivity analyses were undertaken for patients of two GPs who breached the 
recruitment protocol and for the patients of one GP who left the practice during the study 
period.  See section 7.2 ‘Adherence to protocol’ for more detail. 
In reporting between group differences at follow-up (e.g. the proportion of patients with 
one, two, three or four or more medications deprescribed), the Chi square-test for 
Independence (or Fisher’s exact test in instances where cells had expected counts less 
than five) was employed to check for statistically significant differences between groups 
using two-sided criteria and alpha of 0.05.    
 Measures pertaining to patients’ self-reported health status and attitudes towards 
medications and deprescribing 
6.7.3.1 EQ-5D-5L  
Given the use of the EQ-5D-5L as a ‘red flag indicator’ of worse HRQoL over the study 
period, the five levels of the first five domains were each converted to a dichotomous 
outcome for analysis – outcome worse or not.  There is precedent for dichotomising the EQ-
5D-5L domains in this way. (204) The Chi-squared test for independence (with Yates 
Continuity Correction) using two-sided criteria and an alpha of 0.05 were used to analyse 
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the dichotomised outcomes.  A dependent samples t-test using single-sided criteria and 
alpha of 0.05 was used to test for statistically significant differences in the EQ-VAS.     
6.7.3.2 PATD 
The PATD scores were used for two purposes:  
 
1.   To investigate if baseline responses were predictive of the primary outcome; and  
2. To investigate what changes, if any, occurred in PATD scores for the intervention 
group between baseline and follow-up.   
 
6.7.3.2.1 Approach taken to investigate if baseline responses were predictive of the 
primary outcome   
As there is no cumulative score for the PATD or its first ten items, Principal Components 
Factor Analysis was conducted for each of the 10 items of the PATD.  The goal of Factor 
Analysis is to identify underlying variables, or factors, that explain the pattern of 
correlations within a set of observed variables.  It is often used in data reduction to identify 
a small number of factors which explain most of the variance observed in a larger number 
of variables.(211)  Extraction was based on Eigenvalues greater than 1 and the Varimax 
Method of Rotation was used.  There is the potential for factor analysis to generate more 
factors than are actually present by chance for ordinal data.  Therefore, two criteria were 
specified to ensure confidence in the interpretation and naming of items: (212) 
1. Only items with high factor loadings (i.e. conventionally defined as coefficients > 
0.5 in exploratory Factor Analysis) were retained; and 
2. Items were checked to ensure factors for which they had high loadings 
represented similar aspects of the phenonemnon of interest. 
 
6.7.3.2.2 Approach taken to investigate what changes, if any, occurred in PATD scores for 
the intervention group between baseline and follow-up  
The Wilcoxon signed-rank test was used to test for statistically significant changes in each 
of the ten PATD items using two-sided criteria and an alpha of 0.05.   
 Measures pertaining to unplanned self-reported hospitalisations and GP/CP health 
service utilisation   
Poisson regression modelling adjusting for age, gender, number of GP-patient agreed 
regular medications at baseline and number of common chronic comorbidities was used to 
test for statistically significant differences between the number of self-reported unplanned 
hospitalisations during the study period between intervention and usual care patients.   
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An independent samples T-test was used to test for statistically significant differences in 
the number of GP appointments and HMRs between intervention and usual care patients 
using two-sided criteria and an alpha of 0.05.   
 Statistical analysis  
IBM SPSS Statistics Version 24, 2016, was used for all quantitative statistical analyses. 
(213)    
 
 Qualitative analysis 
A qualitative descriptive approach was used for this investigation. This has been shown to 
be an appropriate choice for mixed methods health services research, particularly when 
the purpose is to gain firsthand insight into participants’ experience of a newly adopted 
treatment, service or practice.  (142)  Using the Framework approach, thematic analysis 
was conducted deductively initially, with responses segmented according to interview 
questions which aligned with the intervention phases.(214) The second step involved 
developing themes inductively, with reference to concepts from the feasibility study 
literature. (215) Whilst both GP and patient data sets were analysed separately initially to 
explicate the main themes and contrasts within these themes from each viewpoint, an 
integrated GP and patient perspective was elicited regarding the acceptability of the 
deprescribing appointment/s, as this was the one element of the intervention common to 
both adopters.   
 Conclusion 
This chapter details the methods used for the Phase 3 exploratory mixed methods study.  
Quantitative results of this exploratory study will be presented next in Chapter 7.  Chapter 
8 will present findings of the qualitative aspect of the intervention.     
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Chapter 7  Quantitative results of Phase 3 exploratory study  
The third thesis aim was to test the feasibility, effectiveness and safety of a multifaceted 
intervention to facilitate GP-led deprescribing in community living older people in primary 
care.  The quantitative results pertaining to the adoption and effectiveness of the 
intervention are presented in this chapter.  Specifically, the extent of uptake of the 
intervention (including protocol adherence) and its effect on the medication regimens of 
older people are reported.  As detailed in the preceding chapter, the primary outcome was 
the mean difference in the number of regular medicines deprescribed per patient for which 
there was total agreement between the GP record and patient self-report.  The use of 
‘agreed’ medication changes for the primary and secondary outcome measures in this 
chapter reflects an innovative solution to the data quality issues encountered in this 
pragmatic study.  For each of the agreed outcomes reported, GP- and patient- reported 
outcomes are also presented separately in the relevant appendices.  It is to be noted that 
data from GP records were adjusted for reconciliation using a standardised process 
detailed in Appendix 9.  This was done so as not to bias GP reported outcomes in favour 
of the intervention group, whose GPs were afforded the opportunity for medication 
reconciliation (i.e. deleting, adding or changing the dose of previously listed medications) 
at the deprescribing appointment, in contrast to usual care GPs and their patients.  As it 
turned out, this adjustment had no effect on the GP-patient agreed outcomes, but it 
ensured that, when reviewing the changes according to the GP-record, the effect size of 
outcomes was not artificially inflated for the intervention group simply because of 
reconciliation.    
In reporting the medication outcomes, the use of the mean, rather than the median is not 
usual statistical convention for non-normally distributed counts.  However, in this 
circumstance, it proved the best measure of central tendency due to low kurtosis in the 
dataset.  Therefore, mean differences have been reported for all medication-specific 
outcomes but, in the interest of completeness, both the mean and median have been 
reported for each outcome in the tables throughout this chapter.  The chapter concludes 
with the presentation of data regarding the impact of the intervention on patients’ attitudes 
towards deprescribing, their medication regimens and self-reported quality of life.   
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 Study setting 
 General practice sites 
Five practices agreed to participate in the study; three as intervention sites, two as usual 
care sites.  All five practices were accredited with Australian General Practice 
Accreditation Ltd and owned by one or more GPs working in the practice.  Four of the five 
practices used Best Practice® Medical Software and one used Medical Director®.  
Information about GP and nursing staffing levels, the proportion of older people who 
attended the practice and the number of GPs and patients enrolled per site is presented in 
Table 7-1.   
TABLE 7-1 DESCRIPTIVE INFORMATION FOR EACH OF THE GENERAL PRACTICE SITES  
GP PRACTICE FTE 
GPs 
FTE 
RNs 
FTE 
ENs 
% activea 
patients aged 
≥65 years 
GPs enrolled 
from site  
GP head 
count per site 
Patients 
enrolled 
from siteb 
Intervention 1 6 2 0 17% 3 10 25 
Intervention 2 10 3 0.25 19% 3 12 34 
Intervention 3 6.5 3 0 14% 4 13 23 
Usual Care 1 5 1.25 0 20% 4 7 29 
Usual Care 2 8 3 1 14% 6 12 44 
FTE= Full Time Equivalent; GP = General Practitioner; RN = Registered Nurse; EN = Enrolled nurse.   
aIn accordance with the RACGP definition, an active patient was defined as a person who had attended the 
practice/service three or more times in the two years preceding enrolment.  Full-time equivalence was 
defined as working a minimum of 38 hours per week. 
bNote this refers to patients enrolled, not recruited, to the study from each site. See Figure 7-1 for detail.   
 
Practices involved in the study tended to be large practices that serviced a comparable 
proportion of patients aged 65 years and older.  All were mixed billing practices, with 
policies to bulk-bill children, aged pensioners and concession card holders.  Bulk-billing is 
where a practice directly bills Medicare for a health service and does not charge the 
patient an out-of-pocket fee.  There was one exception - one site charged a nominal out-
of-pocket fee for aged and disability pensioners and concession card holders to limit 
service demand, but this could be waived at the doctor’s discretion.   
Between three and four GPs were recruited per site, with the exception of the fifth practice 
where six GPs agreed to participate as part of the usual care group.  All practices had one 
or more full time equivalent registered nurses (RNs) incorporated within the practice and 
all practices engaged nursing staff for management of patients with chronic disease (for 
example all used nursing staff to assist in conducting federally-funded Health 
Assessments).  All but one site had one or more allied health professionals operating out 
of rooms of the practice.  Only one intervention site practice had a consultant pharmacist 
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(CP) engaged as a non-dispensing practice pharmacist.  This pharmacist was recruited to 
the study and attended the deprescribing workshop. It should be noted however that prior 
to the study, only one of the three GPs recruited to the study from that site had engaged 
this pharmacist to conduct any Home Medicines Reviews (HMRs).    
 Participants  
7.1.2.1 General practitioners 
Twenty GPs enrolled in the study – 10 each in the usual care and intervention groups.  
The baseline characteristics of the GPs are displayed in Table 7-2.  There were no 
significant differences between GPs in the intervention and usual care groups of the study.  
The age and experience range for GPs in the intervention and usual care groups were 
comparable.  With the exception of three intervention GPs, all GPs had attained their 
medical qualifications in Australia.   
TABLE 7-2 BASELINE DOCTOR CHARACTERISTICS 
Characteristic Intervention  
(n = 10) 
Usual care  
(n = 10) 
P valuea 
Mean (SD) age in years  49.6 (13.492) 54.1 (10.461) 0.415b 
Female (%) 50% 50% 1.000 
Mean (SD) number of years registered as a GP  20.6 (15.735) 23.7 (14.743) 0.655b 
Australia as country of qualification (%) 70% 100% 0.211 
Full Time status (defined as 38 hours or more direct 
patient hours per week) (%) 
50% 60% 1.000 
Median (IQR) number of patients per GP recruited to 
the study  
9.50 (4.25-
11.00) 
6.00 (4.75-9.50) 0.493 
aTwo tailed.  bResult no different if equal variances not assumed.   
7.1.2.2 Consultant pharmacists 
Two CPs were recruited to the study as it was determined that this number would be 
adequate to perform HMRs for Intervention patients should GPs wish to refer them for 
HMR during the study period.  Both were female, qualified in Australia and had worked as 
consultant pharmacists for 18 and 19 years, respectively.  As stated above, one of these 
CPs was working as the practice pharmacist for one of the intervention sites.  The second 
CP was external to the other two intervention sites and met the GPs for the first time at the 
deprescribing workshop.   
7.1.2.3 Patients 
Of the 153 patients enrolled in the study, 145 were included in the analysis; 78 in the 
intervention group and 67 in the usual care group. Figure 7-1 shows a flow diagram of 
patient enrolment and analysis.  Reasons for non-enrolment and withdrawal from the study 
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have been provided.  The main reason for ineligibility was that patients were taking fewer 
than five prescribed medications regularly (as opposed to prn medications) at the time of 
enrolment despite practice records indicating otherwise.  During phone recruitment of 
patients, ‘regularly’ was defined as ‘on a daily basis’ to provide clarity. A level of 
discordance between what the patient was taking and what was listed on the general 
practice record was expected as this has been reported repeatedly in previous 
studies.(200, 216).  Note that ‘prescribed’ medications also included supplements or OTC 
medications which were prescribed or at the very least noted in the medical record by the 
GPs, e.g. calcium/vitamin D supplements or paracetamol, but which did not necessarily 
require a written prescription.   
Some patients initially enrolled in the study were in fact ineligible.  This was only learned 
during the data collection process because, to preserve confidentiality, full patient details 
were not available prior to receipt of informed consent from individual patients.  Three 
enrolled individuals were withdrawn from the study as they were unable to be contacted for 
a baseline interview.   
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FIGURE 7-1 FLOW DIAGRAM OF PATIENT ENROLMENT AND ANALYSIS IN THE EXPLORATORY 
STUDY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aIn the intention to treat analysis, three patients (including one deceased patient) in the intervention group did 
not have a deprescribing appointment with their GP.  LOCF=last observation carried forward 
Patients in the intervention and usual care groups demonstrated similar characteristics at 
baseline, as seen in Table 7-3.   
Consented to contact (n= 101) 
 Declined to participate (n=15) 
 Unable to be contacted (n=3) 
 Ineligible (n=10)  
< 5 regular medications (n=7) 
Self-reported cognitive impairment 
(n= 1) 
Spouse in study (n=1) 
Not fluent in English (n= 1) 
Consented to contact (n= 120) 
 Declined to participate (n=13) 
 Unable to be contacted (n= 7) 
 Ineligible (n=18)  
< 5 regular medications (n=13) 
Self-reported cognitive impairment 
(n= 1) 
Spouse in study (n=4) 
Intervention  Usual Care  
Withdrawn from study (n=4) 
 Unable to be contacted for baseline 
interview (n=2) 
 Found to be ineligible post-
recruitment upon review of medical 
file 
Enrolled in other study changing 
usual medication regimen (n = 1) 
HMR in 12 months prior to 
enrolment (n = 1) 
Enrolment 
Intention to treat analysisa (n= 78) 
Includes patients for whom LOCF  
(n = 3).  Reasons -  
 Deceased (n = 2) 
 Unable to be contacted for 
follow-up interview (n =1)   
Withdrawn from study (n=6) 
 Unable to be contacted for baseline 
interview (n=1) 
 Found to be ineligible post-
recruitment upon review of medical 
file 
Enrolled in other study changing 
usual medication regimen (n = 3) 
HMR in 12 months prior to 
enrolment (n = 2) 
Intention to treat analysis (n= 67) 
Includes patients for whom LOCF  
(n = 2).  Reasons - 
 Deceased (n = 1) 
 Unable to be contacted for 
follow-up interview (n =1)   
ITT Analysis 
Withdrawal 
n = 82  n = 73  
n = 78  n = 67  
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TABLE 7-3 BASELINE PATIENT CHARACTERISTICS 
Characteristic Intervention    
(n= 78) 
Usual care  
(n = 67) 
P value  
(2-tailed) 
Median age in years (IQR)  74 (69.75, 80.25) 77 (70.00, 82.00) 0.189 
Male (%)  41.0 32.8 0.309  
Residing alone (%) 32.1 37.3 0.506 
Self-managing medications (%) (i.e. Responsibility 
not devolved to a carer)  
89.6 89.2 0.942  
Median (IQR) number of most common chronic 
conditions per patient (as per BEACHa list)  
Condition frequency (%)  
5 (4-7) 5 (4-7) 0.958 
 
Hypertension 82.1 83.6 0.808 
Hyperlipidaemia 57.7 56.7 0.906 
GORD 51.3 43.3 0.336 
Ischaemic heart disease 39.7 55.2 0.063 
Osteoarthritis 44.9 46.3 0.866 
Type 2 Diabetes 42.3 28.4 0.081 
Depression 33.3 22.4 0.145 
Asthma 25.6 25.4 0.971 
Chronic back pain 24.4 20.9 0.620 
Osteoporosis 23.1 20.9 0.752 
Median (IQR) number of agreedb baseline regular 
medications per patient, excl. short course therapies 
c 
% of patients taking top 10 most frequently occurring 
medication classes of all baseline medication classes 
8 (6-10) 9 (6-10) 0.427 
Statin  70.5 62.7 0.318 
Supplement – single ingredient d 37.2e 46.3e 0.268 
PPI or H2 antagonist 62.8 53.7 0.268 
Antiplatelet 52.6 55.2 0.749 
AT2RB 48.7 37.3 0.167 
Oral hypoglycaemic 30.8 20.9 0.178 
Beta-blocker 42.3 38.8 0.669 
Calcium channel blocker 41.0 43.3 0.784 
Diuretic 33.3 29.9 0.653 
Otherf 17.9 19.4 0.823 
Median number of agreeda baseline prn medications, 
excl. short-term therapies 
1 (0-2) 1 (0-2) 0.140 
% of people for whom English is usual language 
spoken at home 
97.4 98.5 1.000 
aBEACH refers to the Bettering the Evaluation and Care of Health dataset from primary care in which the most 
frequently encountered chronic conditions in primary care in Australia are detailed.  (209)  
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bAgreed indicates medications at baseline for which there was total agreement between the GP record and 
patient-self report. 
c Short course therapies included oral and topical antimicrobial therapies at treatment doses, high dose steroids, 
pain relievers for documented/reported acute complaints, any medication whose instructions include (‘for x 
days’), intra-articular injections, vaccinations, non-medicated creams. 
d‘Supplements – single ingredient’ included a range of vitamin, mineral and complementary medications, the top 
five of which in descending count order were Vit D, Vit B12 injections, fish oil, folic acid and calcium.    
e Note that some patients were taking multiple medications within the one class (e.g. supplement – single 
ingredients). 
 f‘Other’ in usual care arm: acyclovir, anastrozole, baclofen, bortezomib injection, calcitriol, darbepoetin, 
dutasteride, famciclovir, filgrastim injection, finasteride, fluconazole, imatinib, IV immunoglobulins, nicorandil x 3, 
potassium binding resin, pyridostigmine, sulfasalazine, tamsulosin, tranexamic acid, valacyclovir.   
‘Other’ in intervention arm: betahistine, calcitriol, dutasteride x 3, goserelin implant, lomotil, mebeverine, 
melatonin x 2, nicorandil x 3, norgesic, prazosin, quinine, ranibizumab eye injection, tamsulosin x 3, zopiclone. 
 
The documented prevalence of chronic conditions most commonly encountered in general 
practice was the same between the groups. Prevalence of ischaemic heart disease in the 
intervention group compared to the usual care group was somewhat lower (39.7% vs 55.2%, 
two-sided p-value 0.063) while prevalence of type 2 diabetes was somewhat higher (42.3 % 
vs 28.4%, two-sided p-value 0.081).   The proportion of patients taking one or more 
medications from the top 10 most frequently occurring medication classes at baseline did not 
differ between the intervention and usual care group.   
 Adherence to protocol 
Two of the 10 intervention GPs reported a protocol breach in the generation of a sample of 
patients for recruitment to the study.  The first GP admitted that he did not open the patient 
files when reviewing his patient list generated from the software query to confirm each was 
taking the minimum required number of regular medications according to the software.  
Rather, this GP reviewed their list and identified patients who, from memory, were taking ‘a 
large number of medications’.  The second GP advised that he screened his patients 
according to the perceived willingness of the patient to firstly agree to participate in the study 
and secondly, to be compliant with the intervention.  His rationale was that he was not aware 
of the criteria to generate a consecutive sample of patients.  A sensitivity analysis excluding 
the patients of these two GPs was conducted to examine what effect, if any, these protocol 
breaches had on the primary outcome (see 7.4.3 for more detail).    
All 10 intervention GPs attended one of the two five-hour deprescribing training workshops.  A 
total of 75 of 78 (96.2%) intervention patients had an initial deprescribing appointment with 
their GP as scheduled.  One of the three patients who did not have a deprescribing 
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appointment died before this was able to be scheduled.  The remaining two patients provided 
reasons for declining an appointment when approached by the practice as planned.  The first 
patient described the busyness of their work schedule and general sense that the 
appointment was probably unnecessary as their GP would identify any medication related 
issues through usual care.  The second patient misunderstood the study protocol, and 
declined an appointment with their usual GP, as they thought this was to occur with the 
research team.     
In regard to the use of the autofill template to document the GP-patient deprescribing 
appointment/s, all but one of the 10 GPs used the autofill template, and this individual could 
not provide an explanation for her non-use.  For the remaining GPs, there was a high degree 
of variability in the level of detail and content captured in the autofill template.  None of the 
GPs continued to use the autofill template for documentation beyond the study period, but this 
was expected as the template was study specific (the first line of the template to pre-populate 
the consult notes was, “Patient presented as part of the UQ study on deprescribing”).  Some 
GPs did, however, report continuing to use the reasons for ceasing medications when 
changing the ‘Current Medication’ list, which remained available as a dropdown menu when 
making changes to medications in the medical software.   
 Feasibility outcomes 
 GP/CP utilisation  
An independent samples T-test showed there was no significant difference in the mean [SD] 
number of GP appointments per patient in the intervention compared to the usual care group 
(4.88 [2.512] and 4.46 [2.625] appointments respectively, p = 0.325) during the study period 
which averaged four months.  The median (IQR) length of the initial deprescribing 
appointment for intervention patients was 32 (21-46) minutes.  All but two of the 75 
deprescribing appointments were bulk-billed.   
For the 75 intervention and 65 usual care patients for whom GP and patient-reported follow-
up data were available, 10 (13.3%) intervention patients and three (4.6%) usual care patients 
had had an HMR since being recruited to the study. In the intervention group, all ten referrals 
came from two GPs at the site at which the CP was co-located, although interestingly, they 
had not engaged the services of this pharmacist prior to the study.  There was no significant 
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association between an HMR having been performed following a patient’s recruitment to the 
study and assignment to the intervention.    
 Effectiveness outcomes – Medication-specific outcomes 
 Primary outcome 
In terms of the primary outcome, the mean difference between intervention and usual care 
groups in the number of regular medications deprescribed (i.e. ceased or reduced) per patient 
was -0.55, 95%CI -0.897 to -0.212, p = 0.002, see Table 7-4.  Crude totals showed 77 of 649 
(11.9%) baseline regular medications in the intervention group were deprescribed compared 
to 29 of 571 (5.1%) corresponding medications in the usual care group over the 18 week 
study period (p<0.001).   
 Secondary outcomes 
The proportion of patients in the intervention group who had at least one medication 
deprescribed was 52.6% versus 28.4% in the usual care group (p=0.005).  In comparison with 
the usual care group, intervention group patients were 2.3 times more likely to have at least 
one regular medication deprescribed (i.e. ceased or reduced) during the study period 
(incidence rate ratio [IRR] 2.3; 95% CI 1.297 to 3.964, p = 0.004).  The respective proportions 
of intervention and usual care patients who had two or more medications deprescribed were 
26.9% vs 9.0% (p=0.011), for three or more medications 11.5% vs 4.5% (p=0.143) and for 
four or more medications 6.4% vs 1.5% (p=0.217).   
A statistically significant correlation was apparent between the number of regular medications 
at baseline and the likelihood of deprescribing.  The output from the Negative binomial 
regression modelling showed that for every additional regular medication prescribed at 
baseline, the likelihood of having one or more medications deprescribed increased by 16.5% 
(IRR = 1.165, 95% CI 1.074 to 1.263, p < 0.001).   
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TABLE 7-4 AGREEDA GP AND PATIENT-REPORTED CHANGES TO REGULAR MEDICATIONS PER 
PATIENT DURING THE STUDY PERIOD FOR INTERVENTION AND USUAL CARE GROUPS  
Outcome Measure 
of central 
tendency 
Intervention 
(SD) 
N=78 
Usual Care 
(SD)  
N=67 
Mean 
Difference  
(95% CI)c 
IRRd (95%CI) 
 
P value 
 
Primary Outcome - Deprescribedb 
 
Deprescribedb  Mean 0.99 (1.233) 0.43 (0.839) -0.554  
(-0.897- 
-0.212) 
2.267 (1.297-
3.964) 
0.004 
Median 1 (0-2) 0 (0-1) 
Deprescribedb 
excluding 
supplements  
Mean 0.81 (1.058) 0.42 (0.781) -0.390  
(-0.693-  
-0.087) 
1.915 (1.087-
3.374) 
0.025 
Median 0 (0-1) 0 (0-1) 
 
Secondary Outcomes 
 
Ceased Mean 0.62 (1.022) 0.25 (0.682) -0.362  
(-0.644- 
-0.080) 
2.490 (1.255-
4.938) 
0.009 
Median 0 (0-1) 0 (0-0) 
Reducede Mean 0.37 (0.686) 0.18 (0.490) -0.193  
(-0.387-
0.001) 
2.011 (1.023-
3.954) 
0.043f 
Median 0 (0-1) 0 (0-0) 
Commenced Mean 0.24 (0.488) 0.30 (0.798) 0.055  
(-0.159-
0.269) 
0.839 (0.407-
1.730) 
0.635 
Median 0 (0-0) 0 (0-0) 
Increasede Mean 0.09 (0.288) 0.10 (0.308) 0.015  
(-0.83-  
0.113) 
0.791 (0.277-
2.263) 
0.662f 
 
Median 0 (0-0) 0 (0-0) 
a Agreed indicates agreement of the deprescribing change between the GP record and patient-report.  
b Includes ceased and dose-reduced medications. 
c Equal variances not assumed if p-value for Levene’s Test for Equality of Variances was <0.05. 
d IRR - Incidence Rate Ratio (adjusted for number of baseline regular medications, age and gender). 
ePoisson used instead of Negative binomial regression as variance:mean <1.5.   
fNote that the number of baseline medications did not remain a statistically significant predictor in the model. 
 
When comparing patients taking up to nine medications at baseline to patients taking 10 or 
more regular medications at baseline (i.e. hyperpolypharmacy), the latter group were 2.5 
times more likely to have a medication deprescribed, IRR 2.5, 95% CI 1.422 to 4.376, p = 
0.001.  A three-way cross-tabulation and Chi-square test showed that significantly more 
patients with hyperpolypharmacy in the intervention group had at least one medication 
deprescribed (16 of 21 [76%] of patients) compared with similar patients in the usual care 
group (9 of 25 [36%] of patients), 2-sided p = 0.006.  Table 7-5 shows a breakdown of the 
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number of medications deprescribed across both intervention and usual care groups 
according to baseline number of regular medications for each patient.   
TABLE 7-5 CROSS-TABULATION OF THE NUMBER OF MEDICATIONS DEPRESCRIBED OVER THE 
STUDY PERIOD ACCORDING TO THE NUMBER OF BASELINE MEDICATIONS FOR EACH STUDY 
GROUP 
Study group  Baseline medications 
(abbreviated to ‘meds’) 
Number of medications deprescribed over study period 
0 1 2 3 4 5 Total 
Usual care  
(n = 67) 
<9 baseline meds 32 8 1 1 0  42 
≥10 baseline meds 16 5 2 1 1  25 
Total 48 13 3 2 1  67 
Intervention  
(n = 78) 
<9 baseline meds 32 15 7 3 0 0 57 
≥10 baseline meds 5 5 5 1 4 1 21 
Total 37 20 12 4 4 1 78 
 
As detailed in Table 7-6, single ingredient supplements (e.g. Vit B12 injections, oral calcium, 
fish oil, folic acid, slow-release potassium)  were the medications most commonly 
deprescribed in the intervention group (12 out of 77 [15.6%] medications deprescribed), 
followed by proton pump inhibitors (PPI) and H2 antagonists (8 of 77 [10.4%]), statins (8 of 77 
[10.4%]), oral hypoglycaemics (7 of 77 [9.1%]) and diuretics (5 of 77 [6.5%]).  In the usual 
care group, the medications most commonly deprescribed were calcium channel blockers (5 
of 29 [17.2%]), anticonvulsants (4 of 29 [13.8%]) and antiplatelet agents (4 of 29 [13.8%]).    
Having an HMR following recruitment to the study was not shown to have a statistically 
significant effect on the primary outcome of agreed medications deprescribed during the study 
period when tested in regression modelling (IRR for HMR following recruitment to study 0.8, 
95% CI 0.311 to 2.185, p = 0.698). 
7.4.2.1 Medications that were deprescribed, excluding supplements 
When all supplements (single- or multi- ingredient) were excluded, this equated to a decrease 
in the mean (SD) number of regular medications deprescribed per patient from  0.81 (1.058) 
to 0.42 (0.781) in the intervention and usual care groups respectively, with the mean 
difference being -0.390 (95%CI -0.693 to -0.087, p = 0.012), an effect that remained 
statistically significant with an IRR of 1.9 (95% CI 1.087 to 3.374, p = 0.025).  Crude totals 
showed 63 of 584 (10.8 %) non-supplement medications in the intervention group were 
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deprescribed compared to 28 of 501 (5.6%) in the usual care group over the 18 week study 
period (p = 0.002). 
Considering medications deprescribed according to either the GP record or patient-self report 
as the source of truth, the primary outcome, including and excluding supplements, remained 
statistically significant.  See Appendix 15 and Appendix 16.   
TABLE 7-6 REGULAR MEDICATIONS DEPRESCRIBED FOR WHICH THERE WAS GP AND PATIENT 
AGREEMENT 
Medication Class Frequency  Percent Cumulative Percent 
Usual Care 
Calcium channel blocker 5 17.2 17.2 
Anticonvulsant 4 13.8 31.0 
Antiplatelet 4 13.8 44.8 
Diuretic 2 6.9 51.7 
PPI or H2 antagonist 2 6.9 58.6 
AT2RB 1 3.4 62.1 
Beta-blocker 1 3.4 65.5 
Immune suppressant 1 3.4 69.0 
Insulin 1 3.4 72.4 
Long-term antibiotic 1 3.4 75.9 
NSAID 1 3.4 79.3 
Opioid analgesic 1 3.4 82.8 
Other 1 3.4 86.2 
Other antihypertensive 1 3.4 89.7 
Statin 1 3.4 93.1 
Supplement - multiple ingredient 1 3.4 96.6 
TCA 1 3.4 100.0 
Total 29 100.0  
Intervention 
Supplement - single ingredient 12 15.6 15.6 
PPI or H2 antagonist 8 10.4 26.0 
Statin 8 10.4 36.4 
Oral hypoglycaemic 7 9.1 45.5 
Diuretic 5 6.5 51.9 
Other 5 6.5 58.4 
Bisphosphonates 4 5.2 63.6 
AT2RB 3 3.9 67.5 
Calcium channel blocker 3 3.9 71.4 
SSRI/SNRI 3 3.9 75.3 
Anticonvulsant 2 2.6 77.9 
NSAID 2 2.6 80.5 
Supplement - multiple ingredient 2 2.6 83.1 
Allopurinol 1 1.3 84.4 
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Anticoagulant 1 1.3 85.7 
Antiplatelet 1 1.3 87.0 
Beta-blocker 1 1.3 88.3 
Immune suppressant 1 1.3 89.6 
Inhaled beta-agonist 1 1.3 90.9 
Inhaled combination product 1 1.3 92.2 
Inhaled muscarinic antagonist 1 1.3 93.5 
Insulin 1 1.3 94.8 
Oral corticosteroid 1 1.3 96.1 
Other antilipidaemic 1 1.3 97.4 
Paracetamol 1 1.3 98.7 
TCA 1 1.3 100.0 
Total 77 100.0  
Other intervention – zopiclone, norgesic, tamsulosin (as duodart), calcitriol, melatonin SR 
Other usual care – sulfasalazine 
 
7.4.2.2 Medications that were ceased 
In comparison with the usual care group, intervention group patients were 2.5 times more 
likely to have at least one regular medication ceased during the study period (IRR 2.5, 95% CI 
1.255 to 4.938, p = 0.009) such that the mean difference between groups was -0.362 
medications, 95% CI -0.644 to -0.080, p= 0.012.  
A statistically significant relationship was apparent between the number of regular 
medications at baseline and the likelihood of having one or more medications ceased.  The 
output from the Negative binomial regression modelling showed that for every additional 
regular medication at baseline, the likelihood of having one or more medications ceased 
increased by 25% (IRR 1.25, 95% CI 1.135 to 1.377, p = < 0.001).   
As detailed in Table 7-7, single-ingredient supplements (12 of 48 [25%]), diuretics (5 of 48 
[10.4%]), bisphosphonates (4 of 48 [8.3%]) and oral hypoglycaemics (4 of 48 [8.3%])  were 
the classes of medications most commonly ceased in intervention group patients.  In the 
usual care group, the medications most commonly ceased were calcium channel blockers (4 
of 17 [23.5%]), anti-platelets (3 of 17 [17.6%]) and diuretics (2 of 17 [11.8%]).     
7.4.2.3 Medications that were dose reduced 
In comparison with the usual care group, intervention group patients were 2.0 times more 
likely to have the dose of at least one regular medication reduced during the study period 
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(IRR 2.0, 95% CI 1.023 to 3.954, p = 0.043) such that the mean difference between groups 
was  -0.193 medications 95% CI -0.387 to 0.001, p= 0.051.   
Table 7-8 shows that statins (9 of 33 [27.3%]) and PPI or H2 antagonsists (7 of 33 [21.2%]) 
were the medication classes most likely to have doses reduced in the intervention group 
during the study period.  In the usual care group, anticonvulsants were the medication class 
most likely to have doses reduced (3 of 8 [37.5%]).  The number of regular medications at 
baseline was not a statistically significant predictor of medication/s reduced in the regression 
modelling.  
7.4.2.4 Medications that were commenced or dose increased 
As detailed in Table 7-4, there was no statistically significant difference in the number of 
regular medications commenced or to have doses increased between groups during the study 
period: medications commenced (IRR 0.8, 95%CI 0.407 to 1.730, p = 0.635); medications 
with doses increased (IRR 0.8, 95%CI 0.277 to 2.263, p = 0.662).  Similarly, there was no 
statistically significant difference in the number of prn medications started between 
intervention and usual care patients (IRR 0.957, 95%CI 0.129 to -7.112, p = 0.965).   
Consistent with the primary outcome, when GP and patient-reported changes were 
considered separately, corresponding secondary outcomes remained statistically significant.  
The few  exceptions to this were for the outcomes of ceased medications when supplements 
were excluded from the analysis and patient-reported dose-reduced medicines.  See 
Appendix 15 and Appendix 16.   
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TABLE 7-7 REGULAR MEDICATIONS CEASED FOR WHICH THERE WAS GP AND PATIENT 
AGREEMENT 
Medication Classes Frequency Percent Cumulative Percent 
Usual care  
Calcium channel blocker 4 23.5 23.5 
Antiplatelet 3 17.6 41.2 
Diuretic 2 11.8 52.9 
Anticonvulsant 1 5.9 58.8 
Immune suppressant 1 5.9 64.7 
Long-term antibiotic 1 5.9 70.6 
NSAID 1 5.9 76.5 
Opioid analgesic 1 5.9 82.4 
Other 1 5.9 88.2 
Supplement - multiple ingredient 1 5.9 94.1 
TCA 1 5.9 100.0 
Total 17 100.0  
Intervention  
Supplement - single ingredient 12 25.0 25.0 
Diuretic 5 10.4 35.4 
Bisphosphonates 4 8.3 43.8 
Oral hypoglycaemic 4 8.3 52.1 
Other 4 8.3 60.4 
Anticonvulsant 2 4.2 64.6 
Calcium channel blocker 2 4.2 68.8 
PPI or H2 antagonist 2 4.2 72.9 
SSRI/SNRI 2 4.2 77.1 
Supplement - multiple ingredient 2 4.2 81.3 
Antiplatelet 1 2.1 83.3 
Immune suppressant 1 2.1 85.4 
Inhaled beta-agonist 1 2.1 87.5 
Inhaled combination product 1 2.1 89.6 
Inhaled muscarinic antagonist 1 2.1 91.7 
NSAID 1 2.1 93.8 
Other antilipidaemic 1 2.1 95.8 
Paracetamol 1 2.1 97.9 
TCA 1 2.1 100.0 
Total 48 100.0  
Other – zopiclone, tamsulosin, calcitriol, melatonin SR. 
TABLE 7-8 REGULAR MEDICATIONS TO HAVE DOSES REDUCED FOR WHICH THERE WAS GP AND 
PATIENT AGREEMENT 
Medication Classes Frequency Percent Cumulative Percent 
Usual care 
Anticonvulsant 3 37.5 37.5 
AT2RB 1 12.5 50.0 
Beta-blocker 1 12.5 62.5 
Insulin 1 12.5 75.0 
Other antihypertensive 1 12.5 87.5 
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PPI or H2 antagonist 1 12.5 100.0 
Total 8 100.0  
Intervention  
Statin 9 27.3 27.3 
PPI or H2 antagonist 7 21.2 48.5 
AT2RB 3 9.1 57.6 
Oral hypoglycaemic 3 9.1 66.7 
Calcium channel blocker 2 6.1 72.7 
Allopurinol 1 3.0 75.8 
Anticoagulant 1 3.0 78.8 
Antiplatelet 1 3.0 81.8 
Beta-blocker 1 3.0 84.8 
Insulin 1 3.0 87.9 
NSAID 1 3.0 90.9 
Oral corticosteroid 1 3.0 93.9 
Other 1 3.0 97.0 
SSRI/SNRI 1 3.0 100.0 
Total 33 100.0  
Other = Norgesic 
 
7.4.2.5 Medications that were altered through reconciliation 
Step one of the application of the CEASE protocol (91) by a clinician is medication 
reconciliation, i.e. deleting, adding or amending doses of medications to reflect current true 
use. Medication reconciliation was performed 5.1 times more frequently among 
intervention patients compared to usual care patients (IRR 5.0, 95% CI 3.085 to 8.244, p 
<0.001), such that the mean difference in the number of medications reconciled between 
groups was -2.078 (95% CI -2.662 to -1.494, p <0.001). 
 Sensitivity analyses to account for protocol breaches  
Three sensitivity analyses were performed to account for changes in study protocol.  The 
Per Protocol analysis was specified a priori.  The Per Protocol analysis, in contrast to the 
ITT principle described previously, refers to conducting the analysis based on the study 
participants’ (in this case the patients’) actual receipt of, rather than original allocation to, 
the intervention.  The Per Protocol analysis would be comparable to the ITT analysis if 
there was a high level of protocol adherence in the study.   
Two sensitivity analyses were not specified a priori because they could not be pre-empted 
in this exploratory study.  That is, two GPs stated in their follow-up semi-structured 
interview that they deviated from the procedure to identify a consecutive sample of eligible 
patients to be contacted by the research team for recruitment (see 7.2 Adherence to 
protocol, for more detailed information regarding this).  Furthermore, one GP left the 
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practice mid-study and so the analysis was repeated excluding their patients to see if this 
had any impact on the effect size.  As demonstrated in Table 7-9, the effect size remained 
stable and statistically significant, regardless of the unanticipated protocol deviations.   
TABLE 7-9 SENSITIVITY ANALYSES OF AGREEDA GP AND PATIENT-REPORTED CHANGES TO 
REGULAR MEDICATIONS PER PATIENT DURING THE STUDY PERIOD FOR INTERVENTION AND 
USUAL CARE GROUPS 
Outcome Measure 
of central 
tendency 
Intervention 
(SD) [n] 
Usual Care 
(SD) [n] 
Mean 
Differencec  
(95% CI) 
IRRd (95% CI) 
 
P 
value 
 
Medications Deprescribedb – 
 
Per protocol Mean  1.03 (1.241) 
[n=75] 
0.41 (0.825) 
[n=70] 
-0.612  
(-0.957- 
-0.268) 
2.461 (1.410-
4.295) 
0.002 
Median 1 (0-2) 0 (0-1) 
Excl. patients of 
two GPs who 
breached 
recruitment 
protocol  
Mean 0.93 (1.226) 
[58] 
0.43 (0.839) 
[67] 
-0.498  
(-0.877- 
-0.119) 
2.223 (1.223-
4.043) 
0.009 
Median 0 (0-2) 0 (0-1) 
Excl. patients of 
GP who left the 
practice mid-
study  
Mean 1.01 (1.225) 
[67] 
0.43 (0.839) 
[67] 
-0.582  
(-0.941-  
-0.223) 
2.331 (1.315-
4.130) 
0.004 
Median 0 (0-1) 1 (0-2) 
a Agreed indicates agreement of the deprescribing change between the GP record and patient-report.  
b Includes ceased and dose-reduced medications. 
c Equal variances not assumed if p-value for Levene’s Test for Equality of Variances was <0.05. 
d IRR - Incidence Rate Ratio (adjusted for number of baseline regular medications, age and gender). 
 
 Intervention impact on patients’ attitudes to deprescribing and quality of life 
The Patients’ Attitudes Towards Deprescribing (PATD) questionnaire was administered to 
intervention patients at baseline and follow-up.  The EQ-5D-5L was administered to all 
patients at baseline and follow-up.  See Appendix 17 and Appendix 18 for copies of each.   
Pre- and post- intervention PATD responses were used to assess changes in patients’ 
attitudes towards their medication regimens and deprescribing over the study period.  
Baseline scores were also used to test for an association between baseline responses and 
deprescribing outcomes.   
The EQ-5D-5L was used to assess self-reported health-related quality of life (HRQoL) over 
the study period.  The rationale for including this quality of life measure was as a ‘red flag 
indicator’, i.e. to indicate whether the intervention was causing short-term harm, rather 
than longer-term benefit, the latter typically seen over a much longer study period in regard 
to HRQoL.  Consequently, the responses for the first five domains of the EQ-5D-5L which 
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use a five-point Likert scale were dichotomised to reflect an improved or worsened score 
in the domain.  The global health score out of 100 was reported unchanged.   
7.4.4.1 PATD survey responses over study period  
The paired pre- and post-intervention patient response rate was high, with eight out of 10 
statements on the questionnaire survey having a paired response from 73 of 75 patients, 
noting that three of the 78 intervention patients were lost to  follow-up and did not 
participate in the follow-up phone interview.    The PATD ten statements were scored on a 
five-point Likert scale: 1 = Strongly Agree; 2 = Agree; 3 = Unsure; 4 = Disagree and 5 = 
Strongly Disagree.   There were statistically significant changes between pre- and post-
intervention responses for three of the ten statements in the PATD questionnaire, as seen 
in Table 7-10.  Two of the statements pertained to the necessity of the current medication 
regimen and one pertained to the belief of side effects with the current regimen.   
TABLE 7-10 RESULTS FOR PRE-AND POST-TEST PATD QUESTIONNAIRE RESPONSES 
PATD Question (n = paired responsesa) Mean at 
Baseline 
Mean at 
Follow-up 
P (2-
tailed)b 
1. I feel that I am taking a large number of medications (n = 71) 2.47 2.55 0.360 
2. I am comfortable with the number of medications I am taking (n = 
72) 
2.36 2.27 0.386 
3. I believe all my medications are necessary (n = 73) 2.05 1.88 0.013 
4. If my doctor said it was possible I would be willing to stop one or 
more of my regular medications (n = 73) 
1.79 1.91 0.287 
5. I would like to reduce the number of medications that I am taking (n 
= 73) 
2.24 2.33 0.623 
6. I feel that I may be taking one or more medications that I no longer 
need (n = 73) 
3.24 3.76 <0.001 
7. I would accept taking more medications for my health conditions (n 
= 73) 
2.36 2.33 0.509 
8. I have a good understanding if the reasons I was prescribed each of 
my medications (n = 73) 
1.83 1.75 0.524 
9. Having to pay for less medications would play a role in my 
willingness to stop one or more of my medications (n = 73) 
3.37 3.60 0.063 
10. I believe one or more of my medications is giving me side effects 
(n = 73) 
3.05 3.40 0.012 
a Non-paired responses were excluded from the analysis. b Tested using Wilcoxon signed rank test   
For the statement, “I believe all my medications are necessary”, the decrease in mean 
score post-intervention as seen in Table 7-10, reflected greater agreement with the 
statement (z = -2.475, p = 0.013).  That is, overall, more people believed their medications 
were necessary after the intervention than before.  Figure 7-2 shows the shift in response 
between baseline and follow-up.   There were two and five missing responses, at baseline 
and follow-up, respectively.    
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FIGURE 7-2 FREQUENCY OF PAIRED RESPONSES TO PATD STATEMENT "I BELIEVE ALL MY 
MEDICATIONS ARE NECESSARY"  
 
For the negatively worded statement, “I feel that I may be taking one or more medications 
that I no longer need” the increase in mean score post-intervention as seen in Table 7-10 
reflected greater disagreement with the statement (z = -4.067, p = <0.001).  Note that 
greater disagreement with a negatively worded statement is equivalent to greater 
agreement with a positively worded statement.  That is, overall, fewer people believed their 
medications were unnecessary after the intervention than before.  Figure 7-3 shows the 
shift in response between baseline and follow-up.  Notably, 22 participants were unsure in 
response to this statement at baseline, as opposed to only five at follow-up.  There were 
two and three missing responses, at baseline and follow-up, respectively.   
FIGURE 7-3 FREQUENCY OF PAIRED RESPONSES TO PATD STATEMENT “I FEEL THAT I MAY BE 
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For the statement, “I believe one or more of my medications is giving me side effects” the 
increase in mean score post-intervention reflected greater disagreement (z = -2.521, p = 
<0.012) as seen in Table 7-10.  That is, overall, fewer people believed their medications 
were giving them side effects after the intervention than before.  Figure 7-4 provides a 
breakdown of responses.  Notably 12 more patients disagreed with this statement at 
follow-up than at baseline.  Again, there were two and three missing responses, at 
baseline and follow-up, respectively.   
FIGURE 7-4 FREQUENCY OF PAIRED RESPONSES TO PATD STATEMENT “I BELIEVE ONE OR 
MORE OF MY MEDICATIONS IS GIVING ME SIDE EFFECTS” 
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accounted for 69.3% of the total variance.  Factors 1 and 2, which accounted for 45.5% of 
the total variance, were retained for further analysis but the Factors 3 and 4 were 
discarded, with loadings for only one and two of the possible ten PATD survey items. See 
Appendix 17 to review the first ten items of the PATD survey.   
Factor 1 had high loadings for PATD survey items 1, 4 and 5.  This set of questions related 
to a willingness to consider deprescribing at baseline (participants felt they were taking a 
large number of medications, were willing to stop one or more regular medications and 
wanted to reduce the number of medications taken).  Factor 2 had high loadings for PATD 
survey items 2, 3 and 6 but survey responses for item 6 were reverse coded so that all 
scores for this factor were positively correlated.  This set of questions related to 
satisfaction with the medication regimen at baseline and arguably less willingness to 
consider deprescribing (i.e. participants were comfortable with the number of medications 
they were taking, believed that all their medicines were necessary and did not feel they 
were taking medicines that were no longer needed).  
Neither Factor 1 nor 2 were statistically significant predictors of the primary outcome when 
imputed into the Negative binomial regression model (Factor 1 Exp(B) 0.946, 95% CI 
0.636 to 1.407; p = 0.785; Factor 2 Exp(B) 1.148, 95% CI 0.781 to 1.689; p= 0.482). 
7.4.4.3 Quality of life over the study period 
As seen in Table 7-11 below, Chi squared tests for independence did not show a 
statistically significant change in responses pertaining to any of the five HRQoL domains.   
TABLE 7-11 CHI-SQUARED TEST FOR PAIRED-RESPONSES TO DICHOTOMISED EQ5D5L 
STATEMENTS 
Domain % of Intervention patients 
who reported worsened 
score  
(n = 64) 
% of Usual Care patients 
who reported worsened 
score  
(n = 73) 
Continuity 
Correction Sig. (2-
sided) 
Mobility 18.8% 31.5% 0.131 
Personal Care 10.9% 8.3%a  0.823 
Usual Activities  31.3% 21.9% 0.297 
Pain/Discomfort 25.0% 18.3%b  0.462 
Anxiety/Depression  25% 11.0% 0.053 
a n = 72 due to missing data.   
b n = 71 due to missing data.   
 
There were 63 and 70 paired global health score responses for intervention and usual care 
patients, respectively, demonstrating a response rate of 90% or more for both groups.   
There was no statistically significant difference in paired global health change scores (on 
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the 0-100-point scale) between intervention and usual care patients (mean change -1.84 
for the intervention group and -1.30 for the usual care group, p = 0.842).    
 Self-reported unplanned hospitalisations  
Poisson regression modelling adjusting for age, gender, number of GP-patient agreed 
regular medications at baseline and number of common chronic comorbidities showed a 
trend towards reduced numbers of self-reported unplanned hospitalisations among 
intervention patients compared to usual care patients during the study period, IRR 0.4, 
95% CI 0.183-1.014, p = 0.054.   Data were missing for four intervention and two usual 
care patients.  
 Safety protocol 
 Suspected/actual adverse outcomes or experiences 
No actual adverse outcomes were reported to the research team throughout the study 
period.  Two forms to report suspected adverse outcomes or experiences (see Appendix 
3) were completed however, as a result of patient dissatisfaction with the deprescribing 
process.  The first form was completed by the PhD candidate after being contacted by a 
patient directly.  This patient had incorrectly attributed the emergence of a new health 
complaint to the reduction in dose of two medications and the patient was followed up by 
their GP for ongoing care.  The second form was completed by one of the GPs following 
the patient’s expression of dissatisfaction at having her medications altered.  The latter 
incident related in part to the patient feeling that the GP making the change was not their 
principal GP and has been described in detail in Chapter 8.   
 Discussion 
The results in this chapter address the effectiveness and safety of the multifaceted 
intervention on the medication regimens of older community based patients with 
polypharmacy, and patients’ attitudes towards deprescribing and self-reported quality of 
life.  The vast majority (96%) of intervention patients had an initial deprescribing 
appointment as scheduled.  The mean difference between intervention and usual care 
groups in the number of regular medications deprescribed per patient was -0.55, 95%CI -
0.897 to -0.212, p = 0.002.  Compared to usual care patients, intervention patients were 
2.3 times more likely to have one or more medications deprescribed (ceased or doses 
reduced) over the 18-week study period after adjusting for age, gender and the number of 
baseline regular medications.  Crude totals showed 77 of 649 (11.9%) baseline regular 
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medications in the intervention group were deprescribed compared to 29 of 571 (5.1%) 
corresponding medications in the usual care group over the 18 week study period 
(p<0.001).  There was no statistically significant change in the number of medications 
commenced or increased between groups over this same period.  Compared to usual care 
patients, fewer intervention patients with hyperpolypharmacy (≥ 10 regular medications) 
had no medications deprescribed.  The main medication classes deprescribed in 
intervention group patients were single ingredient supplements, proton pump inhibitors and 
H2 antagonists, statins, oral hypoglycaemics and diuretics.   There was no statistically 
significant difference in the number of GP appointments, HMRs, or self-reported 
unplanned hospitalisations between intervention and usual care patients, noting the 
limitation of small event numbers for the latter two measures.   
For intervention patients who, at baseline, were either unsure or disagreed with the 
necessity or appropriateness of their medication regimen, receiving the intervention 
appears to have increased their certainty or agreement that their medication regimen at 
follow-up was in fact necessary or appropriate.  Participating in the study did not 
deleteriously affect self-reported HRQoL and was not associated with any reported harm.   
There are three key methodological limitations to this study.  A threat to the internal validity 
was the potential for selection bias by GPs in the generation of a consecutive sample of 
eligible patients for each GP.  Although a clear and documented procedure was provided 
to each GP (or their nominated delegate) to do this, two GPs advised that they did not 
strictly adhere to this procedure.  It is possible that other GPs, even subconsciously, may 
have influenced the patient selection process.  The rationale for not insisting on random 
patient selection was to avoid the additional burden this would have imposed on GPs (or 
their delegate) and the desire to minimise barriers to project participation, particularly in 
the context of time-limited recruitment challenges.  Even though sensitivity analyses 
showed that the size and statistical significance of the primary outcome was preserved 
when the patients of the two GPs who did not adhere to the procedure were excluded, it is 
possible that these study results may have differed had patients been selected randomly.   
Likewise, the reliance on a convenience sample of practices and clinicians may have 
introduced sampling bias in this exploratory study.  This potential bias is likely to have 
significantly less impact on results than that arising from patient selection bias however, as 
studies to change clinician behaviour typically tend to be conducted in groups of ‘early 
adopters’ (that is, those with interest in the topic for investigation, who are open to new 
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ideas and usually demonstrate a high ‘readiness to change’. (217, 218)  These participants 
are unlikely to be representative of ‘typical’ practices/clinicians, with significantly different 
characteristics.  (217)  It is possible, however, that these ‘early adopters’, with an existing 
interest in the topic of investigation, may have already changed their prescribing 
behaviour, leaving little margin for further deprescribing of inappropriate medicines, 
thereby reducing any positive effect size.   
The absence of independent outcome assessors and reliance on data collection from 
medical records which clearly revealed patients’ group allocation, prevented blinding of 
assessors/investigators, introducing the potential for ascertainment bias.  (219)  This was 
mitigated to some extent by cross-referencing data regarding changes in medications 
between patients and GPs in constructing ‘agreed’ lists of changes, and the high inter-rater 
reliability in the application of a standardised, documented process to categorise 
medication changes only from the GP record.   
There were also several methodological strengths to this study.  This is one of the first 
studies to elicit patients’ attitudes towards their medicines and deprescribing at baseline 
using the PATD questionnaire and to investigate the relationship between baseline scores 
and the outcomes of deprescribing (which was not medication class specific).  Although no 
association was found between baseline PATD responses and deprescribing outcomes, 
the change in PATD scores during the study provide interesting insights.  It is possible that 
the increased belief in the necessity and appropriateness of medicines perceived by some 
patients, could have implications for improved adherence, although this needs to be 
studied further.   
Other strengths relate to robust and standardised data collection processes given the 
pragmatic design.   For example, strategies to ensure a standardised approach when 
collecting data from patients over the phone, included: 1) the development and use of a 
standardised data collection template and question guide for interviewers; and 2) ensuring, 
wherever possible, the same researcher conducted the baseline and follow-up survey.   
Other examples included the use of strategies such as collecting data from medical 
records to the point of saturation (as was employed when documenting patients’ chronic 
conditions at baseline by scrutinising GPs notes, hospital discharge letters and specialist 
correspondence until no new chronic conditions could be detected) and, wherever 
possible, cross-referencing patient-reported outcomes with the medical record to increase 
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the accuracy of the data.  Furthermore, reporting ‘agreed’ medication outcomes mitigated 
to some extent the potential effect of patient recall bias.  Although reporting the medication 
related outcomes in this way diminished the effect size, it was deemed to be the most 
robust and conservative method for presenting the data.   
Some key points are noteworthy when comparing this study to other studies investigating 
interventions to reduce polypharmacy in community living older people.  The systematic 
review and meta-analysis by Johansson et al of strategies to reduce polypharmacy on 
clinically relevant endpoints showed that the weighted mean number of drugs was reduced 
by -0.2 of a medicine in the intervention group but increased +0.2 of a medicine in 
controls.  The mean difference in the number of medicines ceased per patient between the 
intervention and usual care group in this study was -0.362 ( 95% CI -0.652 to -0.071, p= 
0.015), which is an effect size comparable to that reported by Johansson. (30)   This study, 
being exploratory in nature, had a shorter length of follow-up compared to studies detailed 
in Johansson’s review (four months compared to 12 months for most trials, range 1.5-18 
months), so it is therefore unclear if the effect observed in this study would have been 
preserved or changed over time. (30)  This is important to consider given findings from 
previous studies that as many as one quarter of medicines deprescribed are restarted 
within 6 to 12 months.  (220, 221)  
In evaluating this study, no attempt was made to assess the appropriateness of the 
medicines deprescribed using explicit or implicit criteria given their limitations. For 
example, explicit checklists (such as the Beers criteria) are typically divorced from the 
highly contextualised process of individualised therapeutic decision-making, required when 
considering deprescribing in older patients with multimorbidity and polypharmacy.  Implicit 
criteria, such as the Medication Appropriateness Index (MAI), exhibit floor effects, such 
that the number of ‘inappropriate’ ratings tend to be low.(81)  This was clearly 
demonstrated in a pilot study which studied the feasibility of a quality use of medicines 
intervention in a GP and patient cohort very similar to those studied here. (115)   Muth and 
colleagues investigated a complex intervention which prioritised multiple medications in 
community living people aged 65 years and older with three or more chronic conditions 
and five or more chronic prescriptions across 20 general practices in Germany over 12 
weeks.  (115)  The primary outcome was a change in the MAI at the patient level, which 
was not shown to be statistically significant at study completion.  One of the key reasons 
for this was that the baseline MAI scores were very low (indicating high medication 
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appropriateness), leaving very little scope for a further decrease in MAI scoring.  (115)  
The application of the MAI was also highly labour intensive and time consuming, making 
its application unfeasible within the time and resource constraints of this PhD research 
project.   
Similarly, no attempt was made to assess under-dosing of appropriate medicines in this 
study, although it is acknowledged that this also deserves attention in older people with 
polypharmacy. (52-54)  It is speculated however, that deprescribing may be an entry point 
to more appropriate prescribing and medicines use generally.  That is, reducing potentially 
inappropriate polypharmacy may optimise patients’ medication regimens and improve their 
adherence to essential therapy.  (222)  This further supports the need for greater 
investigation of the impact of deprescribing on patient adherence to essential therapy and 
whether it is the deprescribing process or outcome that is important in facilitating any 
potential beneficial effect.     
An important unanswered question from this study regards the fulfilment of intent to 
deprescribe.  Unfortunately, there was insufficient consistent documentation to indicate if, 
for example, GPs wished to deprescribe more potentially inappropriate medicines (PIMs) 
but patients were unwilling.  This would have been interesting to elicit, given conflicting 
qualitative research that GPs report it is patients who are often unwilling to deprescribe 
PIMs, (9) yet patients report that their GP can be highly influential in encouraging them to 
deprescribe medicines. (8) 
 Conclusion 
In summary, the intervention lead to a clinically modest but statistically significant 
deprescribing effect in community living older people.  The intervention was not associated 
with a higher number of GP visits or referrals for HMRs (i.e. the optional component of the 
intervention). Importantly, the intervention was also not associated with any reported harm 
or deterioration in quality of life in the short-term which may have resulted from injudicious 
attempts at deprescribing appropriate medication.  For a subset of patients, there was 
greater belief that their medication regimens were necessary and appropriate.  In the next 
chapter (Chapter 8), qualitative findings will be presented to describe the feasibility of the 
intervention and further explain some of these quantitative findings.   
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Chapter 8  Qualitative findings of Phase 3 exploratory study 
Complementary to Chapter 7 which reported the quantitative perspective on the 
intervention’s effectiveness, this chapter expands on this reporting with the qualitative 
findings of semi-structured interviews with GPs and patients after completion of the 
intervention.  To that end, this chapter provides insights into the implementation of the 
intervention in practice, including adoption of its elements, acceptability, and the likelihood 
of sustainability in routine care.  These three constructs have been defined using the work 
of Proctor et al (144) such that: adoption is the ‘intention, initial decision, or action to try or 
employ an innovation or evidence-based practice’; acceptability is the ‘perception among 
implementation stakeholders that a given treatment, service, practice, or innovation is 
agreeable, palatable or satisfactory’;  and sustainability is ‘the extent to which a newly 
implemented treatment is maintained or institutionalised within a service setting’s ongoing, 
stable operations’.  The perspectives of GPs regarding the earlier phases of the 
intervention are reported first before providing an integrated GP and patient perspective on 
the deprescribing consultations and arising consequences.   As described previously in 
Chapter 6, a qualitative descriptive approach was used, which has been shown to be an 
appropriate choice for mixed methods health services research. (142)  Thematic analysis 
was conducted deductively initially, with responses segmented according to interview 
questions which aligned with the intervention phases.  The second step involved 
developing the themes inductively, with reference to concepts from the study of feasibility 
literature. (215) 
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 Findings 
Findings of the analysis are organised and discussed by way of three descriptive themes: 
1) Adoption into GPs’ practice; 2) Perceived value of deprescribing and; and 3) Spread 
and sustainability.  The first and third themes principally reflect the views of GPs as the 
primary adopters of the intervention.  The second theme is an integrated perspective of 
GPs and patients as joint adopters of the intervention from the point of the deprescribing 
appointment/s onwards.  Extracts throughout this chapter reflect both divergent and 
convergent views and were labelled with a unique identifier.  Quotations from GPs and 
patients are denoted by GPxx and Ptxx, respectively, where x reflects a number from 0-9.     
 Adoption into GPs’ practice   
Adoption of the intervention involved the GP (or for the first activity, their practice delegate) 
actioning or attempting to action the three mandatory components of the intervention (that 
is, identifying potentially eligible patients, participating in the deprescribing workshop and 
having at least one, extended deprescribing appointment with each of their patients).  GPs 
reported a range of factors that were facilitative and/or inhibitory to each of these activities.   
8.1.1.1 Identifying potentially eligible patients  
This element of the intervention, that is, identification of eligible patients, was to be aided 
by a software query. However, this was impeded by out of date medication lists and 
uncertainty about the patient’s preferred GP. In turn, GPs compensated by using the 
manual screening process, which had been devised in advance in anticipating data quality 
issues. 
GP04: It – it had to do the manual checking part of it as well - - - 
Int: Mmm. 
GP04: - because, um, it did – it does do things like throw – I do recall it threw up 
patients that weren’t actually my regular patients that I’d just seen once or twice and 
-  
Int: Right.  Yeah. 
GP04: - um, for some reason.  Um, I’m sure there was some other issues with it -  
Int: Mmm. 
GP04: - the – the – so it did need that sort of manual tuning.  Yeah - 
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Although not perceived to be burdensome by intervention GPs, the task of identifying 
eligible patients clearly did take time and some GPs required prompting for this to occur in 
time for the deprescribing workshop. Moreover, this time had to be found often after hours, 
as described by this GP. 
GP06: “Um, I don’t know. I – I think it depends a little bit on your perception of 
what’s onerous and I’m perfectly happy to sit here and I mean, I’m sure I sat here 
after hours and just went through the list and worked out who was who and went 
through it, but for me, no, it wasn’t onerous.”   
Similarly, regarding identifying patients for the study, one GP stated -  
GP08: I don’t think that it took any - much more time than it does to do any other 
quality improvement process. 
Int: Okay. 
GP08: Less than most, really. 
These comments suggest an acceptance or willingness on GPs’ behalf to invest the time 
to identify patients to make the intervention work.  A number of GPs also highlighted the 
benefit of this exercise, beyond the intervention.  In response to being questioned about 
the time spent identifying patients, one GP responded -  
GP09:  I think it was a good thing for me. 
Int: Right. 
GP09: Because it really did highlight, um, out of that list then well really who am I 
targeting. 
Int: Yes. 
GP09: Um, so for me it was a - it was a win-win. 
One practice took this further and used the process of patient identification to flag 
individuals for other potential activities, like health assessments and multidisciplinary care 
plans.   
GP02:  But it is – it’s sharpened the focus on what the doctors do with care 
planning. 
While the process of identifying patients required an investment of time and effort, it 
appeared acceptable to GPs as it was perceived a necessary first step for the intervention. 
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Some also found value gain in identifying a vulnerable patient group for their own 
awareness or other health activities despite the trade-off of time.  That said, the 
combination of data quality issues and the requirement for prompting to facilitate this task 
in a timely manner raises questions about the sustainability of this aspect of the 
intervention.   
8.1.1.2 Deprescribing training workshop    
There was overwhelmingly positive feedback from all GPs regarding the training 
workshop.  The GP participants reported that the presentation of the evidence pertaining 
to polypharmacy and deprescribing raised their awareness of the need for deprescribing. 
The practical and interactive application of elements of the CEASE framework to case 
studies was also highly valued.   
GP02: The workshop was excellent, um, identifying, um, the problem and the scope 
of problem and some well-presented ways of managing it. 
They articulated that other practical aspects of the workshop, including how to document 
deprescribing interactions in their software, were also helpful in adequately preparing them 
for adoption of the intervention.   
GP05: I thought it was very good, that workshop.  Um, went through - it went 
through all the major issues that we - we were trying to address very well.  It had - 
had a section on the practical, um, step-by-step processes and that about what 
we're doing and it was also adapted to the - the Best Practice system. 
Int: Yes. 
GP05: So we had that auto, ah, fill - - -  
Int: The auto fill shortcut, yeah. 
GP05: - - - which worked very well.  I mean, obviously I came back and had a little 
go with it here as well, but it seemed to work very well.  So I thought I was pretty 
well prepared for it. 
Int: Yes. 
GP05: And we - for - for when - when we did it. 
Int: Yeah.  What - - - 
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GP05: Um, I can't think of any major issues that arose doing it that we hadn't 
covered in the - in the, ah, workshop, yeah. 
This GP’s experience of the workshop, likewise for another, motivated them to present the 
material at a clinical practice meeting and articulate the need for deprescribing to their 
peers.  There was agreement from other GPs that the training workshop should be made 
available to GP colleagues not involved in this study –  
GP09:  I thought it was fabulous.  Um, honestly, I thought that whole day was 
brilliant.  Um, and I'd replicate it again and highly, I suppose, recommend (it to) 
everyone.  Not just anyone - just I suppose outside of the realm of this actual study 
itself of an actual workshop for educating GPs regardless -  
Int: Right. 
GP09: - I think it would be really valuable as well.      
The face-to-face interactive workshop was therefore a key component of the intervention, 
providing important theoretical and practical deprescribing support.  It was also perceived 
as being valuable and applicable to GPs not involved in the exploratory study.  This was 
reinforced by the example of peer knowledge translation in which two GPs were motivated 
to share knowledge from the workshop with other colleagues in their practice.   
8.1.1.3 Deprescribing appointment/s  
Deprescribing appointments with patients were core to the intervention. Most GPs 
indicated that the intervention was more an opportunity for refinement of patients’ 
medication regimens rather than making wholesale change, as described in this extract.       
GP08:  I guess you’d have to think that if you’ve been trying to do that, um, 
deprescribing, um, all along you may have not that much wriggle room left, um, in 
some of the steps that you wanted to take in those individuals. 
They attributed this to a number of factors - either that their prescribing was appropriate to 
begin with and/or that deprescribing was something they had already considered, albeit 
largely opportunistically. Consequently, GPs perceived that their deprescribing efforts 
involved working at the margins, as the same GP articulated -  
GP08:  But my gut feeling is that I probably didn’t actually achieve an awful lot of 
real deprescribing.  Um, I – it would be at the margins, I would’ve thought. 
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Most GPs reported that the majority of work occurred at the initial deprescribing 
appointment.  There were typically time-consuming aspects, including verifying each 
medicines’ indication and discussions with patients about their medicines.  Below, a GP 
explains how these issues, combined with the lack of familiarity with the application of the 
deprescribing process, made these appointments more time consuming initially compared 
to routine appointments.     
GP10: It initially took a long time -  
Int: Right. 
GP10: - just getting heads around and patients, um, understanding exactly what 
we’re doing -    
Int: Yes. 
GP10: -  but after – once you, um – I can’t even remember, um, sort of, put down, 
um – went through the notes and put down a reason for each medication – once 
you worked that out it worked quite quickly -  
Int: Okay. 
GP10: - after that it was quite quick.  
For patients in whom deprescribing was attempted for one or more medicines, subsequent 
visits tended to be used to monitor the effects and outcomes of changes made, rather than 
instigate further change.   
GP02: I think most was achieved in this first visit, in terms of deprescribing. And 
some, um, I found that I wasn’t really deprescribing as much at a later date, it was 
something that I’d reduced the dose and it was a case of moderating that 
adjustment.    
As described in Chapter 7, the follow-up undertaken to confirm that any changes were 
appropriate was not associated with an increase in the number of appointments for 
intervention compared to usual care patients over the study period.   
For the subset of patients where GPs flagged multiple potential changes over the study 
period, a sustained effort over a number of appointments was required.  According to one 
GP, in these cases structured follow-up may be a facilitator of deprescribing as it would 
keep the goals in mind rather than allow them to be forgotten.    
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GP05: Yeah.  It might have been worth doing that actually, more regimented follow-
up because it tends to fizzle out otherwise I think. 
Int: Right. 
GP05: Truthfully.  I can't, you know, I think out of sight, out of mind a bit. 
Int: Yes, yeah. 
GP05: I think maybe after - after a few visits if you don't discuss it; it kind of -  
Int: Yes. 
GP05: - possibly just gets a bit forgotten. 
Int: Forgotten, sure, sure.  So -  
GP05: And then it might have been better to have had a more formal follow-up. 
Other comments indicated minor adaptations to the intervention process to better integrate 
it into existing workflows. Two GPs reported printing out hard copy medication lists, which 
were used as a tool to facilitate discussions, reconcile medication lists and create a 
deprescribing plan with patients, in preference to directly recording this information in the 
medical software in the first instance.  The rationale for this change was described in terms 
of the power of a working partnership with the patient.       
GP02: And I could do it on the screen, but I think the, the consultation, the doctor-
patient experience about going through this together –  
Int: Together, yes. 
GP02: - is more powerful.  Just looking at the screen is not going to take you off 
this.   
Int: Of course.   
GP02:  Compared to (explaining to the patient) the rationale behind it.  
This adaptation allowed the GPs to conduct the appointment and communicate with the 
patient in their preferred manner, leaving the recording of consultation notes (and the 
minimum documentation requirements for the research team) to the end of the interview.   
8.1.1.4 Referral for HMR (optional element)  
Only 10 intervention patients (13%) were referred for an HMR during the study period. The 
referrals came from two of three GPs at the site at which the consultant pharmacist (CP) 
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was co-located. Although the third GP at this same site had routinely referred for HMR, 
this participant ceased referrals during the study period on the mistaken belief that this 
was not permitted.       
The consensus reasoning among the remaining GPs who did not refer patients was that it 
either did not occur to them, or they could not see the value in undertaking a HMR after 
having just done a medication review themselves.   
GP07: - I don’t think the - the pharmacist would offer too much more.  
For some GPs this was reinforced by negative past experiences with inferior quality HMR 
reports, in particular the absence of relevant, individualised recommendations due to a 
lack, on the part of the CP, of tacit knowledge of the patient and their medical history.   
The absence of an existing relationship between the trained pharmacist and GPs at the 
other two sites appeared to be a potential reason for non-referral.  One GP explained –  
GP06: Yeah and if I had any concerns I would have just popped next door (to the 
pharmacy) 
Int: Next door.  Yes.   
GP06: - because I do that constantly.   
The two GPs who referred patients for HMR routinely as part of the intervention, despite 
never engaging that pharmacist prior to the study, had mixed views on the value of this 
service.  One GP felt that the pharmacist involvement was duplicative and unnecessary, 
and they did not agree with some of the pharmacists’ recommendations –  
GP01: No.  I think it was just doubling up. 
Int: It was doubling?  Right. 
GP01: Some of the recommendations she made, I did not agree with her. 
Int: Right, yes. 
GP01: If you ask me which ones, I can’t (remember). 
Int: No, that’s okay.  That’s okay. 
GP01: But yes, I did not agree with her and I actually left the patients on the 
medication.  Whether it’s probably because she doesn’t have a medical background 
to – to see whether the patients need them or not (interruption – phone rang).   
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In contrast, another GP described the pharmacist’s involvement as reassuring –  
GP03:  Yeah, I think it's a good idea -  
Int: Yeah.  
GP03: - - - to round it off and also then you get, um, well, maybe if – if somebody 
checking on you which is good and also it can reinforce to the patients, you know -   
Interestingly, these two GPs referred all patients recruited to the study, although some 
patients declined the service, rather than select the most appropriate patients for HMR.   
Only four of the 10 patients who had an HMR elected to be audio-recorded.  Although the 
feedback was limited, it was also mixed. Patients for the most part found that the 
pharmacist reinforced the GP’s approach.  For one patient for whom there were no 
changes to therapy, the pharmacist’s home visit was perceived as duplicative to the GP’s 
review –  
Pt02: Yes, I didn’t think there was much value in the pharmacist coming. 
 
Conversely, another patient appreciated the opportunity to discuss their medicines with a 
professional they considered to be a medicines expert –  
Pt04: I felt good because once again you’ve got a specialist in a specific field that’s 
giving you more enlightenment on the product so to speak.  Doctors, yes, they do 
know a lot about them but it’s something the pharmacist specialises in, I would think 
would know just that little bit more, that bit more in depth, as to some of the 
repercussions of taking too much of them.   
In summary, the uptake of the optional element of the intervention of HMR referral was low 
in the feasibility study and feedback regarding the service was mixed.   
 Acceptability 
On the whole, GPs were pleased to have participated in the study, perceiving that there 
was an adequate return on the time invested in regard to benefits for themselves and/or 
their patients.  A number reported that they believed the intervention had definitely 
changed how they practiced, although two reported that it did not.  Two themes were 
discerned from the data obtained from GPs and patients pertaining to feasibility of 
changes to practice:  perceived value of the deprescribing intervention; and greater 
satisfaction with care through consultation and collaboration in the medication review.   
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8.1.2.1 Perceived value of the deprescribing intervention  
The majority view of both GPs and patients was that the acceptability of the intervention 
was not necessarily contingent on a successful trial of reducing or ceasing patients’ 
medicines.  For both GPs and patients, there was value and satisfaction in the consultation 
and medication review process in itself. In this example, it was the opportunity to critically 
reflect on the appropriateness of medication regimens.   
GP02: Yeah, so it doesn’t mean that just because you didn’t change any medication 
you didn’t get any value, no. 
Int: Right, okay, so the – there was value even – just in the process? 
GP02: Yeah.  
Int: Even if it didn’t actually lead to - - -  
GP02: Yeah.  
Int: - - - an outcome?  Do you – is that – am I reflecting what you’ve (said)?-   
GP02: Yeah.  
One GP who described the process as being beneficial for himself, went on to speculate 
that patients might also perceive it as better care.  
GP05: Um, I’m sure there was some patients that didn’t make any changes or else 
made changes and they – they reversed.   
Int: Mmm. 
GP05: Um, I guess there’s some benefit to the patient in that they felt probably a 
little bit more cared for through the process. 
This perception was confirmed by patient reports.  The perceived value of the 
deprescribing appointment/s was not dependent on medicines being deprescribed and that 
even no change to therapy could be reassuring.   
Pt62:  It just reinforced in my mind that I’m not on medications that I don’t 
thoroughly understand or that I don’t need.   
Interestingly, reassurance might also be experienced by patients where attempts to reduce 
therapy were unsuccessful.  Here a patient, after an unsuccessful attempt to reduce a 
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number of medications, describes their enhanced acceptance of their regimen due to 
improved understanding conferred by the consultation.   
Pt38:  Yes.  We talked about a lot of reasons for being on these medications.  I’m 
still not happy to be on the medications, but I can understand why they are there.  I 
would like to reduce them, yes, but it doesn’t seem to work. 
As these two patients’ comments imply, the perceived value came through a greater 
understanding and awareness of the need for existing medicines which patients found 
reassuring.  This corresponds to findings in Chapter 7 that a subset of patients reported 
greater belief that their medication regimen was in fact necessary or appropriate after the 
deprescribing consultation.   
The GPs also found value in the awareness raising potential of the intervention.  For 
example, GPs described greater awareness of the potential problems of polypharmacy 
and a formalisation of their thinking and approach to identifying and deprescribing PIMs in 
their patients.  One GP emphasised vigilance of patient outcomes in response to ongoing 
prescription of specific medicines.  
GP02:  I think it just makes you more – more alert about the long-term 
consequences, if you like, of some medicines you're prescribing.  They are going to 
be (on these) for the rest of the person’s life, and that should be judged on the 
outcomes they’re producing, whatever the condition is.  Are we setting up a process 
of monitoring to get the best outcome for the patient?   
This GP went on to articulate that, rather than simply repeating prescriptions, systematic 
tracking of patient progress and critical reflection on medication appropriateness should 
permeate thinking around prescribing.   
GP02:  And then considering at the time we prescribed, is that still on track, or do 
we need to change?  Then to, systematically, go through - some people have been 
coming a long time, and just got to be in the pattern of just running out of scripts, 
let’s just roll over the scripts.    
A number of GPs also found the process of medication review and reconciliation with their 
patients yielded several insights.  As this GP described, there was surprise at the number 
of discrepancies between the medical record and what long-term regular medications 
patients were actually taking.   
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GP01: More because I think um, a lot of the patients who I thought I knew quite well 
and knew about their medications. 
Int: Mmm, yes. 
GP01: I was surprised how many were over-the-counter medications which I was 
not aware of. 
Int: Right, okay. 
GP01: So, there were quite a few.  And then obviously with the deprescribings, I 
went through it as to what can – what is necessary and what is not necessary.   
Int: Yes. 
GP01: But yeah, no that – that I think was probably what – yeah, highlight – yeah, 
was a highlight of the thing, that I actually didn’t know.  Because you don’t always 
ask patients. 
For GPs and patients alike, greater awareness and understanding of the rationales for 
medication regimens arose from having the dedicated time and opportunity to proactively 
discuss and review the medicines together.  This was something not routinely afforded to 
patients in the busyness of usual appointments, as this patient described -  
Pt55:  I thought it (the deprescribing appointment) was very good actually, because 
(usually) you go in and say what’s wrong and everything and the GP will say well I 
think you should try this and we will see how this goes.  You don’t really get the time 
because they are only supposed to give you 15 minutes.  In 15 minutes, you can’t 
really discuss something if you had another reason for going there.  So yes I did 
have time to discuss it and I felt it was beneficial. 
 
As indicated, the shorter appointment times and competing clinical priorities of routine 
appointments generally precluded in depth discussion of less-urgent clinical issues, 
making the extended medication review appointment a particularly beneficial element of 
the intervention.    
Another patient offered that the value of the intervention was in putting the issue of 
deprescribing on the therapeutic agenda for discussion, something that neither the GP nor 
patient had ever previously raised.    
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Pt51 – I think it is excellent that we had that chance because I can’t remember it 
ever happening before.  But I can remember, at various times, talking to friends and 
neighbours about medication, that a lot of us sort of scratch our head, and say well I 
have been on this for so many years, I can’t even remember what it is for.  It 
seemed a little bit strange to me that we never ever sat down with the doctor and 
discussed it or tried to find out whether we still really needed to be on these things.  
I welcomed the whole project.   
A contrasting minority perspective was that a dedicated appointment was in fact 
superfluous because the dynamic of the therapeutic relationship was such that the patient 
normally felt comfortable to ask questions or raise issues with the GP during routine 
appointments.  The following exchange suggests no benefit from having the additional 
appointment to review their medications. 
Int:  So it sounds like you’ve had a great rapport with (usual GP) then and you’ve, 
um, you’ve had plenty of opportunity to ask questions and discuss any concerns 
you might have just as part of a normal appointment with her then? 
Pt49:   Yes. 
Int:   Yep. 
Pt49: Yeah she, ah, yeah she was good, good person to talk to.   
Int: Right. 
Pt49: You know, ah, if you had an appointment, she wasn’t one of these that 
watched the clock. 
Int: Mmm yep. 
Pt49: You had a problem, you sorted it out. 
Int: Right. 
Pt49: Then and there. 
Int: Right. 
Pt49: So that’s the type of person (usual GP) was. 
As this theme implies, GPs and patients appreciated having the dedicated time and 
opportunity for proactive medication review, which delivered benefits through agenda 
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setting and greater mutual awareness and understanding of the medication regimen.  
However, an important minority GP and patient view was that such an appointment was 
unnecessary given the depth and normality of the doctor-patient relationship which 
provided ample opportunity for concerns and discussions about medicines to be raised as 
part of routine care.   
8.1.2.2 Satisfaction through consultation and collaboration  
Central to patients’ satisfaction with the deprescribing process was a sense of adequate 
consultation and collaboration in the nature and timing of any changes to be made.  
Underpinning these collaborative discussions was the quality of the doctor-patient 
relationship.   
When recruiting patients, GPs were asked to nominate individuals for whom they were 
considered the primary or ‘usual GP’, which was also confirmed with patients at the time of 
consenting to the study.  A patient’s satisfaction with their relationship with the GP was 
frequently related to a level of communication and consultation that fully met the patient’s 
needs -  
Pt26:  Oh, yes.  He doesn’t hurry you.  He listens to what you want to say.  He 
doesn’t push you out the door as soon as you’ve got there.”   
Pt73:  No, I don’t know what her feelings are, we have such a good relationship and 
we sit and chat about my health, rather than sort of diagnose it clinically…  
An example showcasing the centrality of good rapport between patients and their doctors 
is detailed below.  The context to the following comments was that a patient was recruited 
to the study under the care of a GP who she had seen many times, but whom the patient 
did not consider her ‘usual GP’.  This individual was taking long-term low-dose 
corticosteroids for an autoimmune condition which appeared not to have been confirmed 
by a specialist.  The GP referred the patient to a rheumatologist and simultaneously 
attempted to reduce her prednisolone from 4mg to 3mg daily.  The patient returned to the 
practice to make a complaint about this with the GP she considered to be her ‘usual’ GP.  
The following responses were provided by the patient at interview as to why she was 
dissatisfied with her deprescribing appointment and participation in the project.     
Pt77:  All doctors are different.  I was just rather cross, even when I was telling 
(‘new’ doctor) how awful I felt, hands tingling, swollen feet and hands, she just kept 
on typing on computer, ‘yes, ‘yes’, and I was getting crosser.  I’m not happy with all 
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these changes and I said, ‘I want to stop’.  Maybe I was uncomfortable.  When I 
made the (second follow-up) appointment it was made with (original GP).  And I 
said, ‘I suppose you’ve heard about (‘new’ GP) and I?’ And I said, ‘Do you still think 
I should go to see the specialist?’, and he said ‘Yes’.  I’ve known (original GP) for a 
very long time.  My son, kids used to see him.  I am more comfortable with (original 
GP). 
In addition to the fact that the patient clearly felt she was not being seen by her ‘usual GP’, 
she also expressed sentiments about inadequate engagement and consultation and 
frustration that changes to medicines were made for a condition that had taken a long time 
to stabilise with the previous dosing of corticosteroid.   
Pt77:… It took a long time to get the dosages that I’m on now stable and then to 
have changes to it, it threw me and I didn’t like it.  It took many trials 
experimenting… to be involved in this thing with you and the School of Medicine, it 
threw you.  With (original GP), if I had marched into to see him, I would have said 
the same thing to (original GP), I would have been cross with him and said it 
straight.  I’m pleased to be back under (original GP).  
Examining this case from the perspective of both GPs provided an insight into how long-
term relationships between doctor and patient may foster clinical inertia, with no 
recognition by either party for the need to critically reappraise long standing medications.  
The patient’s ‘usual’ GP expressed their agreement with the specialist review. The 
longevity of the relationship between patient and ‘usual GP’ and perceived resistance to 
change on the patient’s behalf meant there was little potential for a successful trial of 
deprescribing.   
GP08: So, um, and it’s really a question of who do you consider you have the 
principle relationship with. 
Int: Yes. 
GP08: And on some things, um, you know, ah, I’ve been, for instance saying to that 
- that particular patient that it would be good to review that diagnosis, because she’s 
on some significant (medications) for it.  And - - - 
Int: Yes. 
GP08: - - - ah, she had resisted the idea for many years. 
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Int: Yes, right. 
GP08: Saying, “No.  I don’t want to do that.  I’m very happy with how it’s going.” 
Int: Going, yeah, sure. 
GP08: Um, so really, um, the advice was - and I think that the study triggered some 
more, um, you know, what would you say, um, anxiety in her.   
Int: Her, sure. 
GP08: And, um, I don’t think the outcome was all terrible.  But, ah, it did, it did cause 
some consternation in the, you know, the process of reinvestigation and, um, and 
then change of medications and, I think that became quite a challenge for her. 
This example highlights the inherent tensions when reconciling the patient-centred 
therapeutic agenda with a potentially conflicting medical agenda.  The ‘usual’ GP was left 
trying to preserve the therapeutic relationship whilst still wishing to execute the ‘new’ GP’s 
recommendation for specialist review.    
In some instances, a stable and mutually satisfying relationship seemed to prevent open 
discussion about medication regimens.   One patient, who had a good rapport with his GP, 
appreciated the opportunity afforded by the study to discuss medications.   
Pt04:  I’ve always had a very good rapport with her anyway but sometimes you 
know, you just, it’s just suggested at the time (i.e. the medication) and you don’t 
seem to question anything. 
In this case, the patient also had an HMR as part of the deprescribing process, and found 
that the inclusion of a pharmacist, who they described as a “medicines specialist,” 
facilitated the deprescribing process through the provision of more information -  
Pt04:  That (the HMR) was good as well because once again you’ve got a different 
perspective on the types of medication that you’re taking so, you’re more, yes, 
you’re taking it for this thing, a little bit more depth on what it’s supposed to do or 
why you shouldn’t be taking too many of them and why you should possibly change 
and cut them down or whatever.   
The situation described above is in direct contrast to the earlier statements of a patient 
who felt that their positive relationship with the GP meant that the deprescribing 
appointment was unnecessary, as they could bring any concerns to their GP at any time.  
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It could be inferred that the point of difference in the respective scenarios is the level of 
comfort the individual has in negotiating and shaping the therapeutic agenda with their GP.    
Common to the few cases in which patients were dissatisfied with their GP appointment 
was a sense of inadequate engagement and discussion about their medications, as 
illustrated with this quote.   
Pt30:  To put it blankly, I thought it was a waste of time.  
Int:  Sure. 
Pt30:  I carted all my medication up there.  It was just tipped out on the table.  
Looked at, referred to what was on my chart, on the computer, just checked it, put it 
back in the packet, that’s it, boom, finished.   
Int: Right, ok.   
Pt30:  No, no real, what can I say… No real challenge to get rid of any of the 
medication that I’m taking.  According to the GP it was all necessary to look after 
my health, so that’s it, there was no change, so that was it.  Put it all back in the box 
and I walked out. 
It was interesting to note again that this patient did not speak up and state his expectations 
of the deprescribing appointment with the GP at that appointment. When asked what he 
would have liked to have happened, he explained –  
Pt30:  I really would have liked each medication that I’m taking to be spelled out, 
you know, so I could understand it properly.  I’ve never been really told that, you 
know, what the medication does for me.  It’s always prescribed, if I run out, I just get 
another bloody script, repeat after repeat.  That’s it, no questions asked.   
In this instance, the patient’s dissatisfaction stemmed from a longer-term lack of adequate 
communication, understanding and shared decision making about their health and 
medicines.  This led to a sense of frustration and perceived lack of agency.   
Similarly, a patient who described disappointment in the lack of “discussion, engagement, 
interaction and reflection” with her GP prior to attempting minor changes to her therapy for 
chronic non-cancer pain, described a very negative deprescribing experience -   
Pt47: Let’s just say the changes suggested by the doctor at the time of that 
interview, were of no help at all, in fact if anything they were disastrous.  I have 
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since, after experiencing, after a good eight weeks of ill health, particularly 
depression and anxiety, I did go back to another doctor because my previous doctor 
has left that surgery, and I am now back in a better place.  My medications, we did 
change those and I am now back on medications that are helping me to sort of have 
a satisfactory engagement in life. 
This suggests patients may be primed or predisposed to recall a negative response to 
conservative changes to therapy if they feel such changes occurred without adequate 
engagement in the decision-making process.  It is also possible that the nature of the 
condition, such as its chronicity or potential to cause symptoms, negatively influenced the 
patients’ perception of the outcome of deprescribing.   
Conversely, adequate patient engagement, especially for those who demonstrated greater 
agency, increased an individual’s confidence to attempt a change to therapy, as articulated 
by this patient -  
Pt58: Well, it was a decision between the doctor [and me] so I was quite confident 
to go off them for that time but if anything cropped up, like with my knees… I told 
her the next time that I wanted to go back on them. 
This extract also highlights the importance of strategies to mitigate the decrease in a 
patient’s confidence that may result from a potentially adverse deprescribing outcome.  
Here the patient was reassured by the option of reinitiating therapy if required to treat 
symptom relapse.  Patients were also comforted by the use of a gradual approach to 
deprescribing and planned follow-up and monitoring, as illustrated by this example.   
Pt13: …I have been taken off the medication gradually over a period of time, he 
didn’t just stop them all at once, it was a gradual thing.  He has been checking to 
make sure that I don’t have to go back on them and everything has been fine.   
Adequate communication of the risks of persisting with therapy and a gradual approach to 
change were also suggested as ways to address patient resistance to deprescribing.  This 
was as exemplified by this patient who was tipped towards attempting the withdrawal of 
her hormone replacement therapy, despite her conviction, prior to the deprescribing 
consultation, that this therapy was controlling her menopausal symptoms.   
Pt71:   I think it probably just um – it’s in my, it um probably made me more aware of 
the fact that I should give up the Premarin. 
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Int: Right mmm.  Did you have some um, um concerns or hesitations before, 
before that? 
Pt71: I did. 
Int: Right, and may I ask why that was? 
Pt71: Well because while I was taking it I felt that I was not having the hot flushes 
and I felt well on it and I think because I felt well I was a bit reluctant to see where it 
would go. 
Int: Sure. 
Pt71: But after taking it down slowly, um I think it was beneficial. 
Int: Sure, sure.  So and I can um, can I get you to expand on why you now, that 
you feel it was beneficial coming off that now? 
Pt71: Well mainly because I understand that they um, taking hormone replacement 
therapy can lead to heart attacks. 
Int: Right. 
Pt71: And there is heart history in my family, so… 
As alluded to previously, contextual factors such as the types of long-term medications to 
be considered for deprescribing, the target conditions being treated, or specialty of 
prescriber were important influences on a patient’s willingness to consider deprescribing.   
One patient described his unwillingness to consider changing his two long-standing 
antidepressants, but a willingness to consider a change to his proton pump inhibitor and 
dose reduction of his statin for primary cardiovascular prevention – 
Pt60: Well it (the deprescribing appointment) was good really, we went through 
each tablet one at a time and he asked me if I would go off this and I said no, those, 
not the two antidepressants, we tried the Nexium but I was back on that the next 
morning, as I have reflux.  The Caduet we decided to cut down to 80 and 5 to 40 
and 5, now I am just waiting to have another blood test to see how they are working. 
That’s about it. 
In another example, a patient described that, when it came to any changes to their 
medication, they prioritised the views of the cardiologist, in preference to the GP, citing –  
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Pt45: ‘Cause I see him (the cardiologist) every 6-12 months you know, and 
whatever he says, goes.  He’s the person who keeps me alive.  
Int: Yes. 
Pt45: You know, he (the cardiologist) knows a bit more than (the GP) does I think, 
and he (the cardiologist) knows a hell of a lot more than me, so what he says, I 
agree with.   
Although this individual perceived their GP to be competent, their trust for the cardiologist 
was paramount and so the patient would always prioritise recommendations of the latter 
over and above those of the former, illustrating the highly influential and trumping role of 
specialists for some patients.   
From the GP’s perspective, confidence to attempt deprescribing was largely influenced by 
the patient’s receptivity to having therapy altered and, particularly for preventive therapies, 
the clinical context and certainty of the evidence of benefit for deprescribing.  As the 
following scenario suggests, GPs might be unwilling to assert a deprescribing agenda with 
hesitant patients for fear the efforts are futile and counter-productive, potentially 
threatening the doctor-patient relationship.   
GP01: But she’s also a patient who as soon you stop something, something’s going 
to go wrong. 
Int: Right. 
GP01: Whether it’s definitely wrong, or whether it’s – from her perspective it’s 
wrong. 
Int: Wrong, yep.   
GP01: So we discussed all of that and she just said, “Look, I’m not going to go off 
any of these.  I’m going to take them, whether you say yes or no.” 
As this scenario suggests, GPs might be unwilling to assert a deprescribing agenda with 
hesitant patients for fear the efforts are futile and counter-productive, potentially 
threatening the doctor-patient relationship.   
Akin to the situation for some patients, GPs also described the potential influence of 
specialists with whom they shared care of individual patients.  Several GPs proactively 
engaged specialists in deprescribing, either directly by forwarding letters to them 
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expressing an intent to consider deprescribing, or indirectly by suggesting to the patient 
that they raise the issue of deprescribing at their next scheduled specialist appointment.  In 
one instance, a GP reported ceasing a diuretic in a patient prior to their renal appointment, 
after which the specialist expressed their discontent with the GP.  Although this GP 
provided overwhelmingly positive feedback regarding the intervention and their 
continuation of deprescribing beyond the study period, they admitted this experience 
would make them “gun-shy” in ceasing medications again without specialist consultation.   
The other key influencing factor affecting the confidence of the GP to attempt 
deprescribing was the certainty of the evidence supporting deprescribing.  As one GP 
explained -    
GP05: …The whole deprescribing it's quite - it's obviously much easier if you've got 
a hard bit of evidence based, um, you know - to go on and I think there was that 
issue with the - with the one example of the, um, etidronates, five years, no fracture, 
um, and the evidence is – if it continues not so good.  So that's quite - that's 
obviously one you could hang your hat on quite easily. 
This GP reflected the views of others who went on to explain that clearer evidence to 
support deprescribing, particularly for preventive therapies, would increase GP confidence 
to enact further changes.   
This theme highlights the importance of patients’ faith in their relationships with their 
doctors as a facilitator, or inhibitor, of discussions relating to deprescribing.  Whilst largely 
facilitative, there were several examples in which the relationship was inhibitory to 
conversations or action on deprescribing, potentially for fear of undermining patient trust in 
the relationship.  Patients’ satisfaction and confidence in the deprescribing process 
appeared proportionate to the degree to which they felt consulted and engaged in the 
decision-making process with their GP.  The context surrounding the deprescribing 
decision, including the condition being treated, specific medication involved and the 
opinion of specialists, were also influential in the decision to attempt deprescribing.   
 Spread and sustainability  
The GPs, as the main adopters of the intervention, provided examples of how they 
integrated and expanded deprescribing in their practice during the study period.  They also 
identified key barriers and enablers to sustainability of elements of the intervention in the 
longer term.    
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Several GPs reported that they had opportunistically deprescribed medicines in a much 
wider group of patients in their practice than those recruited into the study.  One GP 
explained how the intervention prompted action with all patients.    
GP10: It was helpful because I started doing it with everyone - - -  
Int: Oh, okay. 
GP10: - - - else, basically, um, all the other patients because the amount of times 
that they’re on medications and you don’t actually know why?  Who started?  When 
- - -even just assessing if they need it – it was actually helpful.  
For the subset of GPs who reported applying the principles of deprescribing or elements of 
CEASE to a much wider patient group, deprescribing was linked to a professional ethic of 
good practice.   
GP10:  It is – was a good reminder to actually practice medicine – how we 
should be practicing anyway. 
Time and competing priorities were identified as significant barriers to sustainability, such 
that, even within the four-month study period, deprescribing had already started to slip off 
the top-priority lists of two GPs.   
GP07: Um, I think the difficult things with deprescribing is that, um, like everything 
else in medicine -  
Int: Yeah. 
GP07: -  is - is after a while you probably, you know, other things, becomes on top 
of your radar… 
In part, this was because of the complexity of those patients in whom the need to 
deprescribe may be most pressing.  
GP04: - because the issue is with the patients for whom this is most, um, beneficial, 
likely to be a problem – are also the very same patients who will come in with their 
list of 13 problems. 
As this GP implied, the competing priorities on the patients’ agendas could scupper the 
agenda of proactive medication review.  As a compromise, GPs described continuing 
efforts to opportunistically deprescribe in patients outside of the study, but adapted their 
approach to mitigate the time pressures in routine care -   
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GP04 “Um, to be honest, I don’t usually explain the process to the patients – to the 
patients not in the study.”   
This adaptation has important implications, considering that patients found value in the 
collaborative decision-making process, rather than necessarily the outcome, of 
deprescribing.   
For other GPs, who reported that the time invested in deprescribing efforts during the 
study period was worthwhile, there was some reluctance to continue this time-intensive 
process on an ongoing basis.  One GP referred to the challenges of allocating time when 
patient load was significant.  
GP01: It all depends on – yeah.  It all depends, I think, on time. 
Int: Yes, yep.   
GP01: Yeah. 
Int: Okay, sure. 
GP01: You know, if I possibly cut back on patients, patient numbers.  Then you’re 
not so exhausted mentally to sort of go through all that.  Um, but – because I do 
generally spend a bit of time with my patients too. 
Int: Sure. 
GP01: I find it hard to sort of worry about that – which it’s – it’s – I know it’s all part 
of their, um, their health and their wellbeing.  But um, sometimes you – you are 
pressed for time. 
Interestingly, two GPs who initially described the barrier purely in terms of time 
subsequently divulged a lack of motivation as well.  Some GPs highlighted that, in the 
absence of someone driving the initiative, and setting the agenda of deprescribing with the 
patients on an ongoing basis, the intervention would be unlikely to be sustained in a 
structured, proactive way. In this exchange the issue of embedding the intervention in 
routine practice beyond the study was highlighted.  
GP04: So in a sense it was slightly artificial in that you did all that (set the agenda 
with patients) for us. 
Int: Yes.  Yeah. 
GP04: You did – um, did the groundwork and so patients came in pre-prepared.   
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Int: Yeah. 
GP04: Um, so there’s – there’s a bit about, um, how do you do that in general 
practice. 
Int: Yes. 
GP04: Now obviously you can just do it but, um, there’s a – the next thing is how 
are you are time and cost effective about that - - - 
Int: Yes. 
GP04: - - - because it’s – unless it’s time and cost effective it’s not going to happen. 
Int: Yeah. 
GP04: So there’s, you know, some thinking to do about that, um, in the practice. 
Other GPs confirmed the sentiment of the challenge to sustainability of the intervention in 
the absence of practice or system level changes.  However, there was no consensus 
regarding the nature of such changes.  One principle suggested making the practice 
manager responsible for conducting queries of databases as the basis for auditing in-
practice polypharmacy and deprescribing efforts and then engaging the pharmacist or 
nurse within the practice to work collaboratively with the team to drive the deprescribing 
agenda in ‘at-risk’ patients.  Another GP suggested linking deprescribing with existing 
Medicare services such as the 75-year-old Health Assessments, although they conceded 
there is already so much other clinical and administrative work to do during these 
assessments.    
The GPs also spoke of current data quality issues as a major barrier to the sustainability of 
identifying eligible patients, undertaking deprescribing itself, and then expanding this on a 
larger scale.  One GP explained the potential for data coding in consultations as an 
efficient way of documenting the rationale for initiating and altering medications in routine 
care.  
GP02: I mean, part of the – that’s another problem, and I think we’re sort of not at a 
level of maturity in terms of understanding things like data quality, as an instructed 
code of data coding, in the case of the consultation, the reason, the main reasons 
for seeing the patient. 
Int: Yes. 
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GP02: And then align the reason for prescribing. 
Int: Yes. 
GP02: Because I think there’s still a big gap in terms of clinician – most clinicians 
have got it turned off because they actually don’t realise that in essence. 
Int: Right. 
GP02: And one follows the other, like, if you’ve been coding reasons for visits, you 
don’t have to keep finding the code for reason to prescribe, because it’s actually 
already on your screen. 
This and similar statements were couched in a broader discussion of the need for better 
communication between prescribers and other health professionals and across health 
sectors.  The national eHealth agenda, including MyHealthRecord, was offered as a 
potential facilitator of this, despite the acknowledgement that it is still in its infancy.   
Overall this theme shows that a number of GPs individually and opportunistically applied 
the principles of deprescribing to patients outside of the study (and targeted the same 
patients in conducting other health promotion activities such as the Medicare-funded 75-
year-old Health Assessments).  The GPs acknowledged that in the absence of system-
level or practice-level change, such as using IT and other infrastructure to integrate 
deprescribing into usual care, the intervention would be unlikely to continue on an ongoing 
basis, in part due to the busyness of routine practice and competing clinical priorities in 
managing complex patients.   
 Discussion 
The findings from semi-structured interviews on the feasibility of the intervention indicate 
that: the three phases of the intervention were adopted by GPs, although prompting was 
required to facilitate the identification of patients; the intervention was largely acceptable to 
GPs and patients; however, the sustainability of the intervention over the longer term 
seems in doubt without supportive changes at a practice- or system-level.  Although the 
findings derive from a small convenience sample of 10 GPs and 52 out of 78 intervention 
patients, there are key learnings relating to the implementation of the deprescribing 
initiative that arose from the descriptive analysis as a whole.   
From the GPs’ perspective, if deprescribing in primary care is to occur in a proactive, 
planned and targeted manner, the identification of patients to target must be streamlined 
173 
 
and rendered efficient and accurate.  This will require attention to data quality issues and 
improvements to software systems to facilitate data-driven quality improvement, issues 
that have been well-documented in primary care in Australia and abroad. (223, 224)  In 
this study, to compensate for the existing data quality and software limitations, GPs were 
willing to spend the time to manually review a software-generated shortlist of potentially 
eligible patients, as they recognised this as an essential, first step to the intervention.  The 
sustainability of such effort in the longer term seems unlikely however, given that 
prompting was required to encourage timely completion of this critical first step.      
The process of having a dedicated deprescribing appointment with patients was in itself 
highly valued by GPs as it forced reflection on their decisions and practices. This was 
despite their believing that, in general, there was limited scope for deprescribing, 
particularly beyond one appointment, as minimising potentially inappropriate polypharmacy 
was already on their radar.  The design of this exploratory study did not accommodate an 
assessment of prescribing quality (i.e. evaluating the indications and appropriate use of 
medicines) so it is plausible that, among a group of highly motivated GPs, achieving major 
gains in deprescribing may be unrealistic.  This conclusion is supported by the findings of 
a pilot study conducted by Muth et al in 2016 in a very similar GP and patient cohort in 
Germany.  This study found that baseline prescribing as assessed using the Medication 
Appropriateness Index (MAI) tended to be appropriate, limiting the capacity to further 
improve prescribing, although an alternative explanation may be the floor effect of the MAI 
which limits its ability to detect inappropriate prescribing.  (115) However, literature also 
supports the case that self-assessment of clinical practice is not always accurate. As other 
studies have shown, GPs reviewing their own prescribing may not be aware of some of the 
examples of inappropriate prescribing until it is pointed out to them, for example through 
third party audit and feedback.  (170-172)   
The findings indicate that the nature and quality of the relationship between GP and 
patient can be both a barrier and a facilitator to the process of deprescribing.  From both 
the GP and patient perspective, having a continuous, therapeutic relationship built on trust 
is fundamental to facilitating deprescribing and this finding is consistent with previous 
research.  (8, 186)  However, a notable and unique finding in this study where instances 
where a positive therapeutic relationship with GPs they trust may have disinclined some 
patients from asking questions about their long-term therapy.  These patients appeared to 
have a lower degree of agency and other studies incriminate lower health literacy as a 
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contributing factor. (225)  Part of the value of this intervention for both patients and GPs 
therefore was in establishing a therapeutic agenda and raising awareness about the 
potential for deprescribing through a dedicated opportunity to review and discuss the 
patients’ current medication regimens and their ongoing appropriateness.  Sinnott et al, 
who reported GPs’ perspectives on an intervention to improve medication management for 
patients with multimorbidity in primary care, similarly found that GPs valued a dedicated 
opportunity to focus on prescribing, something not afforded to them in routine practice.  
(226) 
Patient acceptability of the intervention appeared linked to the degree of consultation and 
collaboration with the GP in the deprescribing process, rather than the outcome, positive 
or negative, of deprescribing.  This, combined with reassuring strategies like planned 
follow-up and close monitoring, could potentially overcome initial patient resistance to 
attempting withdrawal of some medicines.  However, a range of contextual factors such as 
the condition for treatment, medication and specialty of the original prescriber are also 
influential.  To date, these findings and those from other studies (9, 186) appear to indicate 
that, in the face of perceived patient negativity towards changes in medications, the GP 
will default to persisting with the status quo, until a clinical situation or trigger arises which, 
reactively, lends to a strong indication for an attempt at deprescribing.   
The findings in this chapter also indicate that practice level and/or systems change will be 
required to embed and sustain proactive, planned deprescribing in routine practice in 
primary care.  Of particular note was the GP who reported that their focus had already 
started to shift away from deprescribing within the study period.  Whilst the phenomenon of 
‘provider drift’ (i.e. a decay in effort/skill over time) is well established in behaviour change 
research, it was not anticipated that such an effect would be observed within the relatively 
short study period. (227)  The inference is that scheduled follow-up or reinforcement 
activities may be required to mitigate this drift even in the short-term.  Furthermore, it 
appears that the intervention is unlikely to become routine practice without a local 
champion at the practice level, assuming the role akin to the researcher in this exploratory 
study.  As identified by some GP participants, the prompting to identify patients in a timely 
manner and liaison with practice staff to ensure deprescribing appointments had been 
scheduled on time is likely to have contributed to the high level of implementation of the 
intervention.  Studies of other primary care change efforts have similarly found that, 
without an organisational change agent to drive such initiatives on an ongoing basis, 
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change is unlikely to be sustained into the future. (228)  Other identified system barriers to 
sustainable deprescribing, such as poor data quality and limited inter-professional 
communication across different health sectors, were far reaching and not easily changed.    
Finally, in identifying the core elements of this intervention which made it feasible, it 
appears that all three mandatory components (identification of patients through a 
customisable software query teamed with a manual review process, participating in the 
deprescribing workshop and having at least one dedicated, extended appointment with 
patients to review medication regimens) were essential to the adoption and acceptability of 
the intervention.  Based on the limited data available due to poor uptake, there appeared 
little value in blanket referral of all patients for HMR to a CP trained in deprescribing.  
There may, however, be value in selected referral of patients wanting additional 
opportunity to discuss their medicines with a CP.  There is an interesting lesson in the 
feedback of one GP who enthusiastically applied deprescribing principles in patients not 
enrolled in the study, but did so at the expense of engaging the patient in discussion and 
the decision making to save time.  Such an adaptation accommodated the GPs’ desire to 
deprescribe in the absence of a dedicated appointment to do so, but overlooked the fact 
that patients found the collaborative decision-making process more valuable than the 
deprescribing outcome itself.   This demonstrates the importance of communicating to GPs 
the elements of the intervention that patients find valuable.   
 Conclusion 
Whilst the three phases of the intervention were adopted by GPs within the study period 
and the deprescribing appointments and process proved valuable for the majority of 
patients and GPs, there are doubts regarding the sustainability of this intervention over the 
longer term in the absence of accompanying practice- and/or system-level changes.  A 
more important question, is whether such an intervention should be implemented and 
sustained in more practices and this will only be answered once the long-term safety and 
efficacy of such an intervention is confirmed in a large-scale, longer-term cluster RCT.  
These and other important unanswered questions are discussed in the next chapter along 
with a discussion and synthesis of all investigations conducted as a whole.   
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Chapter 9  Discussion, synthesis, implications and future research 
In this chapter, the findings of all investigations conducted to date as a whole are 
synthesised and interpreted.  A summary of principal findings arising from each of the 
study phases are presented, followed by key learnings which are discussed in the context 
of relevant literature.  Finally, the key strengths and limitations of the research design as 
well as the implications for practice and policy and future research directions are 
discussed.   
 Summary of principal findings  
The overarching study aim was to develop and pilot a multifaceted GP-led intervention to 
minimise potentially inappropriate polypharmacy in community living older people, 
addressing GP and CP barriers and enablers to deprescribing in routine care. This was 
supported by three specific aims, which aligned to three sequential study phases, the 
design of which was informed by the UK MRC guidance for complex health interventions.  
The first two phases were developmental and used to inform elements of the complex 
intervention which was piloted in a mixed methods exploratory study in Phase 3.   
In Phase 1, the aim was to investigate prescribers’ perspectives on factors which shape 
their behaviour towards continuing or discontinuing PIMs in adults.  A broad review of the 
literature, not restricted to type of prescriber or age of adult patient, was conducted to 
thoroughly examine all possible literature available on the topic.  Most studies included in 
the systematic review however, explored GPs’ perspectives on managing older, 
community living adults, which aligned with the care setting and patient group of interest 
for further investigation.  Analysis yielded four themes pertaining to prescriber barriers and 
enablers to minimising the prevalence of chronically prescribed PIMs in adults: problem 
awareness; inertia secondary to lower perceived value proposition for ceasing versus 
continuing PIMs; self-efficacy regarding personal ability to alter prescribing; and feasibility 
of altering prescribing in routine care environments given constraints external to the 
prescriber.  This thematic framework contributed to new knowledge by providing a way to 
conceptualise and understand factors which shape prescribers’ behaviour towards 
continuing or discontinuing PIMs in adults.  The analysis showed factors are complex, 
highly interdependent and influenced by clinical context.  The analysis did not however, 
provide detail of the relative contribution or importance of each of these factors (that is, 
there were no clear ‘trumping’ or ‘dominant’ factors) and did not focus exclusively on 
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potentially inappropriate polypharmacy or factors specific to the Australian primary care 
context.   
These unanswered questions justified undertaking the next developmental phase, given 
the overarching purpose of this study.  In Phase 2, the aim was to explore the views of a 
sample of GPs and CPs about potentially inappropriate polypharmacy and the reasoning 
they apply to deprescribing in older people in primary care, including factors that influence 
this process.  The CPs were included as they had been identified as potential change 
agents in primary care in Australia.   The analysis of focus group discussions provided a 
higher degree of granularity in regard to GP and CP beliefs, attitudes and behaviour 
regarding deprescribing and the critical contingencies for action.  Two major themes were 
derived from the analysis: (1) Working through uncertainty; and (2) Perceived risk as a 
frame of reference.  Working through uncertainty encapsulated the immense complexity 
clinicians face when assessing an older person with potentially inappropriate 
polypharmacy, such that weighing harm against benefit in absolute terms at the level of 
the individual was perceived as unfeasible in most instances.  However, strategies and 
circumstances were identified that could mitigate this uncertainty (such as targeting 
medicines which are easier and less harmful to deprescribe in the first instance, adopting a 
gradual approach to changing medicine regimens, and deferring to patients in making a 
deprescribing decision).  Perceived risk as a frame of reference referred to the 
dichotomised view that deprescribing was a risk to be avoided or a risk to be reconciled, 
with tipping points in risk perception identified which might trigger action towards 
deprescribing.    
Analysis identified critical contingencies for deprescribing, particularly the need for a 
continuous therapeutic relationship between the GP and patient built on trust.  
Furthermore, deprescribing appears largely reactive in routine practice in response to clear 
clinical triggers to change, namely an event signalling a change in clinical status (such as 
a fall that was potentially medicine-induced), or the finding of ‘low-hanging fruit’ (i.e. 
medications commonly cited as being overused in the medical press).  Findings also 
suggested that risk reframing (towards deprescribing as a ‘risk to be reconciled’) and 
dedicated time to proactively review therapy may promote deprescribing.  These learnings 
informed the design and components of the multifaceted intervention.  Combining 
knowledge of behaviour change interventions that are likely to be effective with learnings 
from Phases 1 and 2, the three mandatory elements of the multifaceted intervention 
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comprised: 1) the identification of older patients with polypharmacy (to flag suitable 
potential candidates for deprescribing); 2) the face-to-face deprescribing training workshop 
(to raise awareness and reframe risks of potentially inappropriate polypharmacy, 
overcome prescriber inertia and increase self-efficacy to deprescribe); and 3) the 
deprescribing appointment between GPs and patients (to create a dedicated opportunity 
for proactive medication review).  To overcome additional feasibility barriers for GPs such 
limited time, patients could be referred for an HMR to a CP who attended the 
deprescribing training workshop and had full access to the medical record should the GP 
wish.   
The aim of Phase 3 was to evaluate the feasibility, effectiveness and safety of the 
multifaceted GP-led intervention in community living older people in primary care.  The 
intervention was well adopted although prompting was required to facilitate timely 
completion of eligible patient identification and scheduling initial deprescribing 
appointments in some instances.  The intervention lead to a modest change in medicines 
deprescribed which proved safe in the short-term, but, in the absence of system- or 
practice- level changes, it was unclear whether this effect would be sustained over the 
longer-term.  It was also unclear if the observed reduction or cessation of regular 
medications, and their effects on patients’ well-being, would translate to ‘clinically 
important’ outcomes over the longer-term.  Medicines most frequently deprescribed tended 
to be supplements and classes of medications, especially preventive medications, 
commonly reported in the literature as being potentially overused.   
Notably, a subset of patients reported greater certainty in the necessity and 
appropriateness of their medicines after the deprescribing intervention.  This finding was 
consistent with qualitative data from patients who appreciated the opportunity to discuss 
their medicines with their GP and increase their understanding of the necessity of therapy.  
It also raises questions as to whether this intervention might improve adherence to 
essential and appropriate medicines.  Baseline PATD scores were not shown to be 
predictive of deprescribing outcomes.  This lead to speculation as to whether this 
instrument is too blunt to predict a change when the effect size is so small or, whether 
patients will follow their GPs’ lead on deprescribing, as reported in the findings of a 
systematic review by Reeve et al.  (8)  The intervention was not associated with a 
deterioration in quality of life in the short-term, which would be expected as a consequence 
of imprudent deprescribing attempts.   
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The majority of GPs and patients found value in having a dedicated opportunity to 
proactively review medicines and in ‘formal agenda setting’, which is not afforded in 
routine practice.  This was identified as a barrier to deprescribing for GPs in the Phase 2 
qualitative investigation.   
Despite the centrality of a continuous relationship between the GP and patient as a critical 
contingency to deprescribing, a long-term relationship may have precluded some patients 
from raising the issue of medication appropriateness with their GP previously.  Patient 
satisfaction with the intervention was not necessarily linked to the deprescribing outcome, 
but rather the degree of consultation and collaboration, consistent with their needs and 
expectations, throughout the process.  There was very little uptake of referral to CPs for 
HMR during the study period. Referrals which did occur were ‘blanket referrals’, rather 
than referrals based on assessments about which patients would benefit from a 
comprehensive medication review with a pharmacist.  This lead to a sense of duplicative 
effort and patients feeling over-serviced in some instances.   
The exploratory study was a ‘bottom-up’ design of a GP-led deprescribing intervention 
tailored for the Australian primary care context.  In comparison with published literature to 
date, the intervention was unique in that it: 1) encouraged proactive deprescribing using 
structured guidance; 2) leveraged the existing relationship between implementers (i.e. the 
GPs) and patients; and 3) used individually-tailored versus systems-based or drug-specific 
approaches to deprescribing.  The findings indicate that the intervention is feasible, 
modestly effective in facilitating deprescribing and appears safe in the short-term.  The 
GPs and patients perceived that there was an adequate return on investment for the time 
and effort involved in the deprescribing intervention, more as a result of satisfaction with 
the process of review and reflection, rather than as a result of medications actually being 
ceased or having doses reduced.  The long-term safety and effectiveness of this 
intervention, including reinforcing activities to ensure a sustained effect over time, requires 
evaluation in a large-scale, longer term cluster randomised controlled trial (RCT).   
 Key learnings in the context of existing literature 
Taken together, the findings of this study as a whole indicate that deprescribing is an 
inherently uncertain venture and clinicians tend to react in response to a clear clinical 
trigger or, if deprescribing is pursued proactively, they tend to prioritise ‘low hanging fruit’.  
In this case, ‘low hanging fruit’  refers to medicines for which decisions to discontinue were 
endowed with greater certainty, for example, medicines perceived to be overused, whose 
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cessation is unlikely to be resisted by patients, or where a favourable outcome of 
withdrawal seems more predictable.  (186)  As acknowledged by GPs and CPs in the 
Phase 2 focus group findings, this approach delivers early wins though not necessarily the 
best benefit as it sidesteps drugs with potential to do more harm, such as anticoagulant 
and psychotropic agents and opioid analgesics.(186) 
Given clinicians’ tendency towards ‘reactive deprescribing’ and an imperative in health 
research to demonstrate maximum ‘return on investment’ with finite resources, (229) there 
may be greater value in offering the deprescribing intervention at a time of clear clinical 
deterioration for a patient.  This approach is advocated by Garfinkel in a study commonly 
cited to support the effectiveness and safety of deprescribing (the paper is discussed in 
detail section 2.3.4.1, ‘Good Palliative-Geriatric Practice (GPGP) Guide’). (102)  Despite 
several methodological limitations, this Garfinkel study found a mean reduction of 4.4 
medications per person, significant improvement in quality of life and no significant 
adverse effects due to medication discontinuation. (102) There are a multitude of reasons 
which could contribute to the much larger effect size observed Garfinkel’s study, including 
lack of a control group, 19-month compared to four-month follow-up, slightly older and 
potentially sicker patient group and the involvement of a geriatrician to identify medicines 
for discontinuation.  Another interesting aspect of the study, however, was the timing of the 
solicited review in response to an identified change in the patient’s care trajectory.  That is, 
in Garfinkel’s study, the patient’s GP or family member referred the member to an 
outpatient geriatric clinic for comprehensive assessment, presumably in response to some 
degree of clinical or functional deterioration.  At the clinic, the geriatrician then applied a 
deprescribing decision guide as part of the review and wrote a letter to the patient’s GP 
recommending medications to be deprescribed, after counselling the patient/family 
member on the potential changes.  This raises the question as to whether a larger effect 
size (and return on investment) could be seen if the deprescribing intervention was timed 
to respond to a change in the patient’s care trajectory, as identified by the patient’s GP, 
family member or patient themselves, rather than undertaken pre-emptively in the absence 
of a clinical cue to do so.  Further research is required to establish if coupling the timing of 
an intervention with a perceived deterioration in clinical or functional status is a more 
important trigger for deprescribing than a poor clinical or functional prognosis by itself.  
This is supported to some extent by the findings of a systematic review which highlighted 
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high rates of continued inappropriate prescribing of primary and secondary preventive 
medicines in palliative cancer patients.  (230)   
If deprescribing is to be pursued in a proactive, planned and targeted manner, this 
investigation suggests there are two key factors that must be considered:  1) risk reframing 
to engender tension and appetite for change in clinicians; and 2) efficient identification of 
potentially eligible patients for deprescribing.   As reported in the qualitative study in Phase 
2, risk reframing — that deprescribing is a risk to be reconciled, not avoided due to fear of 
unknown/harm from deprescribing — will require high-quality research evidence of the 
long-term safety and efficacy of deprescribing in older people at risk of medication 
misadventure.  Most deprescribing studies to date have been conducted in the hospital or 
residential aged care setting (30, 31),  but well-designed and conducted, large-scale 
research studies supporting deprescribing will be especially important in community living 
older people, where loss of independence and institutionalisation could ensue following an 
adverse event consequent to a deprescribing intervention.  The availability of such high-
quality evidence may assist to alleviate clinicians’ fears of the potential negative 
consequences of deprescribing.  As shown in the Phase 1 systematic review, fear appears 
linked to a state of inertia resulting from omission bias (9) – the situation in which 
individuals deem harm resulting from an act of commission, in this case deprescribing, to 
be worse than harm resulting from an act of omission, in this case persisting with the 
status quo.  (175, 176) 
The identification of potentially eligible candidates for deprescribing must be streamlined 
and efficient to optimise uptake and sustainability.   In this exploratory study, the lack of 
accurate, up-to-date and reliable data hindered clinicians in easily identifying suitable 
candidates for deprescribing based on the eligibility criteria and in quickly identifying when 
and why regular medicines were first initiated and by whom.  This meant that GPs had to 
invest additional effort and time (e.g. manual screening of software-generated patient lists 
and time spent going through past medical records) to identify this information.  Whilst 
GPs reported that the investment of their time and effort to compensate for the data quality 
issues was reasonable in this time limited study, it is likely incomplete and poor-quality 
data would be an insurmountable barrier to sustained deprescribing efforts for many GPs, 
without changes at a practice-level.   
Related to the issue of identifying suitable candidates for deprescribing through use of 
accurate and reliable data, more research is also required to determine how drug specific 
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and generic approaches to deprescribing can best be coupled.  As detailed in Chapter 2, 
many deprescribing studies targeting GPs caring for community living older people have 
investigated the effects of interventions on one or more specifically identified PIMs.  In 
contrast, this study involved the application of a structured guide to support nuanced, 
individualised deprescribing decisions, which could apply to any medicine in any patient 
based on their unique clinical context.  There are both positive and negative aspects to 
both approaches.  Whilst drug-specific approaches can risk compartmentalising patients 
as ‘users’ of medicines which are assumed to be inappropriate, this approach does 
provide clear cues for review.  Measuring the effectiveness of this type of intervention is 
also more straightforward and may be particularly advantageous from a public health 
perspective when the target medicines for deprescribing are informed by population-level 
prescribing data, as has been used in several studies.  (113, 114)  By comparison, a 
generic deprescribing approach relies to a greater degree on the individual clinician 
applying his or her discretion to review and identify (usually) their own prescribing as being 
potentially unnecessary or inappropriate.  Finding a metric to evaluate the effectiveness of 
the intervention is also more challenging.  The combination of data-driven drug-specific 
approaches to flag high-risk candidates in which a generic approach to deprescribing is 
subsequently applied warrants further investigation. 
General practitioners as central coordinators of continuous health care are well placed to 
facilitate deprescribing in complex, community living older people with multimorbidity and 
polypharmacy.  A GP-led intervention, as used in this exploratory study, allows the existing 
relationship with patients to be leveraged, to maximise the chance for decisions to be 
informed by the patient’s preferences, goals and needs — elicited either implicitly or 
explicitly.  However, given the finding in this study that patients’ and GPs’ perceptions of 
value from the deprescribing intervention did not necessarily align, further investigation of 
the role of formally eliciting patient preferences and goals of care to inform deprescribing is 
needed.  This has been evaluated in other fields of research.  For example, Denig et al 
published the results of a pragmatic RCT in primary care in the Netherlands which 
assessed the effects of a patient-oriented decision aid for prioritising treatment goals in 
patients with diabetes on patient empowerment and treatment decisions.  (231)  Although 
the tool was simple and easy to apply, the study findings were limited by relatively poor 
uptake of use of the decision aid by GPs.  This may have contributed to the finding that the 
patient-oriented treatment decision aid did not improve patient empowerment nor clinical 
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parameters, over and above usual care.  The authors conceded that a single exposure to 
such an intervention is unlikely to change patient empowerment and that instead, the use 
of decision aids to inform treatment decisions in patients with chronic disease should 
ideally be repeated and revisited over time, with greater exposure increasing the likelihood 
of a positive effect. (231)  Incorporating specific treatment aids into a generic approach to 
deprescribing may be difficult, but given the potential for preference-setting to promote 
greater patient agency, there is merit in investigating the role of decision aids to support 
shared decision making and goal setting in future.  Shared decision making is particularly 
important when evidence does not strongly support one clearly superior option or where a 
preference-sensitive decision is involved, as is so often the case with deprescribing in 
complex older patients with multimorbidity.  (232)  The qualitative evaluation of patients’ 
perception of value clearly supports this as an area for further research.  
From an awareness perspective, GPs may not be best placed to review their own 
prescribing.  It may not be until a third party points out that a medicine is potentially 
inappropriate that the usual prescriber may be cognisant of this.  (9)  In this exploratory 
study, the involvement of a third party (i.e. medical specialist or referral to a consultant 
pharmacist for review) was at the discretion of the GP.  Whilst some GPs did refer patients 
to medical specialists for review, this was not formally evaluated, and so it remains unclear 
if there was a higher referral rate to medical specialists in the intervention arm for input on 
the appropriateness of patients’ current medicines.  It was clear however that there was no 
difference between intervention and usual care patients in their referral to CPs trained in 
deprescribing for comprehensive medication review.  One approach worthy of future 
investigation is the role of GP peer-review.  This technique has been shown to be a 
feasible and acceptable approach to supporting comprehensive medication review for 
complex patients with multimorbidity and polypharmacy. (226)  It could also be easily 
incorporated into the existing intervention, should it be upscaled to a larger, cluster RCT in 
the form of peer-to-peer review and support in existing groups of GPs within practices, 
after the initial deprescribing training workshop.  This may also function as a reinforcing 
activity to minimise prescriber drift and promote the sustainability of the intervention.   A 
recent overview of strategies to promote health professional behaviour change has shown 
that the most effective interventions are those which emphasise coherence, collective 
action and reflexive monitoring. (233)  That is, for participants the work of interventions 
must make sense and their actual responses (collective action) must align with 
184 
 
expectations of external observers (reflexive monitoring).  Incorporating peer-to-peer 
review and feedback as an element of a sustained intervention may optimise this, without 
increasing the burden of participation.   
Finally, consistent with evidence to date, the experience from this study reinforces that 
facilitating any type of practice change in primary care is difficult, but designing an 
intervention which addresses locally identified barriers supports the change process.  (40)  
The exploratory study showed that all three mandatory elements of the intervention were 
required to achieve the deprescribing effect in the short-term, but it appears that system- 
and or practice-level changes (which are described in more detail below) would likely be 
required to see a sustained effect into the future.  Despite thinking that referral for HMR 
could overcome some of the feasibility issues for GPs such as limited time, this was not 
well adopted in the intervention, and could be altered for a future, larger-scale, longer-term 
RCT.     
 Implications/recommendations for practice and policy  
There are clear lessons and implications for practice and policy to be taken from this study 
as a whole.  From a practice perspective, there is an imperative for improved data quality 
to ensure accurate and up-to-date medical histories and current medication lists for 
patients to facilitate deprescribing.  The need for a central, online patient health record that 
can be shared by health providers across multiple sectors is well recognised and a major 
driver of the current national eHealth agenda in which general practices have been 
incentivised to facilitate patient uptake of the ‘My Health Record’. (234)  In addition to 
improvements to IT infrastructure, it is clear that behaviour change on the part of health 
professionals and patients will be required so health information is firstly entered, and 
secondly, regularly curated in an electronic health record.  (235)  Once realised, computer-
based technology may facilitate data-driven quality prescribing improvements, including for 
example, automatic flagging of patients who could be candidates for deprescribing, by 
medication load or high-risk medications.       
The perspectives of GPs in the intervention study highlighted the important role of the 
researcher in firmly setting deprescribing on their and their patients’ agenda.  Local 
champions or change agents are likely to be key to drive deprescribing, and other quality 
prescribing improvements, in primary care in future.  It is possible that, with the current 
policy context in Australia for the greater role of pharmacists within general practice, these 
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professionals could act as local champions to drive deprescribing and other quality 
prescribing initiatives, informed by local prescribing data.   
There is also a greater need to encourage patient advocacy, literacy, empowerment and 
involvement in regard to deprescribing.  This was highlighted by qualitative findings that 
patients largely welcomed this project.  Notably, patients with strong therapeutic 
relationships with GPs often expressed a lack of agency to question their GP about the 
appropriateness and necessity of their medication regimen, even if it had occurred to them 
to do so.  This was compounded by practical barriers of getting the issue of proactive 
medication review onto the therapeutic agenda, largely because of competing acute, 
clinical priorities.   
Professional organisations and colleges have an important role in encouraging the 
necessary cultural and attitudinal shifts towards ‘less can be more’ in appropriate patients.  
The push for guideline adherence and intensification of therapy needs to be 
counterbalanced by the view that judicious reduction, discontinuation or non-initiation of 
medication, in the context of shared decision making and agreed care goals, is an 
affirmation of highest quality, individualised care. (63)  Risk reframing, highlighting the 
uncertainty and harms of potentially inappropriate polypharmacy in older people is an 
important step to support judicious prescribing and medicines use.  Raising awareness of 
specific cognitive biases (such as commission or regret bias arising from ill-fated action) 
that may inhibit clinicians from adopting deprescribing strategies will need to be part of this 
risk reframing process (198).   
From a policy perspective, embedding and incorporating deprescribing into the curriculum 
for health professionals and students will be a crucial step to normalising and routinising 
deprescribing into medical culture and practice.  This was supported by GPs clearly seeing 
value in the deprescribing training workshop beyond the study and being applicable to a 
much wider general practice audience.  Central to the deprescribing training workshop was 
application of CEASE principals to case studies.  Whilst GPs reported value in working 
through this decision framework for educational purposes, CEASE was not perceived as 
being particularly useful or applicable to support point-of-care decision making on the part 
of experienced clinicians.  Therefore, more research investigating optimal, point-of-care 
decision support is required.   
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Finally, given the fundamental role of the therapeutic relationship between the GP and 
patient as the starting point for deprescribing, consideration should be given to 
implementing a system where patients nominate their preferred GP.  This recommendation 
occurs in the broader policy context in Australia in which there is support for patients with 
chronic and complex conditions to enrol with practices under new care models, such as 
the Health Care Home, for the provision of coordinated, comprehensive care.  (236)  In the 
US and UK, patient empanelment or registration, in which patients are linked to one 
primary care physician, have been critical to facilitating improvements in primary care.  
(224)      
 Strengths and limitations  
There were several strengths to this investigation, including the use of the UK MRC 
framework to inform the study design.  The guidance provided a clear structure for the 
development, feasibility testing and preliminary mixed methods evaluation of the 
multifaceted intervention. Specifically, identifying clinicians’ barriers and enablers to 
deprescribing in the Australian primary care context to inform the elements of the 
intervention are likely to have contributed to the high rate of adoption of the intervention.  
This is supported by the work of Greenhalgh et al, who has highlighted that, when 
implementing innovations in health service delivery, there is empirical evidence as well as 
robust theoretical arguments for strong linkages at the developmental stage between 
researchers and end-users of an innovation.  (237)  An innovation is more likely to be 
widely and successfully adopted if the researchers, when designing the innovation, 
collaborate closely with front-line clinicians for whom it is intended.  This has also been 
described as co-design or co-creation, i.e. the process whereby researchers and 
stakeholders both contribute to the ideation, planning, implementation and evaluation of 
new services as a means for greater translation of research findings into clinical practice. 
(229, 238)  Several specific elements of the intervention were co-designed throughout the 
study, which has been described in detail in a related publication. (239)  The process of 
co-design may have assisted in ensuring fidelity of the intervention, whilst allowing 
adaptation to the local context which is characteristic of interventions that have been 
successfully implemented and routinised. (237)  For example, working closely with practice 
principals or their delegates, the software query used to identify a consecutive sample of 
potentially eligible patients for the study was designed to be customisable according to the 
level of baseline data quality and capture at each site.  Another example of co-design 
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included the refinement of the template for use in the GPs’ medical software to capture 
deprescribing consultation notes, which also functioned as part of the data collection tool 
and a memory prompt for GPs at the point of care.  The template was refined during an 
interactive session at the deprescribing workshop based on invited feedback.   
The mixed methods evaluation of the intervention was a clear study strength and helped to 
explain how the intervention was adopted in practice, its acceptability and value to both 
GPs and patients, and key issues pertaining to the spread and sustainability of the 
intervention.  In evaluating the acceptability of the intervention, the value (i.e. what 
mattered) to patients was identified. This is rarely evaluated in studies and is critically 
important if the needs and priorities of patients in regard to deprescribing are to be 
understood and high-value, patient-centred care is to be realised.  (240)  It is clear that, 
whilst patients found value in the process of this study, further research is needed to elicit 
outcomes that matter to patients, so that care can be designed and organised in a way 
that improves these outcomes. (240) 
The pragmatic approach to reporting agreed medication lists and changes was innovative 
and maximised the validity of findings, although it potentially reduced the effect size of the 
intervention.  It also minimised the data collection burden by GPs which is likely to have 
contributed to the high rate of adoption of the intervention.  It did however result in greater 
effort for the researchers to collate and clean data, which would have to be taken into 
account were this intervention to be tested in a subsequent RCT.   
A key limitation of the investigation was the use of convenience samples of motivated 
clinicians and practices.  This is not unusual in studies to change clinician behaviour, 
which typically involve groups of ‘early adopters’, i.e. those with interest in the topic for 
investigation, who are open to new ideas, and usually demonstrate a high ‘readiness to 
change’. (217, 218)  This sampling bias potentially limits the generalisability of findings to 
‘typical’ clinicians and practices, with two possible consequences.  It could overestimate 
the effect size of the intervention because those sceptical of, or highly resistant to, change 
may be unlikely to adopt the intervention in the first place. (218)  Alternatively, assuming 
the intervention is adopted, the size of the effect could be substantially larger in ‘typical’ 
practices or clinicians, in whom there is more scope for behaviour change and 
improvement.  In this instance, it is speculated that the latter may be more relevant, as 
motivated clinicians recruited to this study, with greater problem awareness, may have 
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already acted to minimise potentially inappropriate polypharmacy, leaving little margin for 
further deprescribing, thereby reducing any positive effect size.     
A final and related point to note for any future study was that practice and GP recruitment 
proved very challenging.  This was despite incentivisation with RACGP-recognised 
continuing professional development and quality improvement points and nominal 
reimbursement for time to attend the deprescribing training workshop and identify eligible 
patients for the study.  Difficulty in recruiting GPs into studies is not uncommon in primary 
care research, and a potential reason why many studies that are done in this setting are 
conducted in groups of ‘early adopters’.  (241)  In a future study, however, greater effort to 
engage professional groups such as RACGP, in addition to the Primary Health Networks, 
may assist in facilitating GP and practice recruitment in this type of research.   
 Future research directions 
In conducting and reporting the findings of this study, the following questions remain 
unanswered.  Consequently, they are suggested as possible directions for further 
research:   
 What are the goals and expectations of patients regarding deprescribing?  
Given research that patients report their GP can be highly influential in 
encouraging them to discontinue therapy (8), this thesis aimed to change 
GPs’ behaviour as an entry point to facilitate deprescribing with their 
patients.  However, patient goals and expectations of deprescribing are an 
unstudied and critical area of research in designing future behaviour change 
interventions in this field.    
 How should ‘deprescribing success’ be defined?  Clearly better metrics are 
needed to evaluate prescribing quality and outcomes, especially when 
generic approaches to deprescribing (i.e. those not targeting a particular 
condition or one or more therapeutic classes of PIMs) are employed.  This 
question is particularly important in light of findings from this investigation 
showing that the goals and outcomes valued by health care professionals 
and organisations and by patients do not always align.  
 How can patients be selected so that deprescribing is better targeted to 
those most likely to benefit, ensuring more judicious use of limited time and 
resources?  In other words, who is most at risk and likely to benefit from a 
deprescribing intervention?  In this study, the number of medications was 
used as a crude proxy of potential medication inappropriateness but reliable, 
predictive models for identifying individuals at risk of harm are needed.  What 
is the possible role of combining systems-based approaches to flag suitable 
candidates for deprescribing (such as electronic reports driven by population-
level prescribing data) with patient-level approaches supporting GPs to make 
nuanced, individualised treatment decisions with patients and how could this 
be best evaluated?   
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 Given the recruitment challenges, is there a demand for deprescribing 
interventions in primary care?  How can motivation for change be best 
engendered to overcome deprescribing inertia?  (237)  Better evidence is 
needed to demonstrate the safety and efficacy of deprescribing but this will 
not be realised without primary care clinicians and practices agreeing to 
participate in this type of research.   
 How can patients be better engaged in decision-making throughout the 
deprescribing process?  What role, if any, do patient oriented decision aids 
have in formally eliciting patients care goals and preferences with regard to 
treatment decisions and how could this influence patient satisfaction with the 
deprescribing process? 
 What impact, if any, does reducing potentially inappropriate polypharmacy 
have on patients’ adherence to essential therapy?  
 Are GPs best placed to lead deprescribing interventions and moderate their 
own prescribing? On the one hand, the existence of a positive therapeutic 
relationship between GPs and their patients appears largely facilitative 
(although there were exceptions to this).  On the other hand, GPs may not 
necessarily be aware of their own potentially inappropriate prescribing.  
 What role, if any, could pharmacists or other members of the primary care 
team play in future?  Could practice-based pharmacists act as local 
deprescribing champions, systematising the identification of patients and 
supporting the medication review process?    
 And most importantly - What is the long-term safety and efficacy of such 
deprescribing interventions in primary care?  This will only be known if large-
scale, longer-term, high quality RCTs are conducted in the primary care 
setting, but this will require means for dealing with the methodological and 
operational challenges that have been highlighted by the findings of this 
exploratory study (and others) 
Many of the questions raised by this thesis are common to studies of other complex, 
proactive interventions which aim to improve health outcomes in community-living older 
people in developed countries (242, 243): which outcomes deliver most benefit to patients, 
clinicians and the health system?; which patients should be targeted to ensure greatest 
return on investment? and; what is the impact of a multi-disciplinary team in achieving the 
outcome/s of interest?  These are all critical questions when attempting to deliver 
improvements, over and above usual care, in existing high-quality primary health care 
systems.  That is, how much benefit, if any, will patients see in terms of independence, 
quality of life and/or hospitalisations for the resources invested, and are these outcomes 
considered most important to patients?   The answers to these questions remain unclear 
for this GP-lead deprescribing intervention.        
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 Conclusion  
Consistent with the overarching study aim, a multifaceted GP-led intervention to minimise 
potentially inappropriate polypharmacy in community living older people, addressing key 
barriers to change, was shown to be feasible in the short-term and conferred a statistically 
significant but clinically modest deprescribing effect. Both GPs and patients reported value 
in the process of medication review, irrespective of the deprescribing outcome.  Further 
research into the long-term safety and effectiveness of deprescribing interventions 
targeting community living older people with polypharmacy is urgently needed.  Facilitating 
any type of practice change, however, is difficult. In optimising the adoption of a complex 
deprescribing intervention within larger-scale, longer-term trials, the learnings from this 
feasibility study must be taken into account.    
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Appendix 2. The CEASE deprescribing framework  
Copyright 2015 by John Wiley and Sons. Reproduced with permission.  Citation - Scott IA, Couteur DG. 
Physicians need to take the lead in deprescribing. Intern Med J. 2015; 45(3):352-6. 
 
Current medicines – ascertain all medicines the patient is currently taking and the reasons 
for each one (also termed medication reconciliation). 
Elevated risk – consider the potential for this patient to be harmed by the medicines being 
prescribed in determining required intensity of deprescribing intervention:  
Consider risk factors such as total number of drugs, age, presence of drugs 
associated with high risk (e.g. opiates, benzodiazepines, psychotropics, 
anticoagulants, hypoglycaemic drugs, cardiovascular drugs), past non-adherence, 
multiple prescribers, impaired cognition and poor social support, substance abuse, 
mental health problems. 
Assess each medicine for its usefulness in relation to its risk by considering: 
Indications for the drug (is the continued prescribing of the drug justified on the 
basis of a verified diagnosis and robust evidence of effectiveness for this indication 
in this patient?); 
Effects of the drug to date on the underlying disease process and/or its symptoms; 
Future benefit–harm trade-offs in the context of life expectancy, time until benefit 
(for preventive medications), goals of care (symptom relief vs disease modification 
vs cure), and patient values and preferences. 
Sort – prioritise those medicines for discontinuation with lowest utility (or highest disutility) 
and greatest ease of discontinuation, while taking patient preferences into account. 
Eliminate – implement a discontinuation regimen, and monitor patients closely for 
improvement in outcomes or onset of withdrawal or rebound syndromes. 
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Appendix 3. Suspected adverse effect/experience from 
deprescribing one or more medications form  
Date  
 
Patient name & DOB   
 
Medication/s reduced or ceased |Date reduced or ceased | Reason for deprescribing  
 
Description of patient adverse effect/experience, including time in relation to 
medication changes (please be as detailed as possible)  
 
Action taken to manage the adverse effect/experience  
 
Clinical outcome (for each subheading below please delete the response/s that do not 
apply)  
Current status:  (Recovered [date] | Not yet recovered | Other) 
 
Seriousness of the effect/experience:  (Life threatening | Hospitalised | 
Required visit to doctor | Other (e.g. Phone call) 
 
Attribution to deprescribing 
In your expert opinion, do you feel that this adverse effect/experience was in any way 
related to deprescribing?  
Yes / No (If yes, please provide as much detail as possible) 
 
Please contact Kristen Anderson – via email <provided> or via mobile <provided> 
upon completion. Please contact her urgently in the case of any event which was life-
threatening or led to hospitalisation.     
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Appendix 4. Search strategy for qualitative systematic review 
PubMed 22 Feb 2014 - 712 search results 
((((((((((((withdraw OR withdrawing OR withdrawal OR cease OR ceasing OR cessation OR stop 
OR stopping OR discontinue OR discontinuing OR discontinuation OR reduce OR reducing OR 
reduction OR deprescribe OR deprescribing OR optim*)) AND (“Prescription drug” OR medicines 
OR medication OR polypharmacy OR prescribing))) OR inappropriate prescribing)) AND 
((Physician OR “family physician” OR “general practitioner” OR GP OR doctor OR clinician OR 
prescriber OR specialist OR health personnel OR "health professional" OR "health care 
professional" OR "health practitioner"))) AND ((((((“semi-structured”[TIAB] OR 
semistructured[TIAB] OR unstructured[TIAB] OR informal[TIAB] OR “in-depth”[TIAB] OR 
indepth[TIAB] OR “face-to-face”[TIAB] OR structured[TIAB] OR guide[TIAB] OR guides[TIAB]) 
AND (interview*[TIAB] OR discussion*[TIAB] OR questionnaire*[TIAB])) OR (“focus group”[TIAB] 
OR “focus groups”[TIAB] OR qualitative[TIAB] OR fieldwork[TIAB] OR “field work”[TIAB] OR “key 
informant”[TIAB])) OR “interviews as topic”[Mesh] OR “focus groups”[Mesh] OR narration[Mesh] 
OR qualitative research[Mesh])))))))))) 
 
Embase 24 Feb 2014 - 1786 search results 
interview:ab,ti OR discussion:ab,ti OR questionnaire:ab,ti OR survey:ab,ti OR 'focus group':ab,ti 
OR 'focus groups':ab,ti OR qualitative:ab,ti OR 'qualitative research'/de AND [english]/lim AND 
[embase]/lim 
AND 
['inappropriate prescribing'/de OR (inappropriate:ab,ti AND prescribing:ab,ti) AND [english]/lim 
AND [embase]/lim 
OR  
(withdraw:ab,ti OR withdrawing:ab,ti OR withdrawal:ab,ti OR cease:ab,ti OR ceasing:ab,ti OR 
cessation:ab,ti OR stop:ab,ti OR stopping:ab,ti OR discontinue:ab,ti OR discontinuing:ab,ti OR 
discontinuation:ab,ti OR reduce:ab,ti OR reducing:ab,ti OR reduction:ab,ti ORdeprescribe:ab,ti OR 
deprescribing:ab,ti OR optim*:ab,ti AND [english]/lim AND [embase]/lim  
AND 
'prescription drug'/de OR medicines:ab,ti OR medication:ab,ti OR polypharmacy:ab,ti OR 
prescribing:ab,ti AND [english]/lim AND [embase]/lim)] 
AND 
physician:ab,ti OR 'family physician':ab,ti OR 'general practitioner':ab,ti OR gp:ab,ti OR doctor:ab,ti 
OR clinician:ab,ti OR prescriber:ab,ti OR 'medical specialist':ab,ti OR specialist:ab,ti OR 'health 
care personnel':ab,ti OR 'health professional':ab,ti OR 'health care professional':ab,ti OR 'health 
practitioner':ab,ti AND [english]/lim AND [embase]/lim 
 
Scopus 12 Mar 2014 - 1966 search results  
 (TITLE(physician OR "family physician" OR "general practitioner" OR GP OR doctor OR clinician 
OR prescriber OR specialist OR "health professional" OR "health care professional" OR "health 
personnel" OR "health practitioner" OR nurse OR pharmacist) AND SUBJAREA(MULT OR MEDI 
OR NURS OR VETE OR DENT OR HEAL)) AND (TITLE-ABS-KEY(interview OR discussion OR 
questionnaire OR survey OR "focus group" OR "focus groups" OR qualitative OR "qualitative 
research") AND SUBJAREA(MULT OR MEDI OR NURS OR VETE OR DENT OR HEAL)) AND 
(((TITLE-ABS-KEY(Withdraw OR withdrawing OR withdrawal OR cease OR ceasing OR cessation 
OR stop OR stopping OR discontinue OR discontinuing OR discontinuation OR reduce OR 
reducing OR reduction OR deprescribe OR deprescribing OR optim*) AND SUBJAREA(MULT OR 
MEDI OR NURS OR VETE OR DENT OR HEAL)) AND (TITLE-ABS-KEY("Prescription drug" OR 
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prescribing OR medicines OR medication OR polypharmacy) AND SUBJAREA(MULT OR MEDI 
OR NURS OR VETE OR DENT OR HEAL))) OR (TITLE-ABS-KEY(inappropriate AND prescribing) 
AND SUBJAREA(MULT OR MEDI OR NURS OR VETE OR DENT OR HEAL))) 
 
CINAHL 20 Mar 2014 - 458 search results 
Physician or "family physician" or "general practitioner" or GP or doctor or clinician or prescriber or 
specialist or "health professional" or "health care professional" OR "health personnel" or "health 
practitioner" 
AND 
("inappropriate prescribing" OR (inappropriate and prescribing) 
OR 
("prescription drug" OR prescribing OR medicines OR medication OR polypharmacy ) AND ( 
Withdraw or withdrawing or withdrawal or cease or ceasing or cessation or stop or stopping or 
discontinue or discontinuing or discontinuation or reduce or reducing or reduction or deprescribe or 
deprescribing or optim* )) 
AND 
interview OR discussion OR questionnaire OR survey OR "focus group" OR "focus groups" OR 
qualitative  
 
PsycINFO 20 Mar 2014 - 565 search results 
 (((AnyField:("prescription drug" OR prescribing OR medicines OR medication OR polypharmacy)) 
AND (AnyField:(Withdraw or withdrawing or withdrawal or cease or ceasing or cessation or stop or 
stopping or discontinue or discontinuing or discontinuation or reduce or reducing or reduction or 
deprescribe or deprescribing or optim*))) OR (AnyField:("inappropriate prescribing" OR 
(inappropriate AND prescribing) ))) AND (AnyField:(Physician or "family physician" or "general 
practitioner" or GP or doctor or clinician or prescriber or specialist or "health professional" or 
"health care professional" OR "health personnel" or "health practitioner")) AND (AnyField:(interview 
OR discussion OR questionnaire OR survey OR "focus group" OR "focus groups" OR qualitative 
OR "qualitative research" )) 
 
INFORMIT 20 Mar 2014 Health collection - 516 search results 
((((((Withdraw OR withdrawing OR withdrawal OR cease OR ceasing OR cessation OR stop OR 
stopping OR discontinue OR discontinuing OR discontinuation OR reduce OR reducing OR 
reduction OR deprescribe OR deprescribing or optim*) AND (“Prescription drug” OR prescribing 
OR medicines OR medication OR polypharmacy))) OR (inappropriate and prescribing))) AND 
(Physician OR “family physician” OR “general practitioner” OR GP OR doctor OR clinician OR 
prescriber OR specialist OR “health professional” OR “health care professional” OR "health 
personnel" OR “health practitioner” OR nurse or pharmacist) AND (interview OR discussion OR 
questionnaire OR “survey” OR “focus group” OR “focus groups” OR qualitative)) 
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Appendix 5. Completed COREQ assessment for each study  
Comprehensiveness of reporting assessment using COREQ (consolidated criteria for reporting qualitative research) checklist.   
Key – Benzo = Benzodiazepines. CME = Continuing Medical Education.  F = Female.  FG = Focus group.  Dept = Department.  GP = General Practitioner.  M = Male.  MD = Medical doctor.  NH = 
Nursing home.  NP = Nurse Practitioner.  NS = Not stated.  PhD = Doctor of Philosophy.  PIP = Potentially inappropriate prescribing. RCT = Randomised Control Trial.  SSI = Semi-structure interview. 
VA = Veterans Affairs.  Other abbreviations refer to study author initials.     
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of 
approa
ch 
How 
were 
particip
ants 
approac
hed? 
e.g. 
face-to-
face, 
telepho
ne, 
mail, 
email 
Initia
l 
letter
, 
follo
w-up 
telep
hone 
NS Lett
er 
via 
seni
or 
part
ner.  
Pra
ctic
e to 
ID 
two 
part
ners 
NS Word
-of-
mout
h, 
posta
l 
maili
ngs, 
phon
e 
solici
tation
s 
NS GPs 
appr
oach
ed 
by 
letter 
Letter Via 
NHs 
with 
phon
e 
follo
w-up 
- 
nece
ssar
y to 
disc
uss 
the 
proje
ct 
due 
to 
phys
ician 
hesit
ancy 
Appr
oach
ed 
GPs 
throu
gh 
group 
coord
inator 
and 
conta
cted 
by 
phon
e or 
email
.   
NS Face
-to-
face 
at 
profe
ssio
nal 
meet
ings, 
emai
l and 
nurs
es 
throu
gh 
calls 
to 
NHs. 
NS - 
Recr
uited 
from 
PC 
resea
rch 
and 
teach
ing 
netw
ork of 
the 
Dept. 
of 
prima
ry 
care 
and 
popul
ation 
studi
es of 
the 
Roya
l 
Free 
and 
UCL 
Med 
Scho
ol 
Throu
gh 
conta
cts at 
prima
ry 
care 
centr
es in 
3 
large 
cities 
in 
Swed
en 
Divis
ion 
of 
Gen
eral 
Prac
tice 
new
slett
ers, 
Flyer
s at 
work
shop
s, 
indiv
idual  
faxe
s 
NS NS NS Tele
pho
ne & 
emai
l 
Ask
ed 
(?fa
ce-
to-
face
) 
and 
then 
telep
hon
e 
follo
w-up 
requ
ired 
to 
enco
urag
e 
high 
Pres
cribe
rs to 
parti
cipat
e 
Lett
er 
and 
follo
w-up 
pho
ne 
call 
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1
2 
Sample 
size 
How 
many 
particip
ants 
were in 
the 
study? 
65 7 22 
GPs
, 
101 
pati
ents
, 
227 
inst
anc
es 
of 
PIP 
8FG, 
5 
SSI 
33 9 10 38 20 39 
GPs 
(20 
tutors
) 
36 
phy
sici
ans 
(2 
NPs
, 1 
pha
rma
cist, 
1 
phy
sici
an 
assi
stan
t), 
prim
ary 
care
, 
Vet 
Affa
irs 
and 
aca
dem
ia 
16 
phys
ician
s (8 
Nurs
es) 
72 
Drs/8
3 
practi
ce 
staff 
(from 
25 
practi
ces), 
192 
patie
nts 
31 28 
GPs 
49GP
s 
22 29 5 
Drs 
(4 
nurs
es, 3 
phar
m, 
17pt
s) 
10 
famil
y 
phys
ician
s, 
prim
ary 
care 
(5 
high, 
5 
low) 
10 
GPs 
(5 
high 
conti
nuer
s, 5 
low 
conti
nuer
s) 
1
3 
Non-
particip
ation 
How 
many 
people 
refused 
to 
particip
ate or 
dropped 
out? 
Reason
s? 
37, 
Not 
state
d 
NS NS NS NS 3 - 
Non
e 
provi
ded 
5 - 
One 
retire
d, 2 
PT, 
2 no 
reas
on 
High 
prescri
bers - 
5 - 
time 
constr
aints; 
Med-
low 
10% - 
not 
stated. 
NS NS - 
39/45
4 
GPs, 
20/80
Tutor
s 
NS NS NS NS Adv
ertis
ed 
parti
cipat
ion.  
Gue
ssin
g 
must 
have 
resp
onde
d 
and 
8 
decli
ned.  
Rea
sons 
18 - 
NS 
NS NS NS - 
?No
ne 
13 
of 
the 
high 
Pres
cribe
rs 
refu
sed 
- 6 
sick 
leav
e, 7 
main
ly 
due 
to 
time 
NS 
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not 
state
d 
Setting 
  
1
4 
Setting 
of data 
collecti
on 
Where 
was the 
data 
collecte
d? e.g. 
home, 
work 
Wor
kpla
ce 
Wor
kpla
ce 
Wor
kpla
ce 
NS NS NS NS Workpl
ace 
NS NS NS NS Work
place 
Wher
e 
group
s 
usuall
y met 
Wor
kpla
ce 
NS Work
place 
Dept 
GP 
Uni 
Med 
Centr
e 
Groni
ngen 
NS Wor
kpla
ce 
Wor
kpla
ce 
1
5 
Presen
ce of 
non-
particip
ants 
Was 
anyone 
else 
present 
besides 
the 
particip
ants 
and 
researc
hers? 
NS N/A 
Des
cripti
ve 
surv
ey 
NS NS NS NS NS No NS NS NS No? NS NS NS NS NS NS NS NS NS 
1
6 
Descrip
tion of 
sample 
What 
are the 
importa
nt 
charact
eristics 
of the 
sample
? e.g. 
demogr
aphic 
data, 
date 
Gen
der, 
aver
age 
age, 
'vari
ety' 
expe
rienc
e 
and 
locat
ion 
Role
, 
quali
ficati
on 
and 
year
s 
sinc
e 
quali
ficati
on 
NS NS -  
sam
ple 
of 
GPs 
work
ing 
in a 
varie
ty of 
differ
ent 
gene
ral 
pract
ices, 
invol
ved 
in a 
local 
CME 
disc
22 
men, 
11 
wom
en, 
Mea
n 
age 
47, 
29 
Cauc
asian
, 3 
East 
India
n, 1 
Asia
n, 
practi
ce 
char
NS 
altho
ugh 
gath
ered 
GPs 
of 
patie
nts 
recru
ited 
from 
one 
Prim
ary 
Care 
Trust
.  
Age 
rang
e 34-
60. 
6M, 
4F. 
No 
furth
er 
Info 
gather
ed 
1994-
1995. 
FT 
Prescri
bers. 
Higher 
Prescri
bers 
all 
male, 
on 
averag
e older 
(5yrs), 
5 more 
years 
in 
practic
e  
NH 
Phys
ician
s 36-
68 
year
s, 16 
NH 
in 
Ger
man 
city. 
Cont
racte
d or 
empl
oyed
.  
Data 
colle
cted 
GPs 
in 
Norw
ay 
who 
enroll
ed in 
CME 
progr
am.  
21/39 
men. 
Med 
age 
47. 
36 
phy
sici
ans 
(2 
NPs
, 1 
pha
rma
cist, 
1 
phy
sici
an 
assi
stan
t), 
prim
ary 
care
, 
Vet 
Data 
colle
cted 
2009
-
2010
.  
Dive
rse 
with 
respi
res 
to 
age, 
gend
er, 
profe
ssio
n, 
clinic
al 
expe
NS - 
Urba
n 
Lond
on 
Drs 
intere
sted 
in 
partic
ipatin
g in 
an 
RCT 
31 
GPs 
(4 
privat
e, 27 
count
y-
empl
oyed)
, 
aged 
33-
63, 
15 
men/
16wo
men, 
mean 
work 
exper
ience 
22 
20 
male
s, 8 
fema
les. 
22 
from 
grou
p 
pract
ices, 
2 
solo, 
4 
othe
r 
setti
ngs. 
Ave 
yrs 
pract
ice = 
33 M, 
16 F. 
Age 
range 
26-
62. 
Mix 
regist
rars, 
traine
rs-
non-
traine
rs, 
acad
emic/
non-
acad
emic, 
inner 
city/ur
15 M, 
7 F, 
mix 
newly 
regist
ered 
& 
exper
ience
d 
(altho
ugh 
biase
d 
towar
ds 
youn
ger 
GPs), 
sole 
and 
large 
Dec10
-
Jan11
. GPs 
trainer
s, min 
5 yrs 
experi
ence 
& third 
year 
traine
e in 
practi
ce at 
the 
time 
of 
study. 
Only 2 
femal
es. 
3 
Drs 
geri
atrici
ans, 
2 
hous
e 
offic
ers. 
Sum
mar
y 
table 
provi
ded 
in 
articl
e.   
All 
high 
pres
cribe
rs - 
male
, 
10yr
s 
olde
r 
than 
low, 
pres
cribe
rs, 
18 
yrs 
mea
n 
empl
oym
6 M, 
4 
F.20
09. 
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ussi
on 
grou
p 
acteri
stics 
infor
mati
on 
provi
ded.   
(18.4 
vs 
13.1). 
Specia
list 
educat
ion - 
50% of 
high 
Prescri
bers, 
85% 
med-
low 
Prescri
bers.  
Some 
higher 
Prescri
bers 
had 
good 
reputat
ions, 
some 
electe
d reps 
2009
. 
Affa
irs 
and 
aca
dem
ia.   
rienc
e (1-
40yr
s) 
and 
posit
ion.  
FT 
and 
PT 
pres
cribe
rs 
yrs, 
Swed
en 
14. 
Mix 
rurali
ty 
ban/r
ural) 
group 
GPs, 
mostl
y 
urban 
Mean 
age 
54 
(39-
65).  
Mix 
urban/
rural. 
ent, 
50% 
spec
ialist
s.  
Low 
pres
cribe
rs - 
3 
male
s, 2 
fem
ales, 
12 
yrs 
mea
n 
empl
oym
ent, 
80% 
spec
ialist
s). 
Info 
gath
ered 
in 
200
8 
Data collection 
  
1
7 
Intervie
w guide 
Were 
questio
ns, 
prompts
, guides 
provide
d by the 
authors
? Was it 
pilot 
tested? 
Yes, 
Not 
teste
d but 
iterat
ive 
appr
oach 
subs
eque
nt to 
debri
efing 
sessi
ons 
Yes, 
but 
not 
teste
d 
App
ropr
iate 
pres
cribi
ng 
indi
cato
rs 
wer
e 
prov
ided  
N Y Y - 
NS 
Yes 
& 
Uns
ure 
Yes & 
NS. 
Q's 
served 
as 
checkli
st.  
Asked 
GPs to 
provid
e 
narrati
ves of 
the 
last 3 
Yes 
& No 
Yes 
& 
new 
them
es 
were 
fed 
back 
into 
later 
FGs 
Yes Yes 
& No 
but 
adde
d 2 
ques
tions 
to 
the 
final 
FG 
as a 
resul
t of 
FB 
No - 
prag
matic 
appr
oach 
(allo
wed 
partic
ipant
s to 
show 
unde
rstan
ding, 
raise 
Yes 
& 
Yes 
Yes  No - 
overvi
ew of 
how 
FG 
cond
ucted 
but 
no 
conte
nt 
No Hypot
hetical 
case 
study, 
outlin
ed 
positio
n of 
GP 
and 
used 
questi
on 
probe
s 
Yes 
- 
publi
shed 
sepa
ratel
y 
Yes 
- Not 
pilot 
teste
d 
No 
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consul
tations 
(gap 
betwe
en 
ideal 
thinkin
g and 
practic
e) 
from 
FG's 
1 &2 
issue
s, 
min 
risk 
of 
them 
chan
ging 
beha
viour  
where 
neces
sary. 
NS 
1
8 
Repeat 
intervie
ws 
Were 
repeat 
intervie
ws 
carried 
out? If 
yes, 
how 
many? 
NS N/A 
Des
cripti
ve 
surv
ey 
NS No No No No No No  NS No NS No No No No NS No No No No 
1
9 
Audio/v
isual 
recordi
ng 
Did the 
researc
h use 
audio or 
visual 
recordin
g to 
collect 
the 
data? 
Audi
o 
tapin
g 
N/A 
Des
cripti
ve 
surv
ey 
Aud
io 
tapi
ng 
Audi
o 
tapin
g 
Audi
o 
tapin
g 
Audi
o 
tapin
g 
Audi
o 
tapin
g 
Audio 
taping 
Rec
orde
d 
(ass
ume 
audi
o) 
Digita
lly 
recor
ded 
Aud
io 
tape
d 
Audi
o 
tape
d 
No  Audio 
tapin
g 
Audi
o 
tapin
g 
Audio 
tapin
g 
Audio 
tapin
g 
Audio 
taping 
Audi
o 
tapin
g 
Audi
o 
tapin
g 
Vide
o-
tape
d 
2
0 
Field 
notes 
Were 
field 
notes 
made 
during 
and/or 
after the 
intervie
w or 
focus 
group? 
Yes 
& 
debri
efing 
N/A 
Des
cripti
ve 
surv
ey 
NS NS NS NS Yes NS NS Yes NS Yes NS Yes Yes NS NS NS NS NS NS 
2
1 
Duratio
n 
What 
was the 
duration 
NS N/A 
Des
cripti
NS FG - 
NS, 
SSI - 
NS 60-
90mi
n 
NS NS 45 
min 
NS 60 
min 
90 
min 
NS 60-
90mi
n 
15-
30 
min 
45-55 
min 
NS 2 hrs 60mi
n 
30-
60 
min 
32 
min 
(17-
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of the 
intervie
ws or 
focus 
group? 
ve 
surv
ey 
5-10 
min 
54mi
n 
rang
e) 
2
2 
Data 
saturati
on 
Was 
data 
saturati
on 
discuss
ed? 
NS N/A 
Des
cripti
ve 
surv
ey 
NS NS Yes Yes NS NS NS  NS NS NS NS Yes Yes Yes Yes Yes NS NS NS 
2
3 
Transcr
ipts 
returne
d 
Were 
transcri
pts 
returne
d to 
particip
ants for 
comme
nt 
and/or 
correcti
on? 
NS N/A 
Des
cripti
ve 
surv
ey 
NS NS NS NS NS  NS NS  NS NS NS NS NS NS Yes NS NS NS NS NS 
Domain 3: Analysis and findings 
Data analysis 
  
2
4 
Numbe
r of 
data 
coders 
How 
many 
data 
coders 
coded 
the 
data? 
2 NS 1 NS NS NS 3 
auth
ors 
1 NS 2 2 
initi
ally, 
then 
one 
afte
r 
the 
codi
ng 
stru
ctur
e 
had 
bee
n 
esta
blis
hed 
3 2 
mem
bers 
partic
ipate
d in 
discu
ssion
s 
2 with 
audit 
by a 
third 
3 
initia
lly to 
deve
lop 
dom
ains 
and 
then 
1 
pers
on 
ther
eafte
r 
2 4 
autho
rs 
2, 3rd 
adjudi
cated  
2 2 1 
auth
or - 
blind
ed 
to 
whic
h 
parti
cipa
nts 
were 
in 
whic
h 
cate
gory 
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2
5 
Descrip
tion of 
the 
coding 
tree 
Did 
authors 
provide 
a 
descript
ion of 
the 
coding 
tree? 
Yes NS NS NS No No Yes Yes Yes Yes Yes Yes NS  Yes Yes  Yes Yes Yes Yes 
- 
publi
shed 
sepa
ratel
y. 
Yes Yes 
2
6 
Derivati
on of 
themes 
Were 
themes 
identifie
d in 
advanc
e or 
derived 
from the 
data? 
Deri
ved 
NS Deri
ved 
NS Deriv
ed 
No 
clear 
them
es 
Deri
ved 
Both - 
Few 
prefor
med 
theme
s were 
used 
Deri
ved 
Deriv
ed 
Deri
ved 
Deri
ved 
Deriv
ed 
Deriv
ed 
Deri
ved 
Deriv
ed 
Deriv
ed 
Derive
d 
Both 
- 
Indu
ctive 
and 
defin
ed 
desc
riptiv
e 
code
s.  
Deri
ved 
In 
adva
nce 
and 
deriv
ed 
(fro
m 
resp
onse
s to 
ques
tions 
from 
exte
nsiv
e 
litera
ture 
revie
w) 
2
7 
Softwar
e 
What 
softwar
e, if 
applica
ble, was 
used to 
manage 
the 
data? 
N/A NS N/A NViv
o 
QS N 
Vivo 
2.0 
N/A NViv
o 7 
N/A N/A NS NS NS N/A Nvivo 
1.2 
NS QSR 
NUD.
IST 
40 
NS NS Nviv
o 
1.2 
NS NS 
2
8 
Particip
ant 
checkin
g 
Did 
particip
ants 
provide 
feedbac
k on the 
findings
? 
 
NS NS NS NS NS NS NS NS NS  NS NS NS NS NS Yes 
- 3 
GPs 
did 
NS NS NS Yes NS NS 
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Reporting 
 
2
9 
Quotati
ons 
present
ed 
Were 
particip
ant 
quotatio
ns 
present
ed to 
illustrat
e the 
themes 
/ 
findings
? Was 
each 
quotatio
n 
identifie
d? e.g. 
particip
ant 
number 
Yes No Yes Yes Yes 
&  
No 
No Yes Yes Yes 
(& 
they 
were 
ident
ified) 
Yes Yes 
& 
Yes 
Yes 
- 
limit
ed 
thou
gh 
and 
no 
parti
cipa
nt 
num
ber 
No Yes Yes 
& No 
Yes & 
No 
Yes Yes Yes Yes Yes 
& 
Yes 
3
0 
Data 
and 
findings 
consist
ent 
Was 
there 
consiste
ncy 
betwee
n the 
data 
present
ed and 
the 
findings
? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Too 
ltd to 
com
ment 
Yes - 
v 
clear 
Yes 
- 
also 
trian
gulat
ed 
findi
ngs 
with 
pts 
Yes Yes Yes Yes Yes Yes 
3
1 
Clarity 
of 
major 
themes 
Were 
major 
themes 
clearly 
present
ed in 
the 
findings
? 
Yes Yes Yes No - 
too 
smal
l 
Yes No Yes Yes Yes 
- 
pres
cribe
r 
appr
oach
es to 
treat
ment 
of 
slee
p 
Yes Yes 3 
clear 
them
es 
altho
ugh 
resul
ts 
secti
on 
was 
limit
ed 
No Yes - 
v 
clear 
Yes Yes Yes Yes Yes Yes Yes 
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disor
ders 
with 
drug
s in 
RAC
F 
3
2 
Clarity 
of 
minor 
themes 
Is there 
a 
descript
ion of 
diverse 
cases 
or 
discussi
on of 
minor 
themes
? 
No Yes 
but 
limit
ed  
No - 
Pre
sent
ed 
one 
inst
anc
e of 
dive
rse 
vie
ws 
re: 
pati
ent 
rece
ptivi
ty to 
cha
nge.  
No - 
too 
smal
l 
No No Yes 
- 
altho
ugh 
limit
ed 
Yes - 
Premis
e of 
paper 
to 
explor
e 
views 
of low 
and 
high 
Prescri
bers. 
Yes 
- 
appa
rent 
in 
thre
e 
subt
hem
es of 
pape
r 
No 
but 
comp
rehen
sive 
given 
diver
se 
aims  
Disc
ussi
on 
of 
conf
licti
ng 
vie
ws 
and 
min
or 
the
mes 
(e.g
. 
guid
elin
es) 
Ltd 
infor
mati
on in 
pape
r  
Confl
icting 
views 
were 
prese
nted 
Yes - 
prese
nted 
confli
cting 
views 
Yes 
& in 
meth
odol
ogy 
desc
ribed 
thes
e as 
'typi
cal' 
or 
varia
nt'  
Yes - 
captu
red 
minor 
them
es in 
text 
but 
not 
under 
subh
eadin
gs 
Yes - 
prese
nted 
'outlie
r 
views
' 
Consi
stently 
prese
nted 
count
erbala
ncing 
point 
of 
view 
The
ory 
and 
data 
trian
gulat
ion - 
stro
nger 
met
hod
olog
y 
Capt
ured 
in 
met
hod
olog
y - 
high 
and 
low 
pres
cribe
rs 
Capt
ured 
in 
met
hod
olog
y - 
high 
and 
low 
pres
cribe
rs 
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Appendix 6. Case study and question guides for focus group 
discussions 
 
Case study and question guide - Perspectives of general practitioners and 
consultant pharmacists on barriers and enablers to deprescribing 
We would like to use this focus group to draw on your experiences and opinions about 
deprescribing, or stopping or reducing medication in community living older people who 
are taking multiple medications but who are not terminally ill. We are not wanting to focus 
on those people who have already transitioned to aged care. Rather, we are looking at 
people who are still living in the community.  
As clinicians, I don’t need to tell you that there is a real tension in managing older, complex 
patients.  Usually these individuals have a number of comorbidities and on the one hand 
we know medications can extend and improve quality of life.  On the other hand, we know 
the higher the number of medications taken concurrently, the greater the risk of harms 
(ranging from poorer cognition and function through to hospitalisations and death).   
Medications aren’t started without good reason. But, as people age, and their care goals 
and life circumstances change, so too can the appropriateness of their therapy.  So 
today/tonight, we are interested to hear the challenges you experience in trying to manage 
these complex older patients and difficulties you face when trying to rationalise 
therapy/make recommendations to rationalise therapy, as well as some of the things that 
make this process easier for you too.   
To really ground our thinking in terms of the types of patients we are wanting to talk about 
tonight, we have a case study.  We don’t want to answer it.  We’re just using this to ground 
our thinking.  Introduce case study.   
 
  
228 
 
Hypothetical case study - Betty, an 81-year-old lady who is a long-term patient of yours. 
Adapted from: Scott IA, Gray LC, Martin JH, Mitchell CA. Minimizing inappropriate medications in older populations: a 
10-step conceptual framework. American Journal of Medicine. 2012;125(6):529-37. 
Past medical history 
– Hypertension 
– IHD with past AMI 2002 complicated by CHF 
– Chronic atrial fibrillation 
– Osteoporosis with past Colles' fracture 
– Depression 
– Osteoarthritis  
– Type 2 diabetes for 15 years; past hypoglycaemia 
– Renal insufficiency (CrCl 21ml/min) 
– Gastro-oesophageal reflux 
– Past falls (x2 last year) when walking on uneven ground 
– Most recent MMSE 26/30 
 
Functional assessment 
– Lives independently in a granny flat with modifications in her daughter’s house 
– Able to perform basic self-cares; daughter does shopping, cooking, washing 
– Limited mobility due to pain and stiffness in hips and knees; uses a wheelie-walker  
– Webster pack; daughter supervises medications  
 
Current Medications 
Carvedilol 12.5mg bd Cholecalciferol (Ostelin®) 1000 IU day 
Perindopril 5mg mane Calcium carbonate (Caltrate®) 600mg mane 
Frusemide 40mg mane Sertraline 100mg nocte 
Amlodipine 5 mg mane Omeprazole 20mg bd 
Spironolactone 12.5mg mane Gliclazide 80mg bd 
Isosorbide mononitrate SR 60mg mane Panadeine 2 tds prn 
Pravastatin 40mg mane Movicol® ii bd 
Digoxin 62.5microgram nocte Oxazepam 15 mg nocte 
Warfarin 3mg nocte Oxycodone 5mg tds prn 
Alendronate 70mg once weekly  
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QUESTION GUIDE - GPs.  (Timing based on 60min focus group)  
OPENING (10 min)  
1. Present case.  What is your initial reaction to this case?   
a. How typical is this sort of patient in your practice?  
b. What are the main challenges you face when prescribing in a patient like Betty?  
 
THOUGTS ABOUT BARRIERS/ENABLERS TO DEPRESCRIBING (25 minutes) 
2. How often do you consider stopping medications in patients like Betty in your practice?   
a. Prompt if appropriate - So stopping medicines is something we all seem to agree 
with in principle, but is it practical to be thinking about or actually be stopping 
medications all the time in your practice? 
 
3. What are the main things that push you to consider stopping medications in your older 
patients?  What things prevent you from considering this?   
 
4. Think of a time when you felt really confident stopping a medication in an older patient.  
What were the circumstances surrounding this?   
 
Now think of a time when you felt really uncertain about the value of stopping a 
medication in an older patient.  What were the circumstances surrounding this? 
a. Are there particular medications or sets of circumstances where you find it 
difficult to deprescribe?  Why? 
 
5. When you stop a medication, what do you use as your guide in determining if this has been 
a good thing to do?  In other words, what does success look like?   
 
TOOLS TO DEPRESCRIBE (15 minutes) 
6. What tools or resources do you use to assist stopping or reducing medications in your 
patients presently?   
 
7. I would now like to present to you a deprescribing framework that could be used to 
assess an individual’s medications to determine whether any medications are no longer 
necessary or are potentially harmful.  This has been developed by the Australian 
Deprescribing Network and is currently in draft.  (Give participants a few minutes to review.) 
 
Would you use this framework in clinical practice?  Why?  Why not?  If not, is there 
anything that you could take away from this framework?  What would help to facilitate the 
process of deprescribing? 
a. What will stop/hinder you from applying this in clinical practice? 
 
8. What would make the process of deprescribing easier for you and your patients?   
 
SUMMARY & CLOSE (10 minutes) 
9. SUMMARISE.  Of all the issues/barriers/enablers discussed, which are the most important 
to you?  Missed anything?  
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QUESTION GUIDE - CPs (Timing based on 60min focus group)   
OPENING (10 min) 
1. Present case.  What is your initial reaction to this case?   
a. How typical is this sort of patient when conducting home medicines reviews? 
b. What are the main challenges you face in undertaking a medication review in 
complex older, patients with excessive polypharmacy like Betty?   
 
THOUGHTS ABOUT BARRIERS/ENABLERS TO DEPRESCRIBING (25 minutes) 
2. When undertaking medication reviews, how often do you suggest to GPs or patients that 
medications be stopped or reduced?   
 
3. What are the main things that push you to make a recommendation to stop or reduce 
medications?  What prevents you from making a recommendation to stop or reduce 
medications in your patients even if you would like to?   
 
4. How do you feel when making a recommendation to stop or reduce a medication which 
results in your -  
a. Deviating from a clinical guideline? 
b. Contradicting the advice of a specialist?  
c. What about the patients?  Would you make a recommendation if the patient doesn’t 
want to stop? 
 
5. When you make a recommendation to stop a medication, how would you know if this 
has been a good thing to do?   
 
TOOLS TO DEPRESCRIBE (15 minutes) 
6. What tools or resources do you use to assist in deciding which medications should be 
stopped or reduced in your patients presently?   
 
7. I would now like to present to you a deprescribing framework that can be used to 
assess an individual’s medications to determine whether any medications are no longer 
necessary or are potentially harmful.  Would you use this framework in clinical practice?  
Why?  Why not?  If not, is there anything that you could take away from this framework?   
a. What will stop/hinder you from applying this in clinical practice? 
 
8. What would make the process of deprescribing easier for you and your patients?   
 
SUMMARY & CLOSE (10 minutes) 
9. SUMMARISE.  Of all the issues/barriers/enablers discussed, which are the most important 
to you?  Missed anything?   
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Appendix 7. Procedure to identify eligible exploratory study 
participants 
1. Run medical software or PENCAT® query for all patients  
a. Aged 65 years or older AND prescribed 8 or more medications*  
From this full list, the aim is for each GP to identify roughly 15-20 patients for ‘consent 
to contact’ by the research team.  In other words, a GP does not need to review the 
whole patient list if it is long – they simply need to review the list consecutively starting 
from the top to –  
2. Identify which patients are ‘yours’ or ‘theirs’ 
3. Exclude patients ineligible for the study.  i.e. Those who have  
a. Conditions that would preclude consent (such as confusion, cognitive 
impairment, mental health disorders with psychosis and/or communication 
difficulties) 
b. A terminal illness 
c. Had Home Medicines Review in the past 12 months 
d. AND document the reason for exclusion next to their name on the list 
4. Ensure remaining shortlisted patients are 
a. Prescribed 8 or more regular medications according to the medical record 
b. Have capacity to give consent 
c. Proficient in English and own a functioning telephone 
If a GP wishes to exclude patients based on other clinical grounds (e.g. patient prone to 
extreme anxiety when receiving phone call from strangers) we simply ask that the GP 
documents the reason for exclusion.  
Please do not exclude patients from the list because you think they will not want to 
participate.   
 
*May also exclude antibiotics or those medications with ‘prn’ in the directions if your 
medical software can facilitate such a search.  Please record the total number of patients 
that this report generates.   
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Appendix 8. Deprescribing autofill template  
Short cut for use in consult notes for UQ Deprescribing Study (short cut key ‘derx’). 
Patient attended for appointment as part of UQ study. 
Medication history taken and list reconciled? Y or N? If no, why?  
Each medication reviewed for utility? Y or N? If no, why? 
Medications eligible for deprescribing – 
 Medication, reason, GP recommended plan, plan after discussion with patient 
 Medication, reason, GP recommended plan, plan after discussion with patient 
 Medication, reason, GP recommended plan, plan after discussion with patient 
Next appointment to be scheduled -  
Reasons when CEASING medications (free text in consult notes OR select from drop 
down list)- 
1. No clear or valid indication (including contraindications) 
2. Prescribing cascade 
3. Actual or potential harms > benefits  
4. Symptom control  
a. Ineffective  
b. Symptoms resolved 
5. Time until benefit questionable  
6. Unacceptable treatment burden 
7. Patient stopped it 
Reasons when RESTARTING medications (free text in consult notes) –  
1. Restart – Symptom relapse 
2. Restart – Withdrawal syndrome 
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Appendix 9. Process for identifying changes due to medication reconciliation  
For medications absent from GP’s medication list at follow-up (requires triangulation of GP & patient baseline & follow-up lists) 
Absent from patient list at baseline? 
  
 
           YES - Classify as RECONCILED - removed            NO   
     
In intervention arm, was it CEASED PRIOR to deprescribing appointment? 
  
  
       
YES – classify as ADJUSTED            NO  
In either arm is it clear or highly likely from the Health Summary whether 
this is CEASED (look at consult notes and cross-reference with specialist 
letters or summaries, patient history, screenshots – if available) 
 
 
YES – classify as CEASED NO – SELECT OPTION TO BIAS 
TOWARDS NULL  
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For medications added to GP’s medication list at follow-up (requires triangulation of GP & patient baseline & follow-up lists) 
 
     Present in patient list at baseline? 
 
 
   
YES - Classify as RECONCILED – added           NO   
 
    In intervention arm, was it STARTED PRIOR to deprescribing appointment? 
  
  
       
YES – classify as ADJUSTED   NO  
In either arm is it clear or highly likely from the Health Summary this has 
been STARTED (look at consult notes and cross-reference with specialist 
letters or summaries, patient history, screenshots – if available)  
 
 
YES – classify as STARTED  NO – SELECT OPTION TO 
BIAS TOWARDS NULL 
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Appendix 10. Patient follow-up data collection form (telephone)   
NB.  Usual care patients were not questioned about PATD or the intervention.  
Hello <insert patient name> 
It’s <insert own name> phoning from the School of Medicine at the University of Qld. (If 
relevant, mention the name of the person who interviewed them last time).  I’m phoning as 
scheduled to have our second phone interview as part of the study with Dr <insert usual 
GP’s name> regarding your medicines.  We are just wanting to go through the same 
questions as last time to see if anything has changed.   
Is now still a convenient time to do this or shall I phone you back later?  It will take 
approximately 25 minutes (Reschedule if unavailable). 
Before we begin, would you have a list of your medications close to hand?    
(If all ok, proceed with interview - please note start and finish time).  
Participant ID  
Date, time & duration of 
interview  
 
INTERVIEW QUESTIONS 
 MEDICATIONS, MEDICATION MANAGEMENT & BELIEFS 
(Look at the baseline data 
collection sheet)  
Tell me, do you still <insert 
appropriate option - 
manage your own 
medications at home OR 
have someone help you 
with this>?   
 
(For example, confirm that 
the patient hasn’t started a 
Webster pack since we last 
spoke.) 
 
 
I’d now like to ask you 
about your medications.  
 
Which medications do you 
take that are prescribed by 
a doctor?   
 
Medication Dose Frequency 
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FIRST PROMPT –   
Do you take any other 
medications on prescription 
such as eye drops, puffers, 
creams or injectable 
medicines? 
 
After each additional 
medication, prompt once 
more. 
 
FINAL PROMPT –  
And does this list include all 
the medications that are 
prescribed to you by all your 
doctors (for example, do you 
see any specialists or other 
GPs who also prescribe 
medications to you)? 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
So, since we last spoke in 
(insert date of first interview), 
can you indicate, if there 
have been any changes to 
your prescription 
medications?   
PROMPT –  
For example, have any of 
your prescription medications 
been stopped (either by you 
or your doctor), have you had 
any new medications started 
or have there been changes 
to the dose of any of these 
medications? 
 
If there have been changes - 
Have you been able to (insert 
appropriate choice - e.g. stay 
off them, stay on the reduced 
dose etc?)  
 
I’m also interested to know 
what you tried to change as a 
result of that appointment?   
 
Medication  Change & outcome 
(i.e. stopped but had 
to restart)  
Who initiated this 
(e.g. GP or patient) 
   
   
   
   
Do you take any non-
prescription medications 
(such as over-the-counter 
medicines, herbal 
medications, or anything 
from a health food store or 
Medication Dose Frequency 
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the health section of the 
supermarket)?  
 
May have already provided 
this.  Prompt as above but 
this may not be necessary if 
already provided.   
 
 
   
   
   
   
   
   
   
So, since we last spoke 
<insert date>, can you 
indicate, if there have been 
any changes to the 
medications that you take 
over the counter?   
 
PROMPT –  
For example, have any of 
these medications been 
stopped (either by you or 
your doctor), have you had 
any new medications started 
or have you changed doses 
of any of these medications? 
 
If there have been changes -  
Have you been able to (insert 
appropriate choice - e.g. stay 
off them, stay on the reduced 
dose etc?)    
I’m also interested to know 
what you tried to change as a 
result of that appointment?   
Medication  Change & outcome 
(i.e. stopped but had 
to restart)  
Who initiated this 
(e.g. GP or patient) 
   
   
   
   
I would now like to ask you 
some questions about how 
you feel about your 
medications and health.  
Ask patient to locate the 
surveys.   
PATD 
If they have not retained this 
form, exclude question 13. 
 
15 Questions  (INTERVENTION PATIENTS ONLY) 
1=Strongly agree; 2=Agree; 3=Unsure; 4=Disagree; 5=Strongly 
disagree. 
Q1 
Q2 
Q3 
Q4 
Q5 
Q6 
Q7 
Q8 
Q9 
Q10 
Q11 – No or Yes ( If yes, remain off, restart, different medication 
  
238 
 
Q12 –  5-10, 10-15, 15-20, 20-25, >25 
Q13 –  
Q14 – Comfortable, uncomfortable, unsure 
Q15 – If one of your regular medications was stopped, what follow     
up would you like?  
Face to face appointment  
Phone call(s)  
Written information via post  
Written information via email  
I wouldn’t need planned follow-up. I would be happy 
contacting a health professional if I had any problems 
QUALITY OF LIFE - EQ-5D-
5L (Administer as scripted) 
 
See separate attachment.   
MEDICAL SPECIALISTS 
Are you under the care of 
any medical specialists?   
 
If yes –  
Which specialists and how 
often do you see them? 
 
If no – PROMPT - so you 
don’t see any specialists on a 
regular basis (e.g. heart 
specialist every 1-2 years)?  
Name of doctor or specialty_______________________________ 
Last visit ______________________________________________ 
Frequency of review &/or next scheduled visit if known 
_____________________________________________________ 
 
Name of doctor or specialty_______________________________ 
Last visit ______________________________________________ 
Frequency of review &/or next scheduled visit if known 
_____________________________________________________ 
 
Name of doctor or specialty_______________________________ 
Last visit ______________________________________________ 
Frequency of review &/or next scheduled visit if known 
_____________________________________________________ 
 
Name of doctor or specialty_______________________________ 
Last visit ______________________________________________ 
Frequency of review &/or next scheduled visit if known 
_____________________________________________________ 
HOSPITAL PRESENTATIONS/ADMISSIONS 
Since we last spoke <insert 
date>, have you presented 
to a hospital emergency 
department for your own 
medical care or stayed in 
hospital for at least one 
night?  
 
How many times?   
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Could you briefly describe 
the reason for these 
presentations/admissions?   
MEDICATION REVIEW 
Since we last spoke <insert 
date>, have you had a 
pharmacist come to your 
home to review your 
medicines and write a 
report to your GP?  This is 
known as a Home 
Medicines Review.   
 
If yes – note number of times 
and most recent HMR date 
(approximations are fine). 
 
 QUESTIONS FOR INTERVENTION PATIENTS ONLY 
Before we finish, I am interested in getting some general feedback from you regarding the 
appointment you had with your GP to review your medicines for appropriateness.      
 
Just to make sure I’ve met the University of Queensland’s requirements I will read the next bit out 
word for word so it might sound a bit stilted but it’s the easiest way of doing it and then we know 
we’ve done it correctly.    
 
With your permission, I would like to audio-record this part of our conversation.  Each person will 
have their own unique experience which will provide us with valuable feedback and for this reason 
it is important that I record this section of the interview so I can document your personal experience 
accurately.  Please be assured that, like all the information you have given me, you will not be 
identifiable from the transcript of this recording in any way.  Any identifying information recorded, 
including your and your GP’s name will be deleted from the transcript that we make from this 
recording.  So <insert patient name>, do we have your consent to audio record your responses to 
the next few questions?  
 
If yes, start recording and repeat –I’ve read the consent statement, do we have your consent to 
audio record your responses to the next few questions?   
 
[If No to questions and recording, thank them and end call.] 
 
Questions –  
 
As part of your participating in this study, you had an appointment with your GP <insert date> to 
have a thorough review of your medicines  
 
Can you tell me what happened in that appointment?   
 
So how did you find that appointment (or process of the doctor going through your 
medicines)?  
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If limited response from the patient, ‘Can you expand by what you mean by that’?   
 
So it sounds like, Dr x <did/didn’t> spend the time to discuss your medication.  Did you feel 
that there was the adequate opportunity to ask questions and discuss any concerns you 
might have regarding your medications?   
 
If medications were reduced or stopped or changed -  
 
So you mentioned that as a result of the appointment, you <insert change>.  When you left, 
did you think you would be able to manage that change?   
 
(If positive response – challenge) So you didn’t have any concerns about <e.g. 
stopping/starting/changing etc x, y or z)?   
 
Have those changes to your medicines had any impact on your ability to manage your 
medicines? 
 
(If relevant, delve further regarding their involvement in appointment, confidence to make the 
changes and whether to make it easier or harder to make the changes.) 
  
Do you have any other general feedback or comments to make before we stop recording? 
 
Thank you very much for your time.  STOP RECORDING 
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Appendix 11. Practice baseline data collection form  
Please complete the following information as accurately as possible –  
Practice Name 
 
 
Practice Principal/s  
 
Practice Manager   
 
Accreditation status (please circle) Accredited  
In the process of gaining accreditation  
Not accredited 
Software Used (please circle) 
 
Best Practice® or Medical Director® 
Please specify the number of individuals (i.e. 
headcount) and number of full time 
equivalents (FTE*) for each type of 
professional  
   
*Each FTE is defined as working 35-45 hours 
per week, so 2 GPs each working 20hrs/week 
would be recorded as 2 individual GPs and 1 
FTE. 
No. of individuals No. FTEs  
GPs   
Enrolled nurses   
Registered nurses   
Nurse practitioners   
Which of the following health services, if any, are on-site at your practice? 
 
(Please tick the applicable option/s) 
Dietitian  
Imaging  
Non-dispensing pharmacist  
Pathology collection centre/lab  
Physiotherapist  
Podiatrist  
Psychologist  
Specialist(s) (specify)  
Other(s) (specify)  
NONE  
  
242 
 
Number of active patients at the practice  
(As per RACGP’s definition of a patient having 
attended the practice three or more times in the 
past 2 years)   
 
Number_______________________________ 
 
How did you calculate this? (Please circle) 
 Practice software query 
 PENCAT® query 
 Estimation 
 Other___________________________ 
 
Number of active patients who are 65 years 
or older  
 
 
Number_______________________________ 
 
How did you calculate this? (Please circle) 
 Practice software query 
 PENCAT® query 
 Estimation 
 Other___________________________ 
 
Number of active patients 65 years or older 
who are prescribed 8 or more regular 
medications  
 
Number_______________________________ 
 
How did you calculate this? (Please circle) 
 Practice software query 
 PENCAT® query 
 Estimation 
 Other___________________________ 
 
Please indicate the usual billing practices for the following patient groups in your practice -   
 
 General __________________________________________ 
 Concession card holder_____________________________ 
 Aged pensioner___________________________________ 
 Disability pensioner_________________________________ 
 Children__________________________________________ 
 Other (please specify)_______________________________ 
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Appendix 12. GP questionnaire 
Minimising potentially inappropriate polypharmacy in community living, older 
people – an exploratory mixed-methods study 
 
1. Name (optional)______________________ 
 
2. Gender ____________________________ 
 
3. Age _______________________________ 
 
4. Country of graduation (primary medical degree) 
 
Australia   Other (please specify) _______________________________ 
 
5. How many years have you been registered as a General Practitioner?  (Please specify 
time and if you hold a FRACGP and/or FRACRRM) ____________________________ 
 
OR           I am a General Practice registrar (i.e. in training). 
 
6. Please list any subspecialties  
 
______________________________________________________________________ 
7. How many direct patient care hours do you work per week? (Include hours of direct 
patient care, instructions, counselling etc and other services such as referrals, 
prescriptions, phone calls etc).   __________________________________________ 
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Appendix 13. Post-Intervention GP interview guide 
Purpose of the interviews is to explore the impact and acceptability of deprescribing intervention. 
1. General opening question regarding experience participating in the study 
How have you found the overall experience of participating in this study?  
 
2. Identification of high risk patients 
How did you find the process of identifying high risk patients for the deprescribing 
intervention?  
 
3. Workshop on deprescribing 
How adequate was the workshop in preparing you for the deprescribing 
intervention?   
Following your experience of deprescribing, are there other 
issues/topics/information that should be covered in future workshops?   
What are your thoughts about further follow-up/support after the workshop?  
 
4. Deprescribing in practice  
In general, what was your experience of applying the deprescribing intervention in 
practice? 
What would you say were the consequences of the deprescribing intervention for 
your interactions with patients? 
What sorts of changes for your patients did you see as a result of the deprescribing 
intervention? 
o Specifically prompt for negative and positive example – draw on patient data. 
What would you say were the consequences of the deprescribing intervention for 
your workload (initial and ongoing)?  
 
5. Influence on general practice 
Has this experience affected your initiation or cessation of medications in other 
patient groups?  If so, how? 
Have you shared your experience with other people in your practice?  
What did you do?     
6. Acceptability  
As a clinician who has been involved in the deprescribing intervention, how 
acceptable to you is the process of the deprescribing intervention? 
Overall, how acceptable to you is the workload involved in the deprescribing 
intervention?  
What aspects of the intervention, if any, would you change?  
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Appendix 14. Diagrammatic representation of data collection & timing 
 
INTERVENTION GROUP 
 
 
 
 
 
 
 
 
 
  
 Study period = Median 125 (IQR = 118-133 & full 
range = 86-198) days  
  
N.B.  Adjusted ‘Current Medication’ Lists from 
GP consultation notes during this period, where 
necessary, to provide best possible baseline 
medication list 
 
  
 
 
 
USUAL CARE  
 
 
 
 
  
 Study period = Median 126 (IQR = 124-129 & full 
range = 123-132) days 
 
Data extraction from practice = T2 Data extraction from practice 
1st Deprescribing appt = T1 
←Phone interviews→ 
Median (IQR) time -22 (-32 to -8) days to T1 
Data extraction from practice = T1 
←Phone interviews→ 
Median (IQR) -55 (-76 to -32) days to T1 
←Phone interviews→ 
 Median (IQR) time between interviews 180  
(157-209) days 
←Phone interviews→ 
Median (IQR) time between interviews 151 
(104-173) days 
Data extraction from practice = T2 
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Appendix 15. Changes to regular medications during the study 
period for intervention and usual care groups 
Outcome Measure of 
central 
tendency 
Intervention 
(SD) 
N=78 
Usual Care 
(SD)  
N=67 
IRRa 
(95%CI) 
P 
value 
Secondary Outcomes - Deprescribedb 
 
GP deprescribed Mean 1.5 (1.697) 0.7 (1.291)  2.478 
(1.518-
4.047) 
<0.001 
Median 1 (0-2) 0 (0-1) 
Patient-reported deprescribed 
 
Mean 1.51 (1.475) 1 (1.393) 1.626 
(1.019-
2.595) 
0.041 
Median 1 (0-2)  1 (0-2) 
Secondary Outcomes  
 
GP ceased Mean 0.88 (1.423) 0.48 (1.223) 2.121 
(1.179-
3.815) 
0.012 
Median 0 (0-1) 0 (0-1) 
Patient-reported ceased 
 
Mean 0.97 (1.238) 0.63 (1.166) 1.805 
(1.049-
3.105) 
0.033 
Median 1 (0-1.25) 0 (0-1) 
GP reduced Mean 0.71 (0-4) 0.22 (0-2) 3.069 
(1.580-
5.962) 
0.001e 
Median 0 (0-1) 0 (0-0) 
Patient-reported reduced Mean 0.54 (0.848) 0.37 (0.693) 1.445 
(0.877-
2.381) 
0.149c,d 
Median 0 (0-1) 0 (0-1) 
GP commenced  Mean 0.47 (0-4) 0.48 (0-4) 1.033 
(0.574-
1.859) 
0.914 
Median 0 (0-1) 0 (0-1) 
Patient-reported commenced  Mean 0.46 (0.715) 0.81 (1.384) 0.685 
(0.393-
1.193) 
0.181 
Median 0 (0-1) 0 (0-1) 
GP-reported unsuccessful 
deprescribing attempts 
Mean 0.27 (0-3) 0.06 (0-2) 4.099 
(1.321-
12.715) 
0.015d 
Median 0 (0-0) 0 (0-0) 
Patient-reported unsuccessful 
deprescribing attempts 
Mean 0.32 (0.655) 0.03 (0.03) 10.236 
(2.310-
45.357) 
0.002d 
Median 0 (0-0.25) 0 (0-0) 
GP increased  Mean 0.22 (0.474) 0.18 (0.424) 1.279 
(0.547-
2.988) 
0.570 
Median 0 (0-0) 0 (0-0) 
Patient-reported increased Mean 0.31 (0.542) 0.31 (0.583)
  
1.009 
(0.504-
2.018) 
0.980 
Median 0 (0-1) 0 (0-1) 
a IRR - Incidence Rate Ratio (adjusted for baseline number of medications, age and gender). 
b Includes ceased and dose-reduced medications. 
cPossion used instead of Negative binomial regression as variance:mean <1.5.   
dNote that the number of baseline medications did not remain a statistically significant predictor in the model. 
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Appendix 16. Changes to regular medications excluding 
supplements during the study period for intervention 
and usual care groups 
Outcome Measure of central 
tendency 
Intervention 
(SD) 
N=78 
Usual Care 
(SD)  
N=67 
IRRa  
(95%CI) 
 
P 
value 
 
Primary Outcomes - Deprescribed b 
 
GP-reported 
deprescribed 
Mean 1.28 (1.404) 0.66 (1.136) 2.092  
(1.269- 
3.446) 
0.004 
Median 1 (0-2) 0 (0-1) 
Patient-reported 
deprescribedc 
 
Mean 1.14 (1.224) 0.75 (1.035) 1.596  
(1.124- 
2.268) 
0.009  
Median 1 (0-2) 0 (0-1) 
 
Secondary Outcomes 
 
GP-reported ceased Mean 0.58 (0.961) 0.43 (1.048) 1.503  
(0.815- 
2.772) 
0.192 
Median 0 (0-1) 0 (0-1) 
Patient-reported 
ceasedc 
 
Mean 0.63 (0.913) 0.43 (0.802) 1.566  
(0.980- 
2.503) 
0.061 
Median 0 (0-1) 0 (0-1) 
GP-reported 
commenced  
Mean 0.44 (0.749) 0.45 (0.909) 1.017  
(0.555- 
1.861) 
0.958 
Median 0 (0-1) 0 (0-1) 
Patient-reported 
commenced  
Mean 0.32 (0.592) 0.55 (1.171) 0.713  
(0.378- 
1.343) 
0.295 
Median 0 (0-1) 0 (0-1) 
a IRR - Incidence Rate Ratio (adjusted for baseline number of medications, age and gender). 
b Includes ceased and dose-reduced medications. 
cPossion used instead of Negative binomial regression as variance:mean <1.5.   
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Appendix 17. Patients’ Attitudes Towards Deprescribing 
questionnaire 
Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. Development and validation of the patients' attitudes towards 
deprescribing (PATD) questionnaire. Int J Clin Pharm. 2013;35(1):51-6. 
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Appendix 18. EQ-5D-5L – Telephone questionnaire  
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-
level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727-36. 
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Appendix 19. SPSS Output - Rotated Component Matrix and 
Total Variance explained from Factor Analysis of 10 
PATD survey items   
Rotated Component Matrixa 
 
Component 
1 2 3 4 
1. Baseline – I feel that I am taking a 
large number of medications 
.806    
2. Baseline – I am comfortable with the 
number of medications that I am taking 
 .586   
3. Baseline – I believe all my medications 
are necessary 
 .889   
4. Baseline – If my doctor said it was 
possible I would be willing to stop one 
or more of my regular medications 
.665    
5. Baseline – I would like to reduce the 
number of medications that I am taking 
.821    
6. Recoded - Baseline - I feel that I may 
be taking one or more medicines that I 
no longer need 
 .765   
7. Baseline – I would accept taking more 
medications for my health conditions 
  .911  
8. Baseline - I have a good 
understanding if the reasons I was 
prescribed each of my medications 
  .543  
9. Baseline – Having to pay for less 
medications would play a role in my 
willingness to stop one or more of my 
medications 
   .872 
10. Baseline – I believe one or more of my 
medications is giving me side effects 
.584    
Extraction Method: Principal Component Analysis.  
Rotation Method: Varimax with Kaiser Normalization.a 
a. Rotation converged in 6 iterations. 
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Total Variance Explained 
Component 
Initial Eigenvalues 
Extraction Sums of Squared 
Loadings 
Rotation Sums of Squared 
Loadings 
Total 
% of 
Variance 
Cumulative 
% Total 
% of 
Variance 
Cumulative 
% Total 
% of 
Variance 
Cumulative 
% 
1 2.651 26.513 26.513 2.651 26.513 26.513 2.476 24.757 24.757 
2 1.894 18.942 45.455 1.894 18.942 45.455 1.938 19.383 44.140 
3 1.294 12.945 58.400 1.294 12.945 58.400 1.285 12.854 56.994 
4 1.093 10.929 69.329 1.093 10.929 69.329 1.234 12.335 69.329 
5 .805 8.051 77.380       
6 .656 6.563 83.943       
7 .517 5.167 89.110       
8 .483 4.827 93.937       
9 .346 3.456 97.393       
10 .261 2.607 100.000       
Extraction Method: Principal Component Analysis. 
 
 
